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Background: Foam sclerotherapy (foam) and endovenous laser ablation (EVLA) have emerged as
alternative treatments to surgery for patients with varicose veins, but uncertainty exists regarding their
effectiveness in the medium to longer term.
Objectives: To assess the clinical effectiveness and cost-effectiveness of foam, EVLA and surgery for the
treatment of varicose veins.
Design: A parallel-group randomised controlled trial (RCT) without blinding, and economic
modelling evaluation.
Setting: Eleven UK specialist vascular centres.
Participants: Seven hundred and ninety-eight patients with primary varicose veins (foam, n= 292; surgery,
n= 294; EVLA, n= 212).
Interventions: Patients were randomised between all three treatment options (eight centres) or between
foam and surgery (three centres).
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Primary outcome measures: Disease-specific [Aberdeen Varicose Vein Questionnaire (AVVQ)] and
generic [European Quality of Life-5 Dimensions (EQ-5D), Short Form questionnaire-36 items (SF-36)
physical and mental component scores] quality of life (QoL) at 6 months. Cost-effectiveness as cost per
quality-adjusted life-year (QALY) gained.
Secondary outcome measures: Quality of life at 6 weeks; residual varicose veins; Venous Clinical Severity
Score (VCSS); complication rates; return to normal activity; truncal vein ablation rates; and costs.
Results: The results appear generalisable in that participants’ baseline characteristics (apart from a
lower-than-expected proportion of females) and post-treatment improvement in outcomes were
comparable with those in other RCTs. The health gain achieved in the AVVQ with foam was significantly
lower than with surgery at 6 months [effect size −1.74, 95% confidence interval (CI) −2.97 to −0.50;
p= 0.006], but was similar to that achieved with EVLA. The health gain in SF-36 mental component score
for foam was worse than that for EVLA (effect size 1.54, 95% CI 0.01 to 3.06; p= 0.048) but similar to
that for surgery. There were no differences in EQ-5D or SF-36 component scores in the surgery versus
foam or surgery versus EVLA comparisons at 6 months.
The trial-based cost-effectiveness analysis showed that, at 6 months, foam had the highest probability of
being considered cost-effective at a ceiling willingness-to-pay ratio of £20,000 per QALY. EVLA was found
to cost £26,107 per QALY gained versus foam, and was less costly and generated slightly more QALYs
than surgery. Markov modelling using trial costs and the limited recurrence data available suggested that,
at 5 years, EVLA had the highest probability (≈ 79%) of being cost-effective at conventional thresholds,
followed by foam (≈ 17%) and surgery (≈ 5%).
With regard to secondary outcomes, health gains at 6 weeks (p< 0.005) were greater for EVLA than for
foam (EQ-5D, p= 0.004). There were fewer procedural complications in the EVLA group (1%) than after
foam (7%) and surgery (8%) (p< 0.001). Participants returned to a wide range of behaviours more quickly
following foam or EVLA than following surgery (p< 0.05). There were no differences in VCSS between the
three treatments. Truncal ablation rates were higher for surgery (p< 0.001) and EVLA (p< 0.001) than for
foam, and were similar for surgery and EVLA.
Conclusions: Considerations of both the 6-month clinical outcomes and the estimated 5-year
cost-effectiveness suggest that EVLA should be considered as the treatment of choice for suitable patients.
Future work: Five-year trial results are currently being evaluated to compare the cost-effectiveness of
foam, surgery and EVLA, and to determine the recurrence rates following each treatment. This trial has
highlighted the need for long-term outcome data from RCTs on QoL, recurrence rates and costs for foam
sclerotherapy and other endovenous techniques compared against each other and against surgery.
Trial registration: Current Controlled Trials ISRCTN51995477.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 27.
See the NIHR Journals Library website for further project information.
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Plain English summary
Many people undergo treatment for varicose veins, which are visible tortuous veins. Different typesof treatment are available. These are surgery (that is, removing the vein by stripping it out), laser
(using the heat energy of the laser to close the vein) or injection of a foam to make the walls of the
vein stick together.
We compared these three treatments in terms of how well they worked from a participant and clinician
perspective and their relative cost-effectiveness. Seven hundred and ninety-eight people with varicose veins
requiring treatment were allocated at random to one of these three treatments. Outcomes were assessed
at 6 weeks and 6 months. We found that all three treatments reduced the symptoms associated with
varicose veins and improved quality of life (QoL). Foam allowed people to return to their normal activities
quickly, but had fewer benefits in terms of patient-reported QoL and more complications.
Foam was also less likely to close the leaky vein, thus increasing the chance of more treatment being
needed in the future. Overall, the main finding is that consideration of both success at 6 months and
estimated 5-year costs and benefits suggests that laser should be considered as the preferred treatment
for patients who are suitable for all three treatment options. We are following the study participants
to 5 years, as long-term results are important to determine the longer-term costs and consequences
(in terms of recurrent varicose veins) of these three treatments.
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Scientific summary
Background
The treatment of patients with varicose veins imposes a considerable workload and financial burden on
the NHS. Foam sclerotherapy (foam) and endovenous laser ablation (EVLA) have emerged as alternative
treatments to surgery for patients with varicose veins, but uncertainty exists regarding their clinical
effectiveness and cost-effectiveness in the medium and long term. In particular, the rate of recurrence of
varicose veins is unclear. If this is greater than after conventional surgery, then the potential short-term
gains of minimally invasive therapy may be lost by the need for additional treatment.
Aims and objectives
Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) is a pragmatic, parallel-group randomised
controlled trial (RCT) designed primarily to assess the clinical effectiveness and cost-effectiveness of three
treatment modalities: (a) foam; (b) EVLA (with delayed foam sclerotherapy to residual varicosities when
required); and (c) surgery.
Primary outcome measures included disease-specific quality of life (QoL), measured by the Aberdeen
Varicose Vein Questionnaire (AVVQ), and generic QoL, measured by the European Quality of Life-5
Dimensions (EQ-5D) and Short Form questionnaire-36 items (SF-36) physical and mental component scores
at 6 months (and 5 years), as well as cost-effectiveness, measured as cost per quality-adjusted life-year
(QALY) gained.
The secondary objective was to compare the three treatments for (a) clinical success, as determined by
residual varicose veins, Venous Clinical Severity Score (VCSS), complication rates and return to normal
activities; (b) QoL [AVVQ, SF-36 physical and mental components and domains, EQ-5D and EQ-5D visual
analogue scale (VAS) at 6 weeks, and SF-36 domains and EQ-5D VAS at 6 months]; (c) anatomical success,
determined by duplex scan [partial or complete ablation of, or the presence of reflux in, the great
saphenous vein (GSV) or small saphenous vein (SSV)] at 6 months; and (d) the cost to the health service
and to patients of each intervention and any subsequent care.
Methods
Seven hundred and ninety-eight patients referred from primary care to vascular surgery departments in
11 UK centres for treatment of their varicose veins were recruited over 48 months (between November 2008
and October 2012). Research ethical approval and full written informed consent were obtained. The trial
involved an off-licensed use of a licensed product, sodium tetradecyl sulphate (STS) (Fibrovein®, STD
Pharmaceutical), for which Medicines and Healthcare Products Regulatory Agency (MHRA) approval
was obtained.
We included adult patients with primary varicose veins which were symptomatic [clinical, etiological,
anatomical, pathological (CEAP) classification C2 grade or above], either unilateral or bilateral, and those
with GSV and SSV with reflux > 1 second on duplex ultrasound. We excluded those with current deep-vein
thrombosis or acute superficial-vein thrombosis; GSV or SSV < 3mm or > 15mm in diameter; tortuous
veins that were considered to be unsuitable for EVLA; and contraindications to foam or to general/regional
anaesthesia which would be required for surgery.
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Study set-up
Patients were randomised within two strata: stratum A included eight hospitals which offered all three
treatment options and stratum B included three hospitals which offered only two treatment options
(foam sclerotherapy and surgery). Outcomes were assessed at 6 weeks and 6 months post treatment.
At 6 weeks, patients in the foam and EVLA arms were offered foam for any residual varicosities.
Randomisation
Participants were randomised using a computer-generated randomisation system managed by the Centre
for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. Participants were randomly
allocated 1 : 1 to all the options available at each site. The minimisation algorithm included centre, age
(< 50 years, ≥ 50 years), sex, presence of GSV or SSV reflux and unilateral or bilateral varicose veins.
Study interventions
Surgery of the main truncal veins and varicose tributaries was performed concurrently. EVLA of the main
truncal veins was performed at an initial treatment, with foam to residual varicosities, if required, carried
out at or after 6 weeks. For foam, 3% STS was administered to truncal and 1% to non-truncal veins.
Foam to non-truncal varicosities was performed in 31% of patients following EVLA and in 38%
randomised to foam.
Statistical analysis
An intention-to-treat analysis was performed. The primary and secondary outcomes were compared using
mixed linear repeated-measures models, adjusting for baseline covariates. For secondary outcomes, a
p-value > 0.005 was considered to be non-definitive. A trial-based cost-effectiveness analysis assessed
mean differences in costs and QALYs at 6 months, and estimates of cost-effectiveness were extrapolated
to 5 and 10 years using a Markov model. Estimates of cost-effectiveness were expressed as incremental
costs per QALY gained, and the net monetary benefit (NMB) approach was used to identify the optimal
treatment modality on grounds of cost-effectiveness, based on a ceiling willingness-to-pay (WTP) ratio of
£20,000 per QALY gained.
The original trial sample size of 1015 (surgery vs. foam: 90% power, 5% significance; EVLA vs. foam
or surgery: 80% power, 5% significance) was revised to 779 based on data which showed that the
correlation between AVVQ at baseline and 6 months was better than originally assumed. We did not
revise our original, minimally clinically important difference.
Results
In total, 6592 patients who attended outpatient clinics with varicose veins were unselectively screened
for eligibility, and of these 3369 (51%) met the eligibility criteria. Of those who were ineligible, 43% did
not fulfil the criteria for treatment in the NHS because they were asymptomatic, had no reflux, or had
concurrent comorbidities or current thrombosis. A further 28% of patients had recurrent varicose veins.
Less than 20% were excluded because the vein diameter was too small, too large or too tortuous.
Of the 3369 eligible patients, 798 (24%) consented to participate in the trial and 76% (2571 patients)
declined. The majority (78%) of patients who were eligible but declined participation did so because they
had a preference for a particular treatment. Of the 798 patients who were recruited, 13 (1.6%) were
excluded after randomisation. Seven hundred and twenty (92%) received their allocated treatment,
27 (3%) received a study treatment other than their randomised treatment and 38 (5%) did not receive
any of the study treatments. Seven hundred and nine (90%) patients attended for the 6-weeks
follow-up appointment and 670 (85%) completed the 6-weeks questionnaire. Six hundred and
seventy (85%) patients attended for the 6-months follow-up appointment and 627 (80%) completed
the 6-months questionnaire.
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Quality of life
Aberdeen Varicose Vein Questionnaire
In all groups, disease-specific AVVQ scores improved over time (i.e. scores reduced). In the foam versus
surgery comparison, the health gain obtained in the AVVQ was lower in patients undergoing foam
[6 weeks p= 0.002; at 6 months, effect size –1.74, 95% confidence interval (CI) −2.97 to −0.50;
p= 0.006]. EVLA and surgery had similar health gains in the AVVQ. The health gain for AVVQ in the
foam versus EVLA comparison was similar at 6 weeks and 6 months.
European Quality of Life-5 Dimensions
There were no differences in the EQ-5D and EQ-5D VAS in the surgery versus EVLA or surgery versus foam
comparisons at 6 weeks or 6 months. There was a significantly greater health gain at 6 weeks in patients
who underwent EVLA than in those in the foam group in the EQ-5D (p= 0.004), but not in the EQ-5D
VAS. There were no differences at 6 months.
Short Form questionnaire-36 items
There were no differences between surgery and foam for the overall physical and mental component
scores or in the surgery versus EVLA comparison. In the comparison of EVLA versus foam, there were no
differences in the SF-36 physical or mental component scores at 6 weeks or the SF-36 physical component
at 6 months. At 6 months, the health gain in the SF-36 mental component was greater for EVLA than for
foam (effect size 1.54, 95% CI 0.01 to 3.06; p= 0.048).
Cost-effectiveness
At 6 months, foam sclerotherapy was the least costly option, followed by EVLA and then surgery. Based on
consideration of costs and QALYs at 6 months, foam had the highest probability of being considered
cost-effective at a ceiling WTP ratio of £20,000 per QALY. A sensitivity analysis showed that EVLA would
generate the greatest NMB at this threshold at 6 months, but only if performed in a clinic setting, rather
than in an operating theatre.
The cost and effect data from the trial were used to populate a 5-year Markov cost-effectiveness model.
For the first 6-month cycle, the model was populated using mean cost and utility data obtained from all
randomised patients. Beyond 6 months, the best available evidence on the risk of clinical recurrence
following each treatment modality was used to model clinical recurrence and subsequent associated costs
and consequences. The model suggests that, for patients considered clinically suitable for all three
treatment options, EVLA had the highest probability (≈ 79%) of being cost-effective at 5 years when
applying a ceiling ratio of £20,000 per QALY gained, followed by foam (≈ 17%) and then surgery (≈ 5%).
In a two-way comparison between foam and surgery, surgery was found to have the greatest probability
of being cost-effective at 5 years, although a great deal of uncertainty surrounds this finding owing to the
significantly higher cost of surgery and lack of long-term recurrence rates data for both interventions.
Clinical outcomes
At 6 months there were no differences in the VCSS between treatment groups. There were fewer residual
veins at 6-months follow-up (lower VAS scores) in the surgery group than in the foam group (nurse- and
patient-reported data, p< 0.001). Fewer patient-reported residual varicosities were noted in the EVLA
group than in the foam group at 6 months (p= 0.005).
Ablation rates
At 6 months, both surgery (p< 0.001) and EVLA (p< 0.01) were more effective than foam. There were no
differences between EVLA and surgery.
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Complications
The event rate for any procedural complication was similar for surgery and foam (7% for surgery and 6%
for foam), but at 6 months complications were significantly more frequent after foam than after surgery
(p< 0.05). Complications which occurred less frequently after surgery than after foam were lumpiness
(6 weeks and 6 months, p< 0.001), skin staining (6 weeks, p< 0.001; 6 months, p< 0.001), persistent
tenderness (6 weeks, p< 0.001) and headache (6 weeks, p= 0.047). Cutaneous numbness was more
common after surgery than after foam, at 6 weeks and 6 months (p< 0.001).
The event rate for any procedural complication was lower for EVLA (1%) than for either foam (7%) or
surgery (8%) (p< 0.001). At 6 weeks, the following occurred less frequently in patients undergoing EVLA
than in those undergoing foam: persistent bruising (p< 0.001), persistent tenderness (p< 0.001),
lumpiness (p< 0.001) and skin staining (p< 0.001). Cutaneous numbness occurred more frequently
following EVLA than following foam (6 months, p= 0.012).
In the surgery versus EVLA comparison, persistent bruising (p= 0.012), persistent tenderness (p= 0.011)
and lumpiness (p= 0.018) occurred more frequently in patients undergoing surgery at 6 weeks, whereas
lumpiness (p= 0.041) and skin staining (p= 0.009) were less frequent after surgery at 6 months. Finally,
cutaneous numbness was less common after EVLA than after surgery (p= 0.037) at 6 months.
Behavioural recovery
We developed an instrument, BRAVVO (Behavioural Recovery After treatment for Varicose Veins), in order
to (a) identify which behaviours are important to patients when recovering from varicose vein treatment,
and (b) measure how quickly patients return to performing these activities after treatment. Results showed
that patients were able to return to a wide range of behaviours more quickly following foam and EVLA
than after surgery.
Conclusions
This is the first RCT involving foam to evaluate disease-specific QoL as a primary outcome measure. It
shows that the health gain achieved with foam (AVVQ) was significantly lower than that for surgery at
6-months follow-up. No differences were noted between surgery and foam in the other QoL outcome
measures. EVLA was marginally superior to foam in terms of the SF-36 mental component, but there were
no differences in the other QoL measures at 6 months. EVLA and surgery were broadly equivalent in terms
of QoL at 6 months. Greater gains in QoL were observed for EVLA at 6 weeks than for surgery, and for
surgery and EVLA than for foam. Foam sclerotherapy produced the greatest NMB at 6 months, at a ceiling
WTP ratio of £20,000 per QALY gained. Markov modelling, based on the trial data and the limited data
currently available on longer-term recurrence rates, suggested that, at 5 years, EVLA is most likely to be
the treatment of choice for suitable patients, based on considerations of both clinical effectiveness and
cost-effectiveness. In a two-way comparison between foam and surgery, we found surgery to have the
higher probability of being cost-effective at 5 years.
The presence of residual varicose veins and the frequencies of some complications were higher after foam
than after either surgery or EVLA. This may have had an impact on QoL. However, participants returned to
normal activities more quickly following foam than following EVLA or surgery. Truncal vein ablation rates
were independently assessed and were found to be significantly lower in the foam group than in the
surgery and EVLA groups. The reduced ablation rates observed for foam may lead to an increased risk of
developing recurrent varicose veins in those patients, with associated reduced QoL and costs of further
treatment. However, the 5-year recurrence rates following foam are unknown.
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Strengths and weakness
The study experienced recruitment difficulties which led to a revision in the target size based on an interim
analysis. This did not lead to any reduction in the predefined clinically important difference in QoL, but
may have disadvantaged the EVLA arm, which had reduced power.
Following an unselected screening process, 43% of patients were found to be ineligible for randomisation.
Of these, 30% were excluded because they would not be offered treatment in the NHS (i.e. they were
asymptomatic, had no truncal reflux or had current thrombosis) and a further 28% had recurrent varicose
veins. Less than 20% were excluded because the vein diameter was too small or large, or too tortuous.
Thus, the results appear generalisable to the majority of patients undergoing treatment of primary varicose
veins in the NHS.
Despite the fact that many eligible patients chose not to take part, those who did appear broadly similar to
those in other RCTs, with the exception that there was a lower-than-expected proportion of females. The
CEAP classification grade, VCSS (pre/post treatment) and QoL (pre/post treatment) were similar to those in
other RCTs. The QoL values were also similar to those published in NHS England patient-reported outcome
measures. Although the complete success rates for the GSV are at the lower end of those published in
other RCTs, many studies defined ‘technical success’ as the combination of complete ablation and partial
success with no reflux. The overall ‘technical success’ rate for CLASS is comparable (91% for EVLA and
82% for surgery). The results for foam (67% complete and partial with no reflux) remain lower than in
some studies, but are comparable with those of two RCTs.
Overall summary
We believe that the results of this trial are generalisable to patients with primary varicose veins who are
suitable for treatment with EVLA, foam or surgery. Our results suggest that EVLA should be considered as
the preferred option in terms of both clinical outcomes at 6 months and estimated 5-year cost-effectiveness.
Recommendations for future research
Long-term outcome data from RCTs on QoL, recurrence rates and costs are required for foam and other
endovenous techniques, compared against each other and against surgery.
Trial registration
This trial is registered as ISRCTN51995477.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Health Technology Assessment-commissioned call
The original application for this study was submitted in 2006 in response to a Health Technology
Assessment (HTA) programme-commissioned call (06/45) for studies involving foam sclerotherapy. The call
specified a primary outcome of quality of life (QoL) at 6 months. As a result of this call, the Comparison
of LAser, Surgery and foam Sclerotherapy (CLASS) trial was funded. This first chapter reflects the NHS
practice and the evidence available at that time. The second chapter discusses changes in NHS practice and
relevant literature published since 2006.
The burden of the problem
The treatment of patients with varicose veins results in a considerable workload and financial burden
to the NHS. Visible varicose veins occur in up to 40% of men and 32% of women.1 This resulted in
approximately 37,500 operations being performed in the year April 2005 to March 2006 in England
alone.2 Approximately 20% of these operations are for recurrent varicose veins.3 Varicose veins may result
in pain, discomfort, itchiness and skin changes.
Throughout the UK prior to 2006, there were considerable variations in access to treatment for
uncomplicated varicose veins. This may have been due to a belief on the part of those commissioning
services, and some vascular surgeons, that it was a cosmetic procedure.4 This was based on the results of a
community-based study which showed no relationship between the presence of varicose veins, reflux in
the main truncal veins and symptoms.5 However, several studies had shown that many patients with
varicose veins had reduced QoL, which was improved following treatment.6–9 A randomised controlled
trial (RCT) of surgery versus conservative management of patients with uncomplicated varicose veins
estimated that the incremental cost per quality-adjusted life-year (QALY) gained was £4682, with a
70% probability that the cost per QALY would be lower than the National Institute for Health and Care
Excellence (NICE) threshold of £20,000.10
Treatment options
At that time, the established mainstay of treatment for incompetent varicose veins was surgery in the form
of saphenofemoral junction (SFJ) ligation or small saphenous vein (SSV) ligation, stripping and multiple
phlebectomies of non-trunk varicosities. Evidence at the time suggested a recurrence rate at 5 years for this
kind of conventional surgery of 32% for great saphenous veins (GSVs) and 50% for small saphenous veins.3
From the time of their introduction around 2000, foam sclerotherapy, endovenous laser ablation (EVLA)
and radiofrequency ablation (RFA) had emerged as possible alternative treatment options that could be
carried out under local anaesthetic. Foam sclerotherapy, EVLA and RFA aim to reduce the surgical trauma,
bruising, scarring and time off work associated with conventional surgery. By 2006, NICE had published
interventional procedures guidance on all these procedures, stating that there was adequate evidence on
their safety and efficacy for use in the NHS.11–13 These newer interventions had the potential to increase
throughput of varicose vein patients without the need for expensive operating theatre facilities. However,
this benefit may be offset by the need for the patient to return for further treatment.
In 2006, there were only two completed RCTs comparing the newer treatments against surgery, both
with limited follow-up. One had been published,14 whereas the other, carried out by one of the CLASS
co-applicants, had not.15 These studies are discussed below (see Foam sclerotherapy and Endovenous laser
ablation). Critics of the newer procedures pointed to the unknown effect of not treating tributaries at the
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1
saphenopopliteal junction and SFJ (an accepted principle of surgery aimed at minimising recurrence) and
the need for several treatment sessions compared with ‘one-stop’ surgery.
Despite uncertainty about clinical effectiveness and cost-effectiveness, the use of these newer treatment
options was increasing in the UK as alternatives to conventional surgery. A survey in 2006 of members
of the Vascular Surgical Society of Great Britain and Ireland and the Venous Forum of the Royal Society of
Medicine revealed that the vast majority of surgeons offered conventional surgery to NHS patients, with
27% of surgeons offering foam sclerotherapy, 19% offering EVLA and 3% offering RFA.16 The following
sections describe each of these treatments.
Foam sclerotherapy
Foam sclerotherapy is a development of conventional liquid sclerotherapy, aimed at more extensive and
reliable ablation of veins through a process of chemical phlebitis. In 2006, use of foam sclerotherapy
represented an ‘off-licence’ use of the licensed sclerosant. Several different liquid sclerosants of varying
concentrations were being mixed with air to produce foam. The use of foam rather than the liquid
sclerosant allows increased contact with the endothelium, and less mixing and dilution with venous blood.
However, the foam could vary in consistency, which may affect efficacy.17 Foam sclerotherapy induces
irritation of the endothelium, leading to thrombosis.
A systematic review of the safety and efficacy of foam found that foam appeared efficacious in terms of
obliterating the main trunk veins,18 but more than one treatment session may be required to achieve this.
In a series of 500 patients, Cabrera19 achieved obliteration of the GSV in 81% of cases; 86% of patients
achieved this after one injection, while 11% required two injections and 4% required a third. Other
published data indicated that only 43% of patients undergoing foam sclerotherapy were adequately treated
in a single treatment, with 48% requiring two sessions and 9% more sessions.20 Across the studies included
in the review, the median rate of recurrence or development of new varicose veins up to 10 years ranged
from 3% to 28%, but the risk of recurrence or development of new veins was not significantly different
to that of comparator treatments.18 The authors concluded that there was insufficient evidence to compare
the effectiveness of foam sclerotherapy reliably with other minimally invasive therapies or surgery.18
In 2006, there was only one RCT of a commercial preparation for foam sclerotherapy [Varisolve® polidocanol
microfoam (BTG International, London, UK)], which was a licensed product in which sclerosant was mixed
with gas (oxygen and carbon dioxide). This was a three-arm study of 710 patients, which compared
Varisolve® against either sclerotherapy (liquid or investigator-generated foam) or conventional surgery
(ligation and stripping of the GSV).14 No differences were detected in the primary outcome of technical
success (ablation of the GSV) at 3 months. At 12 months, technical success was slightly higher in the surgery
than in the Varisolve® group (86% vs. 79%, p= 0.11). Following Varisolve® foam sclerotherapy, patients
required a median of 2 days to return to ‘normal activities’ compared with 13 days following surgery.
QoL was not assessed. No RCTs were identified comparing foam sclerotherapy with EVLA.
The main safety concern regarding foam sclerotherapy was the potential for the foam to enter the deep
venous system, with the risk of deep-vein thrombosis (DVT), and also to enter the systemic circulation,
so reaching the heart and possibly the eye or brain via an atrial septal defect, which is present in 25% of
the population. As a result, the NICE guidance for foam sclerotherapy recommended special arrangements
for consent, audit and research,13 and limits were recommended on the amount of foam injected per
session,21 necessitating additional treatment sessions to deal with non-truncal varicosities. In the systematic
review, the incidence of DVT following treatment varied from 0.3% to 3%, while transient visual
disturbance occurred in up to 2.8% of patients and transient ischaemic attack in 0% to 0.3% of patients.18
The review reported one case of ischaemic stroke occurring immediately after injection, with partial recovery
at 3 months; this occurred in a patient with a patent foramen ovale.18 Other potential adverse events include
thrombophlebitis (15–58%); early skin discolouration over the treated vein (11–50%); skin necrosis
(0.01–0.9%); ulceration (0–7%); and allergy (0.3%).18
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Endovenous laser ablation
Endovenous laser ablation results in thermal ablation of the truncal veins. Most studies describing EVLA
had used either 810- or 940-nm diode lasers based on a haemoglobin absorption peak to red/infrared
light of 800–1000 nm.22 The heat generated by the laser was believed to result in thermal damage to the
endothelium and subendothelial layer, resulting in focal coagulative necrosis and shrinkage and leading
to thrombotic occlusion of the vein.23 However, histological studies at 3 and 6 months following EVLA
indicate failure of endothelial regeneration and progressive damage to the muscle layers of the vein wall,
resulting in further shrinkage and occlusion.24 Studies had shown that between 30% and 99% of patients
receiving EVLA require subsequent treatment for non-trunk varicosities.22
It had been shown that successful occlusion was dependent on the energy used and could be achieved in
all veins treated with ≥ 70 J/cm.25 A RCT carried out by one of the CLASS co-investigators reported on
118 patients randomised to EVLA or surgery.15 At 3-months follow-up, abolition of reflux was achieved
in 98% of EVLA and 92% of surgical patients. EVLA patients had a quicker return to normal activities
and work (p= 0.01). Improvements in the Aberdeen Varicose Vein Questionnaire (AVVQ) score,
a disease-specific quality of life instrument, were similar in both groups. At 1 year follow-up, there was
recanalisation in a minority of the EVLA-treated GSVs, but SFJ reflux remained abolished in 86% of
patients who were available for follow-up.
A systematic review26 assessed the effectiveness and safety of EVLA in 13 case series involving 1289 patients
(1631 limbs) with duplex-proven primary venous reflux; the mean length of follow-up ranged from 1 to
19 months. EVLA was effective in the short term, with occlusion of the GSV occurring in 88–100% of limbs.
Mundy et al.26 concluded that EVLA appeared to be safe, although there were two reported cases of
incorrect positioning of the laser (within the deep venous system), which produced no long-term
complications, and one reported DVT. Other reported complications of EVLA included superficial laser
burns in 5% of patients in one study which used a very high laser energy; ecchymosis or skin discolouration
(23–100% of limbs), which was generally self limiting; phlebitis in 1.6% of limbs; and saphenous
paraesthesia in 1–36.5% of limbs.26 The Australian Medical Services Advisory Committee, in its 2003
assessment report, concluded that EVLA and conventional surgery were similar in terms of safety.27
The Comparison of LAser, Surgery and foam Sclerotherapy trial
It was against this background of continuing uncertainty about the relative clinical effectiveness and
cost-effectiveness of foam sclerotherapy compared with surgery that the National Institute for Health
Research (NIHR) HTA programme commissioned a call and the CLASS trial was funded. The CLASS trial
was an 11-centre, three-arm comparison of foam sclerotherapy, EVLA and surgery, comparing the
relative clinical effectiveness and cost-effectiveness of the three procedures. We chose to include EVLA
in addition to foam sclerotherapy in our application because EVLA and foam were the most commonly
used minimally invasive treatment options within the NHS at that time. We did not include RFA as,
at the time of applying for funding, this technique was more costly and less suited to local anaesthesia on
account of the contact time required between the probe and vein endothelium. However, developments
since then have made RFA faster and suitable to be performed under a local anaesthetic. EVLA and RFA
are now considered to be comparable techniques in terms of outcome.28
Since the start of the CLASS trial, a further five RCTs comparing foam sclerotherapy against surgery and/or
EVLA have been published,29–33 and also 10 RCTs which have compared EVLA against surgery.15,29,31,34–40
These, and relevant changes in NHS practice regarding the treatment of varicose veins, are reviewed in
Chapter 2. Despite these new studies, the 2013 NICE guidelines on the management of varicose veins
found that the evidence comparing conventional surgery with foam sclerotherapy or with endovenous
thermal ablation was of low quality.28
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The structure of the remainder of the monograph is as follows. Chapter 3 describes the methodology
underpinning the CLASS trial. In Chapter 4 we describe the trial participants. Chapters 5 and 6 present the
clinical effectiveness results up to 6 months. In Chapter 7, we discuss the clinical effectiveness results.
Chapter 8 describes the development of an instrument to assess return to normal activity in terms of
behavioural recovery and the trial results in terms of this outcome. Chapter 9 presents the within-trial
cost-effectiveness analysis. In Chapter 10, we present economic modelling beyond the 6-month follow-up
period. Finally, the overall results of the study are discussed in Chapter 11, together with implications for
practice and recommendations for future research.
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Chapter 2 Changes in practice and literature
update
Recent changes in practice
Since the start of the CLASS trial, several surveys have shown an increased use of newer endovenous
treatment options in the NHS.16,41,42 Since 2006, specific codes for the minimally invasive treatment options
have been introduced and Hospital Episode Statistics have shown that the most commonly used minimally
invasive treatment is foam sclerotherapy, followed by EVLA.43 However, overall, 70% of those having
treatment of varicose veins in the NHS still undergo surgery.43
Quality of life as an outcome measure has become increasingly important; the standard NHS contract for
acute services in England requires that all licensed providers of NHS-funded varicose vein procedures ask
patients to complete patient-reported outcome measure (PROM) questionnaires before and after surgery.
This includes the disease-specific AVVQ, the generic European Quality of Life-5 Dimensions (EQ-5D) index
and EQ-5D visual analogue scale (VAS). The PROMs data have shown that varicose vein treatment results in
significant improvement in health for patients, with over 80% experiencing an improvement in the AVVQ
and almost a 50% reduction in the AVVQ score from pre-operative values.44 Despite this clear benefit, the
number of varicose vein treatments being performed in the NHS has fallen (from approximately 36,650 in
2009–1028 to approximately 27,600 in 2011–122) owing to rationing of treatment, as a result of restrictions
in referrals from primary to secondary care.
Literature update: randomised controlled trials of foam
sclerotherapy alone versus surgery or endovenous treatments
EMBASE (1980 to week 37, 2012), Ovid MEDLINE (1946 to September week 2, 2012) and Ovid MEDLINE
In-Process & Other Non-Indexed Citations were searched using terms designed to identify randomised
comparisons of foam sclerotherapy, surgery and EVLA. In addition, the HTA database, Database of
Abstracts of Reviews of Effects (DARE) and Cochrane Database of Systematic Reviews (CDSR) were
searched using similar terms. Identified abstracts were screened for relevant papers. All searches were
updated in 2013. In addition, the reference lists of identified papers were searched for any relevant papers.
At the time of submitting the proposal, there was only one RCT in which foam sclerotherapy was
compared against surgery;14 by mid-2013 a further five RCTs had been published comparing foam
sclerotherapy with surgery and/or thermal ablation (Table 1).29,30–33 All these studies involved treatment to
the GSV only. In two, foam sclerotherapy with concomitant phlebectomies was compared with EVLA.29,32
The outcome of these studies in terms of QoL, technical success, return to normal activities, Venous
Clinical Severity Scores (VCSSs), recurrence rates and costs are discussed below.
In addition, there are four further RCTs which have compared foam sclerotherapy of the GSV with ligation
of the SFJ against conventional surgery.45–48 These are not discussed further because ligation of the SFJ is
not considered minimally invasive treatment, and therefore its use with foam undermines the value of
foam as a simple, minimally invasive treatment option. In addition, this type of treatment is not one which
has been adopted in UK practice.
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Quality of life
Quality of life was assessed in four of the above studies. In the study by Biemans et al.,31 there was no
difference in QoL [assessed by the disease-specific Chronic Venous Insufficiency Quality of Life
Questionnaire (CIVIQ) or the EQ-5D] at 3 months or 1 year. At 3 months, there was no significant
difference in AVVQ scores between treatment groups.32 At 1 year, Rasmussen et al.29 found significant
improvements in the AVVQ and Short Form questionnaire-36 items (SF-36) scores in all treatment groups,
but no difference between any of the treatment groups. Similarly, Shadid et al.33 found no significant
difference in the EQ-5D scores between treatment groups at 2 years.
Technical success
This was assessed in all six studies at various time points up to 2 years. At 1 year, the occlusion rate for
foam sclerotherapy (73%) was significantly lower than for either surgery (88%, p< 0.02) or EVLA (89%,
p< 0.02).31 At 3 months, the technical success rate was found to be similar for foam sclerotherapy and
EVLA (above-knee GSV occlusion rate 69% vs. 74%, p= 0.596).32 At 6 months, Figueiredo et al.30
found no statistically significant difference in technical success between patients randomised to foam
sclerotherapy and those randomised to surgery (vein obliteration in 90% vs. 78%).
In the study by Wright et al.,14 the technical success at 12 months was slightly higher in the surgery group
(86%) than in the Varisolve® group (84%), but this did not reach statistical significance. Rasmussen et al.29
found that the technical success rates at 12 months were significantly lower in patients receiving foam
(84%) than in those receiving EVLA (94%), RFA (95%) and surgery (97%) (χ2 p< 0.001).
TABLE 1 Randomised controlled trials of foam sclerotherapy (alone) vs. conventional surgery or EVLA for the
treatment of primary varicose veins
Study
Number of patients,
centres, vein involvement Comparatorsa Primary outcomes Other outcomes
Biemans
201331
233, single centre, GSV Foam sclerotherapy vs. EVLA
vs. surgery
Anatomical success at
1, 3 and 12 months,
post-operative
neovascularisation
CEAP classification,
complications, QoL
(CIVIQ, EQ-5D)
Lattimer
201232
100, single centre, GSV Foam sclerotherapy with
phlebectomies vs. EVLA with
phlebectomies
Technical success at
3 months
Cost, VCSS, QoL (AVVQ)
up to 3 months, return
to normal activities
Shadid
201233
460, three hospital sites,
GSV
Foam sclerotherapy with
delayed phlebectomies or
further foam sclerotherapy
vs. surgical stripping with
high ligation
2-year recurrence,
defined as reflux
combined with
venous symptoms
Recurrent reflux,
symptoms, QoL (EQ-5D),
adverse events, direct
hospital costs up to
2 years
Rasmussen
201129
500, two centres, GSV Foam sclerotherapy with
phlebectomies vs. EVLA, RFA
or surgery
Technical success at
1 year (GSV closure)
Pain, absence from work
and normal activity, QoL
(AVVQ, SF-36), VCSS,
recurrence rates up to
1 year
Figueiredo
200930
60, single centre, GSV and
SSV
Foam sclerotherapy vs.
surgery with phlebectomy
VCSS up to 6 months Technical success at
6 months, treatment
complications
Wright
200614
710, multicentre, GSV and
SSV
Foam sclerotherapy
(manufactured foam:
Varisolve®) vs. surgery or
sclerotherapy (liquid or
investigator-generated foam)
Technical success at
3 months
Technical success at
12 months, return to
normal activities
CEAP, clinical, etiological, anatomical, pathological; CIVIQ, Chronic Venous Insufficiency Quality of Life Questionnaire;
SF-36, Short Form questionnaire-36 items; VCSS, Venous Clinical Severity Score.
a In studies where surgery was the comparator, this involved high tie, stripping and phlebectomies.
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Duplex findings at medium-term follow-up
This has been assessed by Shadid et al.,33 who found the presence of reflux to be greater in patients
treated with foam sclerotherapy than in those receiving surgery at 2-year follow-up (35% vs. 21%,
p= 0.003).
Return to normal activities
This was reported in three of the five studies. Wright et al.14 found that the time to return to normal
activities following treatment was shorter in the foam sclerotherapy group than in the surgical group
(median 2 vs. 13 days, p< 0.001). In the study by Rasmussen et al.,29 the median time to return to normal
activities was shorter in the patients in the foam sclerotherapy and RFA groups (1 day in each) than in the
EVLA (2 days) and surgery (4 days) groups (p< 0.001). The study by Lattimer et al.32 found that the mean
time to return to normal activities was shorter following foam (3 days) than EVLA (7.5 days) (p= 0.11).
Venous Clinical Severity Scores
The VCSSs were assessed in three studies, and improved significantly after the procedure in all groups,
with no differences noted between groups.29,30,32
Clinical, etiological, anatomical, pathological classification
One study considered the clinical, etiological, anatomical, pathological (CEAP) classification.31 Although the
CEAP classification improved after foam sclerotherapy, EVLA and surgery, there was no difference between
groups at 3 or 12 months.
Clinical recurrence rates
In the study by Rasmussen et al.,29 the 1-year clinical recurrence rates in those randomised to foam,
surgery, EVLA and RFA were similar (14%, 15%, 12% and 7% respectively, p= 0.155).
A further study defined clinical recurrence in terms of a combined end point of reflux combined with
venous symptoms at 2 years.33 This end point was found to occur equally in patients randomised to foam
sclerotherapy (11%) or surgery (9%) (p= 0.407).
Costs
These were reported in three of the studies, with all three reporting that foam was the least costly option.
Lattimer et al.32 calculated the cost of foam sclerotherapy to be approximately one-third of the cost of
EVLA. In the study by Shadid et al.,33 hospital costs over a 2-year period in patients receiving foam
sclerotherapy were less than half of those in the surgery group. Rasmussen et al.29 found that foam
sclerotherapy was the cheapest option, and that EVLA and surgery were more expensive.
Literature update: randomised controlled trials comparing
endovenous laser ablation with surgery
At the time of submitting the proposal, there was only one completed (but unpublished) RCT in which
EVLA was compared against surgery.15 By mid-2013, a further eight RCTs had been published which
compared EVLA against surgery of the GSV,29,31,34–36,38–40,49–51 and one which compared EVLA against
surgery to the SSV37 (Table 2). Two of these studies31,49 also included foam sclerotherapy; these are the
only currently published studies which have compared foam sclerotherapy against EVLA. The outcomes of
these studies in terms of QoL, technical success, return to normal activities, VCSS, recurrence rates and
costs are discussed below.
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TABLE 2 Randomised controlled trials of EVLA against conventional surgery
Study
Number of patients,
centres, vein involvement Comparatorsa Primary outcomes Other outcomes
Biemans
201331
233, single centre, GSV Foam sclerotherapy
vs. EVLA vs. surgery
Anatomical success at
1, 3 and 12 months,
post-operative
neovascularisation
CEAP, complications, QoL
(CIVIQ, EQ-5D)
Samuel
201337
106, single centre, SSV EVLA with
phlebectomies vs.
surgery
Technical success
(abolition of reflux at
6 weeks)
Technical success, return to
work and normal activities,
complications, VCSS, QoL
(AVVQ, EQ-5D, SF-36) up
to 1 year
Rass 201238 400, two centres, GSV EVLA vs. surgery Clinically recurrent
varicose veins at
2 years
Duplex-detected
saphenofemoral
recurrence, QoL (CIVIQ),
adverse events, clinical and
functional outcome (HVVSS)
Flessenkamper
201239
449, three centres,
GSV
EVLA with
phlebectomies± high
ligation vs. surgery
Venous reflux at
proximal section of
the GSV at 2 years
(only 2-month data
published)
Complications (including
post-operative ecchymosis),
CEAP
Carradice
201135,50
280, single centre, GSV EVLA with
phlebectomies vs.
surgery
QoL (SF-36) Clinical recurrent varicose
veins, duplex-detected
reflux, technical success,
VCSS, QoL (AVVQ, EQ-5D),
return to work and normal
activities
Rasmussen
201129
500, two centres, GSV EVLA with
phlebectomies vs.
foam, RFA or surgery
Technical success
(GSV closure) at
1 year
Absence from work and
normal activity, QoL
(AVVQ, SF-36), VCSS,
recurrence rates up to
1 year
Pronk 201040 122, single centre, GSV EVLA with delayed
sclerotherapy vs.
surgery
Clinical recurrence
and technical success
up to 12 months
Recovery, complications,
CEAP
Christenson
201034
200 limbs, single centre,
GSV
EVLA vs. surgery Duplex technical
success at 2 years
VCSS, QoL (AVVQ, SF-36)
Darwood
200815
118, single centre, GSV EVLA with delayed
foam sclerotherapy
vs. surgery
Duplex technical
success, QoL (AVVQ)
at 3 months
Return to normal activity
and work, technical
success, QoL (AVVQ) at
1 year, VCSS
Rasmussen
2007,36 2010,49
201351
121, two centres, GSV EVLA with
phlebectomies vs.
surgery
Technical success,
clinical recurrence at
6 months, 2 years
and 5 years
VCSS, QoL (AVVQ, SF-36),
costs
HVVSS, Homburg Varicose Vein Severity Score.
a In studies where surgery was the comparator, this involved high tie, stripping and phlebectomies.
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Quality of life
Eight studies reported QoL, using instruments which included the AVVQ, SF-36, EQ-5D and the
disease-specific CIVIQ. In all of these studies, no significant difference was noted in patients randomised to
EVLA or surgery at various follow-up time points ranging from 3 months to 5 years.15,29,31,34,35,37,38,50,51
Disease-specific QoL was found to be reduced in patients who developed a clinical recurrence compared
with those who did not (p= 0.001).35 In this study, the clinical recurrence rates were lower in patients
who received EVLA than in those who underwent surgery at 1-year follow-up (p< 0.001).35
Technical success
This was assessed in all 10 of the studies at various time points. In the study by Flessenkamper et al.,
technical success (no inguinal venous reflux) was achieved after 2 months in 92% of the EVLA group,
98% of the EVLA/high-tie group and 100% of the standard surgery group.37,39 Darwood et al.15 found
that, at 3-months follow-up, abolition of reflux was achieved in 94% of EVLA and 88% of surgical
patients (p= 0.227), and that, by 1 year, technical success had reduced in both groups. At 6 months,
Rasmussen et al.36 reported no significant difference in technical success at 1 year (94% in the EVLA group
and 98% in the surgery group, p> 0.05). In the later study by Rasmussen et al.,29 technical success was
94% following EVLA compared with 96% following surgery (p= 0.543). Biemans et al.31 found no
difference in anatomical success following EVLA (89%) or surgery (88%).
In the study by Carradice et al.,35 the technical success rate at 6 weeks was slightly lower in patients
randomised to surgery (92%) than in those who underwent EVLA (99%) (p= 0.005). In the study by
Pronk et al.,40 the technical success was similar in both surgery (90%) and EVLA (91%) groups at 1 year.
In the study by Christenson,34 initial technical success (no detectable reflux at 12 days) was 99% in the
EVLA group and 100% in the surgery group. The one study involving patients undergoing treatment to
the SSV system found that the technical success (abolition of reflux) was greater in the EVLA group (96%)
than in the surgery group (72%) at 6 weeks (p< 0.001).37
Duplex findings at medium-term follow-up
Over a 2-year follow-up, recanalisation (partial or complete) occurred in 7% of the EVLA group and none
of the surgery group (p= 0.051).34 Rass et al.38 found that patients in the EVLA group had a higher rate of
duplex-detected saphenofemoral reflux than those undergoing surgery at 2 years (18% vs. 1%, p< 0.001).
At 5 years, there was no difference in the proportion of open refluxing GSVs between EVLA (18%) and
surgery groups (10%) (p= 0.21).51
Return to normal activities
In the study by Darwood,15 patients randomised to EVLA had a quicker return to normal activities and
work than those randomised to surgery (p= 0.001 and p= 0.005 respectively). Similarly, Rass et al.38 found
that patients having EVLA returned to work more quickly than those having surgery; this was despite there
being no difference in return to basic physical activities between the groups. Pronk et al.40 found that
recovery (mobility, self-care and daily activities) was better in patients randomised to surgery than in those
randomised to EVLA at day 7 (p< 0.05); however, there was no difference in the mean number of days
taken to restart daily activities, work and sport between the groups. In two studies by Rasmussen et al.,29,36
there was no difference in return to normal activities and work between patients randomised to EVLA and
surgery. In the one study to involve patients undergoing SSV treatment,37 patients who had EVLA returned
to normal activities and work earlier than those undergoing surgery (p< 0.001).
Venous Clinical Severity Score
The VCSS was assessed in six studies, and scores improved significantly after treatment in all groups, with
no differences noted between treatment groups.15,29,34,37,49,51 In the study by Rass et al.,38 an alternative
assessment tool (the Homburg Varicose Vein Severity Score) was used; again there was no difference
between treatment groups.
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Clinical, etiological, anatomical, pathological classification
Three studies considered CEAP as an outcome measure. There was no difference in CEAP between
intervention groups at 2 months39 and 1 year31,40 in patients undergoing EVLA versus surgery.
Clinical recurrence rates
These were reported in five studies. The clinical recurrence rates at 1 year, in the study by Pronk et al.,40
were approximately 10% in both the EVLA and surgery groups. In contrast, Carradice et al.35 found the
clinical recurrence rate at 1 year to be lower after EVLA (4%) than after surgery (20%) (p< 0.001).
Rass et al.38 reported recurrent varicose veins on clinical examination in 16.2% of the EVLA group versus
23.1% of the surgery group at 2 years (p= 0.15). Higher 2-year clinical recurrence rates were reported by
Rasmussen et al.49 (surgery 37%, EVLA 26%). In the 5-year results from this study, there was no difference
in recurrence rates (surgery 55%, EVLA 47%, p= 0.72).51 In the study by Rasmussen et al.29 where four
different treatment options were compared, clinical recurrence rates at 1 year were reported as 14%
following foam, 15% following surgery, 12% following EVLA and 7% following RFA (p= 0.155).
Costs
In addition to the Rasmussen study,29 which was discussed previously, the group has reported another
study which assessed the costs of EVLA versus surgery.36 In both studies, the procedure-related costs were
higher for EVLA than for surgery.
Literature update: meta-analysis comparing foam with
endovenous laser ablation and surgery (technical success,
clinical recurrence rates and cost)
Treatment of recurrent varicose veins accounts for 20% of venous procedures in the NHS, and thus the
long-term durability of any treatment is important both for the patient and for economic reasons. It is
assumed that lower initial technical success rates will translate into higher clinical recurrence rates, reduced
QoL, the need for further treatment and thus an increased cost to the NHS in the long term. The NICE
meta-analysis of four studies comprising 966 randomised patients found that foam sclerotherapy was
associated with a higher prevalence of reflux at 3–12 months (compared with conventional surgery), but
there was not a large enough effect to show clear advantage for surgery.28
A meta-analysis of 72 predominantly observational studies (average follow-up 32 months) found that foam
sclerotherapy was less effective than surgery in terms of technical success rates, and EVLA was more
effective than surgery, foam sclerotherapy or RFA.52 A further meta-analysis found that foam sclerotherapy
was associated with a higher clinical recurrence rate in patients with GSV incompetence than the other
newer treatments.53
A cost–utility analysis found that the incremental cost-effectiveness ratios (ICERs) at 5 years for foam
sclerotherapy (vs. conservative care), EVLA (vs. foam sclerotherapy) and RFA (vs. EVLA) were £1366, £5799
and £17,350 per QALY respectively.54 The ICER for conventional day-case surgery compared with RFA was
£19,012. A further analysis undertaken by NICE found that endothermal treatment (i.e. EVLA or RFA) is
the most cost-effective strategy, with an ICER of endothermal treatment compared with foam of £3161.28
In both these analyses, the recurrence rate following the newer treatment options were based on
estimates, owing to the lack of published data.
The systematic reviews and meta-analysis concluded that long-term data on clinical efficacy (particularly
with regard to recurrence), QoL and costs are required from large high-quality prospective RCTs of foam
sclerotherapy and other endovenous techniques, compared against each other and against surgery.52,53,55,56
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Chapter 3 Trial design
In this chapter, we describe the aims and objectives of the CLASS trial, and the trial design. In presentingthis information, we have followed the Consolidated Standards of Reporting Trials – patient-reported
outcomes (CONSORT PRO) guidance.57 We also provide the sample size calculation and describe the
statistical analysis for the clinical effectiveness data. The methods for the cost-effectiveness and economic
modelling chapters are contained within those individual chapters.
Aims and objectives
The primary objective of the CLASS trial was to compare the clinical effectiveness and cost-effectiveness of
two minimally invasive treatment modalities performed under local anaesthetic – foam sclerotherapy of the
main great or small saphenous truncal and non-truncal varicosities, and EVLA including delayed foam
sclerotherapy of non-truncal varicosities – against surgery, in respect of disease-specific QoL (as measured
by the AVVQ) and generic QoL (as measured by the EQ-5D and SF-36) for each intervention at 6 months
(and ultimately to 5 years) and cost-effectiveness as cost per QALY gained.
Following discussion with the HTA programme, the primary outcomes were extended to involve an analysis
of EVLA versus foam sclerotherapy. Thus, the study is a three-way comparison of foam sclerotherapy, EVLA
and surgery. The 5-year results will be presented at a later stage.
The secondary objectives were to compare the two novel interventions against conventional surgery in
respect of:
l clinical success, as determined by residual varicose veins, VCSS, complication rates and return to
normal activities
l technical success (duplex scan-verified partial or complete ablation of, or the presence of reflux in, the
main great or small saphenous trunk veins) at 6 months and any development of deep venous
incompetence and neovascularisation
l the cost to the NHS and patients of each intervention and any subsequent care, including projected
costs to 5 years, based on the 6-month costs via Markov modelling.
Overview of trial design
Comparison of LAser, Surgery and foam Sclerotherapy is a pragmatic, parallel-group trial designed to
assess the clinical effectiveness and cost-effectiveness of (a) foam sclerotherapy of the main great or small
saphenous trunk and non-trunk varicosities, and (b) EVLA of main truncal varicosities, including delayed
foam sclerotherapy of non-trunk varicosities, when compared against surgery (the ‘control’ treatment).
There were two strata; a recruitment site’s placement in one or the other stratum depended on the
treatment options available at that site. Stratum A included eight hospitals which offered all three
treatment options; thus, participants recruited in hospitals in this stratum were randomised to one of the
three interventions. Stratum B included three hospitals which offered two treatment options (foam
sclerotherapy and surgery), and patients recruited in hospitals in this stratum were randomised to one of
these interventions.
The trial design is detailed in Figure 1.
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Participants
Identification of patients
Patients referred from primary care to vascular surgery departments in 11 UK hospitals were identified by
either a member of the clinical service or the local research nurse, and were recorded on the study log
at each site.
Inclusion criteria
Adult patients (aged over 18 years) referred to the surgical outpatient department for treatment of primary
varicose veins with symptomatic (CEAP grade 2 or above) great or small saphenous main truncal
incompetence (reflux > 1 second on duplex scanning) were eligible for inclusion.
Exclusion criteria
The following exclusion criteria applied:
l current DVT, acute superficial vein thrombosis
l allergy to sclerosant
l pregnancy or breast feeding
Excluded 
• Not meeting inclusion criteria
• Refusal to participate 
Assessed for eligibility
Reflux > 1 second on ultrasound, CEAP grade 2 or above
Consented 
Baseline assessment and baseline questionnaire
Randomised
• Stratum 1: surgery vs. foam sclerotherapy vs. EVLA with foam sclerotherapy 
• Stratum 2: conventional surgery vs. foam sclerotherapy 
Foam sclerotherapy
Adults age 18 + years with symptomatic primary varicose veins
with long or short saphenous main stem incompetence  
Referred to the surgical out patient department
EVLA with foam 
sclerotherapy
Surgery
6-week follow-up
Foam sclerotherapy to truncal
veins or non-truncal
varicosities
Foam sclerotherapy to 
residual non-truncal
varicosities
6-week follow-up 
6-month follow-up 6-month follow-up 
6-week follow-up
6-month follow-up
FIGURE 1 Overview of trial design.
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l history of hypercoagulability
l arterial disease (ankle–brachial pressure index < 0.8)
l inability to mobilise post procedure
l needle phobia
l GSV or SSV < 3mm in diameter or > 15mm
l tortuous veins considered to be unsuitable for EVLA owing to difficulties in passing the guide wire
l inability to complete study questionnaires
l history of migraines which are frequent, or migraines which are severe enough to require hospitalisation
l other contraindications mentioned in the sodium tetradecyl sulphate (STS) (Fibrovein®, STD
Pharmaceutical) prescribing information leaflet: varicosities caused by pelvic or abdominal tumours,
cardiac failure, pulmonary oedema, local or systemic infection
l patients who were not fit for a general anaesthetic because of significant systemic disease, morbid
obesity or other causes.
As all varicose vein treatments should be used with care in patients taking oral contraceptives (OCs) or
hormonal replacement therapy (HRT), the surgeon either asked the patient to discontinue the OC or HRT
prior to treatment or prescribed heparin prophylaxis therapy.
Recruitment process
In trial centres where potentially eligible patients could be identified in advance of their attendance at
an outpatient clinic, the postal summary information sheet (see Appendix 1, which contains all study
paperwork, case report forms and questionnaires) was sent to them in advance of their appointment.
Patients who were identified at an outpatient clinic were provided with the summary information sheet at
the clinic (see Appendix 1).
The surgeon informed potentially eligible patients about the CLASS study, the different treatments
available and the risks and benefits of the treatment options. The surgeon also provided patients with a
study information leaflet, and an information leaflet providing detailed information about the alternative
methods of treatment.
In some centres, the duplex scan was undertaken during this initial consultation; in such cases, only those
patients who were eligible on the basis of the results of this scan were informed about the study.
All patients attending an outpatient clinic were logged on the study clinic log. If the patient was potentially
interested in the study, his or her contact details were noted on the study clinic log. For patients who were
not eligible for the study, or who were not interested in taking part, we recorded the reason for this on
the study clinic log.
Around 1 week after the initial consultation, the research nurse telephoned patients who had indicated
that they were potentially interested in taking part in the trial to ascertain whether or not this was still the
case. If the patient was interested in taking part in the study, he or she was invited to a recruitment
appointment at the clinic to provide informed consent. If the patient did not undergo duplex scanning at
the initial consultation, this was undertaken at the recruitment appointment. Participants were asked to
complete a baseline questionnaire. The baseline case report form was also completed at this appointment.
In participants who presented with bilateral varicose veins, the more severely affected leg (as determined
by the participant) was nominated as the study leg. Where possible, the other leg was treated using the
same treatment modality as the study leg, either at the same time as the study leg was treated, or
sometime thereafter.
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In some circumstances (for example, where the duplex scan was completed at the initial consultation and
the patient lived a considerable distance from the recruitment clinic, or it was difficult for him or her to
attend a recruitment clinic), the consent form and baseline questionnaire were sent to the participant, who
was asked to complete these and return them by post. In these circumstances, the research nurse was
available, by telephone, to answer any questions about the study.
If patients wanted to consent to the study at their initial outpatient appointment, this was also permitted.
Randomisation and allocation to intervention
Participants were randomised using a computer-generated randomisation system managed by the Centre
for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. This was available to sites as a
web-based or telephone system.
In the eight recruitment sites which offered all three interventions (stratum A), participants were randomly
allocated 1 : 1 : 1 to EVLA, foam sclerotherapy or surgery using treatment allocation by minimisation.
In the three sites which offered only two of the interventions (stratum B), participants were randomly
allocated 1 : 1 to foam sclerotherapy or surgery. Each of these two strata (based on treatment options
available at the trial centre) had its own separate treatment allocation application. For each application,
the minimisation algorithm included centre, age (< 50 years, ≥ 50 years), sex, presence of GSV or SSV,
and unilateral or bilateral veins.
After randomisation, participants were placed on the appropriate waiting list. The aim was to keep
participants blinded to their treatment allocation until around 2 weeks prior to their treatment. Around
2 weeks prior to treatment, an appointment for treatment was issued by the hospital; at this time the trial
office also informed the participant of his or her randomisation. However, at some sites, local processes
meant that participants were informed of their randomisation by site staff in advance of this. The delay
in informing participants about their treatment allocation was an attempt to minimise the possibility of
unequal dropout between the arms.
A letter was sent to the participant’s general practitioner (GP) at trial entry to inform them that their
patient had agreed to participate in the trial. Around the time that the participant was informed of his or
her treatment allocation, a second letter was sent to the GP informing them of the allocation.
Trial interventions
Surgical treatment
The aim of surgical treatment is to perform saphenofemoral or saphenopopliteal ligation, ligate the groin
or popliteal tributaries, remove the incompetent main varicosed truncal vein through inversion stripping
and perform phlebectomies for non-truncal varicosities as a combined single procedure. Surgical treatment
was performed under a general or regional anaesthetic.
Foam sclerotherapy
The aim of foam sclerotherapy is to fill the incompetent vein with sclerosant under ultrasound guidance by
a process of chemical ablation. STS was used as the sclerosant; 3% was used for main truncal veins and
1% for non-truncal varicosities.
The patient was placed in the reverse Trendelenberg position. A needle was inserted into the incompetent
GSV or SSV under ultrasound control. The leg was then raised and sclerosant foam [via 2-ml double-syringe
Tessari technique, one part (0.5 ml) STS and three parts (1.5 ml) air, with at least 20 passages] injected.
Immediately after injection, it was recommended that there was no movement of the patient or leg for
2–5 minutes, no Valsalva manoeuvre and no muscle activation. In line with the European consensus
guidelines (published at the time of writing the protocol), a maximum of 12ml of foam was recommended
for use at one sitting.21
TRIAL DESIGN
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At the 6-weeks appointment, the need for further foam sclerotherapy to truncal and/or non-truncal veins
was assessed. The protocol allowed for a maximum of four treatment sessions of foam sclerotherapy to be
offered if this was required to treat all the varicose veins and varicosities.
Sodium tetradecyl sulphate was purchased from routine NHS suppliers by each recruitment site. At the
outset of the trial, the STS used was labelled as an investigational medicinal product (IMP) for use in
the trial. Part way through the study, a substantial amendment was approved such that routine stocks of
STS could be used in the trial and did not require to be labelled as an IMP.
Sodium tetradecyl sulphate was securely stored at room temperature or in a refrigerator in the ward,
clinic or theatre. Minimum and maximum temperatures were recorded regularly by the study nurse.
Temperature deviations were noted. STS would have been destroyed if the maximum storage temperature
had exceeded 40 °C (stability data given in the prescribing information leaflet show that STS is stable for
up to 6 months at 40 °C).
Endovenous laser ablation
The aim of EVLA is to destroy the incompetent vein by thermal ablation. EVLA involves cannulating the
GSV at the lowest point of incompetence (mid-calf for SSV) under ultrasound guidance. The leg was
treated flexed and externally rotated at the hip, with the knee slightly flexed. First a guide wire was
inserted and then a 5-Fr catheter passed over this with the tip positioned 0.5–1 cm distal to the junction.
The laser fibre was inserted as far as the tip of the catheter. The catheter was then withdrawn 2 cm so that
the laser fibre protruded beyond the catheter. The table was then placed in the Trendelenberg position,
and cold saline tumescent with lignocaine (Xylocaine®, AstraZeneca) infiltrated along the length of the
trunk vein. This provided anaesthesia, compression of the vein around the catheter and absorption of heat.
The laser fibre was fired continuously during stepwise or continuous withdrawal, aiming to achieve a
target delivery of at least 70 J/cm. EVLA was carried out under local anaesthetic.
The treatment protocol allowed for the immediate treatment of a below-knee incompetent GSV with foam
sclerotherapy if laser access was not possible at the site. If required, this was done at the same treatment
session to the level of the mid-calf.
In one of the study sites (Hull), the protocol allowed phlebectomies for non-truncal varicosities to be
performed at the same time as the EVLA.
At the 6-weeks appointment, the need for foam sclerotherapy to treat any non-truncal varicosities was
assessed. The protocol allowed a maximum of four treatment sessions of foam sclerotherapy to be offered,
if required, to treat all varicose veins.
Post-procedure compression
After all procedures, post-procedure compression was recommended for 10 days. For foam sclerotherapy,
an attempt was made to standardise the type of bandaging and stockings used but this was not possible
across all sites owing to local purchasing agreements.
Outcomes
The primary patient-reported outcome was disease-specific QoL (assessed at 6 months using the AVVQ58)
and generic QoL (assessed at 6 months using the EQ-5D and SF-36 physical and mental component scores).
The AVVQ is an instrument designed to assess the perceived health of patients with varicose veins, and
has been shown to be valid, reliable and responsive to change.9,59,60 It is used as the disease-specific
measure in the NHS PROMs.44,61 The instrument comprises 12 questions and a set of manikin legs, on
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which participants are asked to draw their veins. Possible scores range from 0 to 100, though scores close
to 100 can only be achieved if there are extensive veins covering the front and back of both legs.
The SF-36 has been validated and shown to be reliable.61 It is widely used to assess generic QoL across
different clinical conditions. The 36 questions in the SF-36 are scored as eight separate domains (vitality,
physical functioning, bodily pain, general health, role – physical, role – emotional, social functioning,
mental health) and as two summary scores (physical component summary, mental component summary).
Though it may be presented as an overall score, we have not chosen to do this in CLASS on account of
the lack of sensitivity. All scales are scored from 0 (worst QoL) to 100 (best QoL).
The EQ-5D was developed by the EuroQoL group as a single index valuation for health status. The version
used in CLASS is the EQ-5D-3 levels (EQ-5D-3L), which has five questions (or dimensions: mobility,
self-care, usual activities, pain/discomfort, anxiety/depression), each with three response options, and a
VAS where respondents are asked to rate their current health-related quality of life (HRQoL). Responses
to the five questions equate to 243 health states. Scores range from −0.594 to 1.
Secondary outcome measures included:
l costs to the health service and patients and any subsequent care
l clinical success of venous intervention at 6 weeks and 6 months
l anatomical success of venous intervention at 6 weeks and 6 months
l disease-specific and generic QoL (at 6 weeks: AVVQ, SF-36 physical and mental components and
domains, EQ-5D and EQ-5D VAS; at 6 months: SF-36 domains and EQ-5D VAS)
l behavioural recovery.
Measurement of secondary outcomes
Costs to the health service and participants and any subsequent care
This is fully described in Chapter 9. Projected 5-year costs are described in Chapter 10.
Clinical success
This was determined by the VCSS and a VAS at baseline, 6 weeks and 6 months. The VAS consisted of an
unmarked line of 10 cm length, which had at the two extremes (1) no varicose veins on the left boundary,
and (2) worst possible veins on the right boundary. This was completed by both the patient and the
research nurse. It was used to assess the presence of varicose veins at baseline and residual varicose veins
at 6 weeks and 6 months. Specific complications, which may affect clinical success, were recorded at the
time of treatment and also at 6-weeks and 6-months follow-up.
Anatomical success
The duplex findings in the CLASS study were reported by an independent technician, using a standardised
proforma, which recorded the presence of patency/obliteration and reflux (of one greater than 1 second at
specific anatomical segments) (Box 1). The entire truncal vein was scanned, and if reflux and/or patency
was identified at any site, this was recorded as occurring at the nearest site recorded on the proforma.
The joint statement from the Venous Forum and Society of Interventional Radiology (2007)62
recommended reporting standards for endovenous ablation in the treatment of venous insufficiency.
Anatomical success was defined as successful ablation of the entire treated segment of the target vein
(absent flow or disappearance of the vein on duplex ultrasound). This guidance was used in the CLASS
study. We defined complete anatomical success for the GSV as complete occlusion at the groin (within
3 cm of the common femoral vein), complete occlusion at mid-thigh and either an occluded or a patent
but non-refluxing GSV above the knee. A partial success was defined as patency at one of the predefined
segments of the treated GSV; this was further subclassified as refluxing or non-refluxing. Everything else
was defined as a failure.
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For the SSV, a complete success was defined as occlusion within 3 cm of the popliteal vein and complete
occlusion at mid-calf. A partial success was defined as patency at one of the predefined segments of the treated
GSV; this was further subclassified as refluxing or non-refluxing. Everything else was defined as a failure.
Where a participant had GSV and SSV involvement, a complete success for the whole study leg was
achieved when there was a complete success for both GSV and SSV. A failure occurred when there was a
failure for both GSV and SSV. If either GSV or SSV was a partial success, or one was a complete success
and the other a failure, then it was considered to be a partial success for the whole leg. If there was a
partial success for the whole leg and no reflux in either GSV or SSV, then it was classed as a partial success
without reflux. Where the participant had GSV or SSV involvement only, then the outcome for the whole
study leg was the same as the outcome for the vein.
Disease-specific behavioural recovery
The assessment of behavioural recovery required the development of a specific instrument, and this is
discussed in Chapter 8. The timing and instruments used for data collection are summarised in Table 3;
more detail is provided in Data collection.
Data collection
Recruitment appointment (baseline, before randomisation)
The disease-specific and generic QoL instruments (AVVQ, EQ-5D and SF-36) and the Illness Perception
Questionnaire – Revised (IPQ-R)63 were combined into a single questionnaire for the participant to
complete. Participants were asked to complete this questionnaire at baseline (at the recruitment visit).
Participants could opt to complete this at home, and if they did not return this within 3 weeks, they were
sent a reminder letter, a further copy of the questionnaire and a reply paid envelope. Early on in the
recruitment phase, the randomisation system was amended such that participants could not be
randomised until the questionnaire had been completed.
BOX 1 Specific anatomical segments assessed with duplex scan
Groin – GSV (flush with common femoral vein, i.e. within 1 cm).
Groin – GSV (within 3 cm of common femoral vein).
Common femoral/superficial vein.
Mid-thigh – GSV.
Above knee – GSV.
Below knee – GSV.
SSV (flush with popliteal vein, i.e. within 1 cm).
SSV (within 3 cm of popliteal vein).
Popliteal vein.
Mid-calf – SSV.
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Participants were asked to rate their varicose veins on a VAS (from ‘no varicose veins’ to ‘the worst
varicose veins I can imagine’). Independently, the research nurse also completed an identical VAS.
The baseline clinical form – incorporating CEAP and VCSS for both legs, duplex scan information and vein
involvement in relation to the study leg, as well as some demographic information including height,
weight, employment status, previous treatment and previous DVT – was also completed at the
recruitment appointment.
Personal details, including GP details and a ‘best contact’, were also collected at recruitment. Participants
were asked to nominate a best contact, ideally someone who did not live at the same address as them,
who could be contacted if contact with the participant was lost.
TABLE 3 Timing of instruments
Time point Completed by participant
Completed by research nurse/
clinician/technician
Baseline (before
randomisation)
Questionnaire completed at clinic (or by post)
including:
AVVQ
EQ-5D
SF-36
IPQ-R
Personal details, GP, best contact, etc.
Duplex scan
Vein involvement
VCSS
CEAP classification
Baseline demographic factors
After randomisation, before
treatment
Questionnaire completed by post including:
IPQ-R
None; participant not at clinic
At treatment appointment(s) VAS completed at clinic assessing pain of
procedure
Procedural details
Complications of procedure
6 weeks after treatment Questionnaire including:
AVVQ
EQ-5D
SF-36
Time to return to work/normal activity
Behavioural recovery questionnaire
Recollection of pain during treatment and pain
during follow-up
Presence/absence DVT
Presence/absence residual varicosity
Anatomical success
VCSS
Complications
For patients treated with EVLA or foam,
details of further foam injections
6 months after treatment Questionnaire including:
AVVQ
EQ-5D
SF-36
IPQ-R
Economic questions
Presence/absence DVT
Presence/absence residual varicosity
Anatomical success
Complications
VCSS
IPQ-R, Illness Perception Questionnaire – Revised.
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After randomisation, before treatment
The pre-treatment questionnaire included the IPQ-R. Approximately 2 weeks before the treatment
appointment, the questionnaire was sent to the participant, along with a reply paid envelope. Participants
were asked to complete and return this before they attended for treatment. In view of the time frame for
completion, reminder letters were not sent for this questionnaire. In some circumstances (e.g. when the
treatment date was added retrospectively to the trial database, or immediately before the treatment
appointment), it was not appropriate to send the questionnaire as it could not be completed before the
treatment appointment.
Treatment appointment
A treatment-specific case report form (CRF) was completed by the treating surgeon (or delegate) after
each treatment appointment. The information collected included information specific to the procedure,
the grade of surgeon (and, if appropriate, the anaesthetist), how long the procedure took, details of the
bandaging, any immediate complications associated with the treatment, whether or not the patient was
hospitalised after the treatment and whether or not the contralateral leg was treated contemporaneously.
If the participant was undergoing treatment other than the treatment to which he or she had been
randomised, the CRF captured this information, together with information about the actual
treatment received.
After bandaging, participants were asked to rate the pain experienced during treatment on a VAS ranging
from no pain to the worst imaginable pain.
Six-weeks follow-up appointment
Participants were invited to attend for a 6-weeks follow-up appointment. At the appointment, the research
nurse carried out a clinical examination of the study leg and completed a CRF incorporating the VCSS
and CEAP. The technical success of the treatment was assessed by duplex scanning, performed by an
independent, fully trained technician as described above.
Information about any complications or side effects was also recorded. The research nurse and participant
assessed the presence of varicose veins using a VAS (ranging from ‘no varicose veins’ to ‘the worst varicose
veins I can imagine’).
Participants treated with EVLA or foam sclerotherapy were assessed for further foam sclerotherapy
treatment. In some cases this was carried out at the 6-weeks appointment; in other cases the participant
returned to the clinic at a later date for this.
As at baseline, the disease-specific and generic QoL instruments (AVVQ, EQ-5D, SF-36) were combined
into a single questionnaire for completion by the participant. The Behavioural Recovery After treatment for
Varicose Veins (BRAVVO) instrument relating to behavioural recovery, including time to return to work/
normal activities, was also included in this questionnaire (the development of this instrument is described
in Chapter 8). Two questions on pain were also included. Participants were asked to rate, on a VAS
ranging from no pain to the worst imaginable pain, the worst pain experienced while (1) having the
treatment and (2) recovering after treatment.
Participants who opted to take the questionnaire home were provided with a reply paid envelope for its
return. Participants who failed to return their questionnaire within 3 weeks were sent a reminder letter,
a further copy of the questionnaire and a reply paid envelope. Participants who failed to attend for a
follow-up appointment were offered a second appointment. If they failed to attend this, they were sent
the questionnaire, covering letter and a reply paid envelope for its return. Again, those who failed to
return their questionnaire within 3 weeks were sent a reminder letter, a further copy of the questionnaire
and a reply paid envelope.
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Six-months follow-up appointment
The 6-months follow-up took a similar form to the 6-weeks follow-up. Participants were invited to attend
for a 6-months follow-up appointment. At the appointment, the research nurse carried out a clinical
examination of the study leg and completed a CRF incorporating the VCSS and CEAP. The technical
success of the treatment was assessed by duplex scanning (as described for the 6-weeks follow-up). Where
possible, an individual patient was scanned by the same technician at each time point using the study
designated duplex scanner. Information about complications and side effects of treatment was also
recorded. The presence of varicose veins was assessed by both the participant and the research nurse
using a VAS (as previously described). The research nurse also reviewed the hospital medical records to
collect information on any hospital appointments or admissions.
The disease-specific and generic QoL instruments (AVVQ, EQ-5D, SF-36) and the IPQ-R were again
combined into a single questionnaire for the participant to complete. Questions relating to resource use
(primary and secondary care services), self-purchased health care, and participant time and travel costs
were included in the 6-months questionnaire only (for more details see Chapter 9). Participants could opt
to complete the questionnaire at home; the same reminder schedule was used as for the 6-weeks
questionnaire. Participants who failed to attend for the 6-months appointment were offered a second
appointment and, if they failed to attend this, a copy of the questionnaire was sent to them, along with a
covering letter and a reply paid envelope, with a reminder 3 weeks later.
Data management
A secure, bespoke study database was developed which site staff could access over the internet.
Password-protected access was provided such that sites could only view data from their own site. All data
collected during the course of the research were kept strictly confidential and accessed only by members
of the trial team. Patients’ details were stored under the guidelines of the 1988 Data Protection Act.64
Patients were allocated an individual study number, and this number (rather than the participant’s name)
was used to identify study paperwork.
Clinical data were entered into the database by the research nurse working in each hospital site, together
with data from questionnaires completed at clinic. Data from questionnaires returned by post to the
study office were entered by staff based there.
Staff in the study office worked closely with local research nurses to ensure that the data were as complete
and accurate as possible. Extensive range and consistency checks further enhanced the quality of the data.
Pharmacovigilance and safety reporting
A serious adverse event (SAE) was defined as any medical occurrence that:
l resulted in death
l was life-threatening (i.e. the subject was at risk of death at the time of the event)
l required inpatient hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability/incapacity
l was a congenital anomaly/birth defect
l was an important medical event, which may not have been immediately life-threatening or resulted in
death or hospitalisation but may have jeopardised the patient or required intervention to prevent one
of the other outcomes listed in the definition.
An adverse reaction was defined as an adverse event judged by either the reporting investigator or the
sponsor as having a reasonable causal relationship to the medicinal product (i.e. STS).
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An unexpected adverse reaction was defined as an adverse reaction, the nature and severity of which
were not consistent with the applicable product information. We defined the following SAEs as
potentially ‘expected’:
l DVT (following foam sclerotherapy, EVLA, surgery)
l pulmonary embolism (following foam sclerotherapy, EVLA, surgery)
l anaphylactic shock (following foam sclerotherapy)
l stroke (following foam sclerotherapy)
l retinal arteriole occlusion (following foam sclerotherapy)
l myocardial infarction (following foam sclerotherapy)
l cutaneous necrosis and ulceration (following foam sclerotherapy)
l epileptic fit (following foam sclerotherapy)
l intra-arterial injection (following foam sclerotherapy)
l injury to a major artery (common femoral or superficial femoral artery) (following surgery)
l injury to a major vein (common femoral or popliteal vein) (following foam sclerotherapy, EVLA, surgery)
l injury to a motor nerve (femoral, tibial or peroneal nerve) (following surgery)
l transient ischaemic attack (following foam sclerotherapy)
l migraine (following foam sclerotherapy).
All other SAEs were defined as unexpected.
Adverse events during, or immediately following, treatment were collected on the treatment CRF before
discharge. In line with current clinical practice, participants were advised to contact their GP if they
experienced an adverse event between the period following treatment and the 6-weeks follow-up
appointment. At each follow-up visit, participants were asked if they had experienced any adverse events;
these were collected on the appropriate follow-up CRF.
All SAEs were recorded as such using the SAE form, and reported to the trial office and to the sponsor
within defined time lines. For all SAEs, the local principal investigator was asked to determine whether or
not the event was likely to have been caused by study treatment.
Suspected unexpected serious adverse reactions (SUSARs) would have been reported to the Medicines and
Healthcare Products Regulatory Agency (MHRA) and the Research Ethics Committee in accordance with
prescribed time lines.
Trial oversight
The University of Aberdeen acted as sponsor for the study.
Independent trial steering and data monitoring committees were established. The Trial Steering Committee
(TSC) comprised an independent chairperson (a vascular surgeon) and two further independent members
(a vascular surgeon and a trials methodologist). The TSC met approximately annually over the course
of the trial.
The Data Monitoring Committee (DMC) comprised an independent chairperson (a vascular surgeon)
and two further independent members (a trials methodologist and a statistician). The DMC met
approximately annually.
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Ethics and regulatory approvals
The trial and subsequent amendments were reviewed and given a favourable opinion by Scotland A
Research Ethics Committee (reference 08/MRE0024) and local research and development departments.
The trial was classed as a clinical trial involving an investigational medicinal product (CTIMP) because
of the use of STS in the foam sclerotherapy arm, and was therefore covered by the EU Clinical Trials
Directive. Clinical trial authorisation (CTA) was provided from the MHRA (EudraCT 2008-001069-26,
CTA 21583/0206/001). The trial was conducted according to the principles of good clinical
practice and was registered and assigned an International Standard Randomised Controlled Trial
Number (ISRCTN51995477).
Protocol amendments after trial initiation
A number of protocol revisions were made after trial initiation. These included:
l clarification of the techniques for undertaking foam sclerotherapy and EVLA treatment
l providing guidance on the labelling and storage of STS, and subsequently removing the requirement to
label STS as an IMP
l assessment of behavioural recovery at 6 weeks rather than 6 months
l inclusion of the assessment of pain
l revision of the ‘expected’ adverse events in light of new evidence
l addition of an exclusion criterion relating to migraine.
Patient information leaflets were revised in light of new evidence. Adaptations of study administrative
processes (for example the use of additional letters, revisions to letters, the use of the clinic log) were
also implemented.
Sample size and power
At the outset of the study, we proposed a sample size of 1015 participants from six hospitals across the
two strata. We anticipated that four hospital sites would offer three treatment options (surgery, foam
sclerotherapy and EVLA; stratum A), and that two hospitals would offer two treatment options (surgery
and foam sclerotherapy; stratum B). The proposed sample size is shown in Table 4. Based on previous
studies,10,65 we suggested that it would be reasonable to expect differences between surgery and minimally
invasive treatment (foam or EVLA) of approximately 0.25 of a standard deviation (SD) on the QoL
instruments at 6-months follow-up (in particular, this would equate to a five-point shift in the EQ-5D
score). This estimated difference of 0.25 SDs was observed in Short Form questionnaire-6 Dimensions
(SF-6D) and EQ-5D scores in the small trial by Ratcliffe et al.10 which compared conventional surgery
with sclerotherapy.
TABLE 4 Target recruitment in each of the stratum
Stratum EVLA Foam Surgery
Stratum A (four hospitals) 245 245 245
Stratum B (two hospitals) – 140 140
Total 245 385 385
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Foam versus surgery
For this primary comparison, strata A and B can be combined without introducing any bias. A trial with
385 patients in each group (total 770 patients) will have at least 90% power at a 5% significance level to
detect a change of 0.25 SDs in both AVVQ and EQ-5D. Adjusting for baseline score allows the sample size
to be decreased by a factor of 1− correlation squared, so including 385 participants allows for a 10% loss
to follow-up at 6 months (assuming a correlation between baseline and 6-months scores of at least 0.31).
A correlation of 0.31 is, in our experience, conservative for QoL studies, but should the loss to follow-up
be 15%, the study would still have 90% power to detect a difference of 0.25 SDs. Cost savings will be
sensitive to the number of participants with recurrent varicose veins requiring reintervention in each group.
Allowing for additional loss to follow-up (up to 20%) by 5 years, the study will have 90% power to detect
a 15% difference in recurrence from 32% in conventional surgery to 45% in the other groups (which
would be funded separately).
Endovenous laser ablation versus surgery
For this primary comparison, only participants in stratum A provide a direct randomised comparison, giving
245 participants in each group (490 in total). This trial will have 80% power at 5% significance to detect a
difference of 0.25 SDs. Given adjustment for baseline measures, this allows for a 10% loss to follow-up.
Recruitment to the trial was lower than anticipated for a number of reasons. These included a lower-than-
anticipated proportion of varicose vein referrals who met the eligibility criteria, ‘rationing’ of varicose
vein treatment at some sites leading to a sharp decline in the number of patients being referred for
treatment, and a lower-than-anticipated proportion of eligible patients agreeing to take part. Additional
recruitment sites were sought in an attempt to compensate for the recruitment shortfall, but few UK sites
offered the appropriate treatment options to enable them to participate in the study. Despite some
additional sites, and an extension to the recruitment period, the original recruitment targets were not met.
Thus, the DMC and TSC were asked to consider a revised recruitment target of 779 (Table 5).
We provided the following justification for this request. The correlation, pooled across trial arms, between
the AVVQ at baseline and 6 months post surgery was 0.39, and this has the effect of providing greater
power than originally assumed. In the surgery versus foam comparison, the power achieved with the
sample size of 283 in each arm would be equivalent to 334 in each arm if no correlation was observed.
Similarly, the power achieved with the sample size of 211 in each arm of the surgery versus EVLA
comparison would be equivalent to 249 in each arm if no correlation was observed.
However, at 6 months the response to follow-up was 89%, 1% of questionnaires did not include
sufficient data to derive a valid AVVQ and the proportion of participants withdrawn (including those
withdrawn prior to receiving an intervention) was 7%. Together, these factors indicated that a valid AVVQ
could be expected in 82% of the planned sample.
Therefore, the sample size was effectively 275 (i.e. 82% of 334 in each arm of the surgery vs. foam
comparison) for the purpose of determining power (Table 6).
Similarly, the sample size was effectively 205 in each arm of the surgery versus EVLA comparison (Table 7).
Note that although the proposed revised trial sample size was decreased, there was no change to the
target differences assumed to be clinically important (0.25 SDs); the only amendment to the sample size
calculation was a decrease in the power of the study to detect a 0.25-SD change. Both the DMC and TSC
agreed this amendment.
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Statistical analysis
The trial analysis was by intention to treat (all participants remained in their allocated group for analysis),
giving the least biased estimate of effectiveness between interventions. Three comparisons were
considered for the main trial analysis: (1) surgery versus foam sclerotherapy, (2) surgery versus EVLA and
(3) EVLA versus foam sclerotherapy. Participants from all centres were included in the analysis of
comparison (1), and participants from only those centres randomising to all three treatments were included
in the analysis of comparisons (2) and (3). A single principal analysis of the randomised trial was planned
when all participants had been followed up for 6 months after treatment. Study analyses were conducted
according to a statistical analysis plan, using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
The primary outcome measures (AVVQ, EQ-5D and SF-36 scores at 6 months) and all secondary outcome
measures (AVVQ, EQ-5D and SF-36 scores at 6 weeks; VCSS, presence of residual varicosities, truncal vein
ablation and complication rates at 6 weeks and 6 months; pain at time of treatment and at 6 weeks)
were presented as summaries of descriptive statistics at each time point and comparisons between groups
were analysed using generalised linear models (GLMs). All analyses were adjusted for minimisation
covariates (sex, age group, saphenous involvement, disease laterality and centre) and, where appropriate,
for baseline scores (for AVVQ, EQ-5D, SF-36 and VCSS). If there was a discrepancy between the
minimisation covariate used in the randomisation process and the data recorded in the baseline clinical
form, then the latter was used in the reporting of descriptive statistics and for adjustment in the analyses.
No adjustment was made for multiple comparisons. However, for the secondary outcome measures,
we considered differences to be significant only for p-values < 0.005. The models used to analyse the
continuous outcomes were repeated measures mixed models with a compound symmetry covariance
matrix and centre fitted as a random effect. Truncal vein ablation rates were analysed using ordinal logistic
regression and complication rates were analysed using binary logistic regression. Estimates of treatment
TABLE 6 Power calculation for foam vs. surgery comparison
Target
Effective sample
size in each arm
Detectable effect size
with 90% power (SDs)
Power to detect
0.25 SDs (%)
Previous 350 0.25 91
Revised 275 0.28 83
TABLE 7 Power calculation for EVLA vs. surgery comparison
Target
Effective sample
size in each arm
Detectable effect size
with 80% power (SDs)
Power to detect
0.25 SDs (%)
Previous 258 0.25 81
Revised 205 0.28 72
TABLE 5 Proposed revised sample size in each stratum
Stratum Total EVLA Foam sclerotherapy Surgery
Stratum A 635 211 211 211
Stratum B 144 – 72 72
Total 779 211 283 283
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effect size were expressed as the fixed effect solutions in the mixed models and odds ratios (ORs) in the
logistic regression models. For all estimates, 95% confidence intervals (CIs) were calculated and reported.
Sensitivity analyses were carried out on the primary outcome to investigate the impact of missing
data under various assumptions following recently published recommendations.66 Complete follow-up data
were used in the sensitivity analyses, with values imputed for any missing AVVQ score at 6 months. The
repeated measures models used in the primary analysis assumed data to be missing at random,67 whereas
the sensitivity analyses used multiple imputation where data were assumed to be missing not at random,
because we considered scenarios where there might be systematic differences between missing and
observed values and also where this differed between groups. The first sensitivity analysis assumed no
systematic difference and imputed values were obtained from the generation of 10 data sets and based
purely on observed values (minimisation covariates and AVVQ scores at baseline and 6 weeks). The
remaining sensitivity analyses adjusted the imputed values in the initial sensitivity analysis by either adding
two points to the imputed AVVQ scores or subtracting two points. These adjustments were then repeated
in one arm only, and repeated again by applying the adjustments in the other arm only. We considered
two points on the AVVQ score to be more than the minimum clinically important difference, and hence a
meaningful systematic difference to test in the sensitivity analyses.
The Aberdeen Varicose Vein Questionnaire
The AVVQ consists of 19 items (a diagram at the beginning on which respondents mark the location
and extent of their varicose veins, followed by 12 ordinal response items, of which six require separate
responses for each leg). The outcome measure is scored from 0 to 100 (higher values indicate worse QoL),
and scores were calculated using weightings for each response in the questionnaire. Where a response
was omitted by the respondent, the score for that item was removed from the denominator so that
participants could still score between 0 and 100 even if the questionnaire was not fully completed.59 If the
participant had unilateral disease at the time of completing the questionnaire (determined from the veins
drawn on the diagram), then, for unanswered questions which related to the healthy leg only, it was
assumed that the response should be ‘no’ or ‘none at all’ and a value of 1 was imputed. Once this was
executed, any questionnaires with more missing responses than non-missing responses (i.e. 10 missing
items or more) were considered not to have valid scores.
The Venous Clinical Severity Score
The VCSS consists of 10 ordinal response items, each with four levels (coded from 0 to 3). The overall
score was calculated as the sum of the values across each of the 10 responses, so that a VCSS score
could potentially be in the range from 0 to 30 (higher scores indicate greater severity). If the response to
question 7 was ‘no active ulcers’ and the responses to questions 8 and 9 (relating to active ulcers) were
missing, then questions 8 and 9 were assigned a value of zero. For other missing items, if the equivalent
response was available from the AVVQ then these missing responses were assigned the appropriate value.
A valid VCSS was not obtainable for participants for whom there remained any missing responses.
Process evaluation
Background
As it was not possible for participants to be blinded to their treatment, several steps were taken to increase
our confidence in the trial results based on the primary QoL outcomes. As much as possible, information
provided to participants at recruitment, after randomisation and following treatment was standardised.
We also conducted a theory-based process evaluation to identify possible confounding variables, for
example, expectations or concerns that might differ between treatment groups after participants were
informed of the treatment they would receive and that might, in turn, influence recovery behaviours or QoL.
The theoretical basis for this process evaluation was the common-sense self-regulation model (CS-SRM).68
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The CS-SRM proposes that people respond to a potential health threat in terms of their perceptions,
beliefs and expectations (‘cognitive’ representations) and also in terms of anxieties and concerns
(‘emotional’ representations). People use a range of coping behaviours (e.g. self-medicating, seeking social
support or perhaps avoidance) to manage and regulate these representations. Systematic review evidence
suggests that illness representations play a significant role in help-seeking behaviour and adherence to
treatment recommendations.69,70
Questionnaire measures have been developed and validated to assess the proposed domains of illness
representations. The domains are illness identity; causes; timeline; consequences; control; coherence; and
emotion. Table 8 presents the label, a brief explanation and an example questionnaire item for each of the
domains of the illness perceptions framework.
Methods
The most frequently used, validated scale to assess illness representations is the IPQ-R.63 The IPQ-R assesses
each of the domains in the illness perceptions framework. This questionnaire was administered to trial
participants at baseline, following randomisation and 6 months after treatment.
We were particularly interested in whether or not participants in any of the trial arms reported different
illness perceptions after they were notified of the treatment to which they had been randomised
(but before treatment). We were also interested in whether or not illness perceptions improved following
treatment, particularly with regard to the domain of treatment control, as this would likely reflect
participants’ perceptions of the effectiveness of their treatment, and timeline and consequences, as these
would likely reflect the extent to which participants’ expectations were exceeded following treatment.
TABLE 8 The illness perceptions framework as proposed in the CS-SRM and as measured in the IPQ-R63
Domain label Explanation Example questionnaire item
Identity What is the condition and its experienced
symptoms?
Symptom checklist (see Identity domain)
Cause What are the causes of the condition? Cause checklist (see Identity domain)
Timeline (acute/chronic) How long will the condition last? My varicose veins will last a long time
Timeline (cyclical) Is the condition experienced as episodes? My symptoms come and go in cycles
Consequences How serious are the consequences of the
condition for the person’s everyday life?
My varicose veins have major consequences
on my life
Personal control To what extent does the person have control
over managing or curing the condition?
Nothing I can do will affect my varicose
veins (reverse code)
Treatment control To what extent is treatment effective in
managing or curing the condition?
My treatment will be effective in curing my
varicose veins
Illness coherence To what extent does the person understand
the condition and the way the treatment is
proposed to work?
My varicose veins are a mystery to me
Emotional representations How worried is the person about having the
condition?
When I think about my varicose veins I get
upset
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Analysis
Identity domain
In the IPQ-R, participants are presented with a number of symptoms, some that might be expected to
occur as a result of varicose veins, and some unrelated to varicose veins. Participants are asked to identify
symptoms that they have experienced since developing varicose veins, and whether or not they believe that
these symptoms are related to their varicose veins. The IPQ-R was scored according to the method outlined
on the Illness Perception Questionnaire (IPQ) website (www.uib.no/ipq). The ‘illness identity score’ is the
number of symptoms that are both experienced by the participant and correctly identified as being related
to their varicose veins.63 The symptoms are pain, hardening of the skin, redness of the skin, swelling of
the ankle, discolouration or brown staining on the leg, and breaks in the skin or ulcers on the leg. The
questionnaire also lists unrelated symptoms (sleep difficulties, stiff joints, weight loss, dizziness, fatigue,
sore eyes, breathlessness, loss of strength), but these questions do not count either positively or negatively
towards the individual’s overall illness identity score. Possible identity scores range between 0 and 6.
The ‘percentage of symptoms correctly identified as being related to varicose veins’ is another way of
representing illness identity,63 but differs from the identity score in that it only takes account of the
subset of the six symptoms that the participants reported having experienced. These are calculated as a
percentage for each participant. Where fewer than six symptoms are experienced, these percentages
are higher than the corresponding identity score expressed as a proportion out of six.
Other domains
The other measures of illness perception are presented as mean scores out of 30 [for timeline (acute/chronic),
consequences, personal control and emotional representations], 25 (for treatment control and illness
coherence) or 20 [for timeline (cyclical)], with higher scores indicative of greater illness representation.
The results of the process evaluation for the comparison of foam sclerotherapy and surgery are presented
in Chapter 5 and those for the comparison of EVLA, foam sclerotherapy and surgery in Chapter 6.
Discussion of the process evaluation is given in Chapter 7.
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Chapter 4 Baseline characteristics
This chapter provides a brief overview of all patients involved in the study and describes baselinecharacteristics of the whole cohort of participants pooled across treatment groups. Baseline data
broken down by randomised groups are presented in Chapters 5 and 6.
Figure 2 shows the Consolidated Standards of Reporting Trials (CONSORT) diagram for the entire CLASS
study. In total, 6592 patients with varicose veins were screened for eligibility over 48 months between
November 2008 and October 2012. The mean age of those screened was 51 (SD 15) years, and 64%
were female. Fifty-one per cent of those screened (3369 patients) met the eligibility criteria and 43%
(2847 patients) were ineligible. The eligibility status was unknown (or not recorded in the study clinic log
book) for the other 6%. Common reasons for exclusion were recurrent varicose veins, no reflux or reflux
< 1 second, veins < 3mm or > 15mm in diameter and the presence of comorbidities. Of the 3369 eligible
patients, 798 (24%) consented to participate in the trial and 2571 (76%) declined. The most frequent
reason for declining to take part was a preference for one form of treatment, and therefore a wish not to
undergo randomisation. The reasons for ineligibility and declining to take part are shown in Table 9.
Thirteen patients (1.6%) were found to be ineligible after randomisation, including five patients with veins
> 15mm in diameter and three who were later discovered to have recurrent varicose veins. The remainder were
ineligible because of patient comorbidities or lack of reflux. These patients were treated as post-randomisation
exclusions, and therefore 785 participants were included in the formal trial population.71
Eleven participating centres contributed to recruitment, each in one of two strata. The eight centres in
stratum A randomised to all three treatment arms, and the three in stratum B randomised to foam
sclerotherapy or surgery only, because they were unable to offer EVLA treatment. The numbers of
randomised participants recruited, by centre, are shown in Table 10.
Recruitment and randomisation took place over a period of 48 months. Figure 3 shows the recruitment
rate over time.
All 785 participants attended for baseline clinical assessment and 779 (99%) completed baseline
questionnaires. At the time of primary treatment, 720 (92%) received their randomised allocation, 27 (3%)
received a study treatment other than their randomised treatment and 38 (5%) did not receive any of the
study treatments.
With regard to those patients who did not receive the treatment to which they were randomised, 10 were
randomised to foam sclerotherapy but received EVLA (six patients) or surgery (four patients) as their
primary treatment. Reasons given for this included unsuitability for foam (veins considered too wide,
history of migraine, dizziness/double vision prior to treatment, needle phobia), patient preference and
logistic reasons. Eleven patients were randomised to foam and did not have any treatment within the trial.
The most common reason for this was patient preference; two patients failed to attend for treatment/
pre-treatment review, and one participant suffered a major stroke prior to treatment and was excluded
from treatment and follow-up at this point.
Two patients who were randomised to EVLA received surgery as their primary treatment. In one case, this
was because the patient wished to have treatment under general anaesthetic; in the other case, the
responsible consultant recommended surgery because of the extensive nature of the veins.
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TABLE 9 Description of ineligible patients, and the reasons eligible patients declined to take part
Non-randomised screened patients n %
Reason for ineligibility 2847
Recurrence 789 27.7
No reflux or reflux < 1 second 624 21.9
Patient comorbidity 384 13.5
GSV or SSV < 3mm in diameter or > 15mm 264 9.3
Tortuous veins that are considered to be unsuitable for EVLA 242 8.5
Vein related – no further information 179 6.3
Asymptomatic CEAP grade 2 156 5.5
Thrombosis (current deep-vein incompetence, acute superficial vein thrombosis) 58 2.0
Other 151 5.3
Reason for declining to take part 2571
Patient preference for surgery 838 32.6
Patient preference for EVLA 761 29.6
Patient preference for foam sclerotherapy 341 13.3
Patient did not want foam sclerotherapy 35 1.4
Patient did not want surgery 17 0.7
Patient did not want EVLA 1 < 0.1
Other reasona 554 21.5
Surgeon preference 24 0.9
a This includes patients who declined to give a reason.
TABLE 10 Included participants, by centre and randomised allocation
Stratum Centre Foam Surgery EVLA Total randomised Percentage of total recruitment
A Aberdeen 72 74 74 220 28.0
Hull 55 56 54 165 21.0
Leeds 35 36 35 106 13.5
Bournemouth 22 24 24 70 8.9
Newcastle 11 14 13 38 4.8
Sheffield 5 4 6 15 1.9
Worcester 4 3 2 9 1.1
Blackburn 3 2 2 7 0.9
Stratum A total 207 213 210 630 80.3
B Gloucestershire 37 35 N/A 72 9.2
Exeter 35 34 N/A 69 8.8
Sherwood Forest 7 7 N/A 14 1.8
Stratum B total 79 76 N/A 155 19.7
Total recruitment 286 289 210 785
N/A, not applicable.
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Five patients randomised to EVLA did not undergo treatment. Two patients failed to attend for treatment, two
declined treatment and one patient had cardiac problems which led to cancellation of planned treatment.
Seven participants were randomised to surgery but received foam sclerotherapy as their primary treatment. For
two of these, the reason was medical (unfit for general anaesthetic and back problems/concerns regarding
anaesthetic/positioning). For the other five, the reasons related to a preference for foam sclerotherapy. Eight
participants randomised to surgery opted to have EVLA treatment. All but one of these patients expressed a
preference for EVLA after randomisation. One patient attended for surgery but panicked and was then listed
for EVLA. Twenty-two patients were randomised to surgery and did not receive any treatment. The majority of
these patients indicated a preference not to undergo surgery, but one declined because she was undergoing
tests for possible cancer and three moved out of the study area before surgery was carried out.
At 6 weeks after treatment, 709 (90%) attended clinic for follow-up examination and 670 (85%)
completed questionnaires. At 6 months, 670 (85%) attended clinic for follow-up examination and 627
(80%) completed questionnaires.
Baseline characteristics of the study participants
The mean age of participants was 49.2 (SD 13.7) years and 57% were female, so the trial cohort was
slightly younger and had fewer females than the overall group of patients with varicose veins who were
initially screened (Table 11). The mean body mass index (BMI) was 27.3 kg/m2 (SD 4.6 kg/m2), 61% were in
employment and 221 participants (28%) had varicose veins in both legs; these participants nominated their
worst leg as their ‘study leg’. Eleven per cent of participants had undergone previous varicose vein treatment
of their non-study leg and 1% had received previous sclerotherapy for varicose veins in their study leg.
Quality of life
A valid AVVQ score (our primary outcome) was obtained for all but one of the participants who
completed a baseline questionnaire, and the mean score was 17.9 (SD 9.5) (Table 12). The mean
EQ-5D was 0.79 (SD 0.18).
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TABLE 11 Baseline characteristics of all study participants
Characteristics All participants
Randomised (n) 785
Age (years) (n, mean, range) 785 49.2 18–85
Female (N, n, %) 785 445 56.7
BMI (kg/m2) (n, mean, range) 725 27.3 17–44
Employment status
Self-employed (N, n, %) 773 87 11.3
Employed (N, n, %) 773 468 60.5
Other (N, n, %) 773 218 28.2
Laterality
Unilateral (N, n, %) 785 564 71.8
Bilateral (N, n, %) 785 221 28.2
Previous history of DVT (N, n, %) 776 19 2.4
Previous treatment to contralateral leg (N, n, %) 779 85 10.9
Foam sclerotherapy (N, n, %) 779 16 2.1
Surgery (N, n, %) 779 61 7.8
EVLA treatment (N, n, %) 779 7 0.9
Previous sclerotherapy to tributaries of study leg (N, n, %) 779 7 0.9
TABLE 12 Quality of life at baseline
QoL measure All participants
Randomised (n) 785
AVVQ score (n, mean, SD) 778 17.9 9.5
EQ-5D score (n, mean, SD) 764 0.79 0.18
VAS (n, mean, SD) 771 80.5 15.8
SF-36 summary scores
Physical component summary score (n, mean, SD) 723 48.6 8.3
Mental component summary score (n, mean, SD) 723 51.8 9.2
SF-36 domain scores
Physical functioning (n, mean, SD) 738 50.1 8.5
Role physical (n, mean, SD) 772 50.0 9.1
Bodily pain (n, mean, SD) 772 47.3 8.9
General health (n, mean, SD) 772 49.5 8.4
Vitality (n, mean, SD) 776 51.3 9.4
Social functioning (n, mean, SD) 773 50.7 9.0
Role emotional (n, mean, SD) 770 51.0 8.8
Mental health (n, mean, SD) 774 51.6 9.4
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For SF-36, the mean physical component score of 48.6 (SD 8.3) was lower than the mean mental
component score of 51.8 (SD 9.2) and the population norm score for the physical component of 50 (SD 10).
This indicates that, compared with the wider population, the study cohort had slightly poorer physical
health at baseline and the low SDs suggest that the cohort was a relatively uniform group in terms of QoL.
The main factor contributing to the lower physical component score was the bodily pain domain, with a
subscale score of 47.3 (SD 8.9).
Physical activity
A summary of physical activity data collected at the baseline clinic assessment is presented in Table 13.
Thirteen per cent of participants spent most of their time at work sitting (e.g. in an office) and 31% spent
most of their time at work standing or walking without requiring much intense physical effort. Twenty-four
per cent worked in jobs involving definite physical effort, including handling heavy objects and using tools,
and 6% had employment involving vigorous physical activity including handling very heavy objects.
In the week prior to recruitment, 45% of participants engaged in physical exercise such as swimming,
jogging, aerobics, football, tennis and gym workouts (including 21% who had exercised for more
than 3 hours).
Baseline characteristics of study leg
The majority of participants (653/785, 83%) had GSV reflux only, 56 (7%) had SSV reflux only and the
remaining 76 (10%) had both GSV and SSV involvement (Table 14). The proportions of participants with
left or right leg involvement were similar. The mean widest diameter below the SFJ was 8.7mm for those
with GSV involvement only, and for those with SSV involvement only, the mean widest diameter below
the saphenopopliteal junction was 7.5mm. Of those with any GSV involvement, 90% had reflux above the
TABLE 13 Physical activity at baseline
Physical activity All participants
Randomised (n) 785
Physical activity at work
Mostly sitting (N, n, %) 761 101 13.3
Mostly standing or walking (N, n, %) 761 239 31.4
Definite physical effort (N, n, %) 761 180 23.7
Vigorous physical effort (N, n, %) 761 44 5.8
Not in employment (N, n, %) 761 197 25.9
Physical activity in previous week
Physical activities (N, n, %) 770 348 45.2
Cycling (N, n, %) 755 126 16.7
Walking (N, n, %) 769 756 98.3
Housework/childcare (N, n, %) 767 674 87.9
Gardening (N, n, %) 765 473 61.8
Usual walking pace
Slow (N, n, %) 771 48 6.2
Steady/average (N, n, %) 771 374 48.5
Brisk (N, n, %) 771 293 38.0
Fast (N, n, %) 771 56 7.3
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TABLE 14 Baseline characteristics of study leg
Study leg vein characteristics All participants
Randomised (n) 785
Study leg
Right (N, n, %) 785 382 48.7
Left (N, n, %) 785 403 51.3
Saphenous involvement
GSV only (N, n, %) 785 653 83.2
Widest diameter (mm) (n, mean, range) 587 8.7 3–15
Reflux above knee only (N, n, %) 520 500 96.2
Reflux above and below knee (N, n, %) 520 20 3.8
SSV only (N, n, %) 785 56 7.1
Widest diameter (mm) (n, mean, range) 50 7.5 3–15
GSV and SSV (N, n, %) 785 76 9.7
Widest diameter GSV (mm) (n, mean, range) 72 7.2 3–15
Widest diameter SSV (mm) (n, mean, range) 66 5.4 3–15
Reflux above knee only (N, n, %) 60 27 45.0
Reflux above and below knee (N, n, %) 60 33 55.0
Deep-vein reflux (N, n, %) 767 100 13.0
CEAP classification
C0 No visible or palpable signs of venous disease (N, n, %) 782 0 0.0
C1 Telangiectasis or reticular veins < 3mm (N, n, %) 782 0 0.0
C2 Varicose veins > 3mm (N, n, %) 782 429 54.9
C3 Oedema (N, n, %) 782 102 13.0
C4 Skin and subcutaneous changes (N, n, %) 782 79 10.1
C4a Pigmentation or eczema (N, n, %) 782 130 16.6
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 782 11 1.4
C5 Healed venous ulcer (N, n, %) 782 20 2.6
C6 Active venous ulcer (N, n, %) 782 11 1.4
VCSS (n, mean, SD) 778 5.0 2.5
Presence of varicose veins
Assessed by participant (N, n, %) 785 783 99.7
VAS (n, mean, SD) 785 5.5 2.2
Assessed by research nurse (N, n, %) 785 784 99.9
VAS (n, mean, SD) 785 3.8 2.2
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knee only. All participants had a CEAP classification of C2 or above (reflecting the inclusion criteria for the
trial), and 55% had grade C2 veins. The mean VCSS at baseline was 5.0 (SD 2.5). The severity of varicose
veins, assessed on a VAS from 0 (none) to 10 (worst possible), recorded higher scores (i.e. a perception of
more varicose veins) when assessed by the participant (mean score 5.5, SD 2.2) than when assessed by the
research nurse (mean score 3.8, SD 2.2).
Contralateral leg
The baseline CEAP classification and VCSSs are summarised in Table 15 for the 28% of participants with
bilateral disease. The majority of these participants (63%) had a C2 CEAP classification for their
contralateral leg; the distribution of CEAP classifications was similar for study legs and contralateral legs.
The mean VCSS for contralateral legs was 3.8 (SD 2.3), which was lower than the mean score of 5.0 for
the study legs.
Results from the foam sclerotherapy versus surgery comparison, which included patients from all centres
(n= 575), are described in Chapter 5. Results from the foam versus EVLA and EVLA versus surgery
comparisons, which included patients in the centres which participated in the three arms (n= 630), are
described in Chapter 6.
TABLE 15 Baseline characteristics of contralateral leg
Non-study leg vein characteristics All participants
Randomised (n) 785
Participants with bilateral disease (N, n, %) 785 221 28.2
CEAP classification
C2 Varicose veins > 3mm (N, n, %) 213 135 63.4
C3 Oedema (N, n, %) 213 31 14.6
C4 Skin and subcutaneous changes (N, n, %) 213 16 7.5
C4a Pigmentation or eczema (N, n, %) 213 27 12.7
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 213 1 0.5
C5 Healed venous ulcer (N, n, %) 213 2 0.9
C6 Active venous ulcer (N, n, %) 213 1 0.5
VCSS (n, mean, SD) 209 3.8 2.3
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Chapter 5 Comparison of surgery and foam
sclerotherapy
In this chapter we report the results for surgery compared with foam sclerotherapy, using data from allcentres. A discussion of these results is included in Chapter 7.
Participants
Five hundred and eighty-six participants were randomised to either foam sclerotherapy or surgery; of these,
11 (2%) were post-randomisation exclusions (see Chapter 4), leaving a total of 575 participants included in
the trial analysis (286 in the foam arm and 289 in the surgery arm). The CONSORT diagram (see Figure 2)
describes the flow of participants in the trial.
The proportion receiving treatment as allocated appeared to be higher for foam sclerotherapy (93%) than
for surgery (87%). Retention appeared to be slightly higher for foam, in terms of both follow-up clinic
assessments and completion of participant questionnaires. The 6-weeks clinic was attended by 93% of
participants randomised to foam sclerotherapy compared with 87% of those receiving surgery, and at
6 months the attendance rates were 88% and 82% respectively. The 6-weeks questionnaire was completed
by 86% of participants randomised to foam sclerotherapy compared with 82% of those randomised to
surgery, and at 6 months the response rates were 83% and 74% respectively. A slightly larger proportion of
participants appeared to have withdrawn in the surgery arm at 6 months (11%) than in the foam arm (6%).
Baseline characteristics
Demographic details
The main baseline characteristics of study participants are shown in Table 16. There was a good balance
between groups for most factors, particularly for age and sex, which were minimisation variables. There
was a slight imbalance between groups in terms of bilateral disease. The data shown in Table 16 were
used in the analysis when adjusting for minimisation factors.
Quality of life
Quality of life was assessed prior to the patient being randomised. QoL appeared to be slightly better in
the foam group and this is reflected in the AVVQ, EQ-5D and each of the SF-36 components and
subdomain scores (Table 17). For foam, the baseline AVVQ score was 17.6 (SD 10.0) and for surgery it was
18.2 (SD 9.2) (higher scores indicate worse QoL).
Physical activity
There was a good balance between the groups in terms of physical activity at baseline (Table 18).
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TABLE 17 Quality of life at baseline: comparison of surgery against foam sclerotherapy
QoL measure
Randomised to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 286 289
AVVQ score (n, mean, SD) 284 17.6 10.0 284 18.2 9.2
EQ-5D score (n, mean, SD) 279 0.80 0.18 279 0.78 0.18
VAS (n, mean, SD) 282 80.8 15.6 283 80.2 15.6
SF-36 summary scores
Physical component summary score (n, mean, SD) 275 48.9 8.2 275 48.2 8.8
Mental component summary score (n, mean, SD) 275 52.4 8.9 275 51.2 9.6
SF-36 domain scores
Physical functioning (n, mean, SD) 283 50.1 8.8 281 50.1 8.3
Role physical (n, mean, SD) 284 50.7 8.7 280 49.1 10.0
Bodily pain (n, mean, SD) 283 48.2 8.8 282 46.3 9.3
General health (n, mean, SD) 279 49.8 8.0 284 49.2 8.9
Vitality (n, mean, SD) 283 51.6 9.5 283 50.8 9.5
Social functioning (n, mean, SD) 283 51.5 8.1 283 49.8 9.9
Role emotional (n, mean, SD) 283 51.3 8.2 279 50.5 9.6
Mental health (n, mean, SD) 283 52.1 9.2 282 50.9 9.8
TABLE 16 Baseline characteristics of study participants: comparison of surgery against foam sclerotherapy
Participant characteristics
Randomised to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 286 289
Age (years) (n, mean, range) 286 49.0 19–78 289 49.2 22–85
Female (N, n, %) 286 162 56.6 289 163 56.4
BMI (kg/m2) (n, mean, range) 269 27.1 17–44 261 27.7 17–44
Employment status
Self-employed (N, n, %) 285 37 13.0 282 29 10.3
Employed (N, n, %) 285 169 59.3 282 179 63.5
Other (N, n, %) 285 79 27.7 282 74 26.2
Laterality
Unilateral (N, n, %) 286 215 75.2 289 196 67.8
Bilateral (N, n, %) 286 71 24.8 289 93 32.2
Previous history of DVT (N, n, %) 284 4 1.4 286 9 3.1
Previous treatment to contralateral leg (N, n, %) 284 30 10.6 287 28 9.8
Foam sclerotherapy (N, n, %) 284 10 3.5 287 2 0.7
Surgery (N, n, %) 284 20 7.0 287 22 7.7
Laser treatment (N, n, %) 284 0 0.0 287 4 1.4
Previous sclerotherapy to tributaries of study leg (N, n, %) 284 0 0.0 287 4 1.4
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Varicose vein characteristics
Baseline characteristics describing the varicose veins in the participants’ study and contralateral legs are
shown in Tables 19 and 20 respectively. The groups are well balanced across the majority of factors
(except for deep-vein reflux, where 17% in the foam group were affected compared with 9% in the
surgery group).
Treatment received
Table 21 summarises the primary interventions received (i.e. excluding any delayed secondary foam
treatments), summarised by randomised allocation. For participants randomised to foam, 96% of those
who received treatment had their treatment as randomised (i.e. had foam sclerotherapy). The equivalent
proportion in the surgery arm was 94%. The participants who did not undergo their randomised treatment
are described in Chapter 4.
Procedure and treatment time
At the time of the primary intervention, more participants in the surgery arm had treatment to non-truncal
varicosities (90%) than in the foam arm (31%) (see Table 21). More patients in the surgery arm (15%) had
their contralateral leg treated at the same time than in the foam arm (3%).
The mean treatment duration (the time taken from preparation of the patient to completion of bandaging)
was longer for surgery (53 minutes, SD 22.9 minutes) than for foam (19 minutes, SD 10.6 minutes). Foam
sclerotherapy was performed by consultants much more often (77% of treatments) than surgery (59%).
TABLE 18 Physical activity at baseline: comparison of surgery against foam sclerotherapy
Physical activity Randomised to foam sclerotherapy Randomised to surgery
Randomised (n) 286 289
Physical activity at work
Mostly sitting (N, n, %) 280 38 13.6 279 36 12.9
Mostly standing or walking (N, n, %) 280 102 36.4 279 90 32.3
Definite physical effort (N, n, %) 280 56 20.0 279 72 25.8
Vigorous physical effort (N, n, %) 280 15 5.4 279 13 4.7
Not in employment (N, n, %) 280 69 24.6 279 68 24.4
Physical activity in previous week
Physical activities (N, n, %) 284 129 45.4 282 124 44.0
Cycling (N, n, %) 280 39 13.9 278 55 19.8
Walking (N, n, %) 285 279 97.9 280 275 98.2
Housework/childcare (N, n, %) 284 254 89.4 280 243 86.8
Gardening (N, n, %) 283 187 66.1 279 172 61.6
Usual walking pace
Slow (N, n, %) 283 13 4.6 283 18 6.4
Steady/average (N, n, %) 283 129 45.6 283 144 50.9
Brisk (N, n, %) 283 121 42.8 283 100 35.3
Fast (N, n, %) 283 20 7.1 283 21 7.4
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TABLE 19 Baseline characteristics of study leg: comparison of surgery against foam sclerotherapy
Study leg vein characteristics
Randomised to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 286 289
Study leg
Right (N, n, %) 286 136 47.6 289 138 47.8
Left (N, n, %) 286 150 52.4 289 151 52.2
Saphenous involvement
GSV only (N, n, %) 286 232 81.1 289 239 82.7
Widest diameter (mm) (n, mean, range) 211 8.4 4–15 214 8.7 3–15
Reflux above knee only (N, n, %) 180 169 93.9 183 180 98.4
Reflux above and below knee (N, n, %) 180 11 6.1 183 3 1.6
SSV only (N, n, %) 286 21 7.3 289 21 7.3
Widest diameter (mm) (n, mean, range) 20 7.6 3–11 17 7.7 4–15
GSV and SSV (N, n, %) 286 33 11.5 289 29 10.0
Widest diameter GSV (mm) (n, mean, range) 31 7.3 3–14 28 7.6 3–15
Widest diameter SSV (mm) (n, mean, range) 30 5.0 3–10 26 5.4 3–8
Reflux above knee only (N, n, %) 26 11 42.3 22 10 45.5
Reflux above and below knee (N, n, %) 26 15 57.7 22 12 54.5
Deep-vein reflux (N, n, %) 280 47 16.8 282 25 8.9
CEAP classification
C0 No visible or palpable signs of venous disease (N, n, %) 286 0 0.0 287 0 0.0
C1 Telangiectasis or reticular veins < 3mm (N, n, %) 286 0 0.0 287 0 0.0
C2 Varicose veins > 3mm (N, n, %) 286 169 59.1 287 147 51.2
C3 Oedema (N, n, %) 286 35 12.2 287 39 13.6
C4 Skin and subcutaneous changes (N, n, %) 286 30 10.5 287 32 11.1
C4a Pigmentation or eczema (N, n, %) 286 41 14.3 287 55 19.2
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 286 3 1.0 287 3 1.0
C5 Healed venous ulcer (N, n, %) 286 4 1.4 287 7 2.4
C6 Active venous ulcer (N, n, %) 286 4 1.4 287 4 1.4
VCSS (n, mean, SD) 285 4.9 2.6 286 5.1 2.5
Presence of varicose veins
Assessed by participant (N, n, %) 286 286 100 289 288 99.7
VAS (n, mean, SD) 286 5.4 2.2 289 5.6 2.3
Assessed by research nurse (N, n, %) 286 286 100 289 288 99.7
VAS (n, mean, SD) 286 3.9 2.1 289 4.0 2.2
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TABLE 20 Baseline characteristics of contralateral leg in patients who had bilateral varicose veins: comparison of
surgery against foam sclerotherapy
Non-study leg vein characteristics
Randomised to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 286 289
Participants with bilateral disease (N, n, %) 286 71 24.8 289 93 32.5
CEAP classification
C2 Varicose veins > 3mm (N, n, %) 68 49 72.1 90 50 55.6
C3 Oedema (N, n, %) 68 8 11.8 90 15 16.7
C4 Skin and subcutaneous changes (N, n, %) 68 3 4.4 90 9 10.0
C4a Pigmentation or eczema (N, n, %) 68 6 8.8 90 15 16.7
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 68 0 0.0 90 0 0.0
C5 Healed venous ulcer (N, n, %) 68 2 2.9 90 0 0.0
C6 Active venous ulcer (N, n, %) 68 0 0.0 90 1 1.1
VCSS (N, mean, SD) 67 3.8 2.4 88 3.9 2.2
TABLE 21 Description of primary interventions: comparison of surgery against foam sclerotherapy
Primary intervention
Randomised to foam
sclerotherapy
Randomised to
surgery
Treated (n) 275 267
Received foam (N, n, %) 275 265 96.4 267 7 2.6
Received surgery (N, n, %) 275 4 1.5 267 252 94.4
Received laser (N, n, %) 275 6 2.2 267 8 3.0
Treatment time (minutes) (n, mean, SD) 248 19.0 10.6 247 53.0 22.9
Grade of surgeon
Consultant (N, n, %) 271 208 76.8 261 153 58.6
Consultant nurse (N, n, %) 271 33 12.2 261 3 1.1
Staff grade (supervised) (N, n, %) 271 3 1.1 261 14 5.4
Staff grade (unsupervised) (N, n, %) 271 2 0.7 261 8 3.1
Trainee (supervised) (N, n, %) 271 14 5.2 261 42 16.1
Trainee (unsupervised) (N, n, %) 271 11 4.1 261 41 15.7
Treatment to non-truncal varicosities (N, n, %) 270 84 31.1 260 233 89.6
Concurrent contralateral treatment (N, n, %) 269 7 2.6 261 40 15.3
Subcutaneous heparin (or derivative) (N, n, %) 262 13 5.0 238 115 48.3
Overnight hospitalisation
Planned (N, n, %) 268 0 0.0 203 8 3.9
Unplanned (N, n, %) 268 0 0.0 203 5 2.5
Bandaging not according to protocol (N, n, %) 272 103a 37.9 256 29 11.3
Recommended duration of bandaging
(if not for 10 days) (n, mean, SD)
10 6.8 0.6 27 6.7 3.2
a For all but 10 of these, the deviation from protocol was in relation to the specific bandaging/compression used rather
than the duration of bandaging.
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Only 8% of foam participants received treatment from a trainee, compared with 32% in the surgery
group. The remainder of procedures were performed by staff grades or nurse consultants. Nearly all
patients (98%) randomised to surgery had a general anaesthetic, with six receiving an epidural/spinal
anaesthetic (Table 22). The anaesthetist was a consultant in 83% of cases.
Primary treatment volume of foam
The total mean volume of foam administered was 9.0 ml (SD 2.9ml). When the GSV alone was treated,
the mean volume was 9.2 ml (SD 2.9ml), with 8ml (SD 3.0ml) to the truncal vein and 1.2ml (SD 2.2ml)
to the truncal varicosities (Table 23). There were six patients who received foam in excess of the 12-ml limit
recommended in the protocol, without adverse consequences.
TABLE 22 Description of anaesthetic
Anaesthetic details
Randomised to foam
sclerotherapya
Randomised to
surgery
Received surgery (n) 4 252
Type of anaesthetic
General (N, n, %) 4 4 100.0 248 242 97.6
Epidural/spinal (N, n, %) 4 0 0.0 248 6 2.4
Grade of anaesthetist
Consultant (N, n, %) 4 3 75.0 245 204 83.3
Associate specialist (N, n, %) 4 0 0.0 245 5 2.0
Registrar (N, n, %) 4 1 25.0 245 27 11.0
Staff grade (N, n, %) 4 0 0.0 245 9 3.7
Senior house officer (N, n, %) 4 0 0.0 245 0 0.0
a Patients randomised to foam sclerotherapy, but underwent surgery as their primary treatment.
TABLE 23 Volume of foam administered at primary treatment
Primary foam treatment
Randomised to foam
sclerotherapy
Randomised to
surgerya
Received primary treatment of foam (n) 265 7
Volume of foam (ml) (n, mean, range) 265 9.0 2–15 7 8.3 6–10
GSV involvement only (total) (n, mean, range) 215 9.2 2–15 5 7.6 6–10
GSV (n, mean, range) 215 8.0 0–15 5 6.8 6–8
Non-truncal varicosities (n, mean, range) 215 1.2 0–12 5 0.8 0–4
SSV involvement only (total) (n, mean, range) 20 6.8 2–12 1 10.0 10–10
SSV (n, mean, range) 20 5.4 0–12 1 10.0 10–10
Non-truncal varicosities (n, mean, range) 20 1.4 0–6 1 0.0 0–0
GSV and SSV involvement (total) (n, mean, range) 30 9.0 6–13 1 10.0 10–10
GSV (n, mean, range) 30 6.8 2–12 1 6.0 6–6
SSV (n, mean, range) 30 0.7 0–5 1 0.0 0–0
Non-truncal varicosities (n, mean, range) 30 1.4 0–6 1 4.0 4–4
a Patients randomised to surgery but received foam sclerotherapy as their primary treatment.
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Secondary or tertiary foam treatments
The numbers of participants who received secondary or tertiary treatments of foam sclerotherapy, along
with a breakdown of the location of treatment, is shown in Table 24. Seventeen participants randomised
to foam sclerotherapy (7%) received additional foam treatment to non-truncal varicosities, compared with
one randomised to surgery (1%). There were two participants whose second foam treatment included
foam sclerotherapy to the GSV and also to non-truncal varicosities. The one participant who received a
tertiary treatment had treatment to both the SSV and GSV.
Bandaging/compression
All participants had a bandage or stocking applied to their study leg, nearly all of which were full length.
More foam participants (38%) than surgery participants (11%) received bandaging not according to
protocol (see Table 21). The main reason for this difference was that the protocol specified the brand of
bandaging/compression for patients undergoing foam sclerotherapy, whereas, for surgery, any type of
bandaging for 10 days was sufficient. Of the 103 cases of foam participants whose bandaging was not
according to protocol, only 10 were related to duration and the other 93 were related to the type
of stockings.
Treatment outcome: quality of life
The QoL at 6 weeks and 6-months follow-up are shown in Tables 25 and 26, with the corresponding
statistical analysis in Table 27.
Aberdeen Varicose Vein Questionnaire
At 6 weeks and 6 months, all QoL measures showed an apparent improvement compared with baseline.
The treatment effect estimate for AVVQ (our primary outcome) at 6 weeks was −2.26 (95% CI −3.67
to −0.86, p= 0.002) in favour of surgery and at 6 months the estimate was −1.74 (95% CI −2.97 to
−0.50, p= 0.006).
TABLE 24 Secondary foam treatment
Secondary foam treatment Randomised to foam sclerotherapy Randomised to surgerya
No secondary foam treatment (N, n, %) 251 224 89.2 236 233 98.7
One secondary foam treatment (N, n, %) 251 26 10.4 236 3 1.3
to GSV (N, n, %) 251 9 3.6 236 1 0.4
to SSV (N, n, %) 251 2 0.8 236 1 0.4
to non-truncal varicosities (N, n, %) 251 17 6.8 236 1 0.4
Two secondary foam treatments (N, n, %) 251 1 0.4 236 0 0.0
to GSV (N, n, %) 251 1 0.4 236 0 0.0
to SSV (N, n, %) 251 1 0.4 236 0 0.0
to non-truncal varicosities (N, n, %) 251 0 0.0 236 0 0.0
a Patients randomised to surgery but received foam sclerotherapy as their primary treatment.
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TABLE 26 Quality of life at 6 months following treatment: comparison of surgery with foam sclerotherapy
QoL measure Randomised to foam sclerotherapy Randomised to surgery
Completed 6-months questionnaire (N, n, %) 286 238 83.2 289 214 74.0
AVVQ score (n, mean, SD) 236 9.1 7.9 213 7.8 7.5
EQ-5D score (n, mean, SD) 235 0.90 0.17 206 0.88 0.20
VAS (n, mean, SD) 237 84.5 12.3 210 82.8 15.3
SF-36 summary scores
Physical component summary score (n, mean, SD) 232 52.3 8.5 204 52.4 8.9
Mental component summary score (n, mean, SD) 232 52.2 9.1 204 52.1 8.6
SF-36 domain scores
Physical functioning (n, mean, SD) 237 52.0 7.9 213 51.5 8.8
Role physical (n, mean, SD) 236 52.3 8.1 213 51.9 8.7
Bodily pain (n, mean, SD) 235 53.0 9.5 209 53.7 10.0
General health (n, mean, SD) 238 51.8 8.7 212 51.9 9.6
Vitality (n, mean, SD) 238 53.0 9.6 212 53.0 9.7
Social functioning (n, mean, SD) 235 52.6 8.2 211 51.9 9.0
Role emotional (n, mean, SD) 237 51.5 8.8 211 51.5 9.3
Mental health (n, mean, SD) 238 52.5 9.2 212 51.8 9.3
TABLE 25 Quality of life at 6 weeks following treatment: comparison of surgery with foam sclerotherapy
QoL measure Randomised to foam sclerotherapy Randomised to surgery
Completed 6-weeks questionnaire (N, n, %) 286 247 86.4 289 237 82.0
AVVQ score (n, mean, SD) 246 12.2 9.6 235 10.6 8.8
EQ-5D score (n, mean, SD) 242 0.86 0.16 227 0.88 0.17
VAS (n, mean, SD) 244 80.6 17.3 232 83.1 15.5
SF-36 summary scores
Physical component summary score (n, mean, SD) 242 49.9 8.7 226 49.7 8.9
Mental component summary score (n, mean, SD) 242 52.3 9.0 226 51.7 8.9
SF-36 domain scores
Physical functioning (n, mean, SD) 245 50.8 8.9 235 51.5 8.1
Role physical (n, mean, SD) 246 50.3 9.6 235 48.1 10.3
Bodily pain (n, mean, SD) 244 50.2 9.2 229 49.1 10.1
General health (n, mean, SD) 245 50.8 9.0 232 52.2 8.9
Vitality (n, mean, SD) 245 52.3 9.7 232 51.7 9.3
Social functioning (n, mean, SD) 243 51.1 8.9 230 50.2 9.5
Role emotional (n, mean, SD) 246 51.2 8.6 234 50.0 10.4
Mental health (n, mean, SD) 245 52.5 8.8 232 52.3 9.0
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TABLE 27 Estimates of the effect of treatment on QoL: comparison of surgery with foam sclerotherapy
QoL measure
Randomised to
foam sclerotherapy
Randomised to
surgery Surgery vs. foam sclerotherapy
n Mean SD n Mean SD Effect sizea 95% CI p-value
AVVQ score at baseline 286 17.6 9.9 289 18.2 9.1 N/A N/A N/A
AVVQ score at 6 weeks 246 12.2 9.6 235 10.6 8.8 –2.26 –3.67 to –0.86 0.002
AVVQ score at 6 months 236 9.1 7.9 213 7.8 7.5 –1.74 –2.97 to –0.50 0.006
EQ-5D at baseline 286 0.80 0.18 289 0.78 0.17 N/A N/A N/A
EQ-5D at 6 weeks 242 0.86 0.16 227 0.88 0.17 0.02 0.00 to 0.05 0.071
EQ-5D at 6 months 235 0.90 0.17 206 0.88 0.20 0.01 –0.02 to 0.04 0.732
EQ-5D VAS at baseline 286 80.8 15.5 289 80.2 15.5 N/A N/A N/A
EQ-5D VAS at 6 weeks 244 80.6 17.3 232 83.1 15.5 2.90 0.31 to 5.48 0.028
EQ-5D VAS at 6 months 237 84.5 12.3 210 82.8 15.3 –1.23 –3.42 to 0.96 0.270
SF-36 physical component
score at baseline
286 48.9 8.0 289 48.2 8.6 N/A N/A N/A
SF-36 physical component
score at 6 weeks
242 49.9 8.7 226 49.7 8.9 0.27 –1.03 to 1.56 0.687
SF-36 physical component
score at 6 months
232 52.3 8.5 204 52.4 8.9 1.03 –0.25 to 2.30 0.114
SF-36 mental component
score at baseline
286 52.4 8.7 289 51.2 9.4 N/A N/A N/A
SF-36 mental component
score at 6 weeks
242 52.3 9.0 226 51.7 8.9 –0.44 –1.82 to 0.93 0.527
SF-36 mental component
score at 6 months
232 52.2 9.1 204 52.1 8.6 0.23 –1.10 to 1.56 0.738
SF-36 Physical functioning
at baseline
286 50.1 8.7 289 50.1 8.2 N/A N/A N/A
SF-36 Physical functioning
at 6 weeks
245 50.8 8.9 235 51.5 8.1 0.60 –0.58 to 1.77 0.320
SF-36 Physical functioning
at 6 months
237 52.0 7.9 213 51.5 8.8 –0.28 –1.39 to 0.84 0.625
SF-36 Role physical at
baseline
286 50.6 8.6 289 49.1 9.9 N/A N/A N/A
SF-36 Role physical at
6 weeks
246 50.3 9.6 235 48.1 10.3 –1.56 –3.14 to 0.02 0.053
SF-36 Role physical at
6 months
236 52.3 8.1 213 51.9 8.7 0.65 –0.53 to 1.83 0.278
continued
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TABLE 27 Estimates of the effect of treatment on QoL: comparison of surgery with foam sclerotherapy (continued)
QoL measure
Randomised to
foam sclerotherapy
Randomised to
surgery Surgery vs. foam sclerotherapy
n Mean SD n Mean SD Effect sizea 95% CI p-value
SF-36 Bodily pain at
baseline
286 48.1 8.8 289 46.3 9.2 N/A N/A N/A
SF-36 Bodily pain at
6 weeks
244 50.2 9.2 229 49.1 10.1 –0.39 –1.97 to 1.19 0.627
SF-36 Bodily pain at
6 months
235 53.0 9.5 209 53.7 10.0 1.95 0.42 to 3.47 0.012
SF-36 General health at
baseline
286 49.8 7.9 289 49.2 8.8 N/A N/A N/A
SF-36 General health at
6 weeks
245 50.8 9.0 232 52.2 8.9 1.63 0.41 to 2.85 0.009
SF-36 General health at
6 months
238 51.8 8.7 212 51.9 9.6 0.46 –0.82 to 1.75 0.480
SF-36 Vitality at baseline 286 51.6 9.5 289 50.8 9.4 N/A N/A N/A
SF-36 Vitality at 6 weeks 245 52.3 9.7 232 51.7 9.3 –0.35 –1.72 to 1.01 0.611
SF-36 Vitality at 6 months 238 53.0 9.6 212 53.0 9.7 0.37 –0.96 to 1.69 0.589
SF-36 Social functioning
at baseline
286 51.5 8.1 289 49.8 9.8 N/A N/A N/A
SF-36 Social functioning
at 6 weeks
243 51.1 8.9 230 50.2 9.5 –0.25 –1.70 to 1.21 0.742
SF-36 Social functioning
at 6 months
235 52.6 8.2 211 51.9 9.0 0.38 –0.89 to 1.65 0.554
SF-36 Role emotional at
baseline
286 51.3 8.2 289 50.5 9.4 N/A N/A N/A
SF-36 Role emotional at
6 weeks
246 51.2 8.6 234 50.0 10.4 –1.06 –2.57 to 0.44 0.164
SF-36 Role emotional at
6 months
237 51.5 8.8 211 51.5 9.3 0.49 –0.95 to 1.92 0.505
SF-36 Mental health at
baseline
286 52.1 9.2 289 51.0 9.7 N/A N/A N/A
SF-36 Mental health at
6 weeks
245 52.5 8.8 232 52.3 9.0 0.10 –1.23 to 1.42 0.888
SF-36 Mental health at
6 months
238 52.5 9.2 212 51.8 9.3 –0.04 –1.40 to 1.32 0.956
N/A, not applicable.
a If the effect size is negative for the AVVQ score or positive for EQ-5D, EQ-5D VAS or SF-36, this indicates an effect
which favours surgery.
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Sensitivity analyses
There were some missing AVVQ scores at 6 months (26% for the surgery arm and 17% for foam).
Exploratory analysis shows that participants without a valid AVVQ score at 6 months had mean baseline
AVVQ scores of 18.3 (SD 11.4) for foam and 18.2 (SD 10.3) for surgery. Those with an AVVQ score at
6 months had mean baseline scores of 17.4 (SD 9.7) for foam and 18.2 (SD 8.8) for surgery, indicating
that there are differences in the missing data between groups. The mean AVVQ score at 6 weeks for
participants with missing scores at 6 months is 11.8 for foam (slightly lower than the mean for all foam
participants) and 7.7 for surgery (much lower than the mean for all surgery participants), which suggests
that the treatment effect of −1.74 in favour of surgery may be underestimated in the primary analysis.
Table 28 demonstrates different estimates of the effect of treatment on the primary outcome when all
missing AVVQ scores at 6 months have been imputed under varying assumptions. Under the ‘missing not
at random’ assumption, the estimate of treatment effect is −2.00 (95% CI −3.30 to −0.70). Variously
adding or subtracting two points to or from these imputed values, for either one arm at a time or both
arms simultaneously, the resulting estimates range from −1.47 to −2.52, all significantly in favour of
surgery. The missing AVVQ values for surgery would need to be at least 2.7 points higher (or the missing
values for foam 4.0 points lower) than the imputed values for the difference between the groups to be
non-significant.
Short Form questionnaire-36 items
There were no differences between foam and surgery for the overall physical and mental component
scores or individual domains of the SF-36.
European Quality of Life-5 Dimensions
There were no differences in the EQ-5D or EQ-5D VAS between the foam and surgery groups.
Clinical outcomes
Venous Clinical Severity Score and presence of residual varicose veins
These outcomes at 6 weeks and 6 months are presented in Tables 29 and 30 respectively, with the
estimates of treatment effect sizes when surgery is compared with foam shown in Table 31.
Each outcome showed an apparent improvement in both groups from baseline to 6 weeks and from
6 weeks to 6 months. The VCSS was significantly lower for surgery than for foam after 6 weeks, with an
effect size of −0.52 (95% CI −0.85 to −0.19, p= 0.002). However, there was no difference between
groups at 6 months, when the effect size reduced (−0.23, 95% CI −0.53 to 0.07; p= 0.130).
TABLE 28 Sensitivity of estimates of the effect of treatment on the AVVQ score at 6 months (primary outcome)
using other missing data assumptions: comparison of surgery with foam sclerotherapy
Sensitivity analysis Effect sizea 95% CI p-value
Primary analysis (repeated measures, assuming missing at random) –1.74 –2.97 to –0.50 0.006
Multiple imputation (assuming missing not at random) –2.00 –3.30 to –0.70 0.003
All missing assumed to have AVVQ scores two points lower –2.17 –3.48 to –0.86 0.001
All missing assumed to have AVVQ scores two points higher –1.82 –3.12 to –0.52 0.006
Missing in foam group assumed to have AVVQ scores two points lower –1.65 –2.95 to –0.35 0.014
Missing in foam group assumed to have AVVQ scores two points higher –2.35 –3.65 to –1.05 0.001
Missing in surgery group assumed to have AVVQ scores two points lower –2.52 –3.83 to –1.22 < 0.001
Missing in surgery group assumed to have AVVQ scores two points higher –1.47 –2.77 to –0.17 0.027
a Where the effect size is negative, this favours surgery.
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TABLE 29 Clinical outcomes for study leg at 6 weeks: comparison of surgery with foam sclerotherapy
Clinical outcome measure
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 weeks (N, n, %) 286 265 92.7 289 251 86.9
VCSS (n, mean, SD) 251 2.2 2.0 230 1.8 2.0
Presence of residual varicosities
Assessed by participant (N, n, %) 261 221 84.7 242 173 71.5
VAS (n, mean, SD) 261 2.6 2.0 242 1.7 1.8
Assessed by research nurse (N, n, %) 261 197 75.5 242 125 51.7
VAS (n, mean, SD) 261 1.7 1.6 242 0.8 1.0
CEAP classification
C0 No visible or palpable signs of venous disease (N, n, %) 253 54 21.3 229 80 34.9
C1 Telangiectasis or reticular veins < 3mm (N, n, %) 253 74 29.2 229 92 40.2
C2 Varicose veins > 3mm (N, n, %) 253 92 36.4 229 33 14.4
C3 Oedema (N, n, %) 253 9 3.6 229 2 0.9
C4 Skin and subcutaneous changes (N, n, %) 253 6 2.4 229 6 2.6
C4a Pigmentation or eczema (N, n, %) 253 16 6.3 229 13 5.7
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 253 1 0.4 229 1 0.4
C5 Healed venous ulcer (N, n, %) 253 1 0.4 229 2 0.9
C6 Active venous ulcer (N, n, %) 253 0 0.0 229 0 0.0
TABLE 30 Clinical outcomes for study leg at 6 months: comparison of surgery with foam sclerotherapy
Clinical outcome measure
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 months (N, n, %) 286 251 87.8 289 236 81.7
VCSS (n, mean, SD) 221 1.6 1.7 205 1.4 1.7
Presence of residual varicosities
Assessed by participant (N, n, %) 232 190 81.9 224 146 65.2
VAS (n, mean, SD) 232 2.3 1.9 224 1.4 1.6
Assessed by research nurse (N, n, %) 232 149 64.2 224 110 49.1
VAS (n, mean, SD) 232 1.2 1.3 224 0.7 1.0
CEAP classification
C0 No visible or palpable signs of venous disease (N, n, %) 222 60 27.0 212 74 34.9
C1 Telangiectasis or reticular veins < 3mm (N, n, %) 222 81 36.5 212 85 40.1
C2 Varicose veins > 3mm (N, n, %) 222 53 23.9 212 31 14.6
C3 Oedema (N, n, %) 222 11 5.0 212 3 1.4
C4 Skin and subcutaneous changes (N, n, %) 222 0 0.0 212 4 1.9
C4a Pigmentation or eczema (N, n, %) 222 15 6.8 212 12 5.7
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 222 1 0.5 212 1 0.5
C5 Healed venous ulcer (N, n, %) 222 1 0.5 212 2 0.9
C6 Active venous ulcer (N, n, %) 222 0 0.0 212 0 0.0
COMPARISON OF SURGERY AND FOAM SCLEROTHERAPY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Both the participant and nurse assessments (as assessed by the VAS) showed that there were fewer
residual varicose veins for surgery than for foam at both follow-up time points [p< 0.001 (patient at
6 weeks –0.99, 95% CI –1.31 to –0.68, and at 6 months –0.95, 95% CI –1.27 to –0.63; nurse at 6 weeks
–0.87, 95% CI –1.09 to –0.65, and at 6 months –0.50, 95% CI –0.71 to –0.30)].
The CEAP classification is presented for completeness, although it is generally accepted that this should
not be used as a measure of treatment outcome.72 By 6 months, 75% of those in the surgery arm were
classed as CEAP C0 or C1, compared with 64% of those in the foam sclerotherapy arm.
Ablation rates
These are shown in Tables 32 and 33 for 6 weeks and 6 months respectively. The overall statistical
analyses for the whole leg and the GSV only are shown in Table 34. The number of participants
undergoing treatment to the SSV alone or in combination with the GSV was small, and therefore these
subgroups were not subjected to statistical analysis.
For the whole leg, the rate of successful ablation was significantly higher in the surgery group than in the
foam sclerotherapy group at 6 weeks and 6 months (6 months OR 3.37, 95% CI 2.26 to 5.02; p< 0.001).
Similar results were obtained for treatment to the GSV only at both time points (6 months OR 4.94,
95% CI 3.07 to 7.93; p< 0.001).
Pain
Immediately after treatment, the mean pain score for those randomised to surgery was 2.4 (SD 2.6)
compared with 2.2 (SD 2.0) for those randomised to foam sclerotherapy (see Appendix 2, Table 106).
At 6 weeks, the patients’ recollection of pain during treatment was higher than that recorded after
treatment, and appeared to be higher for those randomised to surgery than for those randomised to foam
sclerotherapy [4 (SD 3.0) vs. 3 (SD 2.4)]. The patients’ recollection of pain during recovery also appeared
higher in the surgery group [4.3 (SD 2.8) vs. 3 (SD 2.4)].
TABLE 31 Estimates of the effect of treatment on clinical outcomes: comparison of surgery with foam sclerotherapy
Sensitivity analysis
Randomised to foam
sclerotherapy
Randomised to
surgery Surgery vs. foama
n Mean SD n Mean SD Effect size 95% CI p-value
VCSS at baseline 286 4.9 2.6 289 5.1 2.5 N/A N/A N/A
VCSS at 6 weeks 251 2.2 2.0 230 1.8 2.0 –0.52 –0.85 to –0.19 0.002
VCSS at 6 months 221 1.6 1.7 205 1.4 1.7 –0.23 –0.53 to 0.07 0.130
Patient VASb at baseline 286 5.4 2.2 289 5.6 2.3 N/A N/A N/A
Patient VASb at 6 weeks 261 2.6 2.0 242 1.7 1.8 –0.99 –1.31 to –0.68 < 0.001
Patient VASb at 6 months 232 2.3 1.9 224 1.4 1.6 –0.95 –1.27 to –0.63 < 0.001
Nurse VASc at baseline 286 3.9 2.1 289 4.0 2.2 N/A N/A N/A
Nurse VASc at 6 weeks 261 1.7 1.6 242 0.8 1.0 –0.87 –1.09 to –0.65 < 0.001
Nurse VASc at 6 months 232 1.2 1.3 224 0.7 1.0 –0.50 –0.71 to –0.30 < 0.001
N/A, not applicable.
a Where the effect size is negative, this favours surgery.
b Patient assessment of presence of varicose veins/residual varicosities.
c Nurse assessment of presence of varicose veins/residual varicosities.
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TABLE 32 Anatomical success at 6 weeks: comparison of surgery with foam sclerotherapy
Anatomical success Randomised to foam sclerotherapy Randomised to surgery
Duplex assessment at 6 weeks (N, n, %) 286 265 92.7 289 251 86.9
GSV involvement only
Complete success (N, n, %) 205 112 54.6 192 162 84.4
Partial success (N, n, %) 205 56 27.3 192 21 10.9
without reflux (N, n, %) 205 47 22.9 192 12 6.3
with reflux (N, n, %) 205 9 4.4 192 9 4.7
Failure (N, n, %) 205 37 18.0 192 9 4.7
SSV involvement only
Complete success (N, n, %) 16 9 56.3 17 5 29.4
Partial success (N, n, %) 16 5 31.3 17 9 52.9
without reflux (N, n, %) 16 5 31.3 17 7 41.2
with reflux (N, n, %) 16 0 0.0 17 2 11.8
Failure (N, n, %) 16 2 12.5 17 3 17.6
GSV and SSV involvement
GSV
Complete success (N, n, %) 29 13 44.8 25 20 80.0
Partial success (N, n, %) 29 8 27.6 25 3 12.0
without reflux (N, n, %) 29 6 20.7 25 3 12.0
with reflux (N, n, %) 29 1 3.4 25 0 0.0
Failure (N, n, %) 29 8 27.6 25 2 8.0
SSV
Complete success (N, n, %) 27 5 18.5 23 2 8.7
Partial success (N, n, %) 27 4 14.8 23 5 21.7
without reflux (N, n, %) 27 3 11.1 23 2 8.7
with reflux (N, n, %) 27 0 0.0 23 3 13.0
Failure (N, n, %) 27 18 66.7 23 16 69.6
Overall treatment of study leg
Complete success (N, n, %) 246 125 50.8 230 167 72.6
Partial success (N, n, %) 246 77 31.3 230 51 22.2
without reflux (N, n, %) 246 64 26.0 230 34 14.8
with reflux (N, n, %) 246 13 5.3 230 17 7.4
Failure (N, n, %) 246 44 17.9 230 12 5.2
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TABLE 33 Anatomical success at 6 months: comparison of surgery with foam sclerotherapy
Anatomical success Randomised to foam sclerotherapy Randomised to surgery
Clinic assessment at 6 months (N, n, %) 286 251 87.8 289 236 81.7
GSV involvement only
Complete success (N, n, %) 182 79 43.4 173 135 78.0
Partial success (N, n, %) 182 44 24.2 173 24 13.9
without reflux (N, n, %) 182 35 19.2 173 4 2.3
with reflux (N, n, %) 182 9 4.9 173 20 11.6
Failure (N, n, %) 182 59 32.4 173 14 8.1
SSV involvement only
Complete success (N, n, %) 17 7 41.2 14 4 28.6
Partial success (N, n, %) 17 3 17.6 14 4 28.6
without reflux (N, n, %) 17 2 11.8 14 4 28.6
with reflux (N, n, %) 17 1 5.9 14 0 0.0
Failure (N, n, %) 17 7 41.2 14 6 42.9
GSV and SSV involvement
GSV
Complete success (N, n, %) 26 6 23.1 21 16 76.2
Partial success (N, n, %) 26 7 26.9 21 2 9.5
without reflux (N, n, %) 26 6 23.1 21 1 4.8
with reflux (N, n, %) 26 1 3.8 21 1 4.8
Failure (N, n, %) 26 13 50.0 21 3 14.3
SSV
Complete success (N, n, %) 23 3 13.0 20 2 10.0
Partial success (N, n, %) 23 2 8.7 20 1 5.0
without reflux (N, n, %) 23 2 8.7 20 1 5.0
with reflux (N, n, %) 23 0 0.0 20 0 0.0
Failure (N, n, %) 23 18 78.3 20 17 85.0
Overall treatment of study leg
Complete success (N, n, %) 221 89 40.3 206 139 67.5
Partial success (N, n, %) 221 59 26.7 206 45 21.8
without reflux (N, n, %) 221 49 22.2 206 25 12.1
with reflux (N, n, %) 221 10 4.5 206 20 9.7
Failure (N, n, %) 221 73 33.0 206 22 10.7
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Complications
Procedural complications
The event rate for any complication was similar in both groups (6% for foam and 7% for surgery)
(Table 35). Six participants in the foam group (2%) and three in the surgery group (1%) each experienced
two complications. In patients randomised to surgery, 2.5% had an unscheduled overnight admission
following their treatment (see Table 21).
TABLE 34 Estimates of the effect of treatment on anatomical success: comparison of surgery with
foam sclerotherapy
Sensitivity analysis
Randomised to foam
sclerotherapy
Randomised to
surgery Surgery vs. foama
N n % N n % OR 95% CI p-value
Truncal vein ablation
Complete success at 6 weeks
(whole leg)
246 125 50.8 230 167 72.6
Partial success without reflux at
6 weeks (whole leg)
246 64 26.0 230 34 14.8
Partial success with reflux at 6 weeks
(whole leg)
246 13 5.3 230 17 7.4
Failure at 6 weeks (whole leg) 246 44 17.9 230 12 5.2 3.07 2.05 to 4.59 < 0.001
Complete success at 6 months
(whole leg)
221 89 40.3 206 139 67.5
Partial success without reflux at
6 months (whole leg)
221 49 22.2 206 25 12.1
Partial success with reflux at
6 months (whole leg)
221 10 4.5 206 20 9.7
Failure at 6 months (whole leg) 221 73 33.0 206 22 10.7 3.37 2.26 to 5.02 < 0.001
Complete success at 6 weeks (GSV) 205 112 54.6 192 162 84.4
Partial success without reflux at
6 weeks (GSV)
205 47 22.9 192 12 6.3
Partial success with reflux at
6 weeks (GSV)
205 9 4.4 192 9 4.7
Failure at 6 weeks (GSV) 205 37 18.0 192 9 4.7 5.12 3.09 to 8.48 < 0.001
Complete success at 6 months (GSV) 182 79 43.4 173 135 78.0
Partial success without reflux at
6 months (GSV)
182 35 19.2 173 4 2.3
Partial success with reflux at
6 months (GSV)
182 9 4.9 173 20 11.6
Failure at 6 months (GSV) 182 59 32.4 173 14 8.1 4.94 3.07 to 7.93 < 0.001
a An OR of > 1 favours surgery.
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Later complications
Complications recorded at the time of the 6-week and 6-month assessments are shown in Tables 36
and 37. Estimates of the effect of treatment on complications are summarised across both follow-up time
points in Table 38, with ORs comparing surgery with foam sclerotherapy. The overall complication rate was
lower for surgery than for foam sclerotherapy at 6 weeks (OR 0.40, 95% CI 0.26 to 0.62; p< 0.001) and
at 6 months (OR 0.64, 95% CI 0.44 to 0.92; p= 0.015).
TABLE 35 Procedural complications at time of primary treatment: comparison of surgery with foam sclerotherapy
Procedural complication Randomised to foam sclerotherapy Randomised to surgery
Treated (n) 275 267
Any procedural complicationa (N, n, %) 275 17 6.2 267 19 7.1
Wound haematoma (N, n, %) 275 1 0.4 267 1 0.4
Damage to major artery (N, n, %) 275 0 0.0 267 0 0.0
Damage to major vein (N, n, %) 275 0 0.0 267 0 0.0
Damage to major nerve (N, n, %) 275 0 0.0 267 0 0.0
Bleeding (N, n, %) 275 0 0.0 267 2 0.7
Visual disturbance/blurred vision (N, n, %) 275 4 1.5 267 0 0.0
Extravasation of foam sclerotherapy (N, n, %) 275 0 0.0 267 1 0.4
Allergic/anaphylactoid reaction (N, n, %) 275 0 0.0 267 0 0.0
Stroke (N, n, %) 275 0 0.0 267 0 0.0
Transient ischaemic attack (N, n, %) 275 0 0.0 267 0 0.0
Myocardial infarction (N, n, %) 275 0 0.0 267 0 0.0
Intra-arterial injection (N, n, %) 275 0 0.0 267 0 0.0
Epileptic fit (N, n, %) 275 0 0.0 267 0 0.0
Headache (N, n, %) 275 2 0.7 267 1 0.4
Transient confusion (N, n, %) 275 0 0.0 267 0 0.0
Panic attack (N, n, %) 275 1 0.4 267 0 0.0
Malaise (N, n, %) 275 0 0.0 267 0 0.0
Cough (N, n, %) 275 1 0.4 267 0 0.0
Chest tightness/heaviness (N, n, %) 275 2 0.7 267 0 0.0
Vasovagal (N, n, %) 275 3 1.1 267 1 0.4
Anaesthetic side effects (N, n, %) 275 0 0.0 267 7 2.6
Sickness (N, n, %) 275 0 0.0 267 4 1.5
Muscle pains (N, n, %) 275 0 0.0 267 1 0.4
Sore throat (N, n, %) 275 0 0.0 267 3 1.1
Damage to teeth, lip or tongue (N, n, %) 275 0 0.0 267 0 0.0
Other procedural complication (N, n, %) 275 9 3.3 267 8 3.0
a Some participants experienced more than one procedural complication.
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TABLE 36 Complications at 6 weeks: comparison of surgery with foam sclerotherapy
Complication Randomised to foam sclerotherapy Randomised to surgery
Clinic assessment at 6 weeks (N, n, %) 286 265 92.7 289 251 86.9
Any complication at 6 weeks (N, n, %) 265 219 82.6 251 168 66.9
Numbness (N, n, %) 265 15 5.7 251 45 17.9
Persistent bruising (N, n, %) 265 49 18.5 251 32 12.7
Persist tenderness/discomfort (N, n, %) 265 122 46.0 251 79 31.5
Skin loss/ulceration (N, n, %) 265 2 0.8 251 1 0.4
Lumpiness (N, n, %) 265 171 64.5 251 83 33.1
Development of thread vein (N, n, %) 265 27 10.2 251 21 8.4
Skin staining (N, n, %) 265 105 39.6 251 20 8.0
Wound infection (N, n, %) 265 2 0.8 251 23 9.2
Backache (N, n, %) 265 5 1.9 251 9 3.6
Headache (N, n, %) 265 13 4.9 251 4 1.6
DVT (N, n, %) 265 3 1.1 251 0 0.0
Pulmonary embolus (N, n, %) 265 0 0.0 251 0 0.0
Stroke (N, n, %) 265 0 0.0 251 0 0.0
Myocardial infarction (N, n, %) 265 0 0.0 251 0 0.0
Loss of vision (N, n, %) 265 4 1.5 251 0 0.0
Damage to major artery (N, n, %) 265 0 0.0 251 0 0.0
Damage to major vein (N, n, %) 265 1 0.4 251 0 0.0
Damage to motor nerve (N, n, %) 265 0 0.0 251 0 0.0
Other complication (N, n, %) 265 16 6.0 251 20 8.0
TABLE 37 Complications at 6 months: comparison of surgery with foam sclerotherapy
Complication Randomised to foam sclerotherapy Randomised to surgery
Clinic assessment at 6 months (N, n, %) 286 251 87.8 289 236 81.6
Any complication at 6 months (N, n, %) 251 144 57.4 236 109 46.2
Numbness (N, n, %) 251 10 4.0 236 37 15.6
Persistent bruising (N, n, %) 251 38 15.2 236 40 17.0
Skin loss/ulceration (N, n, %) 251 2 0.8 236 0 0.0
Lumpiness (N, n, %) 251 67 26.6 236 17 7.2
Development of thread vein (N, n, %) 251 34 13.6 236 26 11.0
Skin staining (N, n, %) 251 92 36.6 236 24 10.2
DVT (N, n, %) 251 2 0.8 236 0 0.0
Pulmonary embolus (N, n, %) 251 0 0.0 236 0 0.0
Other (N, n, %) 251 8 3.2 236 12 5.0
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The event rates for cutaneous numbness (6 weeks OR 3.98, 95% CI 2.11 to 7.50; p< 0.001, and
6 months OR 5.39, 95% CI 2.50 to 11.62; p< 0.001) were significantly higher for surgery than for foam
sclerotherapy. Wound infection occurred in 9.2% of the surgical patients at 6 weeks – a much higher
proportion than the 0.8% of foam patients with wound infection – but clearly this complication only
occurred in foam patients who had treatment other than that to which they had been randomised.
However, the rates for lumpiness (6 weeks OR 0.23, 95% CI 0.15 to 0.34; p< 0.001, and 6 months OR
0.18, 95% CI 0.10 to 0.33; p< 0.001), skin staining (6 weeks OR 0.12, 95% CI 0.07 to 0.21; p< 0.001,
and 6 months OR 0.16, 95% CI 0.10 to 0.28; p< 0.001), persistent tenderness (6 weeks OR 0.52, 95% CI
0.36 to 0.77; p= 0.001) and headache (6 weeks OR 0.31, 95% CI 0.10 to 0.98; p= 0.047) were all
significantly higher for foam sclerotherapy than for surgery. There were no differences for persistent
bruising, skin loss/ulceration or development of thread vein at either time point. There was also no
difference for backache at 6 weeks. At 6 months, data on wound infection, persistent tenderness,
backache and headache were not collected.
TABLE 38 Estimates of the effect of treatment on complications: comparison of surgery with foam sclerotherapy
Complication type
Randomised
to foam
sclerotherapy
Randomised to
surgery Surgery vs. foama
N n % N n % OR 95% CI p-value
Procedural complications at time of
treatment
275 17 6.2 267 19 7.1 1.07 0.55 to 2.09 0.848
Any complication at 6 weeks 265 219 82.6 251 168 66.9 0.40 0.26 to 0.62 < 0.001
Any complication at 6 months 251 144 57.4 236 109 46.2 0.64 0.44 to 0.92 0.015
Numbness at 6 weeks 265 15 5.7 251 45 17.9 3.98 2.11 to 7.50 < 0.001
Numbness at 6 months 251 10 4.0 236 37 15.6 5.39 2.50 to 11.62 < 0.001
Persistent bruising at 6 weeks 265 49 18.5 251 32 12.7 0.63 0.37 to 1.06 0.080
Persistent bruising at 6 months 251 38 15.2 236 40 17.0 1.16 0.70 to 1.92 0.576
Persist tenderness/discomfort at 6 weeks 265 122 46.0 251 79 31.5 0.52 0.36 to 0.77 0.001
Skin loss/ulceration at 6 weeks 265 2 0.8 251 1 0.4 0.64 0.04 to 10.32 0.750
Skin loss/ulceration at 6 months 251 2 0.8 236 0 0.0 N/C N/C N/C
Lumpiness at 6 weeks 265 171 64.5 251 83 33.1 0.23 0.15 to 0.34 < 0.001
Lumpiness at 6 months 251 67 26.6 236 17 7.2 0.18 0.10 to 0.33 < 0.001
Development of thread vein at 6 weeks 265 27 10.2 251 21 8.4 0.75 0.40 to 1.40 0.364
Development of thread vein at 6 months 251 34 13.6 236 26 11.0 0.78 0.44 to 1.38 0.390
Skin staining at 6 weeks 265 105 39.6 251 20 8.0 0.12 0.07 to 0.21 < 0.001
Skin staining at 6 months 251 92 36.6 236 24 10.2 0.16 0.10 to 0.28 < 0.001
Backache at 6 weeks 265 5 1.9 251 9 3.6 2.16 0.67 to 6.95 0.198
Headache at 6 weeks 265 13 4.9 251 4 1.6 0.31 0.10 to 0.98 0.047
N/C, not calculable.
a An OR of > 1 favours foam sclerotherapy; an OR of < 1 favours surgery.
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Serious adverse events
Eleven SAEs were noted among those randomised to foam. Among these were three DVTs; all were assessed
as related to treatment and expected. The other eight SAEs were not related to the foam treatment; full
details are given in Table 39. Ten SAEs were noted among those randomised to surgery. Four of these
(groin infection, post-operative infection, post-operative haematoma, injury to peroneal nerve) were assessed
as being related to treatment. The other six SAEs were not related to treatment (see Table 39).
TABLE 39 Serious adverse events detected up to the time of the 6-months follow-up
Randomised
Treatment
prior to SAE Description of event
Related to
treatment? Expected?
Foam Foam DVT (non-occlusive tongue of thrombus extending from the
SFJ to the common femoral vein); asymptomatic
Yes Yes
Foam Foam Thrombophlebitis extending through the perforator
mid-/proximal calf causing small DVT in the medial
gastrocnemius vein
Yes Yes
Foam Foam DVT (involving < 20% of lumen) in the right common
femoral vein (asymptomatic)
Yes Yes
Foam Foam Possible transient ischaemic attack. CT scan has shown
ill-defined areas in subcortical white matter in both
hemispheres; unclear if ischaemia or demyelinating
No Yes
Foam Foam Headache associated with pre-syncope and vomiting
(history of migraine with hemiplegia)
No Yes
Foam No treatment Prior to treatment experienced right hemisphere
cerebrovascular accident (stroke)
No Yes
Foam No treatment Provisional diagnosis of myeloma No No
Foam Foam Chest pain – thought to be musculoskeletal No No
Foam Foam Urinary retention following elective laparoscopic left
inguinal hernia repair
No No
Foam Foam Breast cancer No No
Foam Foam Road traffic accident – no spinal or bony injury No No
Surgery Surgery Groin infection requiring further surgery for evacuation of
haematoma
Yes Yes
Surgery Surgery Injury to motor nerve (peroneal); presumably as a result of
trauma during phlebectomies
Yes Yes
Surgery Surgery Post-operative haematoma; deranged liver function tests Yes Yes
Surgery Surgery Post-operative infection – abscess to left calf; abscess of the
pilonidal sinus
Yes Yes
Surgery Surgery Surgery to wrong vein No No
Surgery Surgery Sectioned under the Mental Health Act No No
Surgery Surgery Road traffic accident – suffered right shoulder and neck
pain
No No
Surgery Surgery Endoscopic excision of an anal polyp No No
Surgery Surgery Acute upper-left quadrant pain – likely to have been caused
by gall stone and cholecystitis
No No
Surgery Surgery Breast enlargement No No
CT, computerised tomography.
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Process evaluation: Illness Perception Questionnaire – Revised
Detailed descriptive results of the IPQ-R are given in Appendix 2 (see Table 108). There is little change in
either randomised group in mean identity scores or the percentage of symptoms correctly identified as
being related to varicose veins between baseline (recruitment) and after the participant is informed of his
or her randomisation. The scores in each randomised group were similar at both time points. By 6 months,
both measures of illness identity had fallen.
There is little difference between baseline and post-randomisation scores for all other domains. Scores
were also similar between randomised groups at baseline and post treatment. Personal control and illness
coherence scores increased marginally between baseline and 6 months; all other domain scores fell within
this time scale.
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Chapter 6 Comparison of surgery, endovenous
laser ablation and foam sclerotherapy
This chapter reports the results of the three-arm comparison of surgery, EVLA and foam sclerotherapy,using data from the eight centres which randomised participants to all three treatment groups. This
chapter will focus on comparing surgery with EVLA, and EVLA with foam sclerotherapy. Comparisons
between foam sclerotherapy and surgery have been made using data from all centres and are reported in
Chapter 5. A discussion of the results presented in this chapter is included in Chapter 7.
Participants
Six hundred and thirty-six participants were randomised in the three-arm centres, of which there were six
post-randomisation exclusions, leaving a total of 630 participants included in this analysis (207 in the foam
sclerotherapy arm, 213 in the surgery arm and 210 in the EVLA arm). The CONSORT diagram (see Figure 2)
describes the flow of participants in the trial.
The proportion receiving treatment as allocated appeared to be higher for EVLA (97%) than for foam
sclerotherapy (91%) and surgery (85%). Retention appeared to be lower for surgery, both for the
follow-up clinic assessments and completion of participant questionnaires, than for foam sclerotherapy and
EVLA. The 6-weeks clinic was attended by 85% of participants randomised to surgery compared with 91%
for foam sclerotherapy and 92% for EVLA. At the 6-months follow-up, the attendance rates were 78%,
86% and 87% for surgery, foam sclerotherapy and EVLA respectively.
The 6-weeks questionnaire was completed by 81% of participants randomised to surgery compared with
88% for foam sclerotherapy and 89% for EVLA. At 6 months, the questionnaires were completed by
74%, 82% and 83% of participants for surgery, foam sclerotherapy and EVLA respectively. The largest
proportion of withdrawals from the study at 6 months was in the surgery arm (13%), compared with foam
sclerotherapy (7%) and EVLA (4%).
Baseline characteristics
Demographic details
The baseline characteristics of study participants are shown in Table 40. There was a good balance
between groups for most factors, particularly for age and sex, which were minimisation variables. There
was a slight imbalance between groups in terms of bilateral disease. The data shown in Table 11 were also
used in the analysis when adjusting for minimisation factors.
Quality of life
At baseline, the QoL for the surgery group appeared slightly worse than for the other two groups, and this
was reflected in the AVVQ score, EQ-5D and each of the SF-36 components and domain scores (Table 41).
The mean baseline AVVQ score was 18.1 (SD 9.1) for surgery, 17.8 (SD 9.1) for EVLA and 17.4 (SD 9.7) for
foam (a higher AVVQ score indicates worse QoL).
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TABLE 40 Baseline characteristics of study participants: comparison of EVLA with foam sclerotherapy and surgery
with EVLA
Participant characteristics
Randomised to
EVLA
Randomised to
foam sclerotherapy
Randomised to
surgery
Randomised (n) 210 207 213
Age (n, mean, range) 210 49.7 18–80 207 48.3 19–78 213 48.4 22–85
Female (N, n, %) 210 120 57.1 207 119 57.5 213 121 56.8
BMI (kg/m2) (n, mean, range) 195 27.0 17–42 192 27.1 17–44 188 27.8 20–44
Employment status
Self-employed (N, n, %) 206 21 10.2 206 20 9.7 206 20 9.7
Employed (N, n, %) 206 120 58.3 206 123 59.7 206 138 67.0
Other (N, n, %) 206 65 31.6 206 63 30.6 206 48 23.3
Laterality
Unilateral (N, n, %) 210 153 72.9 207 157 75.8 213 148 69.5
Bilateral (N, n, %) 210 57 27.1 207 50 24.2 213 65 30.5
Previous history of DVT (N, n, %) 206 6 2.9 205 2 1.0 210 7 3.3
Previous treatment to contralateral leg
(N, n, %)
208 27 13.0 205 22 10.7 211 20 9.5
Foam sclerotherapy (N, n, %) 208 4 1.9 205 6 2.9 211 1 0.5
Surgery (N, n, %) 208 19 9.1 205 16 7.8 211 16 7.6
EVLA (N, n, %) 208 3 1.4 205 0 0.0 211 3 1.4
Previous sclerotherapy to tributaries of study
leg (N, n, %)
208 3 1.4 205 0 0.0 211 3 1.4
TABLE 41 Quality of life at baseline: comparison of EVLA with foam sclerotherapy and surgery with EVLA
QoL measure
Randomised to
EVLA
Randomised to
foam sclerotherapy
Randomised to
surgery
Randomised (n) 210 207 213
AVVQ score (n, mean, SD) 210 17.8 9.1 206 17.4 9.7 210 18.1 9.1
EQ-5D score (n, mean, SD) 206 0.79 0.17 202 0.79 0.19 207 0.78 0.18
VAS (n, mean, SD) 206 80.6 16.3 205 80.6 16.3 210 80.0 15.5
SF-36 summary scores
Physical component summary score (n, mean, SD) 204 48.6 7.9 199 48.4 8.7 202 48.2 9.0
Mental component summary score (n, mean, SD) 204 51.9 9.1 199 51.8 9.2 202 50.8 9.9
SF-36 subscale scores
Physical functioning (n, mean, SD) 208 50.2 8.3 205 49.8 8.6 207 50.0 8.5
Role physical (n, mean, SD) 208 50.1 8.3 206 50.2 9.1 207 49.0 10.1
Bodily pain (n, mean, SD) 207 47.3 8.5 206 47.6 9.2 208 46.0 9.7
General health (n, mean, SD) 209 49.5 8.3 202 49.1 8.4 210 49.2 8.7
Vitality (n, mean, SD) 210 51.5 9.2 206 51.1 9.8 209 50.2 9.5
Social functioning (n, mean, SD) 207 50.8 8.9 205 50.9 8.4 209 49.8 9.9
Role emotional (n, mean, SD) 208 51.1 8.4 205 51.0 8.8 206 50.1 10.0
Mental health (n, mean, SD) 209 51.6 9.2 206 51.3 9.6 208 50.7 10.2
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Physical activity
There was a good balance between the groups in terms of physical activity at baseline (Table 42).
Varicose vein characteristics
Tables 43 and 44 show the baseline characteristics of the varicose veins in the study leg and the
contralateral leg. The groups are well balanced across the majority of factors (except for deep-vein reflux,
where the rate was 18% for foam, 14% for EVLA and 9% for surgery).
TABLE 42 Physical activity at baseline: comparison of EVLA with foam sclerotherapy and surgery with EVLA
Physical activity
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 210 207 213
Physical activity at work
Mostly sitting (N, n, %) 202 27 13.4 201 30 14.9 205 30 14.6
Mostly standing or walking (N, n, %) 202 47 23.3 201 60 29.9 205 58 28.3
Definite physical effort (N, n, %) 202 52 25.7 201 43 21.4 205 62 30.2
Vigorous physical effort (N, n, %) 202 16 7.9 201 11 5.5 205 9 4.4
Not in employment (N, n, %) 202 60 29.7 201 57 28.4 205 46 22.4
Physical activity in previous week
Physical activities (N, n, %) 204 95 46.6 205 93 45.4 206 94 45.6
Cycling (N, n, %) 197 32 16.2 201 23 11.4 202 38 18.8
Walking (N, n, %) 204 202 99.0 206 201 97.6 204 199 97.5
Housework/childcare (N, n, %) 203 177 87.2 205 186 90.7 204 178 87.3
Gardening (N, n, %) 203 114 56.2 204 130 63.7 203 118 58.1
Usual walking pace
Slow (N, n, %) 205 17 8.3 204 12 5.9 207 14 6.8
Steady/average (N, n, %) 205 101 49.3 204 103 50.5 207 111 53.6
Brisk (N, n, %) 205 72 35.1 204 78 38.2 207 67 32.4
Fast (N, n, %) 205 15 7.3 204 11 5.4 207 15 7.2
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TABLE 43 Baseline characteristics of study leg: comparison of EVLA with foam sclerotherapy and surgery with EVLA
Study leg vein characteristics
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 210 207 213
Study leg
Right (N, n, %) 210 108 51.4 207 103 49.8 213 101 47.4
Left (N, n, %) 210 102 48.6 207 104 50.2 213 112 52.6
Saphenous involvement
GSV only (N, n, %) 210 182 86.7 207 175 84.5 213 184 86.4
Widest diameter (mm) (n, mean, range) 162 9.1 3–15 154 8.2 4–15 159 8.6 4–15
Reflux above knee only (N, n, %) 157 151 96.2 146 138 94.5 152 150 98.7
Reflux above and below knee (N, n, %) 157 6 3.8 146 8 5.5 152 2 1.3
SSV only (N, n, %) 210 14 6.7 207 14 6.8 213 16 7.5
Widest diameter (mm) (n, mean, range) 13 7.1 5–10 13 6.8 3–10 12 7.8 4–15
GSV and SSV (N, n, %) 210 14 6.7 207 18 8.7 213 13 6.1
Widest diameter: GSV (mm) (n, mean, range) 13 6.3 4–15 16 7.5 4–14 12 7.6 3–15
Widest diameter: SSV (mm) (n, mean, range) 10 6.8 3–15 15 4.9 3–10 11 5.1 3–7
Reflux above knee only (N, n, %) 12 6 50.0 13 7 53.8 9 5 55.6
Reflux above and below knee (N, n, %) 12 6 50.0 13 6 46.2 9 4 44.4
Deep-vein reflux (N, n, %) 205 28 13.7 201 36 17.9 207 19 9.2
CEAP classification
C0 No visible or palpable signs of venous disease
(N, n, %)
209 0 0.0 207 0 0.0 211 0 0.0
C1 Telangiectasis or reticular veins < 3mm
(N, n, %)
209 0 0.0 207 0 0.0 211 0 0.0
C2 Varicose veins > 3mm (N, n, %) 209 113 54.1 207 122 58.9 211 107 50.7
C3 Oedema (N, n, %) 209 28 13.4 207 28 13.5 211 29 13.7
C4 Skin and subcutaneous changes (N, n, %) 209 17 8.1 207 21 10.1 211 28 13.3
C4a Pigmentation or eczema (N, n, %) 209 34 16.3 207 29 14.0 211 38 18.0
C4b Lipodermatosclerosis or atrophie blanche
(N, n, %)
209 5 2.4 207 2 1.0 211 0 0.0
C5 Healed venous ulcer (N, n, %) 209 9 4.3 207 3 1.4 211 5 2.4
C6 Active venous ulcer (N, n, %) 209 3 1.4 207 2 1.0 211 4 1.9
VCSS (n, mean, SD) 207 5.0 2.5 206 4.8 2.5 210 5.0 2.4
Presence of varicose veins
Assessed by participant (N, n, %) 210 209 99.5 207 207 100 213 213 100
VAS (n, mean, SD) 210 5.5 2.3 207 5.2 2.2 213 5.6 2.3
Assessed by research nurse (N, n, %) 210 210 100 207 207 100 213 212 99.5
VAS (n, mean, SD) 210 3.6 2.2 207 3.6 2.1 213 3.7 2.3
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Treatment received
Tables 45–48 summarise the primary interventions received (i.e. excluding any delayed secondary foam
treatments). For participants randomised to EVLA, 99% of those who received treatment had their
treatment as randomised. The equivalent proportions were 95% and 93% in the foam sclerotherapy and
surgery arms respectively. Details of those not receiving their randomised intervention are given in
Chapter 4.
Procedure and treatment time
Treatment to non-truncal varicosities at the time of the primary intervention was performed in 87% of
patients in the surgery arm, 30% in the foam sclerotherapy arm and 80% in the one study site in which
concurrent EVLA and phlebectomies were performed (Hull). In all other centres, patients who were
randomised to EVLA underwent delayed treatment as required, either at or after the 6-weeks follow-up, as
stipulated in the protocol. Fewer patients in the foam arm (3%) appeared to have their contralateral leg
treated at the same time than in the surgery (12%) and EVLA (10%) arms.
The mean treatment duration (the time taken from preparation of the patient to completion of bandaging)
was shortest for those randomised to foam sclerotherapy (18.9, SD 10.2, minutes) (see Table 45). This
compares to the other, far longer procedures for surgery (mean duration 51.5, SD 22.9, minutes) and
EVLA (45.9, SD 24.6, minutes). Fewer consultants and more trainees performed surgery compared with the
other treatments. Fifty-two per cent of surgery participants received treatment from a consultant surgeon,
compared with 79% in the foam sclerotherapy group and 73% in the EVLA group. Trainees performed
38% of treatments in the surgical group, 23% in the EVLA group and 10% in the foam sclerotherapy
group. The remainder of procedures were performed by the nurse consultants or staff grades.
Nearly all patients in the surgery group (97%) had a general anaesthetic, with five receiving an epidural/
spinal anaesthetic (see Table 46). The anaesthetist was a consultant in 82% of cases.
TABLE 44 Baseline characteristics of contralateral leg: comparison of EVLA with foam sclerotherapy and surgery
with EVLA
Non-study leg vein characteristics
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Randomised (n) 210 207 213
Participants with bilateral disease (N, n, %) 210 57 27.1 207 50 24.2 213 65 30.5
CEAP classification
C2 Varicose veins > 3mm (N, n, %) 55 36 65.5 47 30 63.8 62 31 50.0
C3 Oedema (N, n, %) 55 8 14.5 47 7 14.9 62 10 16.1
C4 Skin and subcutaneous changes (N, n, %) 55 4 7.3 47 3 6.4 62 7 11.3
C4a Pigmentation or eczema (N, n, %) 55 6 10.9 47 6 12.8 62 13 21.0
C4b Lipodermatosclerosis or atrophie blanche (N, n, %) 55 1 1.8 47 0 0.0 62 0 0.0
C5 Healed venous ulcer (N, n, %) 55 0 0.0 47 1 2.1 62 0 0.0
C6 Active venous ulcer (N, n, %) 55 0 0.0 47 0 0.0 62 1 1.6
VCSS (n, mean, SD) 54 3.6 2.3 46 4.1 2.4 61 4.2 2.4
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TABLE 46 Description of anaesthetic
Anaesthetic details
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Received surgery (N, n, %) 2a 3b 182
Type of anaesthetic
General (N, n, %) 2 2 100.0 3 3 100.0 179 174 97.2
Epidural/spinal (N, n, %) 2 0 0.0 3 0 0.0 179 5 2.8
Grade of anaesthetist
Consultant (N, n, %) 2 1 50.0 3 2 66.7 176 145 82.4
Associate specialist (N, n, %) 2 1 50.0 3 0 0.0 176 2 1.1
Registrar (N, n, %) 2 0 0.0 3 1 33.3 176 25 14.2
Staff grade (N, n, %) 2 0 0.0 3 0 0.0 176 4 2.3
Senior house officer (N, n, %) 2 0 0.0 3 0 0.0 176 0 0.0
a Randomised to EVLA but received surgery.
b Randomised to foam but received surgery.
TABLE 45 Description of primary interventions: comparison of EVLA with foam sclerotherapy and surgery
with EVLA
Primary intervention
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Treated (n) 205 197 195
Received foam (N, n, %) 205 0 0.0 197 188 95.4 195 5 2.6
Received surgery (N, n, %) 205 2 1.0 197 3 1.5 195 182 93.3
Received EVLA (N, n, %) 205 203 99.0 197 6 3.0 195 8 4.1
Treatment time (minutes) (n, mean, SD) 189 45.9 24.6 174 18.9 10.2 178 51.5 22.9
Grade of surgeon
Consultant (N, n, %) 201 146 72.6 195 154 79.0 190 99 52.1
Consultant nurse (N, n, %) 201 0 0.0 195 16 8.2 190 3 1.6
Staff grade (supervised) (N, n, %) 201 1 0.5 195 3 1.5 190 10 5.3
Staff grade (unsupervised) (N, n, %) 201 7 3.5 195 2 1.0 190 6 3.2
Trainee (supervised) (N, n, %) 201 15 7.5 195 11 5.6 190 35 18.4
Trainee (unsupervised) (N, n, %) 201 32 15.9 195 9 4.6 190 37 19.5
Treatment to non-truncal varicosities (N, n, %) 61a 49 80.3 192 57 29.7 188 163 86.7
Concurrent contralateral treatment (N, n, %) 203 20 9.9 193 6 3.1 192 23 12.0
Subcutaneous heparin (or derivative) (N, n, %) 202 14 6.9 186 13 7.0 181 72 39.8
Overnight hospitalisation
Planned (N, n, %) 197 0 0.0 190 0 0.0 161 6 3.7
Unplanned (N, n, %) 197 0 0.0 190 0 0.0 161 5 3.1
Bandaging not according to protocol (N, n, %) 194 18 9.3 194 101b 52.1 185 23 12.4
Recommended duration of bandaging (if not for
10 days) (n, mean, SD)
17 7.4 1.7 9 7.0 0.0 21 7.2 2.5
a Treatment to non-truncal varicosities at the same time as EVLA was only offered in one site.
b The majority of these deviations from protocol occurred because the types of bandages and stockings described in the
protocol were not available in the site.
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TABLE 47 Additional description of EVLA
EVLA details Randomised to EVLA
Randomised to
foam sclerotherapy Randomised to surgery
Received EVLA (n) 203 6 8
GSV involvement only
Watts (n, mean, range) 168 13.8 7–30 2 13.0 12–14 5 13.6 12–14
Length (cm) (n, mean, range) 172 40.9 12–79 2 23.5 21–26 7 36.6 21–54
J/cm (n, mean, range) 170 82.5 40–188 2 71.9 67–77 6 71.6 59–91
Wavelength
810 nm (N, n, %) 134 90 67.2 1 1 100.0 5 4 80.0
1064 nm (N, n, %) 134 10 7.5 1 0 0.0 5 0 0.0
1470 nm (N, n, %) 134 34 25.4 1 0 0.0 5 1 20.0
SSV involvement only
Watts (n, mean, range) 13 12.4 7–14 0 N/A N/A 1 14.0 N/A
Length (cm) (n, mean, range) 13 19.4 7–45 0 N/A N/A 1 12.0 N/A
J/cm (n, mean, range) 12 77.5 53–114 0 N/A N/A 1 75.1 N/A
Wavelength
810 nm (N, n, %) 10 7 70.0 0 N/A N/A 1 1 100.0
1064 nm (N, n, %) 10 0 0.0 0 N/A N/A 1 0 0.0
1470 nm (N, n, %) 10 3 30.0 0 N/A N/A 1 0 0.0
GSV and SSV involvement
Watts (GSV) (n, mean, range) 9 17.6 10–30 0 N/A N/A 0 N/A N/A
Length (cm) (GSV) (n, mean, range) 9 39.8 27–56 0 N/A N/A 0 N/A N/A
J/cm (GSV) (n, mean, range) 9 100.3 61–165 0 N/A N/A 0 N/A N/A
Wavelength (GSV)
810nm (N, n, %) 9 3 33.3 0 N/A N/A 0 N/A N/A
1064 nm (N, n, %) 9 3 33.3 0 N/A N/A 0 N/A N/A
1470 nm (N, n, %) 9 3 33.3 0 N/A N/A 0 N/A N/A
Watts (SSV) (n, mean, range) 5 9.6 7–14 0 N/A N/A 0 N/A N/A
Length (cm) (SSV) (n, mean, range) 5 15.6 5–26 0 N/A N/A 0 N/A N/A
J/cm (SSV) (n, mean, range) 5 63.7 36–82 0 N/A N/A 0 N/A N/A
Wavelength (SSV)
810 nm (N, n, %) 3 2 66.7 0 N/A N/A 0 N/A N/A
1064 nm (N, n, %) 3 0 0.0 0 N/A N/A 0 N/A N/A
1470 nm (N, n, %) 3 1 33.3 0 N/A N/A 0 N/A N/A
Foam sclerotherapy to incompetent
distal GSV at time of (or immediately
following) EVLA treatment (N, n, %)
203 0 0.0 6 0 0.0 8 0 0.0
N/A, not applicable.
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Endovenous laser ablation treatment
Details specific to EVLA are shown in Table 47. Pooled across treatment arms, the mean length for the
GSV was 40.5 cm (SD 14.0 cm) and the mean number of joules per centimetre was 82.9 (SD 29.1). The
majority of treatments (73%) were given at 14W with the other treatments being given at 7, 8, 10, 12, 25
or 30W. The wavelengths used were 810 nm (66%), 1470 nm (26%) and 1064 nm in the remainder.
Primary treatment volume of foam
Among those randomised to foam sclerotherapy, the mean total volume of foam received was 9.1 ml
(SD 3.0ml) (see Table 48). In participants receiving treatment to the GSV only, the mean volume of foam
used was 9.3 ml (SD 3.0ml), with 8.2ml (SD 3.0 ml) injected into the GSV and 1.1ml (SD 2.1ml) into
non-truncal varicosities (see Table 48). There were five patients who received foam in excess of the 12ml
set out in the protocol without adverse complications.
Secondary or tertiary foam sclerotherapy treatment
Table 49 also shows the numbers of participants who received secondary or tertiary treatments of foam
sclerotherapy, along with a breakdown of the location of that treatment. Twenty-five foam participants
(14%), 42 EVLA participants (31%) and two surgery participants (1%) received secondary or tertiary
foam treatments.
Bandaging/compression
All participants had a bandage or stocking applied to their study leg, and nearly all of these were full
length. More foam participants (52%) received bandaging not according to protocol than surgery (12%)
and EVLA (9%) participants (see Table 45). Of the 101 cases of foam participants whose bandaging was
not according to protocol, only nine were related to duration and the other 92 were related to the
unavailability of the type of bandaging and stocking specified in the protocol.
TABLE 48 Volume of foam administered at primary treatment of foam
Primary foam treatment
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Received primary treatment of foam (n) 0 188 5a
Volume of foam (ml) (n, mean, range) 0 N/A N/A 188 9.1 2–15 5 7.6 6–10
GSV involvement only (total) (n, mean, range) 0 N/A N/A 158 9.4 2–15 4 7.0 6–8
GSV (n, mean, range) 0 N/A N/A 158 8.2 2–15 4 7.0 6–8
Non-truncal varicosities (n, mean, range) 0 N/A N/A 158 1.2 0–8 4 0.0 0–0
SSV involvement only (total) (n, mean, range) 0 N/A N/A 14 6.4 2–12 1 10.0 10–10
SSV (n, mean, range) 0 N/A N/A 14 5.6 0–12 1 10.0 10–10
Non-truncal varicosities (n, mean, range) 0 N/A N/A 14 0.8 0–5 1 0.0 0–0
GSV and SSV involvement (total) (n, mean, range) 0 N/A N/A 16 9.2 6–13 0 N/A N/A
GSV (n, mean, range) 0 N/A N/A 16 6.8 3–12 0 N/A N/A
SSV (n, mean, range) 0 N/A N/A 16 0.7 0–5 0 N/A N/A
Non-truncal varicosities (n, mean, range) 0 N/A N/A 16 1.7 0–6 0 N/A N/A
N/A, not applicable.
a Patients randomised to surgery but received alternative treatment.
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Treatment outcome: quality of life
The QoL at 6-weeks and 6-months follow-up are shown in Tables 50 and 51, with the corresponding
statistical analysis in Table 52.
Aberdeen Varicose Vein Questionnaire
At 6 weeks and 6 months, QoL measures in all treatment groups appeared better than at baseline.
There was no significant treatment effect for AVVQ when surgery and EVLA were compared at 6 weeks
(0.21, 95% CI −1.38 to 1.79; p= 0.797) or at 6 months (−0.63, 95% CI −2.16 to 0.90; p= 0.419).
The AVVQ was similar for EVLA and foam (at 6 weeks −1.71, 95% CI −3.27 to −0.15; p= 0.032, and
at 6 months −1.06, 95% CI −2.56 to 0.43; p= 0.163).
Sensitivity analyses
There were some missing AVVQ scores at 6 months (27% for surgery and 18% for both EVLA and foam).
Exploratory analysis shows that participants without a valid AVVQ score at 6 months had mean baseline
AVVQ scores of 18.8 (SD 11.7) for foam sclerotherapy, 18.6 (SD 9.3) for surgery and 20.7 (SD 10.5) for
EVLA. Those with an AVVQ score at 6 months had mean baseline scores of 17.1 (SD 9.2) for foam,
17.9 (SD 9.0) for surgery and 17.32 (SD 8.7) for EVLA, indicating that non-respondents had higher
mean scores at baseline and that the extent of this difference is not the same in each group (the biggest
difference was observed in the EVLA arm). The mean AVVQ score at 6 weeks for participants with missing
scores at 6 months is 13.1 (higher than the mean for all EVLA participants), 12.5 for foam sclerotherapy
(slightly higher than the mean for all foam participants) and 8.8 for surgery (lower than the mean for all
surgery participants), indicating that there are differences in the missing data between groups.
TABLE 49 Secondary foam treatment: comparison of EVLA with foam sclerotherapy and surgery with EVLA
Secondary foam treatment
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
No secondary foam treatment (N, n, %) 136 94 69.1 178 153 86.0 167 165 98.8
One secondary foam treatment (N, n, %) 136 39 28.7 178 24 13.5 167 2a 1.2
to GSV (N, n, %) 136 6 4.4 178 8 4.5 167 0 0.0
to SSV (N, n, %) 136 1 0.7 178 2 1.1 167 1a 0.6
to non-truncal varicosities (N, n, %) 136 34 25.0 178 16 9.0 167 1a 0.6
Two secondary foam treatments (N, n, %) 136 3 2.2 178 1 0.6 167 0 0.0
to GSV (N, n, %) 136 1 0.7 178 1 0.6 167 0 0.0
to SSV (N, n, %) 136 0 0.0 178 1 0.6 167 0 0.0
to non-truncal varicosities (N, n, %) 136 3 2.2 178 0 0.0 167 0 0.0
a Patients randomised to surgery but received alternative treatment.
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TABLE 51 Quality of life at 6 months following treatment: comparison of EVLA with foam sclerotherapy and
surgery with EVLA
QoL measure
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Completed 6-months questionnaire (N, n, %) 210 175 83.3 207 170 82.1 213 157 73.7
AVVQ score (n, mean, SD) 173 7.9 8.4 169 8.9 8.1 156 7.6 7.6
EQ-5D score (n, mean, SD) 172 0.90 0.17 167 0.88 0.19 151 0.87 0.21
VAS (n, mean, SD) 172 85.1 11.7 169 83.6 13.2 154 82.5 15.1
SF-36 summary scores
Physical component summary score (n, mean, SD) 170 52.6 7.3 167 52.0 9.2 149 51.9 9.4
Mental component summary score (n, mean, SD) 170 53.5 7.7 167 51.8 9.7 149 51.7 8.9
SF-36 domain
Physical functioning (n, mean, SD) 174 52.7 6.7 169 51.6 8.4 156 51.0 9.3
Role physical (n, mean, SD) 173 52.6 7.4 169 51.9 8.6 157 51.5 8.9
Bodily pain (n, mean, SD) 171 54.3 8.9 168 52.9 9.9 152 53.0 10.8
General health (n, mean, SD) 173 51.9 9.1 170 51.2 9.2 155 51.6 9.7
Vitality (n, mean, SD) 173 54.1 8.5 170 52.7 10.0 155 52.7 9.6
Social functioning (n, mean, SD) 173 52.7 7.9 168 52.2 9.0 154 51.5 9.5
Role emotional (n, mean, SD) 174 52.5 7.8 169 51.3 9.0 155 51.0 9.8
Mental health (n, mean, SD) 173 54.1 7.7 170 51.8 9.9 155 51.4 9.5
TABLE 50 Quality of life at 6 weeks following treatment: comparison of EVLA with foam sclerotherapy and surgery
with EVLA
QoL measure
Randomised to
EVLA
Randomised
to foam
sclerotherapy
Randomised to
surgery
Completed 6-weeks questionnaire (N, n, %) 210 186 88.6 207 183 88.4 213 173 81.2
AVVQ score (n, mean, SD) 184 10.6 8.5 183 11.8 8.6 171 11.0 9.2
EQ-5D score (n, mean, SD) 184 0.89 0.15 181 0.85 0.17 164 0.86 0.18
VAS (n, mean, SD) 185 84.0 14.2 182 80.4 17.1 169 82.5 16.3
SF-36 summary scores
Physical component summary score (n, mean, SD) 181 51.3 7.8 180 49.4 9.0 165 49.1 9.0
Mental component summary score (n, mean, SD) 181 53.6 6.9 180 52.3 9.3 165 51.3 9.6
SF-36 subscale scores
Physical functioning (n, mean, SD) 185 52.5 6.8 182 50.3 9.3 171 51.3 8.2
Role physical (n, mean, SD) 185 51.9 7.6 183 49.7 10.0 172 47.8 10.5
Bodily pain (n, mean, SD) 183 51.4 9.3 181 50.0 9.3 168 48.0 10.2
General health (n, mean, SD) 181 51.8 8.2 181 50.3 9.6 169 51.9 9.1
Vitality (n, mean, SD) 183 54.3 8.2 181 52.3 9.8 169 50.8 9.5
Social functioning (n, mean, SD) 183 52.1 7.2 181 50.9 9.4 168 49.7 10.1
Role emotional (n, mean, SD) 185 52.7 7.2 183 51.0 8.8 171 49.9 10.4
Mental health (n, mean, SD) 183 54.0 7.3 181 52.3 8.8 169 51.8 9.7
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In Tables 53 and 54, different estimates of the effects of treatment on the primary outcome are shown
when all missing AVVQ scores at 6 months were imputed under varying assumptions. When surgery is
compared against EVLA, using the ‘missing not at random’ (MNAR) assumption, the estimate of treatment
effect is −1.02 (95% CI −2.48 to 0.45, p= 0.174), an increase in the effect size estimated in the primary
analysis (see Table 54). When variously adding or subtracting two points to the imputed values obtained
from multiple imputation, either to one arm at a time or to both arms simultaneously, the resulting
estimates range from −0.48 to −1.55 and represent an increase in the effect size in all but one instance
(but always maintaining the same direction of effect). The missing AVVQ values for surgery would need to
be at least 1.7 points lower (or the missing values for EVLA at least 2.6 points higher) than the values
imputed under MNAR for there to be a significant difference in favour of surgery.
For the comparison between EVLA and foam, the MNAR estimate of treatment effect is smaller than the
primary analysis at −0.56 (95% CI −1.33 to 0.21). Variations to this assumption result in estimates ranging
from −0.38 to −0.75, and in all instances represent a decrease in the effect size (but always maintaining
the same direction of effect). The missing AVVQ values for EVLA would need to be at least 2.5 points
lower (or the missing values for foam at least 2.3 points higher) than the values imputed under MNAR for
there to be a significant difference in favour of EVLA.
TABLE 54 Sensitivity of estimates of the effect of treatment on the AVVQ score at 6 months (primary outcome)
using other missing data assumptions: comparison of EVLA with foam sclerotherapy
Sensitivity analysis Effect sizea 95% CI p-value
Primary analysis (repeated measures, assuming missing at random) −1.06 −2.56 to 0.43 0.163
Multiple imputation (assuming MNAR) −0.56 −1.33 to 0.21 0.153
All missing assumed to have AVVQ scores two points lower −0.55 −1.32 to 0.22 0.163
All missing assumed to have AVVQ scores two points higher −0.57 −1.34 to 0.20 0.146
Missing in foam group assumed to have AVVQ scores two points lower −0.37 −1.14 to 0.40 0.340
Missing in foam group assumed to have AVVQ scores two points higher −0.75 −1.51 to 0.02 0.058
Missing in EVLA group assumed to have AVVQ scores two points lower −0.73 −1.50 to 0.04 0.061
Missing in EVLA group assumed to have AVVQ scores two points higher −0.38 −1.15 to 0.38 0.326
MNAR, missing not at random.
a Where the effect size is negative, this favours EVLA.
TABLE 53 Sensitivity of estimates of the effect of treatment on the AVVQ score at 6 months (primary outcome)
using other missing data assumptions: comparison of surgery with EVLA
Sensitivity analysis Effect sizea 95% CI p-value
Primary analysis (repeated measures, assuming missing at random) −0.63 −2.16 to 0.90 0.419
Multiple imputation (assuming MNAR) −1.02 −2.48 to 0.45 0.174
All missing assumed to have AVVQ scores two points lower −1.20 −2.68 to 0.28 0.111
All missing assumed to have AVVQ scores two points higher −0.83 −2.30 to 0.64 0.267
Missing in surgery group assumed to have AVVQ scores two points lower −1.55 −3.03 to −0.08 0.039
Missing in surgery group assumed to have AVVQ scores two points higher −0.48 −1.94 to 0.99 0.521
Missing in EVLA group assumed to have AVVQ scores two points lower −0.66 −2.13 to 0.80 0.374
Missing in EVLA group assumed to have AVVQ scores two points higher −1.37 −2.84 to 0.10 0.068
MNAR, missing not at random.
a Where the effect size is negative, this favours surgery.
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Short Form questionnaire-36 items
At 6 weeks and 6 months, QoL measures in all treatment groups appeared better than at baseline
(see Tables 50 and 51).
Comparison of endovenous laser ablation with foam sclerotherapy
The overall SF-36 physical component score and physical domains were similar in patients who underwent
EVLA (see Table 52).
The SF-36 mental component score was similar for the EVLA and foam groups at 6 weeks, but at
6 months a greater health gain was obtained with EVLA (1.54, 95% CI 0.01 to 3.06; p= 0.048). There
were no statistical differences in the mental domain scores.
Comparison of surgery with endovenous laser ablation
There were no statistical differences in the SF-36 component score between surgery and EVLA. The
individual domains of role physical, bodily pain, vitality, social functioning and role emotional showed a
significant benefit in favour of EVLA at 6 weeks (p< 0.005) but not at 6 months.
European Quality of Life-5 Dimensions
At 6 weeks and 6 months, QoL measures in all treatment groups appeared better than at baseline.
Comparison of endovenous laser ablation with foam sclerotherapy
At 6 weeks there was a significantly greater improvement in the EQ-5D score (0.04, 95% CI 0.01 to 0.07;
p= 0.004) in patients who underwent EVLA than in those who received foam sclerotherapy. This difference
was not apparent at 6-months follow-up. There were no differences in the EQ-5D VAS at either time point.
Comparison of surgery with endovenous laser ablation
At 6 weeks and 6 months, no differences were noted in the EQ-5D and EQ-5D VAS scores between
patients who received EVLA and those who underwent surgery.
Clinical outcomes
Venous Clinical Severity Score
These outcomes are presented in Table 55 (for 6 weeks) and Table 56 (for 6 months), with the estimates of
treatment effect sizes for the comparisons of EVLA with surgery and EVLA with foam therapy in Table 57.
The VCSS showed an apparent improvement (reduction in score) in all groups from baseline to 6 weeks,
and from 6 weeks to 6 months. There were no differences between EVLA and foam or between surgery
and EVLA in the VCSS at any time point.
Residual varicose veins
The presence of residual varicose veins as assessed by the participant and the research nurse show an
apparent improvement (reduction in score) in all groups from baseline to 6 weeks and from 6 weeks
to 6 months.
Comparison of endovenous laser ablation with foam sclerotherapy
There were no differences at 6 weeks between EVLA and foam sclerotherapy. Participants reported
significantly fewer residual varicose veins in the EVLA group at 6-months follow-up (−0.54, 95% CI −0.91
to −0.17; p= 0.005). There were no differences in the nurse-reported scores.
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TABLE 55 Clinical outcomes for study leg at 6 weeks: comparisons of EVLA with foam sclerotherapy and surgery
with EVLA
Clinical outcome measure
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 weeks (N, n, %) 210 193 91.9 207 189 91.3 213 180 84.5
VCSS (n, mean, SD) 175 1.7 1.7 177 2.2 2.0 163 1.7 1.9
Presence of residual varicosities
Assessed by participant (N, n, %) 187 152 81.3 185 154 83.2 173 125 72.3
VAS (n, mean, SD) 187 2.2 1.9 185 2.4 2.0 173 1.8 1.9
Assessed by research nurse (N, n, %) 186 137 73.7 185 129 69.7 173 83 48.0
VAS (n, mean, SD) 186 1.5 1.5 185 1.6 1.6 173 0.8 1.0
CEAP classification
C0 No visible or palpable signs of venous
disease (N, n, %)
176 29 16.5 179 30 16.8 161 49 30.4
C1 Telangiectasis or reticular veins < 3mm
(N, n, %)
176 50 28.4 179 55 30.7 161 73 45.3
C2 Varicose veins > 3mm (N, n, %) 176 74 42.0 179 76 42.5 161 23 14.3
C3 Oedema (N, n, %) 176 4 2.3 179 3 1.7 161 1 0.6
C4 Skin and subcutaneous changes
(N, n, %)
176 4 2.3 179 6 3.4 161 5 3.1
C4a Pigmentation or eczema (N, n, %) 176 11 6.3 179 9 5.0 161 8 5.0
C4b Lipodermatosclerosis or atrophie
blanche (N, n, %)
176 1 0.6 179 0 0.0 161 1 0.6
C5 Healed venous ulcer (N, n, %) 176 3 1.7 179 0 0.0 161 1 0.6
C6 Active venous ulcer (N, n, %) 176 0 0.0 179 0 0.0 161 0 0.0
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TABLE 56 Venous Clinical Severity Score and presence of residual varicose veins at 6 months: comparisons of EVLA
with foam sclerotherapy and surgery with EVLA
Clinical outcome measure
Randomised to
EVLA
Randomised to
foam sclerotherapy
Randomised to
surgery
Clinic assessment at 6 months (N, n, %) 210 183 87.1 207 178 86.0 213 167 78.4
VCSS (n, mean, SD) 157 1.4 1.5 152 1.7 1.8 142 1.3 1.5
Presence of residual varicosities
Assessed by participant (N, n, %) 168 122 72.6 162 132 81.5 155 101 65.2
VAS (n, mean, SD) 168 1.8 1.9 162 2.3 1.9 155 1.4 1.5
Assessed by research nurse (N, n, %) 167 90 53.9 162 101 62.3 155 73 47.1
VAS (n, mean, SD) 167 1.0 1.4 162 1.1 1.3 155 0.7 1.0
CEAP classification
C0 No visible or palpable signs of venous
disease (N, n, %)
159 31 19.5 153 26 17.0 149 42 28.2
C1 Telangiectasis or reticular veins < 3mm
(N, n, %)
159 71 44.7 153 65 42.5 149 69 46.3
C2 Varicose veins > 3mm (N, n, %) 159 41 25.8 153 45 29.4 149 25 16.8
C3 Oedema (N, n, %) 159 3 1.9 153 8 5.2 149 1 0.7
C4 Skin and subcutaneous changes (N, n, %) 159 1 0.6 153 0 0.0 149 3 2.0
C4a Pigmentation or eczema (N, n, %) 159 7 4.4 153 8 5.2 149 7 4.7
C4b Lipodermatosclerosis or atrophie blanche
(N, n, %)
159 2 1.3 153 0 0.0 149 0 0.0
C5 Healed venous ulcer (N, n, %) 159 3 1.9 153 1 0.7 149 2 1.3
C6 Active venous ulcer (N, n, %) 159 0 0.0 153 0 0.0 149 0 0.0
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Comparison of surgery with endovenous laser ablation
There were significantly fewer residual varicose veins following surgery than following EVLA as assessed by
the nurse at 6 weeks (−0.76, 95% CI −1.04 to −0.48; p< 0.001), but not at 6 months. Results were
similar for participant-reported residual varicose veins at both time points.
Clinical, etiological, anatomical, pathological classification
Although the CEAP is not generally considered an appropriate measure of outcome, it is included for
completeness, but not statistically analysed. All participants had a CEAP classification of C2 or above at
recruitment. By 6 weeks, the proportion of participants with a classification lower than C2 was highest in
the surgery group (76%), compared with only 47% for foam and 45% for EVLA (see Table 55). At
6 months, the proportion of participants with a classification better than C2 remained highest in the
surgery group (74%), compared with 64% for EVLA and 59% for foam (see Table 56).
Pain
Immediately after treatment, the mean pain scores for those randomised to foam sclerotherapy, surgery
and EVLA were 2.2 (SD 2.0), 2.4 (SD 2.6) and 3.5 (SD 2.2) respectively (see Appendix 2, Table 107).
Patient-reported pain is significantly higher for EVLA than for either surgery or foam sclerotherapy. At
6 weeks, patients’ recollection of pain during treatment was higher than that recorded after treatment
for all three treatment modalities. Patients’ recollection of the pain they experienced during foam
sclerotherapy (mean VAS 3.0, SD 2.5) was significantly lower than for either surgery (mean VAS 4.1,
SD 3.0) or EVLA (mean VAS 4.4, SD 2.8). Patients’ recollection of pain during recovery was also
significantly lower for foam sclerotherapy than for either surgery or EVLA. The pain experienced during
recovery for surgery was significantly higher than that for EVLA.
Anatomical success
Success rates for truncal vein ablation at 6 weeks and 6 months are shown in Tables 58 and 59. The
overall statistical analysis for the whole leg and the GSV only is shown in Table 60. The numbers
undergoing treatment to the SSV alone or in combination with the GSV were small, and therefore these
subgroups were not subjected to statistical analysis.
There were no differences in ablation success between surgery and EVLA. However, for all comparisons
between EVLA and foam sclerotherapy, the OR was > 2, and the treatment effect on ablation rates is
highly significant in favour of EVLA in each comparison (p< 0.001). At 6 months, the effect size in favour
of EVLA over foam (GSV only) was 4.83 (95% CI 2.76 to 8.48, p< 0.001).
Complications
Procedural complications
The procedural complications noted at the time of the primary treatment are documented in Table 61.
In the EVLA versus foam sclerotherapy comparison, the event rate for any procedural complication was
significantly lower for EVLA (OR 0.17, 95% CI 0.05 to 0.60; p= 0.006). Similarly, in the surgery versus
EVLA comparison, the event rate for any procedural complication was significantly higher for surgery
(OR 5.41, 95% CI 1.73 to 16.89; p= 0.004). Five participants in the foam group (3%), five in the surgery
group (3%) and none in the EVLA group experienced two procedural complications.
Later complications
Complications noted at the time of the 6-week and 6-month assessments are shown in Tables 62
and 63. Estimates of the effect of treatment on complications are summarised across both follow-up time
points in Table 64, with ORs comparing surgery with EVLA, and EVLA with foam sclerotherapy.
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TABLE 58 Truncal vein ablation at 6 weeks: comparisons of EVLA with foam sclerotherapy and surgery with EVLA
Anatomical success
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 weeks (N, n, %) 210 193 91.9 207 189 91.3 213 180 84.5
GSV involvement only
Complete success (N, n, %) 153 127 83.0 152 96 63.2 143 122 85.3
Partial success (N, n, %) 153 23 15.0 152 36 23.7 143 15 10.5
without reflux (N, n, %) 153 13 8.5 152 29 19.1 143 9 6.3
with reflux (N, n, %) 153 10 6.5 152 7 4.6 143 6 4.2
Failure (N, n, %) 153 3 2.0 152 20 13.2 143 6 4.2
SSV involvement only
Complete success (N, n, %) 12 6 50.0 11 5 45.5 12 3 25.0
Partial success (N, n, %) 12 4 33.3 11 4 36.4 12 7 58.3
without reflux (N, n, %) 12 4 33.3 11 4 36.4 12 5 41.7
with reflux (N, n, %) 12 0 0.0 11 0 0.0 12 2 16.7
Failure (N, n, %) 12 2 16.7 11 2 18.2 12 2 16.7
GSV and SSV involvement
GSV
Complete success (N, n, %) 9 4 44.4 15 9 60.0 11 9 81.8
Partial success (N, n, %) 9 2 22.2 15 3 20.0 11 0 0.0
without reflux (N, n, %) 9 1 11.1 15 1 6.7 11 0 0.0
with reflux (N, n, %) 9 1 11.1 15 1 6.7 11 0 0.0
Failure (N, n, %) 9 3 33.3 15 3 20.0 11 2 18.2
SSV
Complete success (N, n, %) 6 1 16.7 16 2 12.5 11 1 9.1
Partial success (N, n, %) 6 1 16.7 16 3 18.8 11 3 27.3
without reflux (N, n, %) 6 1 16.7 16 2 12.5 11 1 9.1
with reflux (N, n, %) 6 0 0.0 16 0 0.0 11 2 18.2
Failure (N, n, %) 6 4 66.7 16 11 68.8 11 7 63.6
Overall treatment of study leg
Complete success (N, n, %) 170 133 78.2 178 103 57.9 165 125 75.8
Partial success (N, n, %) 170 31 18.2 178 50 28.1 165 32 19.4
without reflux (N, n, %) 170 19 11.2 178 41 23.0 165 21 12.7
with reflux (N, n, %) 170 12 7.1 178 9 5.1 165 11 6.7
Failure (N, n, %) 170 6 3.5 178 25 14.0 165 8 4.8
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TABLE 59 Truncal vein ablation at 6 months: comparisons of EVLA with foam sclerotherapy and surgery with EVLA
Anatomical success
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 months (N, n, %) 210 183 87.1 207 178 86.0 213 167 78.4
GSV involvement only
Complete success (N, n, %) 141 116 82.3 132 67 50.8 127 101 79.5
Partial success (N, n, %) 141 16 11.3 132 31 23.5 127 16 12.6
without reflux (N, n, %) 141 13 9.2 132 22 16.7 127 3 2.4
with reflux (N, n, %) 141 3 2.1 132 9 6.8 127 13 10.2
Failure (N, n, %) 141 9 6.4 132 34 25.8 127 10 7.9
SSV involvement only
Complete success (N, n, %) 9 6 66.7 11 4 36.4 11 3 27.3
Partial success (N, n, %) 9 3 33.3 11 2 18.2 11 3 27.3
without reflux (N, n, %) 9 2 22.2 11 1 9.1 11 3 27.3
with reflux (N, n, %) 9 1 11.1 11 1 9.1 11 0 0.0
Failure (N, n, %) 9 0 0.0 11 5 45.5 11 5 45.5
GSV and SSV involvement
GSV
Complete success (N, n, %) 10 6 60.0 14 5 35.7 9 7 77.8
Partial success (N, n, %) 10 2 20.0 14 4 28.6 9 1 11.1
without reflux (N, n, %) 10 2 20.0 14 3 21.4 9 0 0.0
with reflux (N, n, %) 10 0 0.0 14 1 7.1 9 1 11.1
Failure (N, n, %) 10 2 20.0 14 5 35.7 9 1 11.1
SSV
Complete success (N, n, %) 7 2 28.6 13 2 15.4 9 1 11.1
Partial success (N, n, %) 7 2 28.6 13 1 7.7 9 0 0.0
without reflux (N, n, %) 7 1 14.3 13 1 7.7 9 0 0.0
with reflux (N, n, %) 7 1 14.3 13 0 0.0 9 0 0.0
Failure (N, n, %) 7 3 42.9 13 10 76.9 9 8 88.9
Overall treatment of study leg
Complete success (N, n, %) 156 123 78.8 156 73 46.8 147 104 70.7
Partial success (N, n, %) 156 24 15.4 156 41 26.3 147 28 19.0
without reflux (N, n, %) 156 20 12.8 156 31 19.9 147 15 10.2
with reflux (N, n, %) 156 4 2.6 156 10 6.4 147 13 8.8
Failure (N, n, %) 156 9 5.8 156 42 26.9 147 15 10.2
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TABLE 61 Procedural complications at time of primary treatment: comparisons of EVLA with foam sclerotherapy
and surgery with EVLA
Procedural complication
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Treated (n) 205 197 195
Any procedural complicationa (N, n, %) 205 2 1.0 197 13 6.6 195 16 8.2
Wound haematoma (N, n, %) 205 0 0.0 197 1 0.5 195 1 0.5
Damage to major artery (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Damage to major vein (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Damage to major nerve (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Bleeding (N, n, %) 205 0 0.0 197 0 0.0 195 2 1.0
Visual disturbance/blurred vision (N, n, %) 205 0 0.0 197 4 2.0 195 0 0.0
Extravasation of foam sclerotherapy (N, n, %) 205 0 0.0 197 0 0.0 195 1 0.5
Allergic/anaphylactoid reaction (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Stroke (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Transient ischaemic attack (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Myocardial infarction (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Intra-arterial injection (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Epileptic fit (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Headache (N, n, %) 205 0 0.0 197 2 1.0 195 1 0.5
Transient confusion (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Panic attack (N, n, %) 205 0 0.0 197 1 0.5 195 0 0.0
Malaise (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Cough (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Chest tightness/heaviness (N, n, %) 205 0 0.0 197 1 0.5 195 0 0.0
Vasovagal (N, n, %) 205 0 0.0 197 3 1.5 195 1 0.5
Anaesthetic side effects (N, n, %) 205 0 0.0 197 0 0.0 195 6 3.1
Sickness (N, n, %) 205 0 0.0 197 0 0.0 195 4 2.1
Muscle pains (N, n, %) 205 0 0.0 197 0 0.0 195 1 0.5
Sore throat (N, n, %) 205 0 0.0 197 0 0.0 195 2 1.0
Damage to teeth, lip or tongue (N, n, %) 205 0 0.0 197 0 0.0 195 0 0.0
Other procedural complication (N, n, %) 205 2 1.0 197 6 3.0 195 6 3.1
a Some participants had more than one complication.
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TABLE 62 Complications at 6 weeks: comparisons of EVLA with foam sclerotherapy and surgery with EVLA
Complication
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 weeks (N, n, %) 210 193 91.9 207 189 91.3 213 180 84.5
Any complication at 6 weeks (N, n, %) 193 103 53.4 189 149 78.8 180 118 65.6
Numbness (N, n, %) 193 22 11.4 189 10 5.3 180 30 16.7
Persistent bruising (N, n, %) 193 10 5.2 189 36 19.0 180 22 12.2
Persistent tenderness/discomfort (N, n, %) 193 41 21.2 189 76 40.2 180 57 31.7
Skin loss/ulceration (N, n, %) 193 0 0.0 189 2 1.1 180 1 0.6
Lumpiness (N, n, %) 193 36 18.7 189 104 55.0 180 51 28.3
Development of thread vein (N, n, %) 193 10 5.2 189 21 11.1 180 16 8.9
Skin staining (N, n, %) 193 18 9.3 189 66 34.9 180 11 6.1
Wound infection (N, n, %) 193 3 1.6 189 1 0.5 180 17 9.4
Backache (N, n, %) 193 4 2.1 189 5 2.6 180 7 3.9
Headache (N, n, %) 193 1 0.5 189 9 4.8 180 3 1.7
DVT (N, n, %) 193 0 0.0 189 2 1.1 180 0 0.0
Pulmonary embolus (N, n, %) 193 0 0.0 189 0 0.0 180 0 0.0
Stroke (N, n, %) 193 0 0.0 189 0 0.0 180 0 0.0
Myocardial infarction (N, n, %) 193 0 0.0 189 0 0.0 180 0 0.0
Loss of vision (N, n, %) 193 0 0.0 189 3 1.6 180 0 0.0
Damage to major artery (N, n, %) 193 0 0.0 189 0 0.0 180 0 0.0
Damage to major vein (N, n, %) 193 0 0.0 189 1 0.5 180 0 0.0
Damage to motor nerve (N, n, %) 193 0 0.0 189 0 0.0 180 0 0.0
Other complication (N, n, %) 193 10 5.2 189 14 7.4 180 17 9.4
TABLE 63 Complications at 6 months: comparisons of EVLA with foam sclerotherapy and surgery with EVLA
Complication
Randomised to
EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Clinic assessment at 6 months (N, n, %) 210 183 87.2 207 178 86.0 213 167 78.4
Any complication at 6 months (N, n, %) 183 89 48.6 178 94 52.8 167 77 46.1
Numbness (N, n, %) 183 17 9.2 178 5 2.8 167 28 16.8
Persistent bruising (N, n, %) 183 25 13.6 178 26 14.6 167 34 20.4
Skin loss/ulceration (N, n, %) 183 1 0.6 178 1 0.6 167 0 0.0
Lumpiness (N, n, %) 183 25 13.6 178 46 25.8 167 10 6.0
Development of thread vein (N, n, %) 183 24 13.2 178 23 13.0 167 19 11.4
Skin staining (N, n, %) 183 32 17.4 178 55 30.8 167 13 7.8
DVT (N, n, %) 183 0 0.0 178 1 0.6 167 0 0.0
Pulmonary embolus (N, n, %) 183 0 0.0 178 0 0.0 167 0 0.0
Other (N, n, %) 183 11 6.0 178 8 4.4 167 10 6.0
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Comparison of endovenous laser ablation with foam
The event rates at 6 weeks for persistent bruising (OR 0.17, 95% CI 0.07 to 0.38; p< 0.001), persistent
tenderness (OR 0.36, 95% CI 0.22 to 0.58; p< 0.001), lumpiness (OR 0.38, 95% CI 0.21 to 0.68;
p< 0.001), skin staining (OR 0.41, 95% CI 0.24 to 0.70; p< 0.001), development of thread vein (OR 0.43,
95% CI 0.19 to 0.95; p= 0.037) and headache (OR 0.10, 95% CI 0.01 to 0.79; p= 0.029) were all
significantly lower for EVLA than for foam. At 6 months, lumpiness (OR 0.38, 95% CI 0.21 to 0.68;
p= 0.001) and skin staining (OR 0.41, 95% CI 0.24 to 0.70; p= 0.001) remained less frequent for EVLA
than for foam. The event rate for cutaneous numbness (at both time points) is significantly higher for
EVLA than for foam sclerotherapy (at 6 months, OR 3.85, 95% CI 1.35 to 10.99; p= 0.012).
Comparison of surgery with endovenous laser ablation
The rates for persistent bruising (OR 2.86, 95% CI 1.26 to 6.51; p= 0.012), persistent tenderness
(OR 1.90, 95% CI 1.16 to 3.11; p= 0.011) and lumpiness (OR 1.84, 95% CI 1.11 to 3.05; p= 0.018) at
6 weeks were all significantly higher for surgery than for EVLA. At 6 months, cutaneous numbness
(OR 2.11, 95% CI 1.05 to 4.24; p= 0.037), lumpiness (OR 0.43, 95% CI 0.19 to 0.97; p= 0.041) and skin
staining (OR 0.38, 95% CI 0.19 to 0.78; p= 0.009) occurred more frequently for surgery than for EVLA.
Serious adverse events
Table 65 gives brief details of the seven SAEs reported in participants randomised to EVLA. One of these
(pain in the contralateral leg treated at the same time as the study leg) was assessed as related to
treatment. A further SAE (fall resulting in rib fracture) was assessed as possibly related to treatment
because the participant was still wearing compression stockings at the time of the fall and was thought
to be slightly incapacitated because of these. The other five SAEs were not related to treatment. Details of
the SAEs in those randomised to surgery and foam sclerotherapy are given in Chapter 5 (see Table 39).
Process evaluation: Illness Perception Questionnaire – Revised
Detailed descriptive results of the IPQ-R are given in Appendix 2 (see Table 109). Within each randomised
group, the mean identity scores and the percentage of symptoms correctly identified as being related
to varicose veins at baseline (recruitment) and after the participant had been informed of his or her
randomisation were similar. By 6 months, both measures of illness identity had fallen.
For all other measures of illness perception, there is very little difference between scores at baseline and
post randomisation. For most of the domains, there were decreases in the mean scores between baseline
and 6 months in all groups. The exceptions to this were for personal control and illness coherence, where
the mean scores increased slightly in all groups. For all of these domains, the differences between surgery
and EVLA, and EVLA and foam sclerotherapy were marginal.
TABLE 65 Serious adverse events detected up to the time of the 6-months follow-up: EVLA
Randomised
Treatment
prior to SAE Description of event
Related to
treatment? Expected?
EVLA EVLA Pain in contralateral leg (treated at same time as study
leg); possibly related to osteoporosis
Yes No
EVLA EVLA Fall; rib fracture Possible No
EVLA EVLA Surgery for fractured shoulder No No
EVLA EVLA Pain in thigh and groin; cellulitis No No
EVLA EVLA Injury at work – trauma to hand No No
EVLA EVLA Episode of palpitation No No
EVLA No treatment Migraine No No
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Chapter 7 Clinical effectiveness
Primary outcome: Aberdeen Varicose Vein Questionnaire score
Main findings
This is the first RCT involving foam sclerotherapy to evaluate and report disease-specific QoL as a primary
outcome measure. In all groups, disease-specific AVVQ scores improved over time (i.e. scores reduced).
The health gain obtained in the AVVQ was lower in patients undergoing foam sclerotherapy than in those
receiving surgery at 6 weeks (p= 0.006) and at 6 months (p= 0.0002). This equated to a difference in
scores of 2.26 between the groups at 6 weeks and 1.74 at 6 months, which is likely to be of clinical
significance. The health gains in the AVVQ in patients undergoing foam sclerotherapy and EVLA were
similar, as were those in the EVLA and surgery comparison.
Comparison with published randomised controlled trials/patient-reported
outcome measures
It is of note that the baseline AVVQ scores in the CLASS study (17.91) are similar to those observed in
the PROMs for the NHS in England (18.53 in 2010). At 6 weeks there was a more than 5-point fall
(improvement) in the AVVQ score compared with baseline in all treatment groups. In the surgery arm, by
6 months the AVVQ score more than halved compared with baseline (a fall of 10.4 points). Similarly,
scores in the foam sclerotherapy and EVLA groups almost halved (falls of 8.5 and 9.9 points respectively).
The reduction in AVVQ score (measured at least 3 months post treatment) observed in PROMs data for
NHS England (7.9 points)44 sits within the values observed in CLASS at 6 weeks and 6 months. Thus, the
CLASS results appear generalisable to that obtained in the NHS in England.
The 2007 study by Rasmussen et al.36 reported similar baseline scores to those obtained in the CLASS study but
had slightly greater health gains (a fall of 10.8 in the surgery group and 11.5 in the EVLA group at 6 months
post treatment). Christenson et al.34 reported higher baseline scores than both Rasmussen et al. (2007)36 and
ourselves, and, by 12 months, a slightly greater improvement in patients undergoing EVLA or surgery.
We have shown, as have previous RCTs, that all three treatment modalities are associated with a
health gain (reduction) in the AVVQ score.15,29,32,34,36,37,50 Four of these studies assessed the AVVQ at
4–6 weeks.29,36,37,50 In contrast to our findings, the previous study which compared foam with surgery and
EVLA with foam assessed AVVQ at similar time points to CLASS and found no differences between AVVQ
scores.29 In common with CLASS, the studies that have assessed AVVQ at later time points have also found
no difference between EVLA and surgery.15,29,34,37,50 It is worth noting that the AVVQ was not the primary
outcome measure in any of these previous studies; thus, they are unlikely to have been adequately
powered to detect a difference.
With the exception of one site, we did not perform simultaneous phlebectomies in patients undergoing
EVLA. This site (Hull) had previously performed a RCT which showed significant improvements in
disease-specific QoL (assessed by AVVQ) in patients undergoing simultaneous compared with delayed
phlebectomies following EVLA at 6 weeks and 3 months.73
European Quality of Life-5 Dimensions
Main findings
In all treatment groups, a health gain (increase in EQ-5D score from baseline) was observed at the 6-weeks
and 6-months time points. Most of the health gain was achieved between baseline and 6 weeks. There
was a health gain at 6 weeks in patients randomised to EVLA compared with those randomised to foam
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for the EQ-5D (p= 0.004). There were no differences at 6 months. There were no differences in surgery
versus EVLA or surgery versus foam sclerotherapy. At 6 months, there were no significant differences in
the comparisons of foam sclerotherapy with surgery, EVLA with surgery or EVLA with foam sclerotherapy.
European Quality of Life-5 Dimensions visual analogue scale
At 6 weeks, the EQ-5D VAS score increased in patients randomised to surgery or EVLA. There was no
change in those randomised to foam sclerotherapy. However, by 6 months there was a rise in all treatment
groups (rise of 2.0–4.5). There were no statistical differences between groups at 6 weeks or 6 months.
Comparison with published randomised controlled trials/patient-reported
outcome measures
The CLASS baseline EQ-5D scores (0.79) were similar to the baseline scores in the PROMs (0.77) for NHS
England.44 The health gain observed in CLASS (0.10–0.11) was similar to that seen in the PROMs (0.091).
The EQ-5D VAS baseline score observed in CLASS (80.0–80.6) was similar to that observed in the PROMs
(79.25). However, unlike the improvement seen in our study, in the PROMs the EQ-5D VAS showed no
real change when assessed at least 3 months post treatment (fall of –0.098).
Similar to our findings, previous studies have shown an increase in EQ-5D scores at time points from
6 weeks to 2 years. In the study by Shadid,33 the mean change in the EQ-5D score from baseline to 2 years
(a gain of 0.064 for foam sclerotherapy and 0.061 for surgery) was slightly lower than that obtained in the
CLASS study at 6 months (a gain of approximately 0.1). In the study by Carradice et al.,73 by 6 weeks,
mean scores for both surgery and EVLA groups had increased to 1.0 (substantially higher than the mean
scores observed in CLASS). The study by Samuel et al.,37 which involved only patients with SSV
involvement, also showed an increase in EQ-5D scores (of approximately 0.12 at 12 months for both
surgery and EVLA groups), with the mean scores for surgery reaching 1.0 by 6 weeks. Unlike previous
studies, CLASS showed an early improvement in the EQ-5D in patients receiving EVLA compared with
foam and surgery compared with foam.
Short Form questionnaire-36 items
Main findings
The SF-36 physical component score was higher in all three treatment groups at 6 weeks than at baseline.
Further increases in scores were observed at the 6-months time point.
There were no statistical differences between foam and surgery for the overall physical and mental
component scores or domains of the SF-36. However, the general health domain showed a significant
improvement for surgery compared with foam at 6 weeks (p< 0.005).
Patients randomised to EVLA had similar health gains to those who underwent foam sclerotherapy in the
overall SF-36 physical component and individual physical domains at 6 weeks and 6 months. This
difference was not apparent at 6-months follow-up. Similar improvements in the overall SF-36 mental
component score and domains were shown for both EVLA and foam sclerotherapy.
At 6 weeks, patients randomised to EVLA had a greater health gain than those who underwent surgery in
the SF-36 individual domains of vitality, social functioning and role emotional (p< 0.005). The overall
physical scores were similar but the role physical and bodily pain domains were significantly improved for
EVLA compared with surgery at 6 weeks (p< 0.005).
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Comparison with published randomised controlled trials/patient-reported
outcome measures
Short Form questionnaire-36 items scores were not collected in PROMs. One previous RCT involving a
comparison of EVLA and surgery used the SF-36 as a primary outcome measure.50 This study, by
Carradice et al., showed an initial reduction in some component scores at 1 week, but by 6 weeks
significant improvements were detected in five of the eight domains (physical function, role physical, bodily
pain, general health, vitality). Although the increases are in tune with those seen in CLASS, Carradice et al.50
found no differences between groups. In contrast, in the CLASS trial there were significantly greater
improvements for EVLA than for surgery in six of the domains (p< 0.05) at 6 weeks, with the improvement
in the mental health domain remaining significant at 6 weeks. Four further RCTs which compared EVLA
with surgery have also assessed generic QoL using the SF-36.29,34,36,37 It is of note that all these studies
assessed outcome early (1 month or 6 weeks), as was done in the CLASS study.29,36,37,50 All reported
improvements in some or all domains following treatment, but, unlike the CLASS trial, which showed a
greater gain for EVLA than for surgery, no differences were detected.29,34,36,37 One of these studies also
included a comparison of EVLA and foam sclerotherapy, and found no difference between the treatment
arms.29 In contrast, in the CLASS trial, early benefits in favour of EVLA over foam sclerotherapy were found
in two of the domains (p< 0.05), with a significant improvement in the mental health domain for EVLA
at 6 months. The CLASS trial also showed significant benefits of surgery over foam sclerotherapy in
two domains.
Venous Clinical Severity Score
Main findings
Up to 6 months, the VCSS improved in all three treatment groups. At 6 weeks, the improvement in the
VCSS (reduction in score) was significantly greater in patients undergoing surgery than in those receiving
foam sclerotherapy (0.52-point difference in scores, p= 0.002). A further, smaller reduction was observed
in all groups at the 6-months follow-up, but at this stage there were no statistical differences between groups.
Comparison with published randomised controlled trials
The mean baseline score in CLASS (5.0) was within the range of baseline VCSS scores reported in previous
RCTs (2.4–7).15,29,32,34,36,37,50 All studies noted a reduction in VCSS at 3 months or longer.
In the CLASS study, the VCSS at 6 months was slightly higher (1.6) in the foam sclerotherapy group
(i.e. that group had the most residual vein-related symptoms) than in the EVLA and surgery groups
(1.4 and 1.3 respectively), but the differences were not statistically significant. The magnitude of the fall
(3.1–3.7) was similar to those reported in some RCTs15,32 but greater than that observed by Rasmussen’s
group,36,49 which reported lower baseline scores (2.4–2.8 and 5 respectively) than in CLASS.
The 6-months score was slightly higher than those of some studies (which had scores of 0–1), but many of
these studies had lower baseline scores at the outset.15,29,34,36,50 One previous single-site RCT73 found that
the improvement in VCSS was significantly better at both 6 weeks and 3 months in patients who had
EVLA and simultaneous phlebectomies than in those who underwent delayed phlebectomies. Although
performing EVLA and simultaneous phlebectomies in the CLASS trial might therefore have further
improved VCSS at 6 weeks, patients were given the option of foam sclerotherapy at 6 weeks, and thus it
is unlikely that performing simultaneous phlebectomies would have influenced the 6-months VCSS score.
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Residual varicose veins: visual analogue scale
Main findings
The VAS scores reported by the nurses were consistently lower (representing fewer varicose veins), at all
time points and for all three treatment modalities, than the VAS scores reported by the patients. At 6 weeks,
the patient-reported VAS scores were lower (fewer varicose veins) in the surgery group than in the foam
sclerotherapy group (0.99-point difference, p< 0.001). Similarly, at 6 months the patient-reported
VAS scores were lower (fewer varicose veins) in the surgery group than in the foam sclerotherapy group
(0.95-point difference, p< 0.001). There were no differences between the EVLA and foam sclerotherapy
groups at 6 weeks, but at 6 months the score was lower (fewer varicose veins) in the EVLA group
(0.54-point difference, p= 0.005).
A similar pattern was seen for the nurse-reported VAS scores, with the exception that no differences
were noted between the EVLA and foam sclerotherapy groups at 6-weeks and 6-months follow-up.
The consistently lower scores recorded by the nurses compared with the patients may be due to the nurses’
prior exposure to patients with more complex and extensive varicose veins, which could have given them
a higher ‘threshold’ in their judgements about the visual appearance of leg veins.
The presence of an increased number of residual varicosities in the patients undergoing foam at 6-weeks
follow-up is explained by the fact that patients had not completed their treatment for calf varicosities by
this stage (with the exception of patients at one centre which performed concomitant phlebectomies
with EVLA).
Comparison with published randomised controlled trials
The presence of residual varicose veins was not reported in any of the previous RCTs. However,
patient-reported cosmesis was recorded in the study by Darwood15 and showed no differences between
patients undergoing EVLA and those receiving surgery. The findings in CLASS are an interesting and
potentially important observation, because they suggest that surgeons involved in those trials did not see
residual veins as an issue. By contrast, the expectation of other surgeons (and patients) is that treatment
will get rid of all varicose veins in the treated leg. These contrasting aims and expectations are
fundamental in judging the ‘success’ of any treatment for varicose veins and they are important to
consider in interpreting the conclusions of any study.
Visual analogue scale score and further treatment of residual varicosities
with foam sclerotherapy
The patient-reported VAS scores at 6 weeks for the foam sclerotherapy, EVLA and surgery groups were
2.6, 2.2 and 1.7 respectively. The decision to proceed with further treatment of residual varicosities at the
6-weeks stage in the foam sclerotherapy and EVLA groups was patient led. In the CLASS study, excluding
the patients who underwent concurrent phlebectomies in Hull, 31% of the EVLA patients underwent foam
sclerotherapy to their residual varicosities, including 2% who underwent a second foam sclerotherapy
treatment. In the foam sclerotherapy group, 31% had treatment to their calf varicosities at their primary
treatment session and a further 7% received further foam sclerotherapy to their residual varicosities.
The presence of complications relating to treatment at the 6-weeks time point (see Complications) may
have influenced the patients’ decision regarding whether or not they should proceed with further foam
sclerotherapy treatment to residual varicosities.
Comparison with published randomised controlled trials
In the six studies14,29–33 which involved foam sclerotherapy, only three14,30,33 administered delayed foam
sclerotherapy for residual tributaries (see Chapter 2). Similar to our study, in the Varisolve® study14 8% of
patients had a further treatment session. In contrast, in the study by Figueiredo,30 all but 3 of the 27 patients
underwent one or more further treatment session. In the remaining study33 which offered delayed
phlebectomies or foam sclerotherapy, the number of patients who underwent further treatment is not stated.
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In studies involving EVLA, only two used foam sclerotherapy to treat residual tributaries at a later stage.15,40
In the Darwood study,15 this was performed in 36% of patients, which is a similar rate to the CLASS trial.
Details regarding the number of patients who had delayed foam sclerotherapy in the other study are not
published.40 The remainder of the studies treated the calf varicosities at the same time as the main truncal
veins. Given that few patients randomised to EVLA underwent delayed treatment of residual varicosities
in the CLASS trial, a policy of concomitant treatment of calf varicosities and the main truncal vein may
result in a considerable number of patients receiving unnecessary treatment to calf varicosities.
Duplex-detected ablation of the main truncal vein
(great saphenous vein/small saphenous vein)
The joint statement from the Venous Forum and the Society of Interventional Radiology62 recommended
reporting standards for endovenous ablation in the treatment of venous insufficiency. Anatomical success
was defined as successful ablation of the entire treated segment of the target vein (absent flow or
disappearance of the vein on duplex ultrasound). This guidance was used in the CLASS study; the duplex
findings were reported by independent technicians at set anatomical locations.
In accordance with the above statement, we defined complete anatomical success for the GSV as
complete occlusion at the groin (within 3 cm of the common femoral vein), complete occlusion at
mid-thigh and either an occluded or a patent but non-refluxing GSV above the knee. It is of note that
90% of patients in CLASS who underwent GSV treatment had reflux above the knee only at baseline.
The justification for not including the recorded ‘within 1 cm of the common femoral vein’ site in our
definition was that, with the exception of one centre, this section was not treated. For foam sclerotherapy,
our practice was to apply manual compression at the junction to reduce passage of foam into the common
femoral vein.
Main findings
We have presented the anatomical success rates achieved for the truncal veins of the patient’s study leg
and for those patients undergoing treatment to the GSV alone. Higher rates of ablation success were
obtained for patients undergoing treatment of the GSV alone than for those undergoing treatment of the
SSV alone, or the GSV and SSV combined. There were no statistically significant differences in anatomical
success between surgery and laser at either the 6-weeks or the 6-months time point, but both were
superior to foam at these time points (p< 0.001).
The anatomical success achieved with foam sclerotherapy did not improve between the 6-weeks and
6-months follow-ups. The protocol allowed for further foam sclerotherapy to be given at the surgeon’s
discretion to any patent truncal vein at or after the 6-weeks follow-up, but in practice this was only
performed in 12 participants randomised to foam sclerotherapy. There may be a number of reasons why
further foam sclerotherapy to the truncal vein was not administered. For instance, it is often difficult to
treat segmental isolated sections of the GSV, and the need to treat non-refluxing patent sections of the
GSV is also questionable. It should be noted that of those patients who were considered to have had a
partial anatomical success following foam sclerotherapy, only 4% had GSV reflux present at 6 weeks.
The definition of anatomical success for the SSV disadvantaged surgery, as the vein was not stripped in the
majority of centres in the CLASS study (only 15 patients had stripping of the SSV performed). The number
of patients undergoing SSV treatment was low (n= 56), and therefore we have not performed a statistical
analysis of anatomical success within this group. The proportion of patients who underwent combined
GSV and SSV treatment was also very low and, similarly, was not subjected to formal statistical analysis.
Overall, the results for the SSV appear inferior to those obtained for the GSV, but the ablation success
rates at 6 months appeared to be higher for EVLA than for either surgery or foam sclerotherapy.
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In CLASS, the impact of anatomical success on symptoms, residual varicose veins and QoL following
treatment is unclear. Despite the significant reduction in anatomical success following foam sclerotherapy,
the VCSS, presence of residual varicose veins (nurse assessed) and generic QoL were similar to those
achieved following EVLA and surgery. Thus, although anatomical success rates may be important in terms
of future clinical recurrences, they have little effect (if any) on symptoms or QoL.
Comparison with published randomised controlled trials
The anatomical success rates for the GSV observed at 6 months in CLASS were lower than those reported
in most previous RCTs for all three treatment modalities. This difference is most notable for the complete
anatomical success achieved in CLASS for foam sclerotherapy (51% in the three-arm centres included in
stratum A; 43% in the two-arm centres in stratum B), when compared against success rates of between
72% and 94% in previous studies where success was assessed at between 3 and 12 months.14,29,30,33 In the
study by Lattimer et al.,32 success at 3 months was reported for above and below the knee separately
(69% and 44% respectively). The lower anatomical success rates for foam sclerotherapy occurred despite
the majority of procedures being performed by consultant surgeons in CLASS, so inexperience is unlikely to
be a factor. The reasons for the lower anatomical success rate achieved in stratum B compared with
stratum A are likely to be multifactorial and reflect NHS practice across the UK. For surgery and EVLA, the
difference between CLASS and previous studies is less marked.
At 6 months, 82% of those undergoing EVLA in CLASS had complete anatomical success; this is slightly
lower than the range reported in most previous RCTs (84–99%).15,29,34–36 Again, in the study by Lattimer,32
lower success rates were observed (74% above knee and 15% below knee).
Although lower than for many previous RCTs, the anatomical success rate of 78% at 6 months following
surgery does lie within the range of success rates reported in previous RCTs (72–100%).14,15,29,30,33–37
There are a number of possible reasons for the lower anatomical success rates observed in CLASS. Firstly,
in the CLASS study anatomical success in all but one centre was reported by independent, accredited
vascular technicians. This was not the case in previous studies, which could have resulted in a bias towards
reporting favourable outcomes in those studies. Secondly, the definitions of anatomical success (and/or
failure) vary considerably between studies and many were less stringent in terms of complying with the
joint statement of the Venous Forum, particularly for studies involving foam.62 With the exception of one
previous RCT,32 outcomes were reported as success or failure, yet the definitions of failure varied
considerably (Table 66).
This variation means that the duplex findings said to represent success in one study (for example the
Rasmussen study29) might be considered only a partial success (or even a failure) in the CLASS study.
Indeed, if the complete and partial non-refluxing success rates in the CLASS trial were combined, these
would give ablation rates comparable with those of the Rasmussen paper for EVLA (91.4%). However,
rates still remain lower for surgery (82%) and foam sclerotherapy (67%). Nevertheless, the results achieved
with foam are comparable with the 69% rate obtained in the study by Latimer et al.32 and the 68% rate
obtained by surgeons in the study by Wright et al.14 Thirdly, it is of note that most previous RCTs were
conducted in single centres by enthusiasts in the field. This raises the possibility that these surgeons
achieved better outcomes than the generality of vascular surgeons and their trainees and/or that a bias
resulted towards reporting favourable outcomes. In CLASS, consultants performed 59%, 73% and 77% of
surgical procedures, EVLA and foam sclerotherapy respectively.
The findings of CLASS were in accord with those in the Rasmussen29 and Biemans31 studies which showed
significantly better technical success rates for surgery than for foam sclerotherapy. Only one study found
an advantage of foam sclerotherapy over surgery.30
In two29,31 of the three RCTs29,31,32 which compared foam sclerotherapy with EVLA, technical success was
significantly higher in patients randomised to EVLA, which is similar to our findings in CLASS.
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Of the 10 studies that compared EVLA and surgery, the majority (six) reported no significant difference in
technical success rates and were thus similar to the CLASS study.29,31,34,36,39,40 In contrast, three studies
reported a significantly higher technical success rate for EVLA15,35,37 and one for surgery.38
Complications
Serious adverse events
Ten SAEs were reported in patients randomised to foam sclerotherapy, but only three of these were
related to the treatment. All three were non-occlusive DVT. There were seven SAEs in patients randomised
to EVLA, of which one was related to the procedure (prolonged discomfort in non-study leg treated
simultaneously). In patients randomised to surgery, 4 of 10 reported SAEs were secondary to the operation
(two infections, one haematoma and one peroneal nerve injury).
Procedural complications
These were more common in patients randomised to surgery and foam sclerotherapy than in those
undergoing EVLA (surgery 7.1–8.2%, foam 6.2–6.6%, EVLA 1%; p< 0.001). Patients appeared to report
less pain immediately following the treatment with foam sclerotherapy than after EVLA or surgery.
Patients’ later recollection of pain experienced at the time of treatment and during recovery was also lower
for foam sclerotherapy.
TABLE 66 Definition of anatomical outcomes in previous RCTs
Study Anatomical outcome
Rasmussen 201129 Success: closed or absent GSV with lack of flow
Failure: open part of the treated GSV above the knee of > 10 cm in length
Rasmussen 200736 Success: closed or absent GSV or closed GSV with lack of flow
Failure: open part of the treated vein of > 5 cm in length
Carradice 200935 Success: absent GSV in thigh; closed or absent GSV with absent flow in treated segment
of thigh
Darwood 200815 Success: abolition of reflux in the treated GSV segment
Christenson 201034 Success: absent GSV, closed or absent GSV with no flow including absent junctional reflux
Wright 200714 Success: closed or absent GSV including absent junctional reflux
Samuel 201337 Success: abolition of SSV reflux
Lattimer 201332 Different criteria for success, including:
l occlusion (any length) with or without reflux
l occlusion (with or without reflux) or competency (patent and compressible with absence of
flow or presence of antegrade flow)
l occlusion (with or without reflux)
Rass 201138 Success: closed or absent GSV
Figueiredo 200930 Foam sclerotherapy: (1) total occlusion, (2) partial recanalisation without reflux, (3) partial
recanalisation with reflux, (4) total recanalisation [success is defined as (1) and (2)]
Surgery: failure defined as presence of reflux or residual varicose veins
Biemans 201331 EVLA and foam sclerotherapy: success defined as complete obliteration, without flow or reflux,
of the GSV at the level of the mid-thigh
Surgery: success defined as absence of GSV in saphenous compartment at mid-thigh level
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The majority of the complications in the surgery group were anaesthetic related. Following foam
sclerotherapy, visual disturbance was experienced by 1.5% of patients, but there were no reports of more
serious complications such as stroke, despite historical concerns about the possible effect of foam entering
the systemic circulation.
Later complications
At 6 weeks, complications were increased in patients randomised to foam compared with EVLA or surgery
(p< 0.05) and in patients undergoing surgery compared with EVLA. At 6 weeks, skin staining, bruising,
persistent tenderness/discomfort, development of thread veins and lumpiness were statistically more
common in the patients randomised to foam sclerotherapy than in those who had surgery or EVLA.
Cutaneous numbness was statistically more common in patients randomised to surgery (17.6%) or EVLA
(12%) than in those undergoing foam sclerotherapy (4.4%).
At 6 months, the total complication rate was higher for foam than for surgery (p< 0.05). There were no
differences at this time point between EVLA and foam sclerotherapy. At 6 months, the proportion of
patients who had skin staining had doubled in the EVLA group, presumably because of subsequent foam
sclerotherapy for residual varicosities. Lumpiness was more common in the EVLA and foam sclerotherapy
groups than in those undergoing surgery. Persistent bruising and cutaneous numbness were more
common in those patients randomised to surgery.
Persistent lumpiness may have accounted for the increase in patient- and nurse-reported residual veins
(VAS) at 6 months, because any lumps on the legs can mimic varicose veins. The presence of lumpiness
and skin staining after foam sclerotherapy may have made some patients less willing to undergo further
treatment sessions. Lumpiness, skin staining and tenderness are so common after foam sclerotherapy that
it would be reasonable to consider them as expected sequelae rather than ‘complications’. It is certainly
important that patients be warned that they will occur and that they may take a long time to resolve.
Comparison with published randomised controlled trials
The type and frequency of complications observed in CLASS were similar to those documented in previous
RCTs. It is worthy of note that no DVTs were identified in the patients undergoing EVLA or surgery, but three
occurred in patients undergoing foam sclerotherapy. The role of DVT prophylaxis with low-molecular-weight
heparin in conjunction with foam sclerotherapy has not been established and only 5% of patients received
this in CLASS. This is similar to the proportion who received it in the EVLA group (7%) but much lower than
that in the surgery group (48%).
Illness perceptions
No previous RCTs have assessed illness perception. We assessed illness perceptions at two time points before
treatment (at recruitment, and after the participant was informed of his or her randomisation) and at
6 months. The reason for assessing illness perceptions at two time points before treatment was to assess
whether or not the illness perceptions of participants in any of the trial arms changed after they were notified
of the treatment to which they had been randomised. If there had been differences in illness perceptions
between either the trial arms or the two time points, this may have influenced recovery behaviours or
participants’ self-reporting of QoL post treatment. In particular, if there had been differences between
randomised groups, this may have introduced bias into the study. However, illness perceptions between
baseline and after the participants were informed of their randomisation were very similar, as were illness
perceptions between randomised groups at both time points. This suggests that revealing the randomised
treatment allocation to participants (as was necessary in a trial where blinding of participants was not possible)
did not introduce bias in terms of their reported illness perceptions. This increases our confidence in the QoL
outcomes at 6 weeks and 6 months.
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Illness identity was reduced by 6 months in all groups, and this probably reflects a reduced number of
symptoms experienced by the participants after treatment. In those patients randomised to EVLA or foam,
the percentage of symptoms correctly identified as being related to varicose veins increased; in part this is
again likely to reflect a reduced number of symptoms, but may also reflect increased understanding of
those symptoms likely to be related to varicose veins.
For all three treatments, the timeline domain relating to acute or chronic condition decreased. This means
that participants’ views that varicose veins last a long time had changed, and that they believed the
timeline was shorter. Scores for the treatment control domain also reduced by 6 months. Both of these
observations suggest that participants recognised some effectiveness of their treatment.
The consequences domain had reduced by 6 months in all groups, indicating that participants felt that the
consequences of having varicose veins were less severe than they had previously reported. Emotional
representations also reduced by 6 months in all groups. The findings across these domains are likely to
reflect the effect of treatment on the varicose veins. As previously shown, treatment improves QoL
and clinical outcomes; this analysis shows that there is also a benefit of treatment to patients at an
emotional level.
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Chapter 8 Behavioural recovery after treatment
for varicose veins
As described in Chapter 3, one of the secondary outcomes in CLASS was ‘behavioural recovery’, orreturn to normal activities, which is regarded as an aspect of clinical success. One of the studies
published prior to CLASS being funded showed that return to normal activities was considerably shorter
following foam sclerotherapy than after surgery.14 However, in that study it is not clear if ‘normal activities’
were defined or described for participants. We hypothesised that after any particular treatment there may
be earlier return to some activities but later return to others, when compared against other treatments.
With this in mind, we searched for suitable instruments to assess different types of normal activity, but
found none. We therefore developed an instrument, BRAVVO, to assess distinct aspects of normal
activities. In this chapter, we describe the theoretical underpinning of the development of the instrument
and the development process. We also present the trial results generated by the BRAVVO instrument.
Theoretical background
The development and content validation of the BRAVVO questionnaire was informed by the World Health
Organization (WHO) International Classification of Disability and Function (ICF) model.74 The ICF model
proposes that ‘impairment’ (defined as problems in body function or structure) is only one component of
health outcome, the aspect that is based on a medical model of health or disease. The other two
components of the ICF model are ‘activity’ (tasks or actions that an individual is capable of doing in an
idealised situation) and ‘participation’ (what the individual actually does in an everyday, ‘real world’
situation). Variation in activity and participation is not fully explained by impairment, and so these
constructs are important additional indicators of health outcome. It has been proposed that activity and
participation can be defined in behavioural terms;75 thus, the assessment of activity and participation is
potentially a useful indicator of health outcome following treatment for varicose veins, over and above the
AVVQ (which is primarily a measure of impairment). The BRAVVO questionnaire was therefore developed
as an instrument to assess the activity and participation components of the ICF model following treatment
for varicose veins. Being able to return to these activity or participation behaviours following treatment
suggests recovery in terms of these behaviours, and we have termed this ‘behavioural recovery’.
Development of an instrument to assess return to normal
activities (behavioural recovery)
Methods
We developed a questionnaire to assess behavioural recovery. An interview study was carried out to
identify normal activities and ‘milestone’ behaviours to incorporate into the questionnaire.
Eligibility criteria
Patients who had recently undergone treatment for their varicose veins at Aberdeen Royal Infirmary (ARI)
were eligible to participate in the interview study if they
l had undergone recent treatment for their varicose veins (surgery, EVLA or foam sclerotherapy within
the previous 6–12 weeks)
l were 18 years of age or older
l could speak English and were able to participate in the interview
l consented to participate.
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Recruitment
Potential participants were identified from treatment lists at ARI and purposively sampled to provide a
balance of those who received each of the three forms of treatment (surgery, EVLA or foam sclerotherapy).
In addition to sampling from the three treatment options, diversity sampling was used in an attempt to
gain a mix with regard to sex, age and rural–urban location.
Potential participants were invited, by letter sent from a vascular surgeon based at ARI, to take part in the
interview study. They were each provided with a study information leaflet, invited to make contact with
the research team for clarification of queries or further information, and asked to return a reply-paid slip or
make contact by telephone if they wished to participate in the study. Study paperwork is included in
Appendix 1.
Patients who wished to participate in the study were then contacted by telephone to arrange an interview.
Those who wished to participate but were unable to travel to the hospital campus were asked if they
would be prepared to participate in an interview in their home. Participants were compensated for costs
incurred in taking part (e.g. travel, parking, child care).
Interview schedule
A topic guide (see Appendix 3) was prepared to assist the interviewer in eliciting behavioural milestones
that patients regarded as significant. For the first 11 interviews, milestones were explained as ‘Things that
you looked forward to doing for the first time, were worried about doing for the first time, or felt pleased
that you had achieved when you did them for the first time, after your treatment for varicose veins.’ Based
on the reports of several participants that there was nothing in particular that they looked forward to, this
was altered to ‘What couldn’t you do straight after your treatment?’
Interviews
At the interview, participants were asked to sign a consent form indicating their agreement to participate
in the study and to be audio-taped. An experienced interviewer (DB) used the topic guide to ask open
questions (followed by appropriate prompts as required) to identify the actions that patients regarded as
‘milestones’ during their recovery. Interviews were audio-taped and transcribed verbatim. The interviewer
then anonymised the transcripts.
Analysis of interview data
Interview transcripts (n= 17) were content analysed in four stages in order to identify appropriate items to
include in a questionnaire.
First, one researcher (DB) identified, by highlighting, each utterance (or unit of text) that referred to a
behaviour (‘behavioural description’). To validate this first step, a second researcher (JF) read two
transcripts to identify omissions in highlighting. No omissions were identified.
Second, each unit of highlighted text was pasted into a coding table and a ‘label’ (unique descriptor)
was generated to describe each of the behaviours. Two researchers (DB, JF) independently coded
five transcripts, discussing disagreements until consensus about these labels was reached. The 12 other
transcripts were coded by a single researcher (DB) using this set of labels as a guide, and additional labels
proposed when required.
In the third step of the analysis, using data from all the interviews, two researchers (DB, SC) independently
allocated the units of text identified in the first step to one of the labels identified in the second step.
A frequency table (representing the number of times a particular behaviour had been mentioned across all
the interviews) was generated. Intercoder agreement was assessed and any additional labels identified by
either researcher were included in the frequency table. The relevance or importance of each behaviour was
assumed to be reflected by the frequency data.76
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Finally, in the fourth stage of the content analysis, three researchers (DB, JF, SC) discussed the frequency
table and identified (i) the most frequently mentioned behaviours (that merited a questionnaire item) and
(ii) less frequently mentioned behaviours that could be grouped together to generate a questionnaire item
which would encapsulate these behaviours. The behaviours identified using these methods were used to
generate items for the BRAVVO questionnaire.
International Classification of Disability and Function classification of
behaviours included in the Behavioural Recovery After treatment for
Varicose Veins questionnaire
Distinguishing between impairment and the other constructs (activity and participation) within the ICF
model is relatively straightforward. However, the distinction between activity and participation is contextual
and somewhat subjective. For example, the behaviour of ‘walking for 5 minutes’ should be coded as
activity, as it is the execution of a task or action by an individual that could be performed in an idealised
situation (such as on a treadmill during a health-care assessment). However, the behaviour of ‘walking to
work for 5 minutes’ could be coded as participation as it relates to involvement in a ‘real world’ situation.
In order to identify the ICF constructs measured by the BRAVVO questionnaire, two health psychologists
(who had not been involved with the questionnaire development, and had experience of the ICF model)
independently coded each of the behaviours contained within the questionnaire (e.g. driving a car) as
measuring none, one or more than one of the ICF constructs (impairment, activity, participation).
The research team compared the health psychologists’ coding and discussed any disagreements, with
reference to the context within which the item was framed, until consensus was achieved.
Results
Participants
Seventeen participants (12 female and five male) who had received treatment for varicose veins (eight had
been treated with EVLA, five with foam sclerotherapy and four with surgery) were interviewed. As some
interviews were delayed owing to the personal circumstances of participants, time from treatment to
interview was more variable than planned (range 8–19 weeks). At interview, the participants’ age range
was 30–67 years (mean 48.6 years). Six participants were resident in Aberdeen city and the remainder in
the surrounding area (including commuter towns and more rural areas). Hence, a reasonable level of
diversity was achieved in this sample. Twelve interviews were conducted in an office at the hospital
campus; five were conducted in the participants’ homes.
Generation of labels (unique descriptors)
For five transcripts selected at random (two from participants who had undergone EVLA, two from foam
and one from surgery), two researchers independently proposed labels to describe each identified
behaviour. One researcher proposed 22 labels and the other proposed 30 labels. There was considerable
overlap between the labels proposed by each researcher. However, some of the labels proposed by one
researcher were more specific than those proposed by the other. For example, one researcher labelled
going out socially, going to the cinema and going to a restaurant as three separate behaviours whereas
the other researcher labelled them as a single behaviour. Following discussion of the proposed labels,
29 labels were agreed (see Table 67). Analysis of the text from the remaining transcripts yielded 12 further
labels, making a total of 41 labels (see Table 67).
Frequencies for each behaviour
For all 17 interview transcripts, two researchers independently allocated each behaviour identified in the
transcripts to one of the 41 labels. The level of agreement between researchers was 96%. Four additional
labels were generated at this step, resulting in a final total of 45 labels. The number of participants who
mentioned each behaviour was summarised in a frequency table. The frequency data (Table 67) thus
generated were assumed to be an indicator of the relevance or importance of each milestone across the
patient sample.76
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TABLE 67 Behaviour labels identified from interview data: frequency with which each behaviour was mentioned
across interviews
Behaviour label Frequency
Having a bath/showera 15
Full return to normal work/employmenta 12
Bending leg(s)a 11
Driving – generalb 11
Wearing clothing that exposes the legsa 11
Walking long distances (> 20 minutes)a 9
Walking short distances (< 20 minutes)a 8
Standing still for a long time (e.g. > 15 minutes)a 7
Air travela 5
Caring for childrena 5
Doing houseworka 5
Going out sociallya 5
Lifting heavy objectsa 5
Partial return to normal work/employmenta 5
Sitting in cara 5
Walking – generalb 5
Driving – long distancea 4
Physical activity with childrena 4
Shoppinga 4
Swimminga 4
Dancingc 3
Driving – short distancea 3
Golfc 3
Hill-walkingc 3
Kneelingc 3
Sitting down/getting up from chaira 3
Using gym equipment, e.g. exercise bikec 3
Circuit training/going to gyma 2
Climbing steps or stairsc 2
Getting in and out of cara 2
Going to the cinema/theatrea 2
Horse ridinga 2
Running/jogginga 2
Sleeping properly/getting to sleepc 2
Curlingb 1
Cutting grassc 1
Cyclinga 1
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Generation of questionnaire items
Based on these frequencies, the researchers agreed on the items to be included in the final questionnaire,
sometimes by collapsing labels for infrequently mentioned activities (e.g. the labels for golfing, horse riding
and swimming were collapsed into a single label, ‘sporting activity or exercise’). Although ‘air travel’ was
mentioned in five interviews, it was not included as a questionnaire item because it was unlikely to be
relevant to all potential trial participants. However, if an individual trial participant felt this behaviour was
important to them, they could include it in the open behavioural item (‘Anything else that you do that is
important to you . . .’). The words ‘without discomfort’ were added to behaviours that patients reported
doing during early stages of recovery, when they had noted doing them without discomfort as
a milestone.
During the interviews, participants discussed the bandages and compression stockings worn after
treatment. Although wearing them was not considered to be a ‘milestone’ behaviour, interview
participants reported being pleased and relieved to be able to stop wearing their stocking. Therefore, it
was agreed that a question would be included in the questionnaire about the length of time for which
compression stockings were worn.
Designing the Behavioural Recovery After treatment for Varicose
Veins questionnaire
The final version of the questionnaire contained 15 behavioural items (two of which gave participants the
opportunity to describe a social activity and a physical activity), one open behavioural item, one item about
wearing the support stocking and one sentence completion item (‘To help my recovery, I . . .’).
We developed a standard response format for the 15 behavioural items and the open behavioural item.
Box 2 illustrates the format of the behavioural recovery items and response options; the full BRAVVO
instrument is included in the 6-weeks questionnaire contained in Appendix 1. For the three items that
asked participants about an important social or physical activity, or anything else important to them
(the open behavioural item), the response option ‘I don’t normally do this’ was omitted.
The response options for the item about wearing the support stocking were ‘not at all’, ‘day and night
for ____ days, then during the day only for ____ days’ and a free-text option to record any other pattern
of use.
TABLE 67 Behaviour labels identified from interview data: frequency with which each behaviour was mentioned
across interviews (continued )
Behaviour label Frequency
Divingc 1
Fully participating in club/organisation activityc 1
Going to a restauranta 1
Having friends overa 1
Pole dancingc 1
Running the homea 1
Stand and tanb 1
Stretching leg outc 1
a Twenty-nine labels proposed from five transcripts analysed initially.
b Four additional labels proposed during the assessment of frequency of each behaviour.
c Twelve additional labels proposed from analysis of 12 transcripts.
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
Preliminary versions of the questionnaire were pilot tested with three patients (who had agreed to take
part in the interview study). This pilot testing suggested that the BRAVVO questionnaire was acceptable to
participants, and was comprehensible and thus appropriate for self-completion. We did not change the
items included in the questionnaire, but minor refinements to the wording and formatting of the
questionnaire were made in response to pilot testing.
International Classification of Disability and Function classification of
behaviours included in the Behavioural Recovery After treatment for
Varicose Veins questionnaire
Box 3 presents the ICF classification of the 15 behavioural items. There was full agreement between the
health psychologists on the ICF construct measured by 11 of the 15 behaviours coded. There was partial
agreement for two behaviours (‘partial return to normal work/employment’, ‘full return to normal work/
employment’), with one health psychologist coding these behaviours as participation and the other coding
BOX 2 Format of the behavioural recovery questions and response options
Behaviour
□ I don’t normally do this.
□ I normally do this, but haven’t done so since my treatment.
□ I have done this since my treatment. I did it for the first time:
□ on the day of my treatment OR □ days after my treatment OR □ weeks after my treatment.
BOX 3 International Classification of Disability and Function classification of BRAVVO behavioural items
Behaviours classed as ‘activity’
l Bending the leg(s) (without discomfort).
l Lifting heavy objects (without discomfort).
l Moving from a standing to a sitting position (without discomfort).
l Standing still for a long time, i.e. more than 15 minutes (without discomfort).
l Walking short distances, i.e. less than 20 minutes (without discomfort).
l Walking long distances, i.e. more than 20 minutes.
l Having a bath/shower.
l Driving a car.
Behaviours classed as ‘participation’
l Doing housework.
l Looking after children.
l Wearing clothes that show the legs.
l Partial return to normal work/employment.
l Full return to normal work/employment.
l Going out socially (such as going to the cinema, theatre, restaurant, etc.).
l Sporting activity or exercise (such as swimming, going to the gym, cycling, running, jogging, horse riding,
hill walking, golf, etc.).
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them as measuring both activity and participation. There was also partial agreement on a further
two behaviours (‘doing housework’ and ‘sporting activity or exercise’), with one health psychologist coding
these as activity and the other as both activity and participation. The research team discussed the
four behaviours for which there was partial agreement and consensus was achieved that all four measured
participation. The rationale for this was that all relate to involvement in an everyday, ‘real world’ situation.
In addition, in the case of ‘doing housework’ and ‘sporting activity or exercise’, there is a lack of behavioural
specificity of the tasks or actions involved (i.e. housework could involve light dusting or scrubbing floors).
This may make responses to them more difficult to interpret in terms of behavioural recovery.
Use of the Behavioural Recovery After treatment for Varicose
Veins questionnaire in Comparison of LAser, Surgery and
foam Sclerotherapy
Methods
Data collection
As described in Chapter 3, we incorporated the BRAVVO questionnaire into the larger CLASS
questionnaire administered 6 weeks following treatment. Participants in the CLASS trial were invited to
complete this at their 6-weeks follow-up appointment. Participants who failed to attend for their 6-weeks
appointment were sent a questionnaire to complete at home.
Statistical analysis
Data from the BRAVVO questionnaire were analysed within an interval-censored time-to-event framework
using flexible parametric survival models.77 For each behaviour item, each participant’s response was
converted into the number of days to return to the behaviour. If a participant indicated that return to the
behaviour was on the day of the procedure, this was assumed to be interval censored between day 0 and
day 1. If a participant indicated that return to the behaviour was after a number of weeks, not days,
this was assumed to be interval censored between the previous week and the week indicated. For example,
if a participant reported 5 weeks, it was assumed that the return to the behaviour took place between 28
and 35 days. If a participant indicated that they had not returned to a behaviour they usually did, they were
right censored at 42 days. Participants who indicated that they did not normally do the specific behaviour
were not included in analysis of that behaviour. No missing data were imputed.
We reported the number of days for 50% and 90% of participants to return to each behaviour, estimated
from the parametric survival models (the 50% value represents the median time to return to that
behaviour). This allows extrapolation beyond the 42-day cut-off for behaviours where 90% of participants
had not returned to the activity by 42 days.
The models were fitted on the log cumulative hazard scale, using a restricted cubic spline with one knot to
model the baseline hazard function. Treatment effects are presented as hazard ratios (HRs) and 95% CIs.
All analyses were carried out in Stata 12 (StataCorp LP, College Station, TX, USA).78 Flexible parametric
survival models were fitted using the stpm command.79
The item relating to ‘anything else that you do that is important to you, not already mentioned’ was only
completed by 99 participants (12%). These participants described a wide range of behaviours (including
cooking, cycling, gardening and yoga) that might be expected to have a different recovery trajectory.
For these reasons, we considered it inappropriate to summarise data or calculate HRs for this item.
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Comparison of Behavioural Recovery After treatment for Varicose Veins
results by randomised group
Foam sclerotherapy versus surgery
Participants randomised to foam sclerotherapy were able to carry out most of the behaviours (both activity
and participation behaviours) more quickly than those randomised to surgery (Table 68). In general,
the median time to return to the activity behaviours was 5 days or fewer for those randomised to foam
and up to 9 days for those randomised to surgery. In both groups, there was greater variation in the
median time to return to the participation behaviours than the activity behaviours. For all but two of the
behaviours, the HRs comparing foam with surgery indicated that return to the behaviour took longer in
the surgery arm. The two behaviours for which there was no evidence of a difference in the time to
recover between the trial arms were ‘having a bath or shower’ and ‘wearing clothes that show the legs’.
Endovenous laser ablation versus surgery
For seven of the eight activity behaviours, return to the behaviour took longer for those randomised to
surgery than for those randomised to EVLA (Table 69). Return to the other activity behaviour (having a
bath or shower) was quicker after surgery than after EVLA. For six of the seven participation behaviours,
return to the behaviour took longer for those randomised to surgery than for those randomised to EVLA.
There was no evidence of a difference in time to return to the other participation behaviour (wearing
clothes that show the legs).
Endovenous laser ablation versus foam sclerotherapy
There was little difference in the time taken to return to the majority of activity and participation
behaviours between those randomised to EVLA and those randomised to foam (Table 70). Exceptions to
this were walking short and long distances, looking after children and full return to normal work/
employment, where return to the activity was longer for the EVLA group than for the foam group.
Compression stockings
We asked how long participants wore their stocking constantly (i.e. day and night); those in the foam arm
reported wearing their stocking longer (median 10 days) than those in both the surgery and EVLA arms
(median 7 days for each). We also asked about the number of days (or nights) they wore the stocking after
they stopped wearing it constantly. We calculated the total number of days that participants wore their
stocking (wearing constantly, and then wearing for part of the day or night only); the median time was
shortest for foam (12 days) compared with 14 days for EVLA and 17 days for surgery.
Discussion
In this chapter, we have described the development of the BRAVVO questionnaire as an instrument to
assess behavioural recovery, and reported findings from the CLASS trial in which the instrument was used.
This is a new approach to investigating and describing return to normal activities after treatment of
varicose veins which may be useful for more widespread application.
Strengths and limitations of the Behavioural Recovery After treatment for
Varicose Veins instrument
The instrument has a number of limitations. First, although care was taken to recruit a diverse sample of
participants, this was essentially a self-selected sample of people in one geographical region of the UK,
who might not be typical of patients in general. Second, there were constraints associated with developing
a questionnaire that would be suitable and relevant for use by a wide range of trial participants but
sufficiently short to minimise participant fatigue. Finally, despite pilot testing the questionnaire, the level of
missing data was slightly higher for BRAVVO than for other instruments used within CLASS. It may be
beneficial to consider if rephrasing the questions or response options, or reformatting the questions, may
reduce the level of missing data.
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TABLE 68 Behavioural recovery: foam vs. surgery
Questionnaire item
Proportion carrying
out activity (%)
Number of days until 50%
(and 90%) of participants
can carry out activitya
HRb (95% CI)Foam Surgery
Activity items
Bending the legs without discomfort 50 3.0 4.6 1.38 (1.14 to 1.67)
90 14.1 21.3
Lifting heavy objects without
discomfort
50 4.8 9.8 1.97 (1.59 to 2.44)
90 16.9 34.5
Moving from standing to sitting
without discomfort
50 1.9 3.7 1.63 (1.35 to 1.97)
90 9.3 17.5
Standing still for a long time
(> 15 minutes) without discomfort
50 3.9 7.1 1.67 (1.36 to 2.05)
90 15.8 28.7
Walking short distances
(< 20 minutes) without discomfort
50 1.9 4.4 2.00 (1.65 to 2.42)
90 8.2 19.1
Walking long distances (> 20 minutes) 50 4.5 8.0 1.76 (1.45 to 2.14)
90 15.2 27.1
Having a bath or shower 50 5.4 4.9 0.85 (0.70 to 1.03)
90 11.4 10.3
Driving a car 50 4.1 7.0 1.78 (1.45 to 2.19)
90 12.4 21.1
Participation items
Doing housework 50 2.1 4.5 2.10 (1.72 to 2.56)
90 7.3 15.7
Looking after children 50 1.2 3.5 2.20 (1.61 to 3.00)
90 6.2 17.9
Wearing clothes that show the legs 50 12.4 12.8 1.03 (0.78 to 1.35)
90 56.6 58.7
Partial return to normal
work/employment
50 4.4 9.9 2.16 (1.72 to 2.72)
90 15.4 34.2
Full return to normal
work/employment
50 4.8 11.7 2.56 (2.05 to 3.21)
90 14.9 36.2
Going out socially 50 7.1 9.3 1.29 (1.06 to 1.57)
90 25.8 34.0
Sporting activity or exercise 50 15.7 21.8 1.33 (1.05 to 1.68)
90 62.6 86.7
a The 50% value is equivalent to the median time to return to the activity.
b A HR > 1 shows return to activity took longer in the surgery arm. HRs shown in bold text are statistically significant.
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TABLE 69 Behavioural recovery: EVLA vs. surgery
Questionnaire item
Proportion carrying
out activity (%)
Number of days until 50%
(and 90%) of participants
can carry out activitya
HRb (95% CI)EVLA Surgery
Activity items
Bending the legs without discomfort 50 2.7 4.6 1.49 (1.1 to 1.75)
90 12.6 21.3
Lifting heavy objects without
discomfort
50 5.9 9.8 1.79 (1.39 to 2.27)
90 20.5 34.5
Moving from standing to sitting
without discomfort
50 2.2 3.7 1.56 (1.27 to 1.96)
90 10.4 17.5
Standing still for a long time
(> 15 minutes) without discomfort
50 4.8 7.1 1.41 (1.11 to 1.79)
90 20.0 28.7
Walking short distances
(< 20 minutes) without discomfort
50 3.0 4.4 1.30 (1.04 to 1.61)
90 13.2 19.1
Walking long distances (> 20 minutes) 50 5.6 8.0 1.53 (1.06 to 1.67)
90 19.8 27.1
Having a bath or shower 50 5.5 4.9 0.74 (0.59 to 0.93)
90 12.8 10.3
Driving a car 50 4.4 7.0 1.82 (1.43 to 2.33)
90 12.7 21.1
Participation items
Doing housework 50 2.5 4.5 1.89 (1.49 to 2.38)
90 8.4 15.7
Looking after children 50 1.9 3.5 1.61 (1.15 to 2.27)
90 8.8 17.9
Wearing clothes that show the legs 50 14.6 12.8 0.97 (0.69 to 1.35)
90 75.1 58.7
Partial return to normal
work/employment
50 6.3 9.9 1.75 (1.33 to 2.27)
90 21.1 34.2
Full return to normal
work/employment
50 7.7 11.7 1.79 (1.37 to 2.27)
90 23.5 36.2
Going out socially 50 6.9 9.3 1.41 (1.12 to 1.75)
90 23.9 34.0
Sporting activity or exercise 50 14.2 21.8 1.47 (1.12 to 1.92)
90 55.5 86.7
a The 50% value is equivalent to the median time to return to the activity.
b A HR > 1 shows return to activity took longer in the surgery arm. HRs shown in bold text are statistically significant.
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TABLE 70 Behavioural recovery: EVLA vs. foam
Questionnaire item
Proportion carrying
out activity (%)
Number of days until 50%
(and 90%) of participants
can carry out activitya
HRb (95% CI)EVLA Foam
Activity items
Bending the legs without discomfort 50 2.7 3.0 0.94 (0.75 to 1.17)
90 12.6 14.1
Lifting heavy objects without
discomfort
50 5.9 4.8 1.11 (0.87 to 1.42)
90 20.5 16.9
Moving from standing to sitting
without discomfort
50 2.2 1.9 1.12 (0.90 to 1.40)
90 10.4 9.3
Standing still for a long time
(> 15 minutes) without discomfort
50 4.8 3.9 1.14 (0.90 to 1.44)
90 20.0 15.8
Walking short distances
(< 20 minutes) without discomfort
50 3.0 1.9 1.48 (1.19 to 1.84)
90 13.2 8.2
Walking long distances (> 20 minutes) 50 5.6 4.5 1.32 (1.05 to 1.66)
90 19.8 15.2
Having a bath or shower 50 5.5 5.4 1.19 (0.96 to 1.48)
90 12.8 11.4
Driving a car 50 4.4 4.1 0.95 (0.74 to 1.21)
90 12.7 12.4
Participation items
Doing housework 50 2.5 2.1 1.03 (0.82 to 1.29)
90 8.4 7.3
Looking after children 50 1.9 1.2 1.45 (1.04 to 2.02)
90 8.8 6.2
Wearing clothes that show the legs 50 14.6 12.4 1.17 (0.83 to 1.64)
90 75.1 56.6
Partial return to normal
work/employment
50 6.3 4.4 1.17 (0.89 to 1.52)
90 21.1 15.4
Full return to normal
work/employment
50 7.7 4.8 1.43 (1.11 to 1.85)
90 23.5 14.9
Going out socially 50 6.9 7.1 0.88 (0.70 to 1.10)
90 23.9 25.8
Sporting activity or exercise 50 14.2 15.7 0.80 (0.61 to 1.04)
90 55.5 62.6
a The 50% value is equivalent to the median time to return to the activity.
b A HR > 1 shows return to activity took longer in the EVLA arm. HRs shown in bold text are statistically significant.
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Despite these limitations, the BRAVVO questionnaire represents a systematic first step in identifying the
behaviours that may be used to monitor recovery, as well as the actions that patients may take to
influence their own recovery following treatment for varicose veins. For the first time, it allows researchers
to provide meaningful information to patients about their early recovery and what they may expect to
achieve after their treatment.
Comparison of LAser, Surgery and foam Sclerotherapy results in the context
of previous research
Return to normal activities
In contrast to previous studies,14,15,29,32,36–38,40 where it appears that participants were asked about return to
‘normal activities’, ‘full activity’, ‘daily activity’ or ‘basic physical activities’, and/or return to work and
sporting activities, the BRAVVO questionnaire asks about specific behaviours, all of which are likely to
contribute to ‘normal activities’, and all of which were identified by patients as important milestones
following their treatment. It provides much more specific and meaningful insights into the wide range of
aspects of recovery which are important to patients.
Across the specific behaviours included in BRAVVO, there was variation in the median time to return to the
behaviour (i.e. the time that it took for 50% of participants to return to the behaviour). For example,
the median time for different behaviours varied from 1 day to 15 days in the foam arm, from 2 days to
14 days in the EVLA arm and from 3 days to 21 days in the surgery arm. This suggests that simply asking
about generic ‘normal activities’ (as in previous studies) may miss important differences between different
behaviours. This strengthens the rationale for asking about specific behaviours rather than asking a generic
question about ‘normal activities’. Information about recovery in terms of specific behaviours could be
incorporated into guidance for patients regarding what to expect in the post-treatment period.
Previous studies reporting return to ‘normal activity’ (i.e. using the terms outlined above) have reported
median values of up to 3 days following foam,14,29,32 up to 7 days following EVLA15,29,32,37,38 and up to
21 days following surgery.15,29,37,38 For foam, the median time for some of the behaviours asked about in
CLASS was 3 days or fewer; for other behaviours, the median time was considerably longer (up to 15 days).
For EVLA, the median time for the majority of behaviours we asked about was 7 days or fewer; only two
behaviours had a median time greater than this. For surgery, none of the behaviours we asked about had a
median recovery time longer than 21 days. Although this might suggest that the BRAVVO questionnaire
has captured similar data to the single question used in previous studies, the data from the BRAVVO
questionnaire are more informative. This is because it provides data across a range of specific behaviours
which have different recovery trajectories.
The distribution of time to return to each of the behaviours indicates that there is a proportion of people
who take much longer to return to the behaviour than would be expected. The extent of this delay in
recovery is hard to justify, particularly in light of the information and advice that was given in the study
patient information leaflet (PIL), where we suggested that participants should aim to get back to all their
normal activities as soon as they were able, but that strenuous activity/contact sport should be avoided for
1–2 weeks. There may have been a number of external influences that had an impact on participants’
recovery, including misinformation and fear. Although attitudes to recovery and returning to normal
activities have changed in secondary care, this may not have filtered into primary care or the ‘public
knowledge’. Fear of activity or fear of pain caused by activity has been documented following surgery for
other conditions.80,81 It is possible that some people undergoing treatment for varicose veins will experience
similar fears and this may limit or restrict activity following their treatment. In addition, anecdotal evidence
suggests that many patients fear ‘doing damage’ to their leg following treatment, and particularly
following surgery. These fears may contribute to delays in recovery.
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Two previous studies have observed that patients return to normal activities more quickly after foam than
after surgery.14,29 For all but two of the behaviours we asked about in CLASS, we showed a similar
pattern of results. The exceptions were wearing clothes that showed the legs and showering/bathing.
Our observation about showering and bathing is likely to have occurred as a result of the information
contained in the study PIL. Participants undergoing foam sclerotherapy or EVLA were advised to wear their
stocking for 10 days constantly (i.e. day and night). Those in the surgery group were advised that their
bandages would be removed the day after the operation, after which they should wear a stocking for
10 days, but that it was reasonable to remove the stocking after 4 or 5 days, providing they were active.
Following surgery, they were also told that a shallow bath might be possible if they could raise their leg to
keep the stocking dry.
In three previous studies,15,29,37 the time to return to normal activities was shorter following EVLA than
following surgery. For all but two of the behaviours we asked about in CLASS, the findings were similar in
that those randomised to EVLA could carry out the behaviour more quickly than those randomised to
surgery. One of these behaviours was having a bath or shower, and those randomised to surgery were
able to do this earlier after treatment than those randomised to EVLA. The likely reason for this, as
discussed above, is the information provided in the PIL. Two previous RCTs comparing surgery and EVLA
did not find a difference in mean time to return to daily activities,36,40 and in one further study there was
no difference in median time to return to ‘basic activity’ between surgery and EVLA.38
There have been two previous RCTs which showed a quicker return to normal activities in patients
undergoing foam sclerotherapy than in patients undergoing EVLA.29,32 For four of the behaviours we asked
about in CLASS (walking short and long distances, looking after children, full return to normal work/
employment), participants in the foam arm returned to the behaviour more quickly than participants in the
EVLA arm. For all other behaviours, there was no difference between the arms.
Return to work
Two of the behaviours identified in the interview study, and included in the BRAVVO questionnaire, related
to return to work/employment (partial return and full return). As might be expected, across all three arms
the median time to full return to work was longer than that for partial return to work. In previous studies,
return to work is reported as a single item, without any distinction between partial and full return, which
may be of substantial importance to patients, their employers and the economy as a whole.15,29,36–38,40
The median time to return to either partial or full employment was significantly longer following surgery
than either foam or EVLA. Although there was no significant difference in the median time to partial
return to employment following foam or EVLA, the median time to return to full employment was
significantly longer following EVLA than following foam. This latter finding is perhaps surprising because,
in the PIL, the advice about return to work was identical for foam and EVLA. The advice stated that ‘most
people are able to return to work within two to three days of treatment, but some people go back the
following day or even the same day’. That the time to return to work following surgery was longer than
for either foam or EVLA is less surprising. The advice in our PIL for surgery stated that people can return to
office or sedentary work after 2–3 days, and that most people will be back at work within 1 week after
surgery to one leg and 2 weeks after surgery to both legs. It also stated that there is no reason to remain
off work for this long, if it can be managed with reasonable comfort.
In addition to the information given in the PIL and by the vascular surgeon about return to work, a number
of factors are likely to mediate return to work after treatment for varicose veins. These may include a
person’s employment status (employed or self-employed), the sickness benefits they are entitled to,
the type of work they are employed to do, how long they are ‘signed off’ for by their doctor and the views
of their employer on return to work after an operation.
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In CLASS, the median time to full return to normal work/employment following surgery was 11 days.
This is within the range previously reported. Studies have reported median times of 4.3,29 11.8,38 1715 and
21 days.37
For EVLA, the median time to full return to normal work/employment was 7 days; this is within the range
previously reported (4–10 days).15,29,36–38,40
For foam sclerotherapy, the median time to full return to work/employment was 4 days. In the one
previous study that reported the median number of days for return to work, the median time was shorter
(2.9 days) than that found in CLASS (partial return 4.4 days, full return 4.8 days).29
In our comparison of surgery versus foam sclerotherapy, we showed that there were significant differences
in both partial and full return to work in favour of foam. The one previous study reporting this outcome
has shown that return to work was quicker following foam than following surgery.29
The CLASS trial showed that return to work following EVLA was quicker than following surgery. This is in
line with the findings of three previous RCTs.15,37,38 In the study by Rasmussen et al.,29 there was no
difference in median time to return to work between those undergoing EVLA and those undergoing
surgery. Two further RCTs did not find a difference in time to return to work;36,40 however, in these studies
mean times were compared rather than median times, and this may not be the most appropriate measure
if the distribution is skewed.
In CLASS, there was no difference in time to partial return to work following foam or EVLA, but full return
to work was quicker following foam than following EVLA. The one previous study to report a comparison
of foam and EVLA in relation to return to work found that it was quicker following foam than
following EVLA.29
Further development of the Behavioural Recovery After
treatment for Varicose Veins questionnaire
The 14 core behavioural items were designed to be scored along a time scale (number of days after
treatment to when each behaviour was first performed), and this is how the findings from the CLASS trial
are presented. It may be possible to explore the psychometric properties of the instrument and develop a
method of producing an overall score for the behavioural items of the questionnaire. Through a systematic
process of independent coding of the behaviours contained within the questionnaire by two health
psychologists with experience of the ICF model, we have produced data to show that eight of the items
measure activity behaviours and seven measure participation behaviours. It may be possible to score these
two classes of behaviours as separate subscales.
The results from the application of BRAVVO in the CLASS trial provide useful data for clinicians as they
guide patients through their recovery phase. Similar data following treatment for other conditions may also
be helpful for both clinicians and patients. Although some of the items in BRAVVO may be transferable to
other conditions, we would recommend using similar methods to those described here to identify relevant
items to populate other treatment-specific behavioural recovery questionnaires, and the appropriate time
frame at which to assess these. During the funding process, there was discussion regarding the most
appropriate time point at which to assess behavioural recovery. Although initially planned for the 6-months
follow-up, clinical expertise and interview data indicated that, following treatment for varicose veins,
it would be more appropriate to collect this type of data at the 6-weeks follow-up. There were two
reasons for this. First, the validity of patient recall data was likely to be higher if patients were recalling
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events over the previous 6 weeks than over the previous 6 months. Second, variation in recovery was likely
to be greater over a period of 6 weeks, as most patients would consider themselves to be fully recovered
well before the 6-months follow-up. Hence, BRAVVO data at 6 weeks were likely to have more
explanatory value.
Conclusions
Development of the BRAVVO instrument represents a systematic first step in identifying the actions that
patients may take to influence their own recovery following treatment for varicose veins, as well as
the behaviours that may be used to monitor recovery. Using this questionnaire, we have shown that
patients are able to return to a wide range of behaviours more quickly following foam or EVLA than
following surgery.
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Chapter 9 Trial-based cost-effectiveness analysis
Introduction
The purpose of this chapter is to report on the economic analysis that was conducted using individual
participant cost and effect data collected alongside the RCT. Two comparisons were considered for the
analysis: (1) foam sclerotherapy versus surgery; and (2) EVLA versus foam sclerotherapy versus surgery.
As with the clinical effectiveness analyses, the first comparison was carried out using data from all
recruiting centres, whereas the three-arm comparison was based only on data from the eight centres that
randomised participants to all three treatment options. The methods utilised are described below and,
following this, the results are presented.
Methods
This economic evaluation was constructed as a cost-effectiveness analysis, the measure of effect being
QALYs over the 6-month trial follow-up period. The primary economic outcome was expressed as the
incremental cost per QALY for each treatment option. QALY (utility) weights were derived from participant
responses to the EQ-5D82 at baseline, 6 weeks and 6 months. However, to test the robustness of the
results to the choice of health state utility instrument, and to enable a comparison with the only other
published, UK-based economic evaluation in this area,65 QALYs were also estimated using responses to the
SF-36 via the SF-6D scoring algorithm.83 For each participant, the area under the curve was calculated to
determine the QALYs gained. Total NHS, individual participant and indirect costs were estimated for each
participant based on resource use data collected on case report forms and participant questionnaires
(see Appendix 1). Incremental costs and QALYs associated with the alternative treatment options were
estimated using GLMs, adjusted for baseline EQ-5D score and the minimisation covariates. A ceiling ratio
of £20,000 per QALY (i.e. a treatment was only deemed cost-effective if it cost less than £20,000 per extra
QALY gained) was used to determine cost-effectiveness (i.e. the ICER).28
Non-parametric bootstrapping84 was used to generate CIs for the estimated mean incremental costs and
effects, and to summarise the uncertainty surrounding the ICERs. To illustrate the uncertainty surrounding
the estimates of cost-effectiveness, cost-effectiveness acceptability curves (CEACs) were derived using the
bootstrapped estimates of incremental costs and effects. CEACs demonstrate the probability of an
intervention being cost-effective at different ceiling ratios of decision-makers’ willingness to pay (WTP) per
QALY. To test the robustness of results derived from the base-case analysis, key parameters were subjected
to deterministic sensitivity analyses. Such analyses examine the effect of estimated or uncertain parameters
on the decision.
Unit cost estimation
Unit costs for all resources were obtained for the financial year 2010–11 and were acquired, where
possible, from national sources including the British National Formulary,85 NHS Reference Costs (2011)86
and the Unit Costs of Health and Social Care [Personal Social Services Research Unit (PSSRU) 2011].87
Where national sources were not available, other sources were utilised, for example finance departments
of participating centres.
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NHS costs
Total NHS costs included health service resource use associated with initial treatment, all subsequent
contact with primary care (e.g. GP contacts) and secondary care contact potentially related to the
participants’ varicose veins (e.g. hospital admissions, outpatient appointments).
Cost of treatment procedures
All treatment strategies were performed as day-case procedures; however, the locations and settings
differed. The unit costs of performing each of the three treatment strategies were estimated using a
‘bottom-up’ approach. These costs were collected via a centre-specific resource use and costing
questionnaire, allowing us to capture resource use not recorded on the trial CRFs, and also to cost the
treatment strategies in a centre-specific manner. The additional questionnaire is shown in Appendix 4.
Information collected included average participant waiting time (before and after treatment), location of
treatment and recovery, nursing staff input, equipment use and consumables used for procedures.
The grade of the surgeon or nurse performing each procedure (nurses performed some foam sclerotherapy
treatments), and whether or not they were supervised by a consultant, was recorded on the CRF of each
participant receiving treatment. For surgery, the grade of the anaesthetist present was recorded. The times
of entering and leaving the operating theatre or treatment room were used as a measure of the total
time requirement for all staff (including nursing and support staff) present for the procedure. Further
information, relating to the numbers of nursing and support staff who were typically present for the
different types of procedure and their salary bands, was collected using the centre-specific resource use
and costing questionnaire. This staffing information, together with treatment duration times (obtained for
individual participants), was combined with national unit cost data (PSSRU 2011)87 to estimate the total
cost of staff time for each procedure. The unit costs applied for each grade of staff are presented in
Table 71.
TABLE 71 Unit cost of staff time inputs
Staff Unit cost per hour (£) Cost per minute (£) Source
Nursing staff
Band 2 20 0.34 PSSRU (2011)87
Band 3 24 0.40 PSSRU (2011)87
Band 4 30 0.50 PSSRU (2011)87
Band 5 82 1.37 PSSRU (2011)87
Band 6 107 1.78 PSSRU (2011)87
Band 7 129 2.15 PSSRU (2011)87
Band 8b (consultant nurse) 147 2.45 PSSRU (2011)87
Medical staff
Foundation Year 1 33 0.55 PSSRU (2011)87
Foundation Year 2 core trainee, CCT 42 0.69 PSSRU (2011)87
Specialty trainee 59 0.99 PSSRU (2011)87
Staff grade 95 1.59 PSSRU (2011)87
Associate specialist 131 1.88 PSSRU (2011)87
Consultant medical 136 2.27 PSSRU (2011)87
CCT, certificate of completion of training.
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An extensive list of minor consumables was generated from the trial centre which had recruited most
participants and this cost was applied directly to all procedures. However, major consumables and items of
capital equipment (which could have a significant impact on overall costs) were collected from a number
of participating centres. An overview of the costing approach is described below.
Capital equipment was costed by asking participating centres to report the current market price for major
equipment items used. Two major pieces of capital equipment – duplex ultrasound machines and laser
generators – were required for foam sclerotherapy and EVLA treatments. Centres reported using Sonosite
Micromaxx® or Sonosite M-turbo® ultrasound machines (Sonosite, Inc., Bothell, WA, USA); laser machines
reported were Fotona Lasers XP-2® (Fotona, San Clemente, CA, USA) and Biolitec Lasers® (Biolitec, East
Longmeadow, MA, USA). However, centres offering EVLA reported receiving laser machines on loan from
suppliers. Because the NHS did not incur a cost for any laser generator, no cost was applied for the usage
of this capital item in the base-case analysis (a sensitivity analysis was conducted to test this assumption).
The initial outlay costs of duplex ultrasound machines were annuitised over the expected serviceable
working life of these devices, using an annual depreciation rate of 3.5% to account for the opportunity
cost of the investment over time. The estimated equivalent annual cost was then divided by an estimate of
annual patient throughput to give an estimated cost per use of £8.78.
The unit costs of staff time incorporated an allocation of overhead and capital (building space) costs
attributable to individual grades of staff, but there was nevertheless some concern that these unit costs
would not fully capture the opportunity cost associated with procedures which utilised operating theatres.
All surgical procedures for the GSV and SSV were performed in an operating theatre. Therefore, a secondary
analysis was undertaken, whereby an extra allocated cost per minute for use of an operating theatre was
applied to procedures for which a theatre was stated as the main location for treatment. An additional cost
of £3.64 per minute, derived from Information Services Division (ISD) data,88 was calculated from the
total allocated costs attributable to theatre use divided by total theatre operating time at three large
teaching hospitals in Scotland. These allocated costs include the cost of theatre equipment and cleaning of
consumables. Therefore, for the secondary analysis, the bottom-up estimated costs of equipment use and
cleaning were dropped from total cost estimates for procedures carried out in theatre (to avoid
double counting).
Foam sclerotherapy
Foam sclerotherapy was, for the most part, performed in a clinic setting. The nursing staff requirements
reported for this procedure varied from one to two nurses (band 5 or 6), with some centres also reporting
the presence of a health-care assistant or nurse runner.
Foam sclerotherapy treatment involves the injection of a foam sclerosant into the affected vein(s), guided
by ultrasound. The unit cost of the ultrasound machine usage was also incorporated for each treatment
session. One centre reported using a micropuncture kit for venous access, whereas others reported using
an intravenous cannula (a small, flexible plastic tube that is inserted into the vein). The cost of the
micropuncture kit (which incurs a higher cost than the intravenous cannula) was only applied to the centre
that reported using it. Table 72 shows the unit costs, over and above staff time, of items of resource use
included in the cost calculation for foam sclerotherapy treatment.
Endovenous laser ablation
Centres reported varied locations for performing EVLA. These included outpatient clinic room, treatment
room, short-stay ward and day-case theatre (a minority of centres reported performing procedures here).
All procedures were performed under local anaesthetic, regardless of location. The unit cost of staff time
was estimated as outlined in Table 71.
Disparities were evident among centres performing EVLA in terms of staff (additional to the surgeon)
present at the procedure. On average, centres reported the presence of two additional staff for procedures
performed in a clinic or treatment room setting, whereas those that used a theatre or short-stay ward to
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perform EVLA reported an average of five additional staff. Additional staff types included theatre nurses,
vascular nurse specialists, health-care assistants/support workers, trainee operating department practitioners
and nurse runners. Although the base-case analysis incorporated staff present in a centre-specific manner,
a sensitivity analysis was conducted to assess the impact if EVLA was performed in a clinic or treatment
room setting only and adopted a similar staff profile to foam sclerotherapy.
Endovenous laser ablation requires the use of both an ultrasound machine to identify the veins that need
treatment, and a laser generator to deliver the energy to the vein via the laser fibre. Although it was
assumed that the laser generator would generally be loaned free of charge to the NHS, this still requires
the use of a laser fibre. The price of this non-reusable laser fibre (£256) is a key driver in the overall cost of
this treatment. Table 73 shows the unit costs included in the cost calculation for the EVLA procedure. In
addition, the section of the resource use and costing questionnaire concerned with EVLA captured the
average length of time spent on the ward both before and after the procedure.
Surgery
The staffing requirements for surgery were again costed in a participant-/centre-specific way. All procedures
are carried out in an operating theatre under general or epidural/spinal anaesthetic. Surgery also requires
additional staff time to look after the patient in the recovery room and recovery ward after the procedure,
during recovery from anaesthesia.
TABLE 72 Items included in the cost calculation for foam sclerotherapy
Resource use item Mean unit cost (£) Assumptions Source
Foam sclerotherapy STS 3%: 5.52 per amp
STS 1%:
4.54 per amp
3% used for GSV and SSV
1% used for non-truncal
varicosities
Participating centre (lead centre)
(2013)
Consumables 50.20 Centre using micropuncture kit Participating centres, resource use
and costing questionnaire (2013)
Consumables 26.23 Applied to all centres other than
that using micropuncture kit
Participating centres, resource use
and costing questionnaire (2013)
Capital equipment
(ultrasound machine)
8.78 Per usage Participating centres, resource use
and costing questionnaire (2013)
Preparation cost of
clinic/theatre
24.86 Applied to all centres Clinical opinion (2013), PSSRU
(2011)87
Recovery cost 1.70 10 minutes in recovery area Clinical opinion (2013), PSSRU (2011)87
amp; ampoule.
TABLE 73 Items included in the cost calculation for EVLA
Resource use item Unit cost (£) Assumptions Source
Consumables 65.06 Applied to all centres Participating centre (lead centre) (2013)
Laser fibre 256 Includes catheter and guide wire Participating centre (lead centre) (2013)
Capital equipment
(ultrasound machine)
8.78 Per usage Participating centres, resource use and
costing questionnaire (2013)
Preparation cost of
clinic/theatre
23.78 Applied to all centres Clinical opinion (2013), PSSRU (2011)87
Recovery cost 31.85 Estimated from resource use and
costing questionnaire
Clinical opinion (2013), PSSRU (2011)87
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Centres specified a range of different nursing and support staff present for this procedure, with an average
of five staff in addition to the surgeon and anaesthetist. These staff included anaesthetic nurses, scrub
nurses, assistant scrub nurses, health-care assistants, nurse runners, operating department practitioners
and recovery nurses.
The main capital equipment items required for the surgical procedure are the electrocardiograph (ECG),
pulse oximeter and non-invasive blood pressure monitor. A cost per patient was calculated in a similar way
to that for use of the ultrasound machine.
Time spent by participants in the recovery room after the procedure was also recorded on the CRFs. It was
assumed that the cost of the recovery room time would include half the time of a band 5 nurse, while
further time spent on a recovery ward after leaving the recovery room would incur one-quarter of the time
of a band 5 nurse. Table 74 outlines the cost items, over and above the staffing costs for the procedure
and recovery room time, required for the estimation of the total costs of surgery. Information was collected
from the additional resource use and costing questionnaire on the average time spent by participants on
the day-case ward before and after treatment.
Follow-up health service use costs
Data on the use of secondary health-care services (hospital admissions and outpatient attendances) were
collected using a combination of clinical assessment forms (completed at 6 weeks and 6 months) and a
data abstraction form completed by the research nurse at each centre based on each participant’s medical
records. Data on the use of primary care services over the follow-up period were collected from the
6-months, patient-completed questionnaire. The clinical assessment and data abstraction forms captured
information regarding any hospital admissions and any additional treatment to the study leg (outside the
CLASS trial protocol). Reported hospital admissions were reviewed by clinicians on the trial team, and
those identified as possibly related to treatment were costed using the appropriate NHS reference cost
(Department of Health 2011).86 The average costs of the treatment strategies, derived from the bottom-up
micro-costing of treatment strategies, were applied for additional reported varicose vein treatments to the
study leg that were not recorded in the CLASS treatment CRFs.
Unit costs from nationally available data were used to cost primary care contacts (Table 75). Participants
were asked whether or not they had been in contact with a GP as a result of their varicose veins (visit to
the GP, telephone call and/or GP home visit), and if so, how many contacts they had over the previous
6 months. Questions relating to appointments with other health-care workers (e.g. community or practice
nurse, NHS physiotherapist, NHS occupational therapist) as a result of varicose veins were also recorded
and costed in a similar manner.
TABLE 74 Items included in the cost calculation for surgery
Resource use item Unit cost (£) Assumptions Source
Consumables 159.56 Applied to all centres Participating centre (lead centre) (2013)
Capital equipment (ECG,
pulse oximeter and blood
pressure monitor)
4.15 Per usage Participating centres, resource use and
costing questionnaire (2013)
Preparation cost of theatre 31.36 Applied to all centres Clinical opinion (lead centre) (2013),
PSSRU (2011)87
Time on ward after leaving
the recovery room
47.60 One-quarter of the time of a
band 5 nurse for 140 minutes
Participating centres, resource use and
costing questionnaire (2013), PSSRU
(2011)87
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Follow-up assessment and outpatient costs
An additional outpatient follow-up assessment cost was applied to all participants who received just one
treatment of EVLA or foam sclerotherapy. This was done because the CLASS trial was designed to assess
the clinical effectiveness and cost-effectiveness of EVLA and foam sclerotherapy with additional further
foam sclerotherapy as required. Participating centres reported that it is normal practice for all participants,
having received initial treatment with EVLA or foam sclerotherapy, to return for a follow-up appointment
to assess the need for further treatment. We applied the cost of an outpatient follow-up attendance
(£123) with duplex scan (£53) for all participants in the data set who attended their 6-weeks clinical
assessment following one treatment session with EVLA or foam sclerotherapy. For participants who had
further treatment following initial treatment with EVLA or foam sclerotherapy, we assumed that this was
done at their planned follow-up appointment when the decision was made that it was needed, and so no
additional clinical assessment cost was applied to these participants. However, because the majority of
participants receiving EVLA or foam sclerotherapy as their initial treatment did not receive any subsequent
treatment in the trial, we also carried out a sensitivity analysis in which routine follow-up costs were
excluded for all participants. As surgery patients would not routinely be seen at 6 weeks after surgery in
normal NHS practice, no costs were attributed for this.
In addition, some participants incurred unplanned outpatient appointments during the 6-month follow-up
period, which could potentially have been related to their varicose veins treatment (e.g. surgical and
medical outpatient appointments). These were costed using the appropriate NHS reference cost
(Department of Health 2011)86 and included in the analysis.
Total NHS cost
The total cost to the health service was computed by summing the estimated treatment and follow-up
costs for each participant in the data set. If one of the component costs was missing, then that participant
was dropped from the analysis of complete case data. Two total NHS cost variables were computed, one
excluding the additional cost applied to procedures carried out in theatre, and one which included this
extra cost. This was to ensure that the opportunity cost associated with procedures which utilised
operating theatres was accurately captured.
Costs directly incurred by the participant and indirect costs
Individual participant costs were estimated based on responses to the health-care utilisation questions
included in the 6-months questionnaire. Individual participant costs comprised three main elements:
self-purchased health care; travel costs of making return visit(s) to NHS health-care provider(s); and the
time costs incurred while travelling to and attending NHS care. The estimation of travel costs required
information from participants regarding the number of visits to, for example, their GP, and the unit cost of
making a return journey to each type of health-care provider. The cost of participant time was estimated in
a similar manner. Participants were asked how long they spent travelling to and attending their last visit to
TABLE 75 Primary care unit costs
Practitioner Unit cost (£) Assumption Source
GP clinic visit 36 11.7-minute surgery visit PSSRU (2011)87
GP home visit 120 Home visit lasting 23.4 minutes (including travel time) PSSRU (2011)87
GP telephone conversation 22 7.1-minute telephone conversation PSSRU (2011)87
Community nurse 18.67 20-minute visit PSSRU (2011)87
Practice nurse 12 GP nurse PSSRU (2011)87
NHS physiotherapist 17 30-minute clinic visit PSSRU (2011)87
NHS occupational therapist 17 30-minute clinic visit PSSRU (2011)87
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each type of health-care provider. They were asked what activity they would otherwise have been doing
(e.g. paid work, housework, leisure activities) had they not attended the health-care provider, enabling a
calculation of the opportunity cost associated with their health-care contact. These data were presented in
natural units and costed using standard economic conventions, such as the Department of Transport
estimates for the value of leisure time.89 Table 76 presents the unit costs used to value participant time in
the analysis. These unit time costs were combined with estimates of the number of health-care contacts
derived from the 6-months questionnaire. Costs were also acquired for any additional private health care
that participants had for their varicose veins which was recorded in the 6-months questionnaire.
Indirect costs were defined as the production losses resulting from treatment when the participant was
unable to return to normal activity. Information regarding participants’ recovery was collected in the
6-weeks questionnaire. Included in this section was the length of time to return to normal activities,
comprising doing housework, looking after children and partial or full return to normal work/employment.
As with the calculation of participant time cost, these data were recorded in natural units and costed using
standard economic conventions (see Table 76). This estimate gave the cost of days lost associated with the
participants’ health care. Individual participant, indirect and NHS costs were combined and a further
analysis was conducted.
Health outcome measures
The EQ-5D and SF-36 were completed by participants at baseline, 6 weeks and 6 months using a
self-completion questionnaire, ensuring that all movements in HRQoL which occurred during the follow-up
period were accurately captured. A preference-based index score was derived for each participant’s
response to the EQ-5D using the UK population time trade-off tariff,82 and responses to the SF-36 were
converted into a preference-based index score using the SF-6D scoring algorithm.83 Although both these
index scores are anchored on full health (1) and death (0), making them suitable for estimating QALYs for
individual participants, the EQ-5D is the instrument favoured by NICE for this purpose. Therefore, the
EQ-5D was used to estimate participant QALYs in the base-case economic analysis.
Quality-adjusted life-years for each participant were computed by assuming that changes in utility between
measures at adjacent time points follow a straight line between the points. The average utility over each
time period (baseline to 6 weeks, and 6 weeks to 6 months) was calculated and multiplied by the duration
of that time to compute the corresponding QALYs. If an EQ-5D value was missing for a participant at any
time point, that patient was dropped from the analysis of complete case data.
TABLE 76 Unit costs applied to participant time associated with treatment and health service utilisation
Activity Cost per hour (day), £ Assumption Source
Paid work 12.62 (100.96) Median hourly earnings, excluding overtime ONS (2011)90
Housework 10.10 (80.77) Annual salary of £21,000 NHS Pay Review
Body 2012 Report91
Child care 12.62 (100.96) Median hourly earnings, excluding overtime ONS (2011)90
Caring for relative/friend 12.62 (100.96) Median hourly earnings, excluding overtime ONS (2011)90
Unemployed 4.46 (35.68) Values of non-working time TAG (2011)89
Voluntary work 12.62 (100.96) Median hourly earnings, excluding overtime ONS (2011)90
Leisure activities 4.46 (35.68) Values of non-working time TAG (2011)89
ONS, Office for National Statistics; TAG, transport analysis guidance.
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Statistical analysis of economic data
The economic analysis was conducted by intention to treat. Cost, QALY and resource use data were
summarised and analysed using Stata version 12.1.78 The mean incremental costs associated with EVLA
and foam sclerotherapy versus surgery were estimated using a GLM, with adjustment for minimisation
variables (age < 50 years, sex, SSV or GSV, unilateral or bilateral) and participant baseline values as
appropriate (e.g. baseline utility scores). A GLM model allows for heteroscedasticity by specifying a
distributional family, which reflects the relationship between the mean and variance.84 To test the
appropriate family, a modified Parks test was conducted. The test identified the Gamma family, which
allows for right skewness in the cost data and assumes that the variance is proportional to the square of
the mean, as appropriate. The specification of a link function is also required for a GLM model; this
specifies the relationship between the set of regressors and the conditional mean.84 The link test
recognised the identity link as the appropriate link function. The identity link leaves the interpretation of
the coefficients unchanged from that of the ordinary least squares (OLS) regression, in that the covariates
act additively on the mean. To further ensure that the correct model was specified, the Akaike information
criterion (AIC) was used to assess the model fit. An OLS regression was implemented to estimate mean
incremental differences in QALYs associated with EVLA and foam sclerotherapy, adjusting for minimisation
variables and participant baseline values in a similar manner. To account for the potential lack of
independence in costs and outcomes for participants within centres, cluster robust standard errors and
CIs are reported for the estimated mean incremental costs and effects.
To characterise the uncertainty surrounding the estimates of incremental cost-effectiveness, clustered
bootstrapping was used to generate 1000 estimates of the mean costs and effects by treatment allocation
group. CEACs were generated using these 1000 estimates, using the net monetary benefit (NMB)
approach. The NMB associated with a given treatment option is given by the formula:
NMB= (effect Rc)−cost, (1)
where effects are measured in QALYs and Rc is the ceiling ratio of WTP per QALY. Using this formula, the
strategy with greatest NMB was identified for each of the 1000 bootstrapped replicates of the analysis,
for different ceiling ratios of WTP per QALY. Plotting the proportion of bootstrap iterations favouring each
treatment option (in terms of the NMB) against increasing WTP per QALY produces the CEAC for each
treatment option. These curves present graphically the probability of each treatment strategy being
considered optimal at different levels of WTP per QALY gained.
Deterministic sensitivity analysis
Deterministic sensitivity analyses were conducted, focusing on the impact of altering key costing
assumptions and restricting the comparisons to subgroups of the population. All the sensitivity analyses
were conducted with the exclusion of additional operating theatre costs. We assessed the impact of
excluding the routine follow-up costs (the cost of an outpatient follow-up appointment and duplex
ultrasound scan) following EVLA and foam sclerotherapy. This was to reflect that the majority of
participants receiving these treatment strategies as their initial treatment did not receive any further foam
sclerotherapy treatment in the trial. We tested the impact of restricting the comparisons to subgroups
of the population (e.g. those with unilateral disease only and also those with unilateral disease and
involvement of the GSV only). The impact of using the SF-6D to calculate QALYs was assessed. Two further
sensitivity analyses were conducted for the three-arm comparison, assessing the impact on the results for
EVLA of (i) incorporating a staff profile if the procedure was performed in a clinic/treatment room setting,
and (ii) including the cost per usage of the laser generator.
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As the base-case cost-effectiveness analyses were conducted for participants with complete cost and QALY
data, multiple imputation was carried out using Stata’s chained equations procedure to replace each
missing resource use, cost and EQ-5D variable with a different plausible value in 10 imputed data sets.78
Ten imputations was found to produce stable estimates of incremental costs and effects. The cost and
QALY analysis models were then run across the 10 imputed data sets and combined using Rubin’s rules92
to produce a single set of results. Multiple imputation was conducted on both the full data set and the
data that remained when those participants receiving no treatment and follow-up (and thus incurring no
costs) were dropped.
Results
The results from the two-arm comparison (foam sclerotherapy vs. surgery) are described below, and
following this, the results from the three-arm comparison (EVLA vs. foam sclerotherapy vs. surgery)
are presented.
Foam sclerotherapy versus surgery
Resource use and costs
Table 77 documents the main components included in the treatment cost estimation for participants
(randomised to foam sclerotherapy or surgery). Of the 286 participants randomised to foam sclerotherapy,
268 presented for their allocated treatment, although two of these participants were found to be
unsuitable for foam sclerotherapy treatment. Ten participants randomised to foam sclerotherapy received
either surgery (n= 4) or EVLA (n= 6). Eleven participants randomised to foam sclerotherapy received no
treatment within CLASS. The mean number of treatments for those participants receiving foam
sclerotherapy was 1.12. The surgical arm included 289 participants. Of these, 253 received their allocated
treatment, but 19 received treatment in the form of foam sclerotherapy (n= 11) or EVLA (n= 8). The mean
number of foam sclerotherapy treatments among those receiving this treatment modality was similar to
that in the foam group (1.09 treatments). Twenty-one participants randomised to surgery received no
treatment within CLASS.
For participants randomised to foam sclerotherapy, the mean cumulative time spent receiving this
treatment modality was 29.7 minutes. This was considerably shorter than the time spent by participants
receiving surgery in the surgery group (64.56 minutes). Staff costs for the procedure were derived from the
duration times and the grades and numbers of staff present for each procedure; therefore, the overall staff
costs were considerably higher in the surgery arm (£599 compared with £144 for foam sclerotherapy).
A considerable difference was also evident between the foam sclerotherapy and surgery arms in terms
of recovery, consumable and theatre use costs. The estimated total mean treatment costs, inclusive of
staff costs, consumables, equipment use, clinic/theatre preparation and recovery time costs, amounted to
£241 for foam sclerotherapy and £891 for surgery.
Table 78 shows follow-up resource use and costs over the 6-month follow-up period, by treatment
allocation group. Resource use and costs were generally similar for the foam sclerotherapy and surgery
arms, although unplanned outpatient appointments were slightly more frequent in the foam sclerotherapy
arm and primary care use was slightly higher in the surgery arm. Attendance at the 6-week and 6-month
assessments was > 90% in both arms; however, only the cost of the 6-week assessment was included in
the economic analysis for participants receiving foam sclerotherapy. There were no reports of hospital
admissions related to treatment in the foam sclerotherapy group, and the number reporting this outcome
in the surgical group was low (0.02 of those randomised to surgery).
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TABLE 77 Treatment costs by treatment allocation group
Treatment details Randomised to foam sclerotherapy Randomised to surgery
Number randomised 286 289
Treatment received
Presented for foam (n, %) 268 93.7 11 3.8
Number of foam treatments
(n, mean, SD)
268 1.12 0.35 11 1.09 0.30
Presented for surgery (n, %) 4 1.4 253 87.5
Presented for EVLA (n, %) 6 2.1 8 2.8
No recorded treatment (n, %) 11 3.9 21 7.3
Treatment durationsa
Cumulative procedure time (minutes)
Foam sclerotherapy (n, mean, SD) 261 29.70 16.53 288 1.10 7.08
Surgery (n, mean, SD) 285 0.78 7.63 270 64.56 33.67
EVLA (n, mean, SD) 283 0.62 6.05 288 1.20 7.89
Treatment costs
Staff procedure costs
Foam sclerotherapy (n, mean, SD) 261 £144 £87 288 £5 £36
Surgery (n, mean, SD) 285 £8 £75 270 £599 £340
EVLA (n, mean, SD) 283 £4 £37 288 £8 £50
Recovery time costs (n, mean, SD) 285 £3 £9 271 £72 £34
Consumable costs (n, mean, SD) 286 £44 £52 289 £150 £54
Theatre use (n, mean, SD) 260 £23 £50 269 £238 £121
Equipment costs (n, mean, SD) 286 £9 £4 289 £4 £2
Preparation costs (n, mean, SD) 286 £27 £10 289 £29 £9
Total treatment costs
Foam sclerotherapy (n, mean, SD) 261 £218 £104 288 £8 £49
Surgery (n, mean, SD) 285 £10 £103 270 £859 £429
EVLA (n, mean, SD) 283 £8 £76 288 £17 £108
Total staff procedure costs
(n, mean, SD)
257 £159 £107 268 £617 £321
Total treatment costsb (n, mean, SD) 257 £241 £142 268 £891 £391
a Treatment duration times are the mean times of all patients randomised to the treatment strategy.
b Total treatment costs exclude the additional cost for the use of theatre.
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Table 79 documents the total mean NHS costs associated with both treatment strategies to 6-months
follow-up. These are reported for both the primary (excluding the additional cost for operating theatre use)
and secondary (including the extra cost for operating theatre use) analysis of NHS costs. For the primary
analysis, the mean total cost for those randomised to foam sclerotherapy was £458, compared with £1057
for those randomised to surgery. When the additional cost of theatre (£3.64 per minute in the operating
theatre) is included, the mean total cost of foam sclerotherapy increases slightly to £479, and the mean
total cost of surgery increases to £1314.
Health outcomes: European Quality of Life-5 Dimensions and Short Form
questionnaire-6 Dimensions
The EQ-5D and SF-6D results are summarised by treatment allocation group in Table 80. These data
showed a general improvement in generic HRQoL in both foam sclerotherapy and surgery treatment
allocation groups between baseline and 6 weeks, and between 6 weeks and 6 months. The increase in
TABLE 78 Follow-up resource use and costs by treatment allocation group
Post-treatment care costs
Randomised to foam
sclerotherapy
Randomised to
surgery
Number randomised 286 289
Primary care
GP consultations (n, mean, SD) 234 0.36 0.74 213 0.56 1.19
Other health professional consultations (n, mean, SD) 234 0.28 1.96 213 0.44 1.05
Total cost of GP consultations (n, mean, SD) 234 £13 £27 213 £20 £42
Total cost of consultations (other health professionals)
(n, mean, SD)
234 £4 £30 213 £6 £15
Total primary care costs (n, mean, SD) 234 £17 £40 213 £26 £44
Secondary care (planned)
Attendance at 6-week assessmenta (n, mean, SD) 265 260 98.1 251 241 96.0
Attendance at 6-month assessmentb (n, mean, SD) 250 230 92.0 235 217 92.3
6-week assessment costa (n, mean, SD) 265 £173 £24 251 £169 £35
6-month assessment costb (n, mean, SD) 250 £162 £48 235 £163 £47
Secondary care (unplanned)
Unplanned medical/surgical outpatient appointments (n, mean, SD) 286 0.25 1.15 289 0.20 0.77
Cost of unplanned outpatient appointments (n, mean, SD) 286 £35 £138 289 £29 £93
Admissions (n, mean, SD) 272 0 0 254 0.02 0.12
Admission costs (n, mean, SD) 272 £0 £0 254 £5 £42
a One follow-up attendance is retained as a cost following foam sclerotherapy and EVLA in the economic analysis.
b Research costs removed from the economic analysis.
TABLE 79 Total NHS costs by treatment allocation group
NHS costs
Randomised to foam
sclerotherapy
Randomised to
surgery
Number randomised 286 289
Total NHS costs (primary analysis) (n, mean, SD) 206 £458 £201 196 £1057 £327
Total NHS costs (secondary analysis) (n, mean, SD) 206 £479 £215 196 £1314 £399
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the EQ-5D score between baseline and 6 weeks was more marked in the surgery arm, whereas the
improvement was greater in the foam sclerotherapy arm between 6 weeks and 6 months. Overall,
the QALYs accrued over 6 months were slightly lower in the surgery arm, although this was likely to have
been due to a slight imbalance in EQ-5D scores at baseline.
Incremental cost-effectiveness: primary analysis
It was found that surgery was associated with a slight gain in QALYs following adjustment for baseline
EQ-5D and minimisation variables, but it was also associated with a significantly higher health service
cost than foam sclerotherapy (Table 81). Therefore, foam sclerotherapy was less costly than surgery (cost
saving), but at the expense of HRQoL, which was lower.84 The ICER was £102,106, which represents the
cost saving per QALY lost with foam sclerotherapy versus surgery. NICE generally judges an intervention as
being cost-effective if the additional cost required to fund it is < £20,000 per QALY gained (i.e. the ICER
is < £20,000). Conversely, assuming equal value placed on a QALY gained and a QALY lost, one would
require an ICER > £20,000 of cost savings before the decision-maker would be willing to sacrifice one
QALY. As the ICER is above the threshold value, based on this decision rule, foam sclerotherapy would
have a favourable ICER.
To explore the uncertainty surrounding the estimate of cost-effectiveness, a CEAC was derived using the
results of 1000 bootstrapped replicates of the estimated mean incremental costs and effects. Figure 4
shows the empirical estimate of the joint distribution of mean incremental costs and effects (for foam
sclerotherapy vs. surgery) obtained using the results of the bootstrap replicates. The estimates indicate that
foam sclerotherapy is significantly less costly, with a non-significant tendency to produce fewer QALYs
than surgery. Applying a ceiling WTP ratio of £20,000 per QALY, Figure 5 illustrates that, when using the
EQ-5D as the measure of outcome, foam sclerotherapy has a 99.8% probability of being considered
cost-effective at 6 months. The sensitivity of these findings to missing data is assessed using multiple
imputation (see Deterministic sensitivity analysis).
TABLE 80 Health state utilities by treatment allocation group
HRQoL Randomised to foam sclerotherapy Randomised to surgery
Number randomised 286 289
EQ-5D
Baseline (n, mean, SD) 279 0.803 0.179 279 0.783 0.178
6 weeks (n, mean, SD) 242 0.860 0.161 227 0.876 0.169
6 months (n, mean, SD) 235 0.895 0.174 206 0.881 0.202
Total QALYs (n, mean, SD) 217 0.435 0.072 188 0.432 0.082
SF-6D
Baseline (n, mean, SD) 272 0.767 0.122 269 0.754 0.128
6 weeks (n, mean, SD) 240 0.774 0.121 218 0.765 0.116
6 months (n, mean, SD) 227 0.805 0.122 199 0.802 0.127
Total QALYs (n, mean, SD) 202 0.392 0.054 166 0.390 0.052
TABLE 81 Incremental cost-effectiveness: foam sclerotherapy vs. surgery
Intervention Incremental costs (95% CI), £ Incremental QALYs (95% CI) ICER (£)
Surgery – – –
Foam sclerotherapy −602 (−740 to −464) −0.006 (−0.021 to 0.009) 102,106
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Incremental cost-effectiveness: secondary analysis
The secondary analysis (incorporating an additional cost for the use of an operating theatre) reinforces the
findings of the primary analysis, increasing the cost saving associated with foam sclerotherapy. Under these
alternative costing assumptions, the ICER increases to £142,973, representing the cost saving per QALY
lost for foam sclerotherapy versus surgery (Table 82).
Similar to the primary analysis, although the cluster falls further below zero on the cost axis (i.e. cost
saving), Figure 6 illustrates that foam sclerotherapy has a significantly lower cost with a non-significant
tendency to produce fewer QALYs. Figure 7 shows that when the additional cost of operating theatre
use is included, foam sclerotherapy retains the higher probability of being considered cost-effective at
6 months up to the ceiling WTP of > £130,000 per QALY.
In
cr
em
en
ta
l c
o
st
s 
(£
)
–100
–300
–500
–700
–900
–1100
Incremental QALYs
–0.06 –0.04 –0.02 0.00 0.02 0.04 0.080.06 0.10 0.12 0.14
FIGURE 4 Incremental cost-effectiveness scatterplot for foam sclerotherapy vs. surgery at 6 months.
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FIGURE 5 Cost-effectiveness acceptability curves for foam sclerotherapy vs. surgery at 6 months.
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TABLE 82 Incremental cost-effectiveness: foam sclerotherapy vs. surgery (secondary analysis)
Intervention Incremental costs (95% CI), £ Incremental QALYs (95% CI) ICER (£)
Surgery – – –
Foam sclerotherapy −843 (−1004 to −682) −0.006 (−0.021 to 0.009) 142,973
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FIGURE 6 Incremental cost-effectiveness scatterplot for foam sclerotherapy vs. surgery, including additional theatre
use costs at 6 months.
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FIGURE 7 Cost-effectiveness acceptability curves for foam sclerotherapy vs. surgery, including additional theatre
use costs at 6 months.
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Deterministic sensitivity analysis
The overall conclusions drawn from the base-case analysis remain robust to changes in the key costing
assumptions and restriction to subgroups (Table 83). Under the first adjustment (excluding routine
follow-up costs for foam sclerotherapy), the ICER increases, representing a greater cost saving per QALY
lost. Scenario 2 (restricting the analysis to participants with unilateral disease only) has a broadly similar
ICER value to that obtained in the base-case analysis. However, by restricting the analysis to participants
with unilateral disease and GSV involvement only, the ICER, and hence the case for cost-effectiveness,
reduces considerably, with a lower cost saving per QALY lost. A greater cost saving per QALY lost is
evident when the SF-6D is used to calculate QALYs. The results appear robust to the missing data, with
similar results obtained using multiple imputation to replace missing cost and utility values. For all analyses,
the ICER remains above a threshold value of £20,000–30,000 per QALY. These analyses demonstrate that
foam sclerotherapy remains the preferred option from a cost-effectiveness perspective, a conclusion that
remains robust under a range of plausible assumptions.
Endovenous laser ablation versus foam sclerotherapy versus surgery
Resource use and costs
This analysis includes all participants recruited in the eight centres who were randomised to all three treatment
options. Table 84 illustrates the resources used and corresponding costs of treatment by treatment allocation
group (EVLA, foam sclerotherapy and surgery). Forty-nine of the participants randomised to EVLA (n= 210)
underwent either foam sclerotherapy (n= 46) or surgery (n= 3). Of the 207 participants randomised to
receive foam sclerotherapy, nine received either EVLA (n= 6) or surgery (n= 3). Of the participants
randomised to surgery (n= 213), 17 participants underwent either EVLA (n= 8) or foam sclerotherapy (n= 9).
More participants in the surgery arm received no treatment (n= 17) than in the foam sclerotherapy (n= 10) or
EVLA (n= 5) arms.
TABLE 83 Deterministic sensitivity analysis for foam sclerotherapy vs. surgery
Intervention Incremental cost (95% CI), £ Incremental QALYs (95% CI) ICER (vs. surgery) (£)
Scenario 1: routine follow-up costs excluded following foam sclerotherapy and EVLA
Surgery – – –
Foam sclerotherapy −753 (−903 to −604) −0.006 (−0.021 to 0.009) 127,682
Scenario 2: analysis based on participants with unilateral disease only
Surgery – – –
Foam sclerotherapy −553 (−694 to −412) −0.006 (−0.031 to 0.020) 99,867
Scenario 3: analysis based on participants with unilateral disease and only GSV involvement
Surgery – – –
Foam sclerotherapy −561 (−722 to −400) −0.018 (−0.044 to 0.009) 31,771
Scenario 4: analysis based on QALYs derived from the SF-6D
Surgery – – –
Foam sclerotherapy −602 (−740 to −464) −0.001 (−0.013 to 0.011) 478,055
Scenario 5: analysis based on full multiple imputation data sets
Surgery – – –
Foam sclerotherapy −553 (−676 to −430) −0.009 (−0.024 to 0.007) 64,600
Scenario 6: analysis based on multiple imputation data sets with participants receiving no treatment and follow-up dropped
Surgery – – –
Foam sclerotherapy −581 (−721 to −441) −0.008 (−0.023 to 0.006) 68,901
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TABLE 84 Treatment costs by treatment allocation group
Treatment details Randomised to EVLA Randomised to foam sclerotherapy Randomised to surgery
Number randomised 210 207 213
Treatment received
Presented for EVLA (n, %) 203 96.7 6 2.9 8 3.8
Presented for foam (n, %) 46 21.9 191 92.3 9 4.23
Number of foam treatments
(n, mean, SD)
46 1.07 0.25 191 1.15 0.39 9 1.00 0.00
Presented for surgery (n, %) 3 1.4 3 1.5 183 85.9
No recorded treatment
(n, %)
5 2.4 10 4.8 17 8.0
Treatment durationsa
Cumulative procedure time (minutes)
EVLA (n, mean, SD) 194 59.41 28.48 204 0.86 7.11 212 1.63 9.17
Foam sclerotherapy
(n, mean, SD)
197 4.41 11.50 185 29.34 18.08 212 0.89 4.72
Surgery (n, mean, SD) 209 0.69 7.08 207 1.07 8.95 197 62.60 34.06
Treatment costs
Staff procedure costs
EVLA (n, mean, SD) 194 £326 £154 204 £5 £43 212 £10 £58
Foam sclerotherapy
(n, mean, SD)
197 £19 £52 185 £137 £91 212 £4 £20
Surgery (n, mean, SD) 209 £6 £64 207 £10 £88 197 £615 £362
Recovery time costs
(n, mean, SD)
209 £32 £10 207 £4 £11 198 £74 £37
Consumable costs
(n, mean, SD)
210 £322 £58 207 £50 £60 213 £150 £58
Theatre use (n, mean, SD) 193 £31 £96 185 £14 £46 196 £231 £122
Equipment costs
(n, mean, SD)
210 £11 £4 207 £10 £4 213 £4 £2
Preparation costs
(n, mean, SD)
210 £29 £12 207 £28 £12 213 £29 £9
Total treatment costs
EVLA (n, mean, SD) 194 £699 £195 204 £11 £90 212 £23 £126
Foam sclerotherapy
(n, mean, SD)
197 £33 £79 185 £214 £111 212 £6 £33
Surgery (n, mean, SD) 209 £9 £94 207 £14 £121 197 £876 £457
Total staff procedure costs
(n, mean, SD)
183 £349 £163 182 £157 £118 195 £637 £340
Total treatment costsb
(n, mean, SD)
183 £737 £204 182 £245 £161 195 £916 £412
a Treatment duration times are the mean times of all patients randomised to the treatment strategy.
b Total treatment costs exclude the additional cost for use of theatre.
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The cumulative mean time spent in treatment (see Table 84) was again considerably lower for those
participants randomised to foam sclerotherapy than it was for those randomised to surgery. Participants
randomised to EVLA spent slightly less time in treatment than those randomised to surgery. It should be
noted that the small difference in time spent in treatment between EVLA and surgery (based on intention
to treat) was influenced by the fact that a higher proportion of participants in the surgery arm received
treatment other than that to which they had been allocated, or no treatment. The mean time from
entering to leaving the treatment room was similar for EVLA (59.41 minutes) and surgery (62.60 minutes).
The cumulative duration of time spent receiving foam sclerotherapy was considerably lower (29.34 minutes).
Based on the treatment duration estimates, coupled with information on the numbers and grades of staff
present at each procedure, the estimated staff procedure costs were £326, £137 and £615 for participants
randomised to EVLA, foam sclerotherapy and surgery respectively.
Recovery time costs were highest, as expected, for participants randomised to surgery. Consumables were
considerably higher in the EVLA group, on account of the high cost of the laser fibre (unit cost £256).
Additional costs for the use of theatre were higher in the surgery arm, whereas equipment and
preparation costs were generally similar across the EVLA, foam sclerotherapy and surgery groups.
As in the comparison of foam sclerotherapy versus surgery, in this analysis the treatment cost data showed
foam sclerotherapy to be the least costly treatment option. Total treatment costs, inclusive of staff costs,
consumables, equipment use, clinic/theatre preparation and recovery time costs, were £737, £245 and
£916 for participants randomised to EVLA, foam sclerotherapy and surgery respectively.
Table 85 shows the follow-up resource use and cost data up to 6 months post treatment. Numbers of
reported GP and other health professional consultations were slightly higher in the surgery group than
in the EVLA and foam sclerotherapy groups; they were similar in each of these two groups. Attendance for
the 6-week and 6-month assessments were > 80% in all treatment allocation groups. Numbers of
unplanned outpatient appointments were similar among the three groups. No hospital admissions were
reported in either the EVLA or the foam sclerotherapy group, and only a low number were observed in the
surgery arm.
Table 86 shows the mean total NHS costs by treatment allocation group to 6-months’ follow-up. As
expected, total mean NHS costs (excluding additional operating theatre costs) were considerably higher in
the surgery arm (£1113), with foam sclerotherapy being the least costly (£453), followed by EVLA (£951).
A similar ranking was evident when additional theatre costs were included, with the difference in cost
between surgery and EVLA and foam sclerotherapy increasing substantially.
Health outcomes: European Quality of Life-5 Dimensions and Short Form
questionnaire-6 Dimensions
The EQ-5D and SF-6D scores are presented by treatment allocation group and time point in Table 87. An
improvement in HRQoL was observed between baseline and 6 weeks in all treatment allocation groups
(the increase being more pronounced in the EVLA-treated group in particular). A further increase in HRQoL
was evident in all three treatment arms between 6 weeks and 6 months. However, the largest increase
during this time interval occurred in participants allocated to foam sclerotherapy. Overall, the mean
unadjusted QALYs accrued over 6 months were highest in the EVLA group.
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TABLE 85 Follow-up resource use and costs by treatment allocation group
Post-treatment care costs Randomised to EVLA
Randomised to
foam sclerotherapy
Randomised to
surgery
Number randomised 210 207 213
Primary care
GP consultations (n, mean, SD) 170 0.36 0.94 168 0.33 0.69 156 0.57 1.28
Other health professional consultations
(n, mean, SD)
170 0.18 0.58 168 0.35 2.30 156 0.42 1.10
Total cost of GP consultations (n, mean, SD) 170 £14 £40 168 £11 £24 156 £20 £45
Total cost of consultations with other health
professionals (n, mean, SD)
170 £2 £8 168 £5 £35 156 £6 £16
Total primary care costs (n, mean, SD) 170 £16 £43 168 £16 £42 156 £26 £47
Secondary care (planned)
Attendance at 6-week assessmenta (n, mean, SD) 192 184 95.8 189 184 97.4 180 172 95.6
Attendance at 6-month assessmentb (n, mean, SD) 182 164 90 177 160 90.4 166 154 92.8
6-week assessment costa (n, mean, SD) 192 £169 £35 189 £172 £28 180 £168 £36
6-month assessment costb (n, mean, SD) 182 £159 £53 177 £159 £52 165 £163 £46
Secondary care (unplanned)
Unplanned medical/surgical outpatient
appointments (n, mean, SD)
210 0.30 0.77 207 0.24 1.29 213 0.24 0.86
Cost of unplanned outpatient appointments
(n, mean, SD)
210 £39 £97 207 £31 £149 213 £34 £103
Admissions (n, mean, SD) 199 0 0 195 0 0 183 0.02 0.15
Admission costs (n, mean, SD) 199 £0 £0 195 £0 £0 183 £7 £49
a One follow-up attendance is retained as a cost following EVLA and foam sclerotherapy in the economic analysis.
b Research costs removed from the economic analysis.
TABLE 86 Total NHS costs by treatment allocation group
NHS costs Randomised to EVLA
Randomised to
foam sclerotherapy
Randomised to
surgery
Number randomised 210 207 213
Total NHS costs (excluding all theatre costs)
(n, mean, SD)
142 £951 £179 144 £453 £225 141 £1113 £332
Total NHS costs (including theatre costs)
(n, mean, SD)
142 £975 £205 144 £465 £239 141 £1367 £404
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Incremental cost-effectiveness: primary analysis
Based on an adjusted regression analysis of participants with complete cost and QALY data (n= 389),
EVLA was found to produce a small (non-significant) increase in QALYs over both surgery and foam
sclerotherapy at 6 months. In comparison with surgery, foam sclerotherapy had an ICER of £103,633 per
QALY lost at 6 months, whereas EVLA was found to be ‘dominant’, that is, less costly and marginally more
effective (Table 88). The ICER for EVLA versus foam sclerotherapy was £26,107 per QALY gained (EVLA
was more costly and more effective than foam sclerotherapy). Therefore, applying a ceiling WTP threshold
of £20,000, foam sclerotherapy was the favourable option from a cost-effectiveness perspective, accruing
more NMB at the 6-month time frame.
The joint distribution of the incremental costs and effects for EVLA and foam sclerotherapy versus surgery,
obtained from the bootstrap replicates of the analysis models, are plotted in Figure 8. Based on the
analysis of complete case data, the majority of the points for EVLA fall below zero on the cost axis (i.e. cost
saving) and above zero on the QALYs axis (increased QALYs), indicating a high probability of EVLA being
both less costly and more effective than surgery.
To characterise the uncertainty surrounding the cost-effectiveness estimates, a CEAC (Figure 9) was derived
from the bootstrapped estimates of mean incremental costs and effects. At a ceiling WTP threshold of
£20,000 per QALY, foam sclerotherapy has a 78.9% chance of being cost-effective, followed by EVLA
(20.9%) and surgery (0.2%). However, at a WTP threshold of ≈ £25,000, the CEACs for EVLA and foam
sclerotherapy cross, and EVLA has the highest probability of being the optimal strategy on grounds of
cost-effectiveness. Applying a ceiling WTP threshold of £30,000 per QALY, EVLA has a 59.4% probability of
TABLE 87 Health state utilities by treatment allocation group
QoL measure Randomised to EVLA Randomised to foam sclerotherapy Randomised to surgery
Number randomised 210 207 213
EQ-5D
Baseline (n, mean, SD) 206 0.792 0.169 202 0.793 0.187 207 0.777 0.184
6 weeks (n, mean, SD) 184 0.894 0.145 181 0.853 0.172 164 0.864 0.180
6 months (n, mean, SD) 172 0.903 0.171 167 0.884 0.192 151 0.872 0.212
Total QALYs (n, mean, SD) 155 0.443 0.071 159 0.431 0.078 139 0.426 0.086
SF-6D
Baseline (n, mean, SD) 201 0.759 0.121 197 0.760 0.125 198 0.752 0.131
6 weeks (n, mean, SD) 176 0.793 0.114 179 0.771 0.123 159 0.758 0.120
6 months (n, mean, SD) 165 0.821 0.112 164 0.802 0.127 146 0.794 0.133
Total QALYs (n, mean, SD) 139 0.402 0.048 151 0.391 0.056 122 0.387 0.054
TABLE 88 Incremental cost-effectiveness based on complete case data
Intervention
Incremental
cost (95% CI), £
Incremental
QALYs (95% CI)
ICER
(vs. surgery) (£)
ICER
(EVLA vs. foam
sclerotherapy) (£)
NMB
ranking at
Rc £20,000
Surgery (n= 122) – – – – 3
Foam sclerotherapy
(n= 129)
−662
(−826 to −498)
−0.006
(−0.030 to 0.017)
103,633 – 1
EVLA (n= 134) −156
(–316 to 4)
0.013
(−0.003 to 0.029)
Dominant 26,107 2
Rc, ceiling ratio.
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being cost-effective. To assess the impact on these findings of missing data, multiple imputations
were conducted.
Incremental cost-effectiveness: secondary analysis including additional costs
for use of theatre
Applying the additional cost for the use of an operating theatre results in an increase to the reported
incremental cost savings associated with EVLA and foam sclerotherapy (Table 89). A greater cost saved per
QALY lost is evident for foam sclerotherapy versus surgery. The addition of extra theatre costs has very
little impact on the ICER for EVLA versus foam sclerotherapy, and the NMB rankings remain the same.
The joint distribution of the incremental costs and effects are shown for EVLA and foam sclerotherapy
versus surgery in Figure 10. These follow a similar pattern to those reported for the primary analysis,
although the clusters fall further below zero on the cost axis (i.e. greater incremental cost saving). The
surgical group retains a very low probability of being cost-effective (Figure 11) across all feasible ceiling
WTP ratios, and at £20,000 foam sclerotherapy has an 81.4% probability of being cost-effective. The
CEACs for EVLA and foam sclerotherapy begin to converge at ≈ £15,000 and again cross at a WTP
threshold of ≈ £25,000 per QALY gained.
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FIGURE 8 Incremental cost-effectiveness scatterplot for EVLA and foam sclerotherapy vs. surgery at 6 months.
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FIGURE 9 Cost-effectiveness acceptability curves for EVLA, foam sclerotherapy and surgery at 6 months.
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TABLE 89 Incremental cost-effectiveness with inclusion of additional theatre costs, based on complete case data
Intervention
Incremental
cost (95% CI), £
Incremental
QALYs (95% CI)
ICER
(vs. surgery) (£)
ICER
(EVLA vs. foam
sclerotherapy) (£)
NMB
ranking at
Rc £20,000
Surgery (n= 122) – – – – 3
Foam sclerotherapy
(n= 129)
−911
(−1104 to −718)
−0.006
(−0.030 to 0.017)
142,649 – 1
EVLA (n= 134) −395
(−591 to −200)
0.013
(−0.003 to 0.029)
Dominant 26,625 2
Rc, ceiling ratio.
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FIGURE 10 Incremental cost-effectiveness scatterplot for EVLA and foam sclerotherapy vs. surgery, including
additional theatre use costs at 6 months.
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FIGURE 11 Cost-effectiveness acceptability curves for EVLA, foam sclerotherapy and surgery, including additional
theatre use costs at 6 months.
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Deterministic sensitivity analysis
The sensitivity analyses conducted (Table 90) demonstrate that foam sclerotherapy appears more
cost-effective under several scenarios: specifically, when the routine follow-up cost is excluded (scenario 1),
the cost per laser generator usage is incorporated (scenario 3) or QALYs are calculated from the SF-6D
(scenario 6). The base-case results also appear robust to the missing data with similar results, favouring
foam sclerotherapy, obtained using multiple imputation to replace missing cost and EQ-5D values
(scenarios 7 and 8). However, the cost-effectiveness of EVLA versus foam sclerotherapy did improve
substantially under certain scenarios. By applying the same staff profile for EVLA as for foam sclerotherapy,
EVLA appears the favourable option, with an ICER of £17,146 per QALY gained. Under this scenario
(scenario 2), there is a greater cost saving estimate for EVLA versus surgery. The ICER for EVLA versus foam
sclerotherapy also falls below the £20,000 threshold when the analysis is restricted to subgroups (i.e. those
with unilateral disease only and participants with unilateral and GSV involvement only).
The overall conclusions drawn from the base-case analysis again remain robust to several of the sensitivity
analyses presented. EVLA could offer a cost-effective alternative if the treatment is performed with a
similar staff profile to foam sclerotherapy. The subgroup analyses results also suggest that EVLA continues
to dominate surgery, and has a favourable ICER when compared with foam sclerotherapy.
Costs directly incurred by participants and indirect costs
A further analysis was conducted incorporating both participant and indirect costs into the analysis.
Participant costs comprised three main elements: self-purchased health care; travel costs for making a
return visit(s) to NHS health care; and time costs of travelling and attending NHS health care. Indirect costs
were defined as the production losses resulting from treatment when the participant was unable to return
to normal activity. The cost of days lost was estimated using the same unit costs applied to participant
time. These were calculated as outlined above (see Methods). Where a participant’s own reported costs
associated with a specific type of health service visit were missing, the mean cost by centre for that type of
visit was applied.
Foam sclerotherapy versus surgery
Table 91 illustrates the mean indirect and participant costs of attending GP and outpatient appointments
and also hospital admissions over the follow-up period. Mean indirect costs for foam sclerotherapy and
surgery were £420 and £989 respectively. The costs associated with attending GP appointments were
similar between groups, whereas the cost of attending outpatient appointments was somewhat higher in
the foam sclerotherapy group. This was due to the assumption that participants would routinely attend a
follow-up outpatient assessment appointment after foam sclerotherapy, but would not do so after surgery.
The surgery participants incurred a higher mean cost in terms of hospital admissions, but this cost was
very small owing to the low number of additional admissions (related to varicose veins treatment) which
occurred during the follow-up period. Combining the indirect and participant costs with the total NHS
costs has very little impact on the overall findings (Table 92).
To explore the uncertainty surrounding the cost-effectiveness estimate, a CEAC was derived from the
results of 1000 bootstrapped replicates of mean incremental costs and effects. Figure 12 illustrates that
foam sclerotherapy has a 100% probability of being the preferred option from a cost-effectiveness
perspective at 6 months.
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TABLE 90 Deterministic sensitivity analysis
Intervention
Incremental cost
(95% CI), £
Incremental QALYs
(95% CI)
ICER
(vs. surgery) (£)
ICER
(EVLA vs. foam
sclerotherapy) (£)
NMB
ranking at
Rc £20,000
Scenario 1: routine follow-up costs excluded following foam sclerotherapy and EVLA
Surgery – – – – 3
Foam
sclerotherapy
−805 (−998 to −612) −0.006
(−0.030 to 0.017)
126,056 – 1
EVLA −292 (−477 to −107) 0.013 (−0.003 to 0.029) Dominant 26,494 2
Scenario 2: EVLA performed with same staff profile as foam sclerotherapy
Surgery – – – – 3
Foam
sclerotherapy
−658 (−828 to −488) −0.006
(−0.030 to 0.017)
103,058 – 2
EVLA −326 (−424 to −228) 0.013 (−0.003 to 0.029) Dominant 17,146 1
Scenario 3: cost of laser machine usage incorporated
Surgery – – – – 3
Foam
sclerotherapy
−662 (−826 to −499) −0.006
(−0.030 to 0.017)
103,713 – 1
EVLA −123 (−282 to 37) 0.013 (−0.003 to 0.029) Dominant 27,865 2
Scenario 4: analysis based on participants with unilateral disease only
Surgery – – – – 3
Foam
sclerotherapy
−614 (−776 to −451) −0.009
(−0.048 to 0.030)
67,780 – 2
EVLA −105 (−271 to 61) 0.019 (0.001 to 0.036) Dominant 18,402 1
Scenario 5: analysis based on participants with unilateral disease and only GSV involvement
Surgery – – – – 3
Foam
sclerotherapy
−623 (−797 to −448) −0.020
(−0.058 to 0.018)
31,300 – 2
EVLA −114 (−281 to 53) 0.011 (−0.005 to 0.027) Dominant 16,422 1
Scenario 6: analysis based on QALYs derived from the SF-6D
Surgery – – – – 3
Foam
sclerotherapy
−662 (−826 to −498) −0.002
(−0.020 to 0.016)
340,775 – 1
EVLA −156 (−316 to 4) 0.012 (−0.001 to 0.026) Dominant 35,920 2
Scenario 7: analysis based on full multiple imputation data sets
Surgery – – – – 3
Foam
sclerotherapy
−585 (−730 to −440) −0.010
(−0.031 to 0.010)
56,217 – 1
EVLA −103 (−255 to 47) 0.007 (−0.008 to 0.021) Dominant 31,589 2
Scenario 8: analysis based on multiple imputation data sets with participants receiving no treatment and
follow-up dropped
Surgery – – – – 3
Foam
sclerotherapy
−621 (−782 to −459) −0.009
(−0.030 to 0.011)
65,523 – 1
EVLA −126 (−281 to 28) 0.007 (−0.007 to 0.021) Dominant 30,723 2
Rc, ceiling ratio.
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TABLE 91 Individual participant costs: foam sclerotherapy vs. surgery
Costs Foam sclerotherapy Surgery
Number of participants 286 289
Indirect costs (n, mean, SD) 223 £420 £554 220 £989 £788
Participant GP cost (n, mean, SD) 234 £4 £18 213 £4 £13
Participant outpatient cost (n, mean, SD) 286 £17 £53 289 £4 £13
Participant hospital cost (n, mean, SD) 272 £0 £0 254 £1 £5
Total participant cost (n, mean, SD) 232 £22 £63 210 £9 £21
Total costs primary analysis
Total participant, NHS and indirect costs (n, mean, SD) 180 £895 £611 175 £2053 £889
TABLE 92 Incremental cost-effectiveness, including NHS, indirect and participant costs: foam sclerotherapy
vs. surgery
Intervention Incremental costs (95% CI), £ Incremental QALYs (95% CI) ICER (£)
Surgery – – –
Foam sclerotherapy −1173 (−1371 to −974) −0.006 (−0.021 to 0.009) 198,802
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FIGURE 12 Cost-effectiveness acceptability curves, including NHS, indirect and participant costs: foam sclerotherapy
vs. surgery.
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Endovenous laser ablation versus foam sclerotherapy versus surgery
Table 93 documents the mean indirect and participant costs associated with use of health services over the
follow-up period. The surgery treatment strategy incurred the highest mean indirect costs (£1075), followed
by EVLA (£628) and foam sclerotherapy (£466). Mean participant costs of attending GP appointments were
slightly higher in the surgery group, whereas higher costs of attending outpatient appointments were
observed in the EVLA and foam sclerotherapy groups; again, this was due to the assumed need to attend
a routine assessment appointment following these treatment modalities. As for the analysis of foam
sclerotherapy versus surgery, combining the mean indirect and mean participant costs with NHS costs had
very little impact on the incremental cost-effectiveness findings in this analysis (Table 94).
To characterise the uncertainty surrounding the cost-effectiveness estimates, a CEAC was derived
(Figure 13). At a ceiling WTP threshold of £20,000 per QALY, foam sclerotherapy had an 85.4% probability
of being cost-effective, whereas EVLA had a 14.6% chance and surgery had a 0% probability of being the
preferred option. At a WTP threshold of £30,000 per QALY, foam sclerotherapy retains the highest
probability (54.5%) of being the cost-effective option, followed by EVLA (probability of 45.5%), and the
probability of surgery being the preferred option does not increase. The CEACs for foam sclerotherapy and
EVLA do not cross until the WTP threshold is > £30,000.
TABLE 93 Participant costs: EVLA vs. foam sclerotherapy vs. surgery
Costs EVLA Foam sclerotherapy Surgery
Number of participants 210 207 213
Indirect costs (n, mean, SD) 174 £628 £653 164 £466 £597 164 £1075 £852
Participant GP cost (n, mean, SD) 170 £2 £7 168 £4 £21 156 £5 £15
Participant outpatient cost (n, mean, SD) 210 £14 £22 207 £14 £38 213 £4 £14
Participant hospital cost (n, mean, SD) 199 £0 £0 195 £0 £0 183 £1 £6
Total participant cost (n, mean, SD) 167 £17 £24 167 £19 £48 153 £11 £23
Total participant, NHS and indirect costs
(n, mean, SD)
124 £1541 £632 127 £945 £661 129 £2196 £930
TABLE 94 Incremental cost-effectiveness, including NHS and participant costs: EVLA vs. foam sclerotherapy
vs. surgery
Intervention
Incremental cost
(95% CI), £
Incremental
QALYs (95% CI)
ICER
(vs. surgery) (£)
ICER (EVLA vs. foam
sclerotherapy) (£)
NMB ranking
at Rc £20,000
Surgery – – – – 3
Foam
sclerotherapy
−1271
(−1459 to −1083)
−0.006
(−0.030 to 0.017)
198,977 – 1
EVLA −660
(−849 to −471)
0.013
(−0.003 to 0.029)
Dominant 31,546 2
Rc, ceiling ratio.
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Discussion
Summary of key results
Based on the primary analysis of foam sclerotherapy versus surgery data, foam was found to result in a
cost saving of £102,106 per QALY lost in comparison with surgery. Considering that society might be
required to receive compensation of at least £20,000 for a QALY loss, this result is highly favourable for
foam, suggesting good value for money for the NHS in comparison with surgery. The high value of the
ICER is driven by the comparatively modest cost of foam sclerotherapy treatment. The results were robust
to a range of alternative assumptions relating to unit cost estimation, restriction of the analysis to specific
subgroups and multiple imputation of missing data.
For the analysis of EVLA versus foam sclerotherapy versus surgery, very similar results were obtained for the
comparison between foam sclerotherapy and surgery. From the three-way comparison of data at 6-months
follow-up, EVLA was found to be less costly and marginally more effective than surgery, and therefore
‘dominant’ (i.e. better than surgery in terms of both costs and QALYs). In the base-case analysis it was
estimated that the ICER for EVLA versus foam sclerotherapy was ≈ £26,000. Therefore, adopting the same
ceiling WTP ratio of £20,000 per QALY, foam sclerotherapy produced the greatest NMB at 6 months,
followed by EVLA, followed by surgery. Considering the results of the probabilistic analysis, foam
sclerotherapy had the greatest probability of being cost-effective (≈ 78%) at a threshold value of £20,000
per QALY, whereas EVLA had a ≈ 21% chance and surgery a < 1% chance. However, increasing the
WTP threshold to £30,000, EVLA was found to have the higher probability (≈ 60%) of being the most
cost-effective option.
Further, EVLA was found to generate greater NMB under certain scenarios presented in the sensitivity
analysis, namely, when EVLA incorporated a similar staff profile to foam sclerotherapy (performing the
procedure with the presence of a surgeon and one or two additional nurses); when the analysis was
restricted to include participants with unilateral disease only; and when the analysis was based on
participants with unilateral and GSV involvement only. The base-case results demonstrated that EVLA
generated a cost saving of £156 compared with surgery. This cost saving increased when EVLA was
assumed to adopt a similar staff profile to foam sclerotherapy (£326). However, when the cost per usage
of the laser generator (assumed as loaned free of charge) was included in the EVLA treatment, the cost
saving versus surgery reduced (£123).
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FIGURE 13 Cost-effectiveness acceptability curves, including NHS, indirect and participant costs: EVLA vs. foam
sclerotherapy vs. surgery.
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Explanation of results
The ICER for foam sclerotherapy versus surgery in both analyses (foam sclerotherapy vs. surgery and EVLA
vs. foam sclerotherapy vs. surgery) showed that foam sclerotherapy had reduced effectiveness but at a
lower cost. The ICER remained robust to all scenarios presented in the sensitivity analyses. On the basis of
the data presented, it would be accepted NHS practice to conclude that foam sclerotherapy would be
considered the favourable option from a cost-effectiveness perspective at the 6-month time frame.
Similar results were found for foam sclerotherapy versus surgery in the three-way comparison. The ICER
remained robust to all scenarios presented in the sensitivity analysis. EVLA was found to give a small
increase in QALYs compared with both foam sclerotherapy and surgery. EVLA was, on average, less costly
and more effective than surgery, and was thus dominant. However, the ICER for EVLA versus foam
sclerotherapy showed that although it produced higher QALYs, it did so at an increased cost. The ICER for
EVLA versus foam sclerotherapy in the base-case analysis was higher than the accepted threshold, and for
this reason foam sclerotherapy remains the preferred option from a cost-effectiveness perspective at
6 months.
Strengths and limitations
One of the key strengths of this study was the multicentre RCT design, which comprised 11 centres
around the UK, adding to the applicability of results more widely. The inclusion of a comprehensive
cost-effectiveness analysis, based on best practice guidelines, within a RCT is another key strength. A
detailed micro-costing method was implemented, ensuring that variations in treatment strategy costs
across participating centres were accurately reflected in the analysis. To ensure that results were robust to
the primary outcome measure (EQ-5D), QALYs were also estimated using responses from the SF-36
(converted into the SF-6D).
Some data were missing for cost and QALY outcomes. However, multiple imputation of missing resource
use, cost and EQ-5D data did not alter the conclusions of the analysis. It should be noted that the results
of the trial-based cost-effectiveness analysis pertain only to a short period of follow-up (6 months).
Therefore, any differences across treatment arms in terms of recurrence over the longer term, and the
associated cost and QALY implications, were not addressed in this phase of the study. For this reason,
we developed an economic model (see Chapter 10) to extrapolate results from the 6-month trial-based
analysis over a longer time horizon. In addition, further data will be collected from participants after
5 years.
Summary/conclusions
To summarise, within the trial period it was found that foam sclerotherapy had the highest probability of
being the most cost-effective option under base-case assumptions. These results remained robust under all
scenarios presented in the sensitivity analysis for foam sclerotherapy versus surgery. However, our analysis
shows that under certain circumstances in the three-arm analysis (EVLA vs. foam sclerotherapy vs. surgery),
EVLA may generate the greatest NMB in comparison with foam sclerotherapy and surgery. Data from the
subgroup analyses would suggest that EVLA is more likely to be cost-effective in the subgroup of
participants treated for unilateral GSV involvement only. Further, if EVLA could be performed using a
similar staff profile to foam sclerotherapy, it may offer a cost-effective approach to treatment.
Although these results provide useful information on the short-term costs and effects of the different
procedures, they are not sufficient for determining the optimal approach to treatment over a longer time
horizon. This is because any differential effects of the treatments on costs and outcomes may persist far
into the future. In addition, the risk of clinical recurrence beyond 6 months may be found to differ
significantly between the alternative treatment strategies, altering the cost-effectiveness rankings of
treatments in the long term. Therefore, Chapter 10 reports on the findings of a decision modelling
exercise, designed to extrapolate these cost-effectiveness findings over extended time horizons. Extended
follow-up of the CLASS cohort to 5 years will provide a means of validating this modelling exercise in
the future.
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Chapter 10 Cost-effectiveness modelling
Introduction
The aim of this chapter is to assess the cost-effectiveness of the alternative treatment modalities for
varicose veins over the longer term. The within-trial analysis provides useful information on the short-term
costs and effects of the alternative interventions, but it is important to discover whether or not the effects
of treatment on outcomes persist into the future. This is because recurrence of varicose veins in the long
term after any particular treatment will lead to reductions in QoL and further costs. In order to address this
issue, additional information was gained through modelling expected future costs and outcomes over
longer time horizons (through to 5 and 10 years). The specific objectives of this chapter are to:
l describe the development of a model to extrapolate the costs and consequences of surgery, foam
sclerotherapy and EVLA treatments over extended time horizons of 5 and 10 years
l compare the treatment modalities incrementally in terms of costs and QALYs, using the NMB
framework to identify the optimal strategy.
Methods
General structure of the model
A cost-effectiveness Markov model was developed using TreeAge Pro 2012, R2.1 (TreeAge Software, Inc.,
Williamstown, MA, USA). The model was based on care pathways developed in consultation with clinical
members of the team, describing the possible temporal sequences of events that patients may experience
following their initial treatment. The model structure describes the logical and temporal sequence of events
from the initial treatment until the patient’s death.
The model was constructed to simulate transitions between discrete health states on a 6-month time
interval (Markov cycle). For the first 6-month cycle, model data were taken directly from CLASS trial data.
Beyond 6 months, the best available evidence on the risk of recurrence following initial treatment with the
alternative treatment modalities was used to model subsequent costs and consequences over an extended
time horizon. The model was designed to inform the optimal approach to treatment in patients considered
clinically suitable for all three surgical procedures (as was the case for all patients randomised in the CLASS
trial). It simultaneously compared the three treatment modalities, but did not include a no treatment
(or conservative management) arm. As the model focused on the three-way treatment comparison, the
model input parameters were based only on data from centres that randomised patients to all
three procedures.
Modelled cohort
The model was analysed for a cohort of patients with mean age and sex matching those of participants
recruited at CLASS trial sites which offered randomisation between all three treatment modalities. Initially,
the model was populated based on cost and utility data obtained from all randomised patients, but the
impact of basing model inputs on patients with unilateral disease only (and those with unilateral disease
and GSV involvement only) was also assessed.
Definition of health states
For the base-case analysis, a simple model was specified using five main states: ‘pre-treatment primary
varicose veins’, ‘post-primary treatment of varicose veins’ (following surgery, foam sclerotherapy or EVLA),
‘clinical recurrence’, ‘post treatment of recurrent varicose veins’ and ‘death’ from all causes (Figure 14).
All patients commenced in the ‘pre-treatment primary varicose veins’ state, and then moved to the
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corresponding post-treatment state for the start of the second model cycle. Over subsequent model cycles,
a constant risk of clinical recurrence, specific to the initial treatment modality received, was applied to
patients in the post-treatment states. Following clinical recurrence, patients could either present for further
treatment (surgery, foam sclerotherapy or EVLA), and then transit to the ‘post treatment of recurrent
varicose veins’ state, or they could remain in the ‘clinical recurrence’ state. For patients experiencing a
second recurrence following secondary treatment, a simplifying assumption was made that these patients
would not proceed to further treatment. The impact of allowing any number of further repeat treatments
for clinical recurrence was also assessed through sensitivity analysis.
Clinical recurrence
To inform the risk of recurrence in the model, existing systematic reviews assessing the longer-term clinical
effectiveness of the alternative treatment modalities for varicose veins were consulted.28,52,56,93 The most
recent of these was carried out for NICE Clinical Guideline 168 on varicose veins in the legs.28 Within the
review prepared for the NICE evaluation, the authors presented the findings of a random-effects network
meta-analysis of treatment-specific probabilities of clinical recurrence over time. This analysis was based on
summary data from eight RCTs that included clinical recurrence as an outcome, seven comparing surgery
against endothermal treatment (including EVLA), two comparing surgery against foam sclerotherapy and
one comparing foam sclerotherapy against endothermal treatment. The duration of follow-up in the
majority of included studies was 12 or 24 months, although one small trial comparing surgery and
endothermal treatment reported follow-up to 36 months.94 It should be noted that the endothermal
treatments (EVLA and endovenous radiofrequency ablation) were pooled for the purpose of this meta-
analysis. The monthly probabilities of recurrence presented in the updated NICE guideline were applied in
the model, transformed into constant 6-month probabilities (Table 95). Application of these probabilities
yields predicted recurrence rates at 5 years of ≈ 40% for foam sclerotherapy, ≈ 37% for surgery and
≈ 29% for EVLA. It should be noted that plans are in place to assess clinical recurrence at 5 years after
treatment through extended follow-up of the CLASS trial participants, but these data are not yet available.
Sensitivity analysis was used to assess the impact of varying the recurrence rates on the cost-effectiveness
of the alternative treatment modalities.
Utilities estimates
The utility estimate for pre-treatment primary varicose veins was taken as the mean baseline EQ-5D score
across all treatment arms of the CLASS trial. For the base-case model, the utility values applied to the
post-treatment states were derived by regressing the 6-month EQ-5D values on treatment group, baseline
EQ-5D score and the minimisation variables (Table 96). The method of recycled predictions84 was used
to recover the mean estimated 6-month utility value following surgery, and the estimated mean utility
increments associated with foam sclerotherapy and EVLA were applied to patients receiving these
treatment modalities. Cluster robust standard errors, obtained from the regression analysis of utility data,
were used to fit distributions to the incremental utility parameters for probabilistic sensitivity analysis (PSA).
Further, the utility pay-off in the first model cycle was adjusted so that the QALYs generated in the first
6 months were consistent with those derived from the within-trial analysis. It was assumed that following
TABLE 95 Monthly probabilities of clinical recurrence applied in the model28
Treatment Mean Standard error Assumed distributional form
Surgery 0.008818 0.00306 Beta
Foam sclerotherapy 0.0115 0.009929 Beta
EVLA 0.006532 0.003448 Beta
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
clinical recurrence, patients would revert back to the pre-treatment EQ-5D utility value. This assumption is
conservative in favour of treatments with higher clinical recurrence rates, because some previous evidence
suggests that the utility decrement associated with recurrence might be greater than the utility increment
associated with initial treatment success.28
Resource use and costs
The costs included in the model were derived from the analysis of patient-level cost data collected in the
CLASS trial (reported in Chapter 9), supplemented by assumptions about further resource use associated
with clinical recurrence. The model-based analysis adopted a health and social care perspective,
although no social care costs were identified as being relevant to the comparison of the alternative
treatment modalities.
Initial treatment costs
For the initial 6-month cycle, we employed the same general linear regression model used to analyse the
CLASS patient-level cost data. However, for the purpose of populating the economic model, the analysis of
cost data was not restricted to patients with complete QALY data. The approach of recycled predictions
was used to recover the estimated mean cost in the surgery arm (at 6 months), adjusted for any potential
imbalance in the covariates at baseline. This cost accounts for the initial treatment, any perioperative
complications experienced and any subsequent resource use occurring within the first 6 months of
follow-up (Table 97). The incremental costs associated with foam sclerotherapy and EVLA, compared with
surgery (derived from the regression model), were applied to recover the expected costs for patients
receiving these treatment modalities in the model.
TABLE 96 European Quality of Life-5 Dimensions utility values applied in the model
State EQ-5D utility value Standard error
Assumed
distributional form
Pre-treatment primary varicose veins 0.790 0.009 Beta
Post-treatment for primary veins (surgery) 0.884 0.0104a Beta
Post-treatment utility increment (foam sclerotherapy) −0.009 0.018b Normal
Post-treatment utility increment (EVLA) 0.016 0.0121b Normal
Clinical recurrence 0.790 0.009 Beta
a Cluster bootstrapped standard errors.
b Cluster robust standard errors.
TABLE 97 Initial treatment and 6-month follow-up costs applied in the model
Description
Initial 6-month
cost (£) Standard error (£)
Assumed
distributional form
Conventional surgery 1110 80a Gamma
Incremental cost (foam sclerotherapy) −655 85b Normal
Incremental cost (EVLA) −160 83b Normal
a Cluster bootstrapped standard error.
b Cluster robust standard errors.
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Costs of recurrence
Assumptions were required regarding the approach to management of clinical recurrence. In the base case
it was assumed that the approach to initial treatment would not determine the approach to treating
clinical recurrence. Initially, the assumptions regarding the treatment of clinical recurrence were taken from
the modelling exercise undertaken to inform the NICE guideline.28 Based on consultation with the NICE
Guideline Development Group (GDG), the authors of the NICE report assumed that 75% of patients
experiencing a recurrence would receive further interventional treatment, and that regardless of initial
treatment modality, 12% would receive surgery, 42% would receive foam and 46% would receive EVLA.
For the costs of these procedures for recurrent varicose veins, we applied the same estimated 6-month
mean costs as applied for the initial treatment, derived from our analysis of the directly collected trial data
(see Table 97). However, we also assessed the impact of applying the NHS reference cost for the treatment
of recurrent varicose veins86 in a sensitivity analysis.
It was further assumed that patients receiving treatment for recurrence would spend 1 year on average in
the ‘clinical recurrence’ state prior to receiving treatment. The impact of this assumption was assessed
through sensitivity analysis. In the economic model developed for the NICE guideline, it was also assumed
that patients experiencing a clinical recurrence would, on average, incur the cost of a further 2.5 GP visits
(£75)87 and subsequent assessment in an outpatient setting (£165) – including a duplex scan (£52.84)86 –
prior to treatment. To retain consistency with this previous analysis, these additional costs were also
incorporated in the current model.
Complications
Although complications have the potential for significant cost and outcome implications, it was assumed
that serious long-term complications would be rare and that these would not differentially affect resource
use across the treatment groups. In addition, the differential impact of any short-term complications on
resource use is implicitly captured in the model via application of the 6-month cost estimates obtained
from the trial-based cost-effectiveness analysis (see Chapter 9), while the impact of any complications on
health status is captured through application of the 6-month QALY and EQ-5D estimates. Therefore,
resource use associated with any long-term complications, other than clinical recurrence, was not explicitly
included in the model.
Mortality
Within any cycle of the model, patients also faced a risk of dying from any cause. These age- and
sex-specific probabilities of death were based on UK interim life tables.90,95
Analysis
The model was initially run over a 5-year time horizon, which is the duration to which the CLASS study
follow-up will ultimately be extended in order to provide a validity check on initial model-based estimates
of cost-effectiveness. Following this, we explored the impact of extending the model time horizon to
10 years, assuming constant risks of clinical recurrence. Future costs and QALYs were discounted at a rate
of 3.5% per annum in line with the NICE reference case.96 The model-based analysis was restricted to the
health and social care perspective, comparing the expected health service costs and QALYs generated by
each treatment modality incrementally from the least costly to the most costly. In order to help identify the
optimal approach to treatment, the NMB framework was used, where the NMB for any given strategy is
equal to the accrued QALYs multiplied by the ceiling ratio (Rc) of WTP per QALY gained, minus the
strategy costs.
NMB= (QALYs Rc)−costs. (2)
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To help interpret the results for decision-making, the accepted value of £20,000 was placed on the Rc of
WTP per QALY,96 and the strategy generating the greatest NMB at this value of Rc identified. In order to
characterise the uncertainty surrounding selection of the optimal strategy, the model was analysed
probabilistically and the mean costs and effects reported. Each input parameter in the model was assigned
an appropriate distribution reflecting the uncertainty surrounding it. The probabilistic analysis proceeded by
randomly selecting a value from the assigned distribution for each model parameter, and recomputing the
model results. This process was repeated 10,000 times to produce an empirical estimate of the uncertainty
surrounding the model-based estimates of NMB. Distributions for the incremental cost and utility parameters
(for foam and EVLA vs. surgery) applied in the model were defined using the mean regression-based estimates
with cluster robust standard errors (see Tables 96 and 97).
Deterministic sensitivity analysis
Further deterministic sensitivity analysis was undertaken to assess the robustness of the findings to various
parameter and structural assumptions applied in the base-case analysis. Deterministic sensitivity analysis
assessed the impact on findings of:
l applying additional overhead costs to reflect the opportunity cost of operating theatre space for
procedures using this resource
l basing the model cost and utility input parameters on the estimates obtained from the trial-based
multiple imputation analysis
l basing the model cost and utility input parameters on the trial-based estimates obtained for patients
with unilateral disease only (to eliminate any potential bias in estimated cost-effectiveness associated
with patients receiving simultaneous treatment for their contralateral leg)
l altering assumptions about the proportional distribution of patients receiving different treatment
modalities (surgery, foam sclerotherapy and EVLA) for clinical recurrence
l altering assumptions about the proportion of patients with clinical recurrence who proceed to further
surgical treatment
l increasing/decreasing the duration of time between clinical recurrence and subsequent treatment
l allowing patients to come back for further surgical treatment for any number of clinical recurrences,
over an extended time horizon
l applying the NHS reference cost for treatment of recurrent unilateral varicose veins, rather than the
bottom-up trial-based estimates of mean procedure costs
l assuming equal utility between treatment arms at 6 months
l basing utility inputs on responses to the SF-36, scored via the SF-6D.
Sensitivity to alternative structural assumptions
Given the uncertainty surrounding the estimated differences in generic HRQoL between treatment arms at
6 months, an alternative model specification was also assessed using pre- and post-treatment health states
defined by clinical severity. Within this model it was assumed that changes in QoL are determined solely
by transitions across the clinical severity states, and are not otherwise influenced by the treatment
modality received.
Four mutually exclusive clinical states were defined based on the VCSS.97 This instrument was chosen as
the basis for defining the health states as it reports the presence of varicose veins and the severity of
symptoms based on an objective clinical assessment, rather than the patients’ subjective perception. It was
felt desirable that the severity states in the model should reflect underlying clinical status rather than
perceived status. The defined states were also found to correlate reasonably well with participants’ EQ-5D
scores, which reflect participants’ self-reported general health status and are used for estimating QALYs
within the model. The states chosen for this model are summarised in Table 98.
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Figure 15 provides a diagram of this alternative model structure. The modelled cohort was initially spread
across the pre-treatment states 2–4, reflecting the fact that all participants in the CLASS trial had varicose
veins at baseline. Probabilities of transition to the alternative post-treatment states were derived using a
multivariate ordinal logistic regression model. The ordinal post-treatment VCSS state at 6 months was
regressed on treatment allocation group, pre-treatment VCSS state and the minimisation factors [age
group, sex, vein involvement (GSV/SSV/both) and laterality (unilateral/bilateral)]. This model predicts the
probability of transition to each of the clinical severity states at 6 months, based on treatment allocation
group adjusted for baseline disease status and the minimisation covariates. These treatment-specific
predicted probabilities of moving to the alternative post-treatment severity states were applied in the
decision model.
The utility value for each model state was taken as the estimated mean EQ-5D index score for patients in
that state (Table 99). In this structural specification, no adjustments were made to the mean state utility
values by treatment allocation group. This modelling assumption constrains the modelled QALYs to be
influenced only by the impact of the alternative treatments on the probabilities of transition to the
different clinical health states following treatment, as well as the risk of recurrence over time. A further
assumption applied in this model was that clinical recurrence results in the patient moving down one
clinical severity state (apart from those patients already in state 4 following initial treatment), taking the
EQ-5D utility value back to the pre-treatment level for that state. This alternative model was analysed in
the same way as described above, using 10,000 probabilistic iterations.
Results
Base-case analysis
Table 100 presents the findings of the base-case modelling exercise over a 5-year time horizon. Mean costs
and effects are reported based on 10,000 probabilistic iterations of the model. The findings indicate
increased costs and QALYs associated with EVLA in comparison with foam sclerotherapy. The incremental
cost per QALY gained (EVLA vs. foam) is below the accepted Rc of £20,000. Surgery is associated with
increased costs compared with EVLA, but on average produces slightly fewer QALYs over 5 years. This is
driven by the slightly lower number of QALYs observed for surgery at 6-months follow-up, a slightly lower
EQ-5D score applied at 6 months and beyond, and a slightly higher clinical recurrence rate applied to
TABLE 98 Description of health states in the Markov model
State Description
State 2: pre treatment VCSS score 1–3 prior to treatment
State 3: pre treatment VCSS score 4–6 prior to treatment
State 4: pre treatment VCSS score > 6 prior to treatment
State 1: post treatment VCSS score 0 post treatment
State 2: post treatment VCSS score 1–3 post treatment
State 3: post treatment VCSS score 4–6 post treatment
State 4: post treatment VCSS score > 6 post treatment
State 2: recurrence VCSS score 1–3 post recurrence
State 3: recurrence VCSS score 4–6 post recurrence
State 4: recurrence VCSS score > 6 post recurrence
Dead Death from all causes
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FIGURE 15 Diagram showing the alternative model structure. Drop 1, drop 1 severity state; Drop 2, drop 2 severity states;
pACM, probability of death from all causes; pGrp1, probability of moving to clinical severity state 1 following treatment;
pGrp2, probability of moving to clinical severity state 2 following treatment; pGrp3, probability of moving to clinical severity
state 3 following treatment; pGrp4, probability of moving to clinical severity state 4 following treatment; propGrp2,
proportion starting model in clinical severity state 2; propGrp3, proportion starting model in clinical severity state 3; propGrp4,
proportion starting model in clinical severity state 4; Tx1, ultrasound-guided foam sclerotherapy; Tx2, surgery; Tx3, EVLA.
COST-EFFECTIVENESS MODELLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
surgery compared with EVLA. This leads to surgery being dominated by EVLA, that is, EVLA is less costly
and more effective. Applying a ceiling WTP ratio of £20,000 per QALY to help interpret the probabilistic
results, EVLA had the highest probability (78.7%) of being cost-effective, with foam sclerotherapy second
(16.8%) and surgery third (4.5%).
Figure 16 plots the proportion of probabilistic iterations favouring each of the alternative strategies
(in terms of NMB) at increasing levels of WTP per QALY. This figure shows that as WTP increases
beyond £30,000, EVLA has ≈ 80% chance of being considered the optimal strategy from a
cost-effectiveness perspective.
Table 101 and Figure 17 summarise the results when adopting a 10-year time horizon (assuming a
constant risk of recurrence over time). A similar pattern of results is obtained, although the incremental
cost per QALY gained for EVLA versus foam decreases to £2065. There is also slightly more uncertainty
over the optimal treatment modality when adopting the 10-year time horizon (see Figure 17), but EVLA
retains the highest chance (76%) of being cost-effective at a ceiling ratio of £20,000 per QALY.
Deterministic sensitivity analysis
Table 102 demonstrates the sensitivity of the base-case modelling results to uncertainty surrounding
several key input parameters and modelling assumptions. In general, the findings are robust to most
changes. However, the ordering of strategies does partially switch when using the full multiple imputation
data set to inform the cost and utility parameters of the model (see scenario 2 in Table 102). Under this
scenario, the mean increased cost of surgery in relation to foam and EVLA drops somewhat, owing to a
TABLE 99 European Quality of Life-5 Dimensions utility values applied in the model
State EQ-5D utility value Standard error Distribution for PSA
State 2: pre treatment 0.809 0.0117 Beta
State 3: pre treatment 0.802 0.0083 Beta
State 4: pre treatment 0.745 0.0179 Beta
State 1: post treatment 0.940 0.0104 Beta
State 2: post treatment 0.894 0.0099 Beta
State 3: post treatment 0.799 0.0338 Beta
State 4: post treatment 0.754 0.0203 Beta
State 2: recurrence 0.809 0.0117 Beta
State 3: recurrence 0.802 0.0083 Beta
State 4: recurrence 0.745 0.0179 Beta
TABLE 100 Base-case analysis over a 5-year time horizon
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Foam sclerotherapy 664 0 4.000 0 0 0.168
EVLA 1095 431 4.119 0.118 3640 0.787
Surgery 1300 206 4.040 −0.078 Dominated 0.045
Note
Rc is ceiling ratio of WTP per QALY gained.
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FIGURE 16 Cost-effectiveness acceptability curve based on 5-year time horizon.
TABLE 101 Base-case analysis over a 10-year time horizon
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Foam sclerotherapy 815 0 7.265 0 0 0.165
EVLA 1238 424 7.470 0.205 2065 0.76
Surgery 1475 237 7.332 −0.138 −1716 0.075
Note
Rc is ceiling ratio of WTP per QALY gained.
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FIGURE 17 Cost-effectiveness acceptability curve based on 10-year time horizon.
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TABLE 102 Deterministic sensitivity analysis results
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Scenario 1: including additional overhead costs for procedures carried out in theatre
Foam sclerotherapy 684 – 4.000 – – 0.174
EVLA 1122 438 4.119 0.118 3703 0.8
Surgery 1561 439 4.040 −0.078 Dominated 0.027
Scenario 2: cost and utility inputs based on full multiple imputation analysis
Foam sclerotherapy 677 – 3.975 – – 0.114
EVLA 1094 417 4.116 0.142 2943 0.769
Surgery 1237 144 4.057 −0.060 Dominated 0.116
Scenario 3: cost and utility inputs based on multiple imputation analysis, with participants receiving no
treatment and follow-up dropped
Foam sclerotherapy 665 – 3.996 – – 0.174
EVLA 1097 432 4.115 0.119 3626 0.738
Surgery 1272 175 4.044 −0.071 Dominated 0.088
Scenario 4: applying cost and utility input parameter values based only on patients with unilateral disease and
no simultaneous treatment to contralateral leg
Foam sclerotherapy 646 – 3.990 – – 0.172
EVLA 1081 436 4.138 0.148 2947 0.778
Surgery 1233 152 4.037 −0.101 Dominated 0.051
Scenario 5: applying cost and utility input parameter values based only on patients with unilateral disease and
GSV involvement
Foam sclerotherapy 646 – 3.929 – – 0.115
EVLA 1085 439 4.107 0.179 2456 0.784
Surgery 1251 166 4.039 −0.069 Dominated 0.102
Scenario 6: 60% of patients with clinical recurrence proceed to further treatment
Foam sclerotherapy 622 – 3.995 – – 0.168
EVLA 1066 444 4.115 0.120 3702 0.786
Surgery 1262 196 4.035 −0.080 Dominated 0.046
Scenario 7: 90% of patients with clinical recurrence proceed to further treatment
Foam sclerotherapy 706 – 4.006 – – 0.168
EVLA 1124 418 4.123 0.117 3576 0.788
Surgery 1339 215 4.045 −0.077 Dominated 0.044
Scenario 8: all patients with clinical recurrence receive conventional surgery
Foam sclerotherapy 734 – 3.999 – – 0.169
EVLA 1143 409 4.118 0.119 3451 0.785
Surgery 1363 221 4.039 −0.079 Dominated 0.046
continued
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TABLE 102 Deterministic sensitivity analysis results (continued )
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Scenario 9: all patients with clinical recurrence receive foam
Foam sclerotherapy 603 – 3.997 – – 0.17
EVLA 1053 450 4.116 0.119 3768 0.786
Surgery 1245 192 4.037 −0.079 Dominated 0.045
Scenario 10: application of NHS reference cost (£1216) to all treatments for clinical recurrence
Foam sclerotherapy 755 – 4.000 – – 0.169
EVLA 1157 402 4.119 0.118 3401 0.786
Surgery 1383 225 4.040 −0.078 Dominated 0.046
Scenario 11: 2-year delay between clinical recurrence and receiving further treatment
Foam sclerotherapy 605 – 3.987 – – 0.172
EVLA 1049 444 4.108 0.122 3656 0.782
Surgery 1242 192 4.027 −0.081 Dominated 0.047
Scenario 12: allowing any number of repeat treatments for subsequent clinical recurrences, with a
10-year time horizon
Foam sclerotherapy 927 – 7.283 – – 0.164
EVLA 1285 358 7.478 0.196 1831 0.765
Surgery 1547 262 7.345 −0.134 Dominated 0.071
Scenario 13: assuming no difference in post-treatment utility scores between alternatives
Foam sclerotherapy 664 – 4.033 – – 0.549
EVLA 1095 431 4.052 0.019 22,268 0.378
Surgery 1300 206 4.039 −0.013 Dominated 0.073
Scenario 14: assuming no difference in post-treatment utility scores between alternatives, with a
10-year time horizon
Foam sclerotherapy 815 – 7.311 – – 0.42
EVLA 1238 424 7.365 0.054 7881 0.454
Surgery 1475 237 7.328 −0.036 Dominated 0.127
Scenario 15: utility inputs based on participant responses to the SF-36 (scored using the SF-6D)
Foam sclerotherapy 665 – 3.706 – – 0.216
EVLA 1095 431 3.772 0.066 6503 0.782
Surgery 1301 205 3.706 −0.066 Dominated 0.003
Scenario 16: equal recurrence rates applied following EVLA and surgery
Foam sclerotherapy 664 – 4.002 – – 0.169
EVLA 1095 431 4.119 0.117 3691 0.78
Surgery 1255 160 4.053 −0.066 Dominated 0.052
Note
Rc is ceiling ratio of WTP per QALY gained.
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cluster of patients in the surgery arm, receiving no treatment within CLASS, being assigned costs in line
with the mean treatment cost (across all arms) in the imputation analysis. These patients were dropped out
of the complete case analysis owing to withdrawal from follow-up. Using multiple imputation to put these
patients back into the analysis reduces the mean cost of surgery and, consequently, increases its chances
of being cost-effective. However, EVLA still retains the highest chance of being cost-effective. Further,
when the patients receiving no treatment and no follow-up are dropped from the multiple imputation
analysis, the relative order of the strategies is restored to that observed for the base-case analysis
(see scenario 3 in Table 102). The base-case findings were also found to hold when restricting the analysis
to patients with unilateral disease only and to patients with unilateral disease and GSV involvement only.
When applying the assumption of no difference in generic QALYs between the strategies up to 6 months,
and no difference in the mean EQ-5D score at 6 months, foam sclerotherapy has the highest probability
of being cost-effective at 5 years (see scenario 13 in Table 102), with EVLA second and surgery third.
However, the base-case ordering is restored when the time horizon for this analysis is extended to 10 years
(see scenario 14 in Table 102).
Secondary analysis for bilateral varicose veins
As well as assessing the sensitivity of the base-case cost-effectiveness findings to alternative parameter
values and assumptions, a further model-based analysis was undertaken to ascertain the likely
cost-effectiveness of using the alternative treatment modalities in patients with bilateral disease. Several
assumptions were required for this analysis, as participants with bilateral disease in the CLASS trial were
assigned only one study leg to be treated, in accordance with the CLASS protocol. Therefore, the CLASS
data are not ideally suited to assessing the cost-effectiveness of using the individual treatment modalities
(where clinically appropriate) to treat bilateral varicose veins.
To inform this analysis, it was assumed that QALY and utility gains following bilateral treatment would
follow the same pattern as observed for the treatment of unilateral veins. This assumes that using the
alternative treatment modalities in both legs would result in similar outcomes for both legs, and that the
worst leg determines patients’ QoL. It was further assumed that for surgery, treatment of both legs would
be carried out in a single session, whereas for foam and EVLA the second leg would be treated in a
separate session. Therefore, in this model the cost of surgery (for unilateral disease) was inflated by 1.23,
the ratio of the mean surgery cost for unilateral disease over the mean surgery cost for patients in the
CLASS trial having surgery for their contralateral leg at the same time. For foam and EVLA, we added the
full cost of an additional treatment session, based on the mean cost estimates for unilateral treatment
derived from the trial data. These assumptions are conservative in favour of surgery, as EVLA may also be
carried out for the second leg within a single treatment session.
Finally, to reflect the fact that costs associated with clinical recurrence are likely be higher in patients with
bilateral disease, we applied the NHS reference cost (£1611) for the treatment of recurrent bilateral
varicose veins.86
The results of this analysis are presented in Table 103. They show that under this scenario EVLA becomes
the most costly option. However, as a result of application of the estimated QALY and utility gains for
EVLA versus surgery in the model, and application of a slightly lower estimated recurrence risk for EVLA,
EVLA retains an estimated QALY gain of 0.1 over surgery at 5 years. The consequence of this is that EVLA
has an ICER below £20,000 in comparison with surgery, and the highest chance of being cost-effective at
this threshold.
The impact on the results of applying the same EQ-5D utility weight for surgery and EVLA at 6 months and
beyond (see scenario 2 in Table 103), and of applying the same clinical recurrence risk (see scenario 3 in
Table 103), was also assessed. The findings are robust to these changes individually, but when applied
simultaneously, the ICER for EVLA rises above £20,000 per QALY gained, and surgery has the higher
chance of being cost-effective (see scenario 4 in Table 103).
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Sensitivity to alternative structural assumptions
Table 104 and Figure 18 summarise the results obtained when using alternative structural assumptions to
construct the model. With this model, it was assumed that the alternative treatments have no differential
impact on the generic HRQoL of patients, other than that driven by their effects on the clinical severity of
patients’ venous disease (as assessed by the VCSS).
In line with the clinical analysis of the VCSS score, this model predicts higher QALYs with EVLA than with
foam, and slightly higher QALYs with surgery than with EVLA. However, the incremental cost per QALY
gained with surgery versus EVLA remains slightly above £30,000 at 5 years, and, consequently, the
probability of surgery being cost-effective remains lower than that for EVLA at the ceiling ratio of £20,000
per QALY. Furthermore, increasing the time horizon for this analysis to 10 years (Table 105, Figure 19)
increases the chance of EVLA being the preferred option owing to its slightly lower estimated clinical
recurrence rate.
TABLE 103 Results of modelled scenarios for single modality treatment of bilateral disease
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Scenario 1: base-case bilateral treatment scenario
Foam sclerotherapy 1137 – 3.990 – – 0.206
Surgery 1631 493 4.037 0.047 10,440 0.09
EVLA 1953 323 4.138 0.101 3207 0.704
Scenario 2: applying the same EQ-5D utility weight for EVLA and surgery at 6 months
Foam sclerotherapy 1137 – 3.990 – – 0.204
Surgery 1631 493 4.105 0.115 4290 0.249
EVLA 1953 323 4.138 0.033 9799 0.574
Scenario 3: applying the same recurrence risk for EVLA and surgery
Foam sclerotherapy 1137 – 3.990 – – 0.204
Surgery 1548 411 4.050 0.060 6891 0.111
EVLA 1953 406 4.138 0.088 4591 0.685
Scenario 4: applying scenarios 2 and 3 simultaneously
Foam sclerotherapy 1137 – 3.990 – – 0.21
Surgery 1548 411 4.121 0.131 3128 0.505
EVLA 1953 406 4.138 0.017 24,341 0.284
TABLE 104 Secondary analysis over a 5-year time horizon
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Foam sclerotherapy 667 – 4.022 – – 0.302
EVLA 1096 429 4.063 0.042 10,329 0.397
Conventional surgery 1301 205 4.070 0.006 31,977 0.301
Note
Rc is ceiling ratio of WTP per QALY gained
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FIGURE 18 Cost-effectiveness acceptability curve based on the alternative model structure with a 5-year
time horizon.
TABLE 105 Secondary analysis over a 10-year time horizon
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs
Incremental
cost per
QALY (£)
Probability
cost-effective
at Rc £20,000
Foam sclerotherapy 817 – 7.314 – – 0.251
EVLA 1240 422 7.409 0.094 4474 0.440
Conventional surgery 1476 237 7.406 −0.003 Dominated 0.309
Note
Rc is ceiling ratio of WTP per QALY gained.
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FIGURE 19 Cost-effectiveness acceptability curve based on the alternative model structure with a 10-year
time horizon.
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Given the slightly counterintuitive impact of applying the observed mean EQ-5D utility scores for patients
in clinical severity states 3 and 4 following primary treatment (the mean values for these states were lower
post treatment than they were pre treatment, resulting in modelled recurrence leading to a utility increase
for some patients), we also examined the impact of applying the mean EQ-5D utility values obtained across
the baseline and 6-months time points for these states in the model. This had very little impact on the
results (Figure 20).
Discussion
Summary of key results
The modelling in this chapter suggests that, over a 5- and 10-year time horizon, EVLA is likely to be the
preferred option on grounds of cost-effectiveness, costing only £3640 per QALY gained in comparison
with foam sclerotherapy, and costing less and producing slightly more QALYs than surgery. Based on
probabilistic analysis, EVLA had a ≈ 79% chance of being cost-effective at a ceiling WTP ratio of £20,000
per QALY.
These findings, based on extrapolation of the incremental costs and outcomes obtained from the analysis
of complete trial data, were generally found to be robust to uncertainty surrounding various model
parameter inputs and assumptions, including multiple imputation of missing data and the basing of model
inputs on patients with unilateral disease. Although the CLASS data are not ideally suited to assessing the
cost-effectiveness of the alternative treatment modalities for patients with bilateral disease (where clinically
appropriate), a further sensitivity analysis was carried out to address this question, applying a number of
different assumptions (see Table 103). Under most of the scenarios, EVLA retained the highest probability
of being cost-effective. However, when it was assumed that EVLA and surgery have exactly the same utility
outcome at 6 months, and also the same clinical recurrence rate, surgery had the higher chance of being
cost-effective. This last result was still based on the conservative assumption (favouring surgery) that when
using EVLA to treat bilateral disease, treatment of the second leg would generally be carried out in a
separate treatment session. Therefore, it is likely that EVLA should also be preferred on grounds of
cost-effectiveness for the treatment of bilateral disease in situations where all three treatment modalities
are clinically viable options for the treatment of both legs.
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FIGURE 20 Cost-effectiveness acceptability curve based on the alternative model structure with a 5-year time
horizon (assuming equal utility for states 3 and 4 both pre and post treatment).
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The model-based probability of EVLA being the preferred option at the ceiling WTP ratio of £20,000 per
QALY was found to be somewhat sensitive to the application of alternative model structuring assumptions.
The base-case model extrapolated estimates of the direct effects of the alternative treatments on generic
HRQoL (as measured by the EQ-5D). This translated into a small gain in QALYs for EVLA over surgery
which, coupled with the lower cost of EVLA, resulted in it having a high probability of being cost-effective
compared with surgery. However, the estimated QALY and utility gains associated with EVLA were not
significant at 6 months. Therefore, we assessed the impact of (1) setting equal utility gains following the
alternative treatment options; and (2) mapping changes in utility to transitions across health states defined
by the VCSS. Both these approaches resulted in greater uncertainty surrounding selection of optimal
treatment modality on grounds of cost-effectiveness. However, EVLA did retain the higher probability of
being cost-effective at the WTP threshold of £20,000 per QALY.
Explanation of findings
The finding that EVLA has the highest chance of being the most cost-effective option is driven by a
number of factors: (1) its greater estimated QALY and utility gains at 6 months versus foam sclerotherapy
and, to a lesser extent, surgery; (2) its lower cost at 6 months compared with surgery; and (3) its slightly
lower estimated clinical recurrence rate compared with foam sclerotherapy and surgery. Although none of
the estimated differences between EVLA and surgery (with respect to post-treatment EQ-5D values and
the probability of recurrence) were significant at the traditional 5% level, it was the mean estimates or
estimated mean differences (between the alternative treatment modalities) that were used as model inputs
(with the uncertainty surrounding each input appropriately characterised as a probabilistic distribution). The
uncertainty surrounding each model parameter was then simultaneously propagated through the model
(using 10,000 probabilistic iterations) to characterise the uncertainty surrounding the model outputs,
that is, the estimated mean costs and effects of the alternative treatment modalities. This uncertainty
surrounding the model outputs was then expressed as a probability of each strategy being cost-effective
when using a ceiling ratio of £20,000 to value the model outcome (QALYs).
Strengths and limitations
The model was populated, where possible, using estimates of the mean difference in costs and effects
derived from the analysis of individual patient data on resource use and outcomes collected prospectively
alongside the CLASS study. Therefore, the results should be internally valid and generalisable across
settings in the UK.
In the absence of data on long-term clinical recurrence for the CLASS cohort, the risk of clinical recurrence
was modelled using data derived from a network meta-analysis of existing trials which reported clinical
recurrence as an outcome.28 Although this provides the best current source of evidence on recurrence, the
quality of trials included in this network meta-analysis varied, and EVLA and endothermal radiofrequency
ablation were pooled for the analysis. In addition, some RCTs included subjects undergoing only high tie
without stripping, which would result in a higher clinical recurrence rate. In CLASS, all patients had
preoperative scans to determine the involvement of single or multiple truncal veins, and all affected truncal
veins were stripped. Furthermore, follow-up generally extended to only 12 or 24 months in the included
trials (only one small trial94 reported outcomes at 36 months) and definitions of clinical recurrence were not
always well defined and varied from study to study. Therefore, uncertainty remains regarding the
applicability of these recurrence rates to patients in the CLASS trial (and more generally), and also the risks
of recurrence beyond 24 months and the utility impact of clinical recurrence according to varying
definitions. This underlines the importance of collecting further data on clinical recurrence and its impact
on generic HRQoL via the extended follow-up of CLASS participants. Plans are in place to do this at
5 years, which will provide a means of validating and updating the modelling undertaken in this chapter.
Comparison with other cost-effectiveness studies
In general, the modelling approach used in this chapter is consistent with that used in previous economic
modelling studies of treatments for varicose veins. Michaels et al.65 previously developed a Markov model
to assess the cost-effectiveness of conventional liquid sclerotherapy in comparison with surgery for patients
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
with moderate and severe uncomplicated varicose veins. Four severity states were defined using an
anatomical classification combined with evidence for the presence/absence of reflux, which was used to
estimate the risk of subsequent clinical recurrence. The clinical severity states were defined as pre- and
post-treatment states, in a similar manner to the way in which the clinical states were defined in the
secondary analysis model described in this chapter. However, the states in our model were based on the
VCSS rather than the anatomical distribution of varicose veins. In addition, Michaels et al.65 assigned the
same utility weights (obtained from post-treated patients) to their severity states both pre and post
treatment (owing to a lack of correlation between baseline utility values and the anatomical health states).
This may have resulted in a lack of sensitivity for capturing changes in utility associated with remaining in
the same severity state following treatment.
A further difference between the CLASS and Michaels models relates to the fact that Michaels et al.65
explicitly included some complications of surgery and sclerotherapy in their model, whereas the impact of
any complications was implicitly captured in the models described in this chapter by applying the mean
costs and QALYs observed for patients enrolled in the CLASS trial at 6-months follow-up. Further, observed
utility at 6 months was extrapolated beyond this time point, and was assumed to capture the utility impact
of any differences in complication rates between the treatment options at 6 months and beyond.
Based on their model, Michaels et al.65 reported an ICER for surgery versus conventional liquid
sclerotherapy of £1728 per QALY based on a 10-year time horizon. However, the relevance of this prior
analysis is now questionable as foam sclerotherapy has superseded the use of conventional liquid
sclerotherapy. Furthermore, for purposes of decision-making, it is not appropriate to consider the relative
cost-effectiveness of sclerotherapy and surgery in isolation of the other appropriate comparator, EVLA.
Gohel et al.54 similarly developed a Markov model to assess the cost-effectiveness of conservative
management, foam sclerotherapy, EVLA, RFA and surgery. This was a simpler model than that developed
by Michaels et al.,65 simulating the continued success or recurrence of reflux in patients following either a
completely successful or a partially successful (residual varicosities or incomplete occlusion) primary
treatment. The effects of the alternative treatments on initial outcome at 3 months and subsequent
recurrence of reflux were based on reviews of existing RCTs, and the costs of treatments were adapted
from NHS reference costs.86 Finally, health state utilities associated with primary varicose veins and
successfully treated varicose veins were taken from a previous trial of surgery. It was assumed that patients
not experiencing a successful primary treatment would remain at the pre-treatment utility level, but that
those patients with residual varicosities would be offered additional foam sclerotherapy (assumed
successful) and those with incomplete occlusion at 3 months would receive another treatment with the
same probability of success as the primary treatment.
Based on this model, Gohel et al.54 estimated that EVLA carried out under local anaesthetic would have
the highest chance of being cost-effective at a ceiling ratio of £20,000 per QALY, with day-case surgery
having the next highest probability, followed by RFA and foam sclerotherapy. Although the finding that
EVLA has the highest probability of being cost-effective is consistent with our analysis, the probabilistic
ordering of strategies from the model by Gohel et al.54 was somewhat different to ours. Although it is
difficult to unpick all the reasons for this, it may be partly explained by the fact that Gohel et al.54 used
estimates for the recurrence of reflux as the QoL driver (rather than clinical recurrence) and also applied
less precise costs to their alternative treatment modalities (basing these on NHS reference costs).
Furthermore, differences in model structure may also explain the differences in findings.
The structure and assumptions applied in our primary analysis are more in line with those used in the
model developed to inform the recent NICE Clinical Guideline 168.28 However, some differences do exist in
terms of the cost and utility estimates applied in the models. Based on the direct collection of individual
patient-level resource use data through CLASS CRFs and questionnaires, combined with a survey of
participating centres to collect information on additional resource use, we estimated a somewhat narrower
difference in cost between EVLA and surgery compared with that inferred from the estimates used in the
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NICE guideline model. This was due to differences in our estimated mean treatment durations (based on
prospectively collected patient-level data) as well as differences in the reported staffing profile for the
different procedures. Our estimates are more likely to be generalisable to UK practice because they were
derived using time and staffing data collected prospectively alongside the CLASS trial rather than clinical
opinion. Furthermore, rather than assuming equal utilities following different treatment modalities at
6 months (as was done in the NICE guideline model), we applied the estimated mean incremental
differences between foam and surgery and between EVLA and surgery. For the first 6-month cycle, the
model was also specified to return the mean QALYs observed for patients in alternative treatment
allocation arms of the CLASS trial.
Despite the differences between our analysis and that used to inform development of NICE Clinical
Guideline 168, the conclusions of our analysis are generally similar. EVLA retained the highest probability
of being cost-effective under most scenarios tested. However, the NICE guideline also concluded that foam
sclerotherapy would be the most cost-effective option in situations where EVLA is not considered a viable
option, based on an ICER for surgery versus foam > £20,000 per QALY gained. Although our modelling
was based on data that do not allow us to directly address this question (suitability for all three treatment
modalities was an inclusion criteria in the CLASS trial), it does indicate that, for the CLASS cohort, the
incremental cost per QALY gained for surgery versus foam is generally below £20,000.
Conclusion of model-based cost-effectiveness analysis
Overall, our modelling suggests that for patients in whom all three treatment modalities are a clinically
viable option, EVLA has the highest probability of being cost-effective at accepted thresholds of WTP per
QALY. This finding is consistent with the results of recent modelling undertaken to inform the NICE clinical
guideline on the management of varicose veins. However, we cannot rule out the possibility that surgery
may be the preferred option in patients in whom EVLA is not viable. We cannot directly address this
question, as our modelling was based on cost and utility inputs derived from patients eligible for all three
treatment options.
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Chapter 11 Final discussion
The CLASS trial has shown that at 6-months follow-up all three treatment modalities – foam, EVLA andsurgery – improved disease-specific and generic QoL and achieved similar improvements in the VCSS.
EVLA and surgery were broadly equivalent in terms of the improvements in disease-specific QoL, VCSS and
anatomical success (ablation of GSV or SSV trunks). However, EVLA showed greater early improvements in
four of the eight SF-36 domains than surgery, although these were not present at 6 months.
In this first RCT involving foam sclerotherapy to evaluate and report disease-specific QoL as a primary
outcome measure, the health gain achieved with foam sclerotherapy was significantly lower than that for
surgery at 6-months follow-up. At 6 weeks the health gain in the AVVQ was also significantly lower for
foam sclerotherapy than for surgery. At 6 months, the health gain in the SF-36 mental component was
also significantly lower for foam sclerotherapy than for EVLA. The EQ-5D health gain with foam
sclerotherapy at 6 weeks was also significantly lower than with EVLA, but there were no differences at
6 months.
As well as having lower QoL health gains, patients who had foam sclerotherapy had more residual varicose
veins than those undergoing EVLA or surgery at 6-months follow-up. Foam sclerotherapy was also
associated with a significantly greater rate of procedural complications than EVLA, and of complications at
6 weeks than surgery and EVLA. At 6 months, the overall complication rate remained higher for foam
sclerotherapy than for surgery. However, the recovery and return to normal activities was quicker for foam
and EVLA than for surgery. Furthermore, at 6 weeks patients’ recollection of the pain experienced at the
time of the procedure and in the recovery was less following foam sclerotherapy than either EVLA
or surgery.
The anatomical success rate was significantly lower for foam sclerotherapy than for surgery or EVLA. This is
likely to result in a greater risk of developing recurrent varicose veins and need for further treatment in
patients who underwent foam sclerotherapy. In contrast, the trial-based cost-effectiveness analysis showed
that at 6 months foam sclerotherapy had the lowest costs, followed by EVLA and then surgery. Based on
consideration of costs and QALYs at 6 months, foam sclerotherapy had the highest probability of being
considered cost-effective at the accepted Rc of £20,000 per QALY. However, foam sclerotherapy was not
associated with the greatest clinical benefit.
Some differences were evident between the cost estimates incorporated in our analysis and those used in
the recent NICE guideline.28 We estimated a somewhat larger cost difference between foam sclerotherapy
and EVLA, whereas a somewhat smaller cost difference was estimated between EVLA and surgery. The
main reason for this was that in some centres within the CLASS trial EVLA was performed in a theatre
setting, which required a larger number of staff to be present, whereas in others it was performed in a
clinic setting, which used the same staff profile as foam. A sensitivity analysis was conducted to test the
impact of EVLA incorporating a similar staff profile to foam sclerotherapy. Under this scenario, the ICER of
EVLA versus foam sclerotherapy fell below the accepted threshold of £20,000 per QALY gained. Further,
the cost saving from EVLA versus surgery significantly increased. Thus, when EVLA was performed in a
clinic setting with a similar staff profile to that used for foam, it produced the greatest NMB at 6 months
compared with both foam sclerotherapy and surgery.
However, these early results cannot be used to determine definitive recommendations for the treatment of
varicose veins because late recurrence rates and the need for further treatment also need to be considered.
This is a very important determinant of cost-effectiveness in the longer term. This underlines the
importance of the 5-year follow-up of patients in the CLASS study.
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Markov modelling based on the trial data and the limited data currently available on longer-term
recurrence rates suggests that, at 5 years, EVLA has the highest probability of being cost-effective (≈ 79%),
followed by foam sclerotherapy (≈ 17%) and surgery (≈ 5%), for patients considered clinically suitable for
all three treatment options. It should be noted, however, that the outcome of this model is quite sensitive
to the projected recurrence rates. Data from clinical recurrence rates at 5 years are not available from
controlled trials at present, with the exception of the recent study by Rasmussen51 comparing EVLA with
surgery. The recurrence rates used for the CLASS modelling were based on figures used in the recent NICE
economic analysis.28 Using these assumptions, our analysis suggests that EVLA is likely to be the treatment
of choice for suitable patients, based on considerations of both clinical effectiveness and cost-effectiveness.
Although the CLASS findings are not directly applicable to patients considered clinically unsuitable for
EVLA (suitability for all three treatment options was an inclusion criterion in the CLASS trial), our modelling
does suggest that the incremental cost per QALY gained with surgery versus foam sclerotherapy will fall
below £20,000 by 5 years in the CLASS cohort. In a two-way comparison between foam sclerotherapy and
surgery, we found surgery to have the higher probability of being cost-effective at 5 years, although a
great deal of uncertainty surrounds this finding owing to the significantly higher cost of surgery and
uncertainty relating to its generic QoL and longer-term benefits over foam.
If the above model-based findings are confirmed by long-term follow-up of the CLASS cohort, and
considered generalisable to patients not suitable for EVLA, then conventional surgery may be preferred
over foam sclerotherapy on grounds of cost-effectiveness in these patients. Furthermore, other clinical
benefits, such as the significantly greater improvement in disease-specific QoL, reductions in some
complications at 6 months and the higher anatomical success rate associated with surgery, may also be
considered when determining the choice of treatment for patients not suitable for EVLA. The recent NICE
clinical guideline,28 which recommends foam sclerotherapy as the preferred treatment in patients who are
not suitable for EVLA, therefore presents a dilemma for clinicians, patients and commissioners in terms
of balancing clinical effectiveness, patient choice and cost when choosing which treatments to offer if
the patient is not suitable for EVLA.
Strengths and limitations
Proportion of ineligible patients and overall recruitment rates
In this study, 43% of screened patients were found to be ineligible for inclusion in the trial. The main
reason for this was the presence of recurrent varicose veins (28%) and the lack of truncal GSV or SSV
reflux (22%). The proportion of ineligible patients is higher than in previous studies, where review of case
notes or other methods of screening in advance of the patient’s appointment may have been used. The
lack of advance screening in CLASS is evident from the number of patients who were excluded because
they either had recurrent veins or did not have symptomatic varicose veins.
Of the eligible patients, only 24% were recruited to CLASS. This is lower than most of the previously
published RCTs involving varicose veins,38,40,50 although the 2007 Rasmussen study36 only achieved an 11%
recruitment rate and the study by Darwood et al.15 failed to reach its recruitment target. A previous
HTA-funded study involving vascular surgeons recruiting patients with severe limb ischaemia also
experienced similar recruitment rates to the CLASS study (29%), and this was attributed to a lack of
clinical equipoise.98
Among the patients who were eligible but declined to take part, 78% either had a preference for one of
the treatment options or did not wish to undergo one of the treatment options within the study. More
patients declined to take part in the study because they wanted surgery (33%) than declined because they
did not want surgery (< 1%). For EVLA, a similar proportion of patients expressed a preference (30%) and
1% declined because they did not want this treatment. In contrast, the proportion of patients who
preferred foam sclerotherapy was much lower (preference for foam 13%). Clearly, many factors may have
affected a patient’s decision to take part in the study and preference for one treatment over another.
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Although surgeon preference was cited infrequently as a reason (1%), the treating vascular surgeon is
likely to have had a significant influence on the patient’s decision-making.
In order to explore this further, a study was performed at one of our sites. This found that the surgeons
presented balanced descriptions of the treatments but that they made the assumption that the patients
might have a preference, and patients, in turn, felt that they were expected to have a preference.
Revised target sample size
The original trial sample size of 1015 (surgery vs. foam, 90% power, 5% significance, EVLA, EVLA versus
foam or surgery 80% power, 5% significance) was revised to 779 based on data which showed that the
correlation between AVVQ at baseline and at 6 months was better than originally assumed. This analysis
was prompted by the lower than expected recruitment rate. The reduction in sample size did not lead
to any reduction in the predefined clinically important difference in QoL, but may have disadvantaged the
EVLA arm in which the power was lower. This revision was approved by both the TSC and DMC.
Number of statistical comparisons
There were a large number of comparisons involving primary and secondary outcomes, and therefore it
may be inferred that some differences may have occurred by chance. Thus, for the secondary outcome
measures, we consider differences to be significant only for p-values < 0.005.
Generalisability
Despite the fact that many eligible patients chose not to take part, those who did participate appear
broadly similar to those in other RCTs (see Chapter 7), with the exception of a lower than expected
proportion of females (56% of participants were female, but 75% of those invited to participate were
female). Although most (or all) of the previous RCTs involving varicose veins have had higher proportions
of female participants, our experience is consistent with a number of other studies which have shown that
females are less likely than males to participate and are more difficult to recruit to RCTs.99–104 It has been
suggested that this may reflect less favourable attitudes towards medical research among women. It is of
note that the mean baseline AVVQ score for women was slightly higher than for men (18.2 vs. 17.4),
although this difference was not statistically significant and was unlikely to have had a bearing on their
recruitment to the study.
The CEAP classification grade, VCSS (pre/post treatment) and QoL (pre/post treatment) were similar to
those in other RCTs.15,29–34,37,38,49–51 The QoL values were also similar to those published in NHS England
PROMs. Given this, and the fact that less than 20% of patients were excluded because the vein diameter
was too small, large or tortuous, the results of this study appear generalisable to the majority of patients
seeking treatment for primary varicose veins.
Truncal ablation rates
The reasons for the lower ablation rates observed in the CLASS study compared with previous reports
have been fully discussed in Chapter 7. Although the complete success rates for the GSV are at the lower
end of those published in other RCTs, many of these defined ‘technical success’ as the combination of
complete ablation and partial success with no reflux. The overall ‘technical success’ rate for CLASS is
comparable (91% for EVLA and 82% for surgery). The results for foam (67% complete and partial with no
reflux) remain lower than in some studies, but are comparable with those in the RCT by Latimer et al.32
and those achieved by surgeons in the study by Wright et al.14 It is important to note that, despite the
apparently lower ablation rates, the improvements in QoL and VCSS were comparable with those
published in previous RCTs15,29–34,37,38,49–51 and in the PROMs for NHS England. In addition, this is the
largest multicentre RCT to date involving EVLA, foam and surgery, and its results reflect those of
the generality of vascular surgeons and their trainees, rather than those of enthusiasts in single centres.
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
161
Unlike those in previous RCTs, the duplex scans by which truncal ablation was assessed were performed by
independent, accredited vascular technologists, with the exception of those performed at one centre. This
was done in order to minimise the bias which can occur when surgeons who have treated patients do the
follow-up scans. An attempt was made to quality assure the scans, but as none of the sites were able to
video-record a whole examination, this proved impossible. An audit of still images taken at set anatomical
locations was of no value owing to the lack of anatomical landmarks on the images, which meant that
the duplex scanning site could not be verified. There was also no means of standardising the angle of the
probe, or probe or calf compression. These difficulties reflect the general limitations of duplex scanning
and are not specific to our study. The technique for performing the scan was standardised prior to
commencing the trial following discussion between the vascular technologists at the 10 centres, and
results were recorded on a set proforma. These dedicated vascular technologists are likely to be more
skilled and reliable than the varied clinicians who scanned in other studies.
Concomitant phlebectomies
The issue of whether or not varicosities should be treated at the same time as the main truncal veins
remains controversial. This is highlighted as an area of future research in the recent NICE clinical
guideline.28 One previous single-centre RCT has shown significant improvements in disease-specific QoL
and VCSS at 6 weeks and 3 months following concomitant, as opposed to delayed, phlebecotomies.73
In CLASS, patients in the EVLA group only received treatment to the main truncal vein, without
concomitant phlebectomies (with the exception of patients at one site), unlike those in the surgery group.
Nevertheless, we observed significant improvements in the AVVQ and VCSS in patients undergoing either
surgery or EVLA compared with foam sclerotherapy at 6 weeks. Importantly, there was no difference in
these outcomes in patients undergoing EVLA or surgery at the 6-weeks follow-up. These findings suggest
that the strategy of performing concurrent phlebectomies in patients undergoing EVLA is unnecessary,
with respect to improving QoL or VCSS in the short term. Furthermore, approximately one-third of patients
who underwent EVLA in CLASS elected to have treatment for residual varicosities at or after 6-weeks
follow-up, so it could be inferred that the use of concomitant phlebectomies would have been
unnecessary treatment for the remaining two trials of participants. It is unclear if this will affect future
recurrence rates.
The CLASS trial also raises concerns regarding whether or not foam sclerotherapy is the most appropriate
means to treat any residual varicose veins. EVLA showed benefits over foam sclerotherapy in terms of
disease-specific and generic QoL as well as reduced complications at 6 weeks. These benefits did not
persist to 6 months, by which stage one-third of the patients in the EVLA group had undergone
foam sclerotherapy.
Clinical, etiological, anatomical, pathological grade
The majority of patients in the CLASS study had CEAP grade 2 varicose veins, which is consistent with
other studies and with the known distribution of venous disease in the population. NICE referral guidelines
for varicose veins published in 2001 recommended referral of symptomatic primary varicose veins, which
are associated with impaired QoL.105 It is apparent that rationing is being imposed in most areas, which
means that only patients with more severe CEAP grades are offered referral for treatment. Thus, the results
from CLASS may not be as generalisable to current NHS practice as they should be if referral guidelines
were adhered to. The study was designed before this rationing became widespread. Within CLASS, there
was evidence of a clear inequity in the provision of treatment for varicose veins in centres across the
country, which has arisen primarily as a result of cost pressures and, indeed, this influenced differences in
recruitment rates between centres. It is not clear what the long-term health and QoL effects of not treating
many people with varicose veins will be. If it does lead to an increased incidence of venous ulceration, this
will have substantial cost consequences for the NHS, in addition to increased morbidity and decreased QoL
for affected patients.
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Sensitivity of the European Quality of Life-5 Dimensions to detect
differences between treatment modalities
As would be expected in patients undergoing treatment for varicose veins, the AVVQ, designed specifically
to assess QoL in these patients, was more sensitive to change than either of the generic QoL instruments
(SF-36 and EQ-5D). This sensitivity was demonstrated in terms of the magnitude of change from baseline
at both 6 weeks and 6 months post treatment and was crucial in confirming improvements both across
and between the treatment groups. The AVVQ showed differences between groups at 6 weeks which
favoured surgery and EVLA over foam sclerotherapy, and differences at 6 months which favoured surgery
over foam sclerotherapy. By contrast, the EQ-5D showed only a benefit for EVLA over foam sclerotherapy
at 6 weeks but no differences at 6 months. However, the EQ-5D was principally used in the evaluation
of cost-effectiveness as it is the instrument routinely used for this type of QoL analysis.28
Lack of inclusion of radiofrequency ablation as a treatment option
We chose to include EVLA and foam sclerotherapy in the CLASS trial because these were the two most
widely used of the newer, local anaesthetic treatment options within the NHS at that time. We considered
RFA as an alternative to EVLA, but it was more costly and less suited for local anaesthesia owing to the
longer contact time required between the probe and the vein endothelium. In addition, EVLA seemed to
be in greater demand from patients and to have found favour with more vascular specialists at the time
when the trial was being designed. However, subsequent developments have made RFA faster, such that it
is now routinely performed under a local anaesthetic. Nevertheless, it remains more expensive than EVLA.
Endovenous laser ablation and RFA are now considered to be comparable techniques in terms of outcome.
Furthermore, in the recent NICE Clinical Guideline 16828 RFA was considered equivalent to EVLA; the two
treatments were grouped together throughout the recommendations as ‘endothermal ablation’.
Behavioural recovery
The 14-item BRAVVO questionnaire was made up of items and behaviours which patients identified
as being important to their recovery, many of which have not been considered in previous studies.
Development of the BRAVVO instrument represents an important first step in identifying the behaviours
that patients perceive to be important and will allow for a more detailed explanation to patients of the
anticipated recovery following treatment, as well as a more sensitive comparison of the effect of different
treatments on recovery.
Comparison of LAser, Surgery and foam Sclerotherapy 5-year
follow-up
Treatment of recurrent varicose veins accounts for 20% of venous procedures performed in the NHS, and
was responsible for ineligibility in 28% of patients considered for this trial; thus, the durability of primary
treatment is important both for patients and for economic reasons. Few RCTs involving foam sclerotherapy
or EVLA have assessed clinical recurrence rates, and they provide only limited short- to medium-term
(i.e. 2-year) clinical results. The 5-year recurrence rate for EVLA has recently been reported in one small
RCT51 but has not been reported for any RCT of foam sclerotherapy.14,29–33,51 Patients with recurrent
varicose veins have significantly worse QoL than patients with primary varicose veins106 and show less
improvement in QoL after treatment,7,107 so using a primary treatment which minimises the risk of
recurrence is an important consideration.
Implications for practice
The CLASS trial has shown that EVLA (performed under a local anaesthetic, in a predominantly clinic-based
setting) has the highest probability of being cost-effective at accepted thresholds of WTP per QALY. This
finding is consistent with the results of recent modelling undertaken to inform the NICE clinical guideline28
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on the management of varicose veins. The CLASS trial cannot directly inform the choice between surgery
and foam in patients in whom EVLA is not a treatment option, as eligibility for all three treatment options
was an inclusion criterion of the CLASS trial. However, less than 20% of patients were ineligible for the
CLASS trial because the vein was too tortuous (9%), or either too small or too large in diameter (9%).
Thus, the majority of patients with primary veins referred for treatment in the NHS appear to be suitable
for thermal ablation. Furthermore, in CLASS only one eligible potential participant declined to be
randomised because he/she did not wish to undergo EVLA.
For patients in whom thermal ablation may be unsuitable or declined, the results from the CLASS trial
suggest that surgery rather than foam sclerotherapy should be considered. In a two-way comparison
between foam and surgery, surgery was found to have the greatest probability of being cost-effective at
5 years, although a great deal of uncertainty surrounds this finding owing to the significantly higher cost
of surgery and lack of long-term recurrence rate data for both interventions. However, surgery was
associated with greater gains in the AVVQ at 6 months, a higher truncal ablation rate and reduced residual
varicose veins compared with foam sclerotherapy. There were no differences in terms of the VCSS or
complication rates, but return to normal activities was quicker following foam sclerotherapy than
following surgery.
The CLASS trial also raises concerns regarding whether or not foam sclerotherapy is the most appropriate
means to treat non-truncal varicosities in patients undergoing EVLA.
Recommendations for research
The CLASS trial has highlighted the need for long-term outcome data from RCTs on QoL, recurrence rates
and costs for foam sclerotherapy and other endovenous techniques, compared against each other and
against surgery. With one recent exception,51 follow-up from RCTs involving foam sclerotherapy or EVLA is
currently limited to 2 years. In the current absence of data on long-term clinical recurrence, the risk of
clinical recurrence in CLASS was modelled using the network meta-analysis performed by NICE28 which
included recurrence rates up to 2 years. Although this provides the best current source of evidence on
recurrence, uncertainty remains regarding the applicability of these recurrence rates to patients in the
CLASS trial and the risks of recurrence beyond 24 months. This underlines the importance of collecting
further data on clinical recurrence and its impact on generic QoL via the extended follow-up of
CLASS participants.
We have previously discussed the controversial issue of whether or not varicosities should be treated at the
same time as the main truncal veins. The CLASS trial provides further impetus for future research in this
area as highlighted in the recent NICE clinical guideline.28
Conclusion
The CLASS trial is the largest multicentre trial to have compared surgery with the two most commonly
performed newer treatment options, namely foam sclerotherapy and thermal ablation by EVLA. It has
comprehensively assessed both the clinical effectiveness and cost-effectiveness of these treatment options
within the NHS. The 6-month outcomes and 5-year economic model clearly suggest that EVLA should be
considered as the first-line treatment in patients with varicose veins. In patients not suitable for EVLA,
surgery rather than foam sclerotherapy should be considered on grounds of clinical effectiveness and
cost-effectiveness.
We await the 5-year results of CLASS, which are essential to determine recurrence rates and the true
cost-effectiveness of EVLA, foam sclerotherapy and surgery.
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Appendix 1 Trial paperwork
 
Summary of the CLASS Trial 
Comparison of LAser, Surgery and foam Sclerotherapy 
 
We are conducting a study to find out which treatment is best for patients who have varicose 
veins.  We understand that you have been referred to the hospital about your varicose veins.  
You might be eligible to take part in our study, and we would be grateful if you would 
consider taking part. 
 
In our study, we are comparing three different treatments.  All of the treatments get rid of 
varicose veins in the short term but have their own advantages and disadvantages.   
 
In our study, we will compare how well each treatment works in getting rid of varicose veins 
and in improving the quality of life of patients.  We will also look at the recovery and side 
effects of the treatments and their “value for money”. 
 
Standard surgical treatment - removal of the veins under general anaesthetic 
 
Laser treatment - laser treatment to the veins which causes them to close off and shrivel up 
 
Foam sclerotherapy - injections into the veins which causes them to close off and shrivel 
up 
 
We are inviting patients to take part in this study.  Patients who agree will: 
· be asked to sign a consent form; 
· be allocated to receive one of these treatments by chance; 
· have the treatment they have been allocated to; 
· be asked to complete questionnaires when they join the study, six weeks after their 
treatment, six months after their treatment and then every year for five years 
· be invited to a follow-up clinic visit six weeks, six months and five years after their 
treatment (travel expenses will be available to cover the cost of coming to these 
appointments). 
 
By taking part in the study, patients will give up the right to choose which treatment they 
receive.   
 
If you are interested in finding out more about the study, the surgeon will tell you about it 
when you come to your hospital appointment.  At this appointment we will give you an 
information leaflet about the study and one about varicose veins and the different 
treatments.  In the meantime, you can call us on the number above if you would like any 
more information sent to you.   
 
If you do not want to take part in the study, please tell the surgeon when you come to your 
hospital appointment. 
 
Thank you 
Patients and doctors rely increasingly on the results of studies like this to make sure they are 
making the right decisions about treatment. 
 
Thank you for reading this leaflet.  We hope it was useful in helping you to decide whether or 
not you would like to help us by participating in this study.  
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Summary of the CLASS Trial 
Comparison of LAser, Surgery and foam Sclerotherapy 
 
We are conducting a study to find out which treatment is best for patients who have varicose veins.  
We would be grateful if you would consider taking part in this study. 
 
In our study, we are comparing three different treatments.  All of the treatments get rid of varicose 
veins in the short term but have their own advantages and disadvantages.   
 
In our study, we will compare how well each treatment works in getting rid of varicose veins and in 
improving the quality of life of patients.  We will also look at the recovery and side effects of the 
treatments and their “value for money”. 
 
Standard surgical treatment - removal of the veins under general anaesthetic 
 
Laser treatment - laser treatment to the veins which causes them to close off and shrivel up 
 
Foam sclerotherapy - injections into the veins which causes them to close off and shrivel up 
 
We are inviting patients to take part in this study.  Patients who agree will be: 
· Asked to sign a consent form; 
· Allocated to receive one of these treatments by chance; 
· Have the treatment they have been allocated to; 
· Asked to complete questionnaires when they join the study, six weeks after their treatment, 
six months after their treatment and then every year for five years 
· Invited to a follow-up clinic visit six weeks, six months and five years after their treatment 
(travel expenses will be available to cover the cost of coming to these appointments). 
 
By taking part in the study, patients will give up the right to choose which treatment they receive.  
They will be told which treatment they have been allocated to receive about two weeks before their 
treatment.  
 
You can read more about varicose veins, the different treatments, and about this study in the patient 
information leaflets.  
 
Thank you 
Patients and doctors rely increasingly on the results of studies like this to make sure they are making 
the right decisions about treatment. 
 
Thank you for reading this leaflet.  We hope it was useful in helping you to decide whether or not you 
would like to help us by participating in this study.  
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
 
 
 
 
 
 
 
 
 
 
 
You are invited to take part in this research study.  Before you decide, it is important for you to 
understand why the research is being done and what it will involve for you.  Please take the time to 
read this information leaflet carefully and discuss it with others, if you wish.  Please ask us if there is 
anything that is not clear, or if you would like more information.  Take as much time as you need to 
decide whether or not you want to take part. 
 
  
 
PATIENT STUDY INFORMATION LEAFLET 
 
BOOKLET 1 
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PART 1 
 
What is the purpose of the study?  The purpose of this study is to find out which treatment 
is best for patients who have varicose veins. We will do this by treating patients who agree to 
take part with either the standard treatment that is surgery, or alternatively newer treatments 
which are foam sclerotherapy alone or laser treatment and foam sclerotherapy. These 
treatments are described below and in more detail in the leaflet “Varicose veins and 
treatment” which you have been given. We will compare the treatments to find out which is 
better for getting rid of varicose veins and improving your general health and well-being 
(quality of life). Patients will be allocated by chance to one of the treatments using a process 
which is similar to tossing a coin.  
 
More about varicose veins: Varicose veins are veins under the skin of the legs that have 
become widened, bulging and twisted. They are very common and do not cause medical 
problems in most people. They may cause aching, discomfort, and heaviness of the legs, 
which are usually worse at the end of the day.  Sometimes the ankle can swell, too. Varicose 
veins in some cases may occasionally become red and painful or bleed. In a few patients 
they may lead to skin rashes, a brown discolouration of the skin around the ankle or a break 
in the skin.  
 
More about standard surgical treatment: This involves removal of the varicose veins 
under a general anaesthetic. A small cut is then made in the crease of the groin or behind 
the knee.  The main vein is tied off just where it joins the deep vein.  This vein is removed by 
passing a fine wire down it and removed through a small incision further down the leg. 
Varicose veins marked before the operation are removed through tiny cuts.   
  
Possible advantages and disadvantages of standard surgery 
· Standard surgery removes all the varicose veins at a single procedure.  It should not be 
necessary to have anything more done to get rid of any remaining varicose veins. 
· Varicose vein surgery is normally done under a general anaesthetic.   
· Bruising is common.  People with smaller varicose veins may get very little bruising but 
people with big varicose veins may be very bruised.  All the bruising goes away. 
· There may be some discomfort from the groin wound and occasionally the groin wound 
can become infected. 
· You can become fully active as quickly as you want after standard surgery. 
· Most surgeons advise wearing a support stocking for 10 days and avoiding getting the legs 
wet (in a bath or shower) during this time.    
· Standard surgery gives a good long term result to many people but varicose veins may 
gradually reappear over the years. 
· It is a tried and tested treatment which has been used for many years. 
· In summary, surgical treatment involves a general anaesthetic, an incision in the groin or 
knee and often some bruising.  However, all the varicose veins can be dealt with 
thoroughly by a single treatment, in one or both legs.   
 
More about foam sclerotherapy: This involves injection of a fluid “sclerosant” which is 
mixed with a small quantity of air in the form of tiny bubbles. This causes the walls of the 
vein to glue together so that they close off and shrivel up. Foam sclerotherapy involves a 
number of injections into the veins of the leg and is done under local anaesthetic.  These 
injections are carried out with the help of ultrasound pictures to be sure that the tip of the 
needle is correctly positioned in the vein. More than one treatment session may be required, 
particularly for varicose veins on both legs and veins which are very extensive.  
 
Possible advantages and disadvantages of foam sclerotherapy 
· Foam sclerotherapy is done under local anaesthetic, but sometimes no anaesthetic is 
required at all. 
· No surgical incisions are required. 
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· The veins which have been treated may remain lumpy, hard and sometimes tender for 
several weeks or even months. 
· More than one treatment session may be required, particularly for varicose veins on both 
legs and for veins which are very extensive. 
· You can become fully active as quickly as you want after foam sclerotherapy treatment. 
· Bandages and a support stocking are put on the leg after foam sclerotherapy treatment, 
and need to be worn for 10 days.  These must be kept dry. 
· Varicose veins may gradually reappear in the years after foam sclerotherapy treatment: 
this is rather more likely than after surgery.  They can be treated with further foam 
sclerotherapy if required. 
· In summary, foam sclerotherapy is a simple treatment to have but firm compression from a 
support stocking is important afterwards.  The treated veins may be hard and tender for 
some time and there may be some brown staining.  Repeat treatment sessions may be 
needed, particularly if there are varicose veins in both legs.  New veins may gradually 
appear. 
 
More about laser treatment:  Laser treatment uses heat to damage the walls of the vein 
causing them to glue together so that they close off and shrivel up. Using ultrasound pictures 
a special laser fibre is inserted into the vein through a tiny incision near the knee and is 
advanced up to the top of the vein in the groin. Local anaesthetic and cold fluid are injected 
around the vein. Pulses of laser light are then used to seal off the vein.  Sometimes we may 
need to use a combination of laser treatment in the thigh and foam sclerotherapy around the 
knee or upper calf. If required, this will be done at the same treatment session. The veins 
further down the leg often shrink after laser treatment, but if they persist they can be treated 
by foam sclerotherapy. One hospital in this study will use phlebectomies (removal of 
varicose veins through tiny incisions) at the same time as laser treatment. 
 
Possible advantages and disadvantages of laser treatment  
· Laser treatment can be done under local anaesthetic, rather than general anaesthetic. 
· No incision is needed in the groin. 
· It avoids the bruising which can sometimes occur after standard surgery, but you may 
experience some lumpiness and tenderness in the thigh which can take several weeks to 
settle. 
· Foam sclerotherapy or phlebectomies may be required to get rid of all the varicose veins. 
This may mean returning for treatment on another occasion. 
· You can become fully active as quickly as you want after laser treatment. 
· Most surgeons advise wearing a support stocking for 10 days and avoiding getting the legs 
wet (in a bath or shower).  
· Laser treatment seems to give results as good as standard surgery up to five years but 
varicose veins may gradually reappear over the years. 
· In summary, laser treatment can be done under local anaesthetic, requiring several 
injections into the thigh.  Additional treatment may be needed to get rid of all the varicose 
veins. 
 
Have any studies like this been done before?  Yes, there are a number of studies that 
have shown that either foam sclerotherapy or laser treatment can get rid of varicose veins. 
However, these studies have not involved all three treatments and did not assess how well 
each treatment worked in the long-term. Currently we do not know what is the best treatment 
in terms of getting rid of veins, quality of life and value for money. 
 
Why have I been chosen?  You have been chosen because we believe that you are 
suitable for this study. You have varicose veins which may be treated by surgery, foam 
sclerotherapy or laser treatment.  
 
Do I have to take part?  No. It is entirely up to you to decide whether or not to take part.  If 
you do decide to take part, please keep this information leaflet and the one on “Varicose 
veins and treatment”. You will be asked to sign a consent form.  You are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
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What will happen to me if I take part?  If you agree to take part in the study, the study 
nurse will contact you by telephone in order to arrange a clinic appointment. At this 
appointment, you will undergo an ultrasound scan of your veins if you have not already had 
one. This scan involves placing jelly and a probe over the vein. It is painless and lasts up to 
20 minutes. You will then be asked to sign a consent form and fill in a questionnaire. The 
nurse will be available to help with any queries you may have.  If there is not enough time at 
the clinic or if you would prefer, you can complete the questionnaire at home.  
 
You will undergo treatment of your varicose veins by either standard surgery, foam 
sclerotherapy or laser treatment usually within 4 months. You will be informed of what 
treatment you are due to receive and the date of this treatment at least two weeks before 
you are due to attend. At this stage you will be asked to fill in a short questionnaire which will 
be sent to your home. This questionnaire will let us know if your views on your varicose 
veins have changed since you agreed to take part in the study.   
 
You will have 2 further clinical visits to the hospital clinic at 6 weeks and 6 months after 
treatment. You can receive travel expenses. At the clinic you will undergo an examination of 
your legs, an ultrasound scan and be asked to fill in a questionnaire. The nurse will be 
available to help with any queries you may have. Each clinic visit should take approximately 
1 hour.  If you require further treatment with foam sclerotherapy to any remaining varicose 
veins this will be carried out whenever possible at the same clinic appointment by a doctor.  
 
We are seeking further funding to continue the study to 5 years following your treatment. 
Assuming we are successful, we will ask you to fill out a questionnaire each year. These will 
be sent to you by post. At 5 years following your treatment for varicose veins we will ask you 
to attend a clinic appointment in order to undergo an examination of your leg and an 
ultrasound scan. 
 
If you agree to take part we will also ask for your permission to consult your medical records.  
This ensures that the information about you is correctly recorded in the study documentation. 
 
What will I have to do?  You will be asked to attend clinic appointments as described 
above. Your varicose veins will be treated using either standard surgical treatment, foam 
sclerotherapy or laser treatment. 
 
What is the drug, device or procedure that is being tested?  Foam sclerotherapy and 
laser treatment are being compared with standard surgery. Both of these new treatments are 
being increasingly used in the NHS and are approved by the National Institute for Health and 
Clinical Excellence (NICE).  
 
What are the possible disadvantages and risks of taking part?  By taking part in the 
study you will give up your right to choose which treatment you receive.  You will be 
allocated to receive one of the treatments by chance. You will also be given less notice of 
which treatment you will undergo.  We will tell you which treatment you are due to receive 
about two weeks before your treatment.  Your treatment however will not be delayed by your 
decision to take part in the study. There is a common waiting list for all patients with varicose 
veins whether they are taking part in the study or not.    
 
There are potential disadvantages/risks of all three treatments. All three treatments for 
varicose veins are associated with a low risk of developing a clot in the deep veins of the leg 
known as a deep vein thrombosis.  Rarely, a clot like this may break up and travel to the 
lungs.  Varicose veins may come back in the future. The main risks of each treatment are 
summarised below. For more details please read the leaflet on “Varicose veins and 
treatment”. This gives information on rare but important complications that may occur. 
 
Surgery:  You may experience discomfort following surgery. It is common for the area under 
the wound in the groin or behind the knee to feel tender for a few days and thickened for a 
few weeks. Bruising is common, and will settle. Infection is an occasional problem, 
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particularly in groin wounds. The scars on your legs are easily noticeable to start with, but 
will continue to fade for many months after the operation.  Very occasionally, some people 
develop a little brown staining where the veins were removed, or the appearance of tiny red 
or blue veins. Nerves under the skin can be damaged when removing varicose veins close 
to them and small areas of numbness are quite common. The risk of a deep vein thrombosis 
following surgery is about 1% (1 in 100). Very rarely the main artery, vein or nerve in your 
leg may be damaged.  
 
Many people develop a few new varicose veins during the years after a varicose vein 
operation. Five years after operation about one person in eight has troublesome varicose 
veins again. 
 
Foam sclerotherapy:  You may experience discomfort following the injection of foam. The 
veins which have been treated may remain lumpy, hard and sometimes tender for several 
weeks. Skin staining over the veins may occur but will fade with time.  Rarely, the skin at the 
injection site may break down and require treatment.  Very occasionally, some people 
develop tiny red or blue veins. The risk of a deep vein thrombosis following foam injections is 
about 1% (1 in 100). Some patients experience some temporary confusion after foam 
treatment – but this generally lasts only a few minutes.  There is a small risk that you may 
experience a brief (about 30 minutes) period of disturbed vision (blurred vision or loss of 
vision) – the risk is 1% (1 in 100), no permanent damage to eye sight has been reported.  
Occasionally, people report headache, or migraine-like symptoms after foam sclerotherapy.  
There is a very small risk of a stroke following foam treatment.  All the surgeons involved in 
this study take care to limit the amount of foam that is used at any one time and this 
minimises the risk.  That is the reason that we often treat only one leg at a time, even if both 
legs are to be treated.  Worldwide, three patients have been reported as having foam 
injected into an artery rather than a vein.  One patient has had a fit following foam, but it is 
unclear if this was related to the treatment.  A severe allergic reaction known as anaphylaxis 
may rarely occur.   
 
More than one treatment session may be required, particularly for varicose veins on both 
legs and veins which are very extensive. Bandages and a support stocking are put on the 
leg after foam sclerotherapy treatment and need to be worn for 10 days.  These must be 
kept dry. Many people develop a few new varicose veins during the years after a foam 
sclerotherapy. There have not been enough scientific reports on the long term results of 
foam sclerotherapy to give precise figures.  
 
Laser treatment:  You may experience discomfort following laser treatment. You may 
experience some lumpiness and tenderness in the thigh/back of leg which can take several 
weeks to settle. You may also get patches of numbness over the vein which will disappear 
with time. The risk of a deep vein thrombosis following laser treatment is about 1% (1 in 
100).  Very occasionally, laser treatment can damage the main vein in the leg.  Additional 
treatment in the form of foam sclerotherapy may be required to get rid of all the varicose 
veins. This may mean returning for treatment on another occasion. Most surgeons advise 
wearing a support stocking for about 10 days and avoiding getting the legs wet (in a bath or 
shower) for the 10 days. Many people develop a few new varicose veins during the years 
after a laser treatment. There have not been enough scientific reports on the long term 
results of laser treatment to give precise figures.  
 
What are the possible benefits of taking part?  We hope that the results from the study 
may benefit people with varicose veins in the future and will help us recommend the best 
type of treatment. If you are allocated foam sclerotherapy or laser treatment then you will 
avoid a general anaesthetic, a groin incision and bruising. But unlike surgery you may need 
to attend for more than one treatment session. The long term results of surgery are well 
known but there is much less information available for foam sclerotherapy and laser 
treatment. After all three treatment options you can become fully active as quickly as you 
want.  
  
What happens when the research study stops?  You will be followed up in the usual way.  
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What if there is a problem?  Any complaint about the way you have been dealt with during 
the study or any possible harm you might suffer will be addressed (see part 2 of this leaflet).  
 
Will my taking part be confidential?  Yes. All the information about your participation in 
this study will be kept confidential. The details are included in part 2 of this leaflet. 
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PART 2 
 
What if new treatment becomes available?   If a new treatment or information becomes 
available during the study, you will be made aware of this and you may decide whether or 
not to continue in the study. You may decide this at any time and your decision will not affect 
the long-term care you receive in the hospital. If you decide to continue in the study you will 
be asked to sign an updated consent form. Also, on receiving new information your doctor 
might consider it to be in your best interest to withdraw from the study. He/she will explain 
the reasons and arrange for your care to continue. If the study is stopped for any reason you 
will be told why and your continuing care will be arranged.  
 
What will happen if I don’t want to carry on with this study?  You can withdraw from the 
study at any time, but, you should keep attending the hospital to have your varicose veins 
treated. 
 
What if there is a problem?  If you have a concern about any aspect of the study, you 
should ask to speak with the researchers who will do their best to answer your questions 
(contact details on page 12 of this leaflet). If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints procedure. Details can be obtained 
from the hospital. 
 
If taking part in this research project harms you, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action but you may have to pay for it. Regardless of this, if you wish to complain 
about any aspects of this study, the normal National Health Service mechanisms may be 
available to you. 
 
Will my taking part in the study be kept confidential?  All information that is collected 
about you during the course of the research will be kept strictly confidential. Personal data 
from all study participants will be collected and stored at the CLASS Trial Office in Aberdeen.  
By consenting to take part in this study, you are agreeing that your medical records and data 
collected during the study may be looked at by individuals directly involved in the trial, from 
regulatory authorities, from the University of Aberdeen or from the NHS Boards or Trusts, 
where it is relevant to your taking part in this research. The purpose of this review of your 
medical records is to ensure that the information about you is correctly recorded in the study 
documentation. You should be aware that all records of your participation in the study will be 
handled, stored and destroyed in compliance with the Data Protection Act of 1998. 
 
Will any genetic tests be done?  No.   
 
What will happen to the results of the study?  When the study is finished all the results 
will be analysed and the results may be published in a medical journal (while maintaining 
confidentiality of your identity) and presented at scientific meetings. We will send out a study 
newsletter every 6 months to keep you updated on the progress of the study.  
 
Who is organising and funding this study?  This study is being funded by the NHS 
National Institute for Health Research Health Technology Assessment programme. The 
study has been designed by UK vascular surgeons and researchers. Patients will be 
recruited at different hospitals in England and Scotland. It is being coordinated by the Centre 
for Healthcare Randomised Trials (CHaRT) located in the Health Services Research Unit at 
the University of Aberdeen, Scotland. 
 
Will my doctor be paid for including me?  The doctor conducting the research will not be 
paid for including you in the study or looking after you during the course of the study. 
 
Will my own GP know that I am taking part in this study?  With your consent, we will 
inform your GP that you are taking part in the study. We will also ask for your permission to 
record the name and address of a family member or friend who we could contact if we have 
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difficulty getting in touch with you during the planned five year follow up period (for example 
if you moved house).  We call this your “best contact”.  Please tell them that you have 
nominated them as your “best contact”. 
 
Who has reviewed the study?  This Study has been approved by the Main Research 
Ethics Committee and Local Research Ethics Committee. The study also is registered and 
approved by the Medicines and Healthcare products Regulatory Agency (MHRA). 
 
 
Who can I contact for more information?   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Local recruitment contact details] 
Thank you 
Patients and doctors rely increasingly on the results of Clinical Trials like the CLASS trial to 
make sure that they are making the right decisions about treatment. Thank you for taking the 
trouble to read this information leaflet, we hope that it will have been helpful in enabling you 
to decide whether or not you would like to help us by participating in this study. 
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We are performing a research study which compares three different treatments for varicose 
veins: foam sclerotherapy, laser treatment or standard surgery.  You will have been provided 
with the patient study information leaflet on this study (booklet 1).  We know that each of the 
treatments do get rid of varicose veins in the short-term, but they have different advantages 
and disadvantages.  The trial compares how well each treatment works in getting rid of 
varicose veins and in improving quality of life.  It also compares the recovery and the side 
effects of the different treatments.  In addition, the trial will compare the “value for money” of 
the treatments (that is, how much it costs to give a particular amount of improvement to the 
quality of people’s lives). 
 
Information in this leaflet is divided into these sections: 
 
1. Information about varicose veins and the problems they can cause.    
 
2. A detailed description of: 
· What happens at the time of each treatment  
· The possible problems and side effects which can occur  
· Advice about the recovery and return to activity after treatment  
 
3.  A summary of the possible advantages and disadvantages for each treatment.  
 
For more information, please contact: 
 
 
 
 
 
[Local recruitment contact details] 
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Section 1.  Information about varicose veins and the problems they can cause. 
 
What are varicose veins? 
Varicose veins are veins under the skin of the legs which have become widened, bulging 
and twisted. They are very common and do not cause medical problems in most people. 
 
Blood flows down the legs through the arteries, and back up the legs through the veins. 
There are two main systems of veins in the legs - the deep veins which carry most of the 
blood back up the legs to the heart, and the veins under the skin, which are less important 
and which can form varicose veins.  All these veins contain valves which should only allow 
the blood to flow upwards.  If the veins become widened and varicose these valves no 
longer work properly.  Blood can then flow backwards down the veins and produce a head of 
pressure when standing, walking about, or sitting.  Lying down or "putting your feet up" 
relieves this head of pressure and usually makes the legs feel better.  Both symptoms and 
treatment depend on how badly the valves in the veins are working, although the 
inconvenience people get from their varicose veins is very variable. 
 
What problems can varicose veins cause? 
Very many people have no symptoms at all from their varicose veins, except for the fact that 
they are noticeable, and their appearance can be embarrassing. Simply having varicose 
veins is not a good reason for having treatment.  Other than cosmetic embarrassment the 
common symptoms of varicose veins are aching, discomfort, and heaviness of the legs, 
which are usually worse at the end of the day.  Sometimes the ankle can swell, too.  These 
symptoms are not medically serious, but can be treated if they are sufficiently troublesome.  
Although varicose veins can get worse over the years, this often happens very slowly and 
worry that "they might get worse" is not a good reason for treatment if the veins are not 
causing symptoms. 
 
In a few people the high pressure in the veins causes damage to the skin near the ankle, 
which can become brown in colour, sometimes with scarred white areas.  Eczema (a red 
skin rash) can develop. If these changes are allowed to progress, or if the skin is injured, an 
ulcer may result.  Skin changes are therefore a good reason for going to see your GP and 
for referral to a specialist.   
 
Other problems which varicose veins can occasionally produce are phlebitis and bleeding.  
Phlebitis (sometimes called thrombophlebitis) means inflammation of the veins, and is often 
accompanied by some thrombosis (clotting of blood) inside the affected veins, which 
become hard and tender.  This is not the same as deep vein thrombosis and is not usually 
dangerous.  It does not mean that the varicose veins necessarily have to be treated. The risk 
of bleeding as a result of knocking varicose veins worries many people, but this is very rare.  
It will always stop with firm pressure and the veins can then be treated to remove the risk of 
further bleeding. 
 
How can varicose veins be treated? 
The symptoms of varicose veins can often be improved by wearing support stockings or 
tights.  Compression stockings up to the knee (like “flight socks”) are often prescribed for 
people with discomfort, swelling or skin trouble.  Many people do not get on well with 
compression stockings because they find them difficult to put on, or they find them hot and 
uncomfortable. 
 
People who have troublesome symptoms but for whom compression hosiery is not an 
acceptable long-term solution can have treatment to get rid of their varicose veins.   
 
This trial is comparing three treatments which remove the varicose veins or seal them off so 
that they shrivel up.  These three treatments are described in this leaflet. 
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Section 2. A detailed description of each treatment, possible problems and side-
effects, and advice about recovery and return to activity. 
 
 
Foam Sclerotherapy - the procedure  
 
How long will I be in hospital for foam treatment?  Foam sclerotherapy is done as an 
outpatient.  The arrangements differ from hospital to hospital: sometimes the procedure is 
done in an outpatient clinic and sometimes in an operating theatre.  
 
What happens before the treatment?  When you arrive at the clinic a nurse will meet you 
and will measure your legs for stockings. The surgeon doing the foam treatment will talk with  
you about what is going to happen. You need to remove your trousers and socks or 
stockings for the treatment.  It is best not to wear tight trousers as you may have difficulty 
putting them on over the bandage and stocking afterwards. 
 
What happens during foam sclerotherapy treatment?  Foam sclerotherapy involves one 
or more injections into veins of the leg, which are given while you are lying on a couch.  
These injections are often carried out with the help of ultrasound pictures to be sure that the 
tip of the needle is correctly positioned in the vein.  If the vein is easy to see and feel then 
ultrasound may not be required.  Depending on the vein being injected and the type of 
needle used, an injection of local anaesthetic may be given first.  Sometimes gaining safe 
and secure access to a vein may need more than one attempt: it is very important to be sure  
that foam is not injected outside the vein. 
 
After the needles have been secured in selected veins, the leg is usually elevated before 
foam is injected.  Pressure may be applied to the groin or elsewhere to prevent foam 
entering deeper veins.  Nevertheless, after each injection you will be asked to move the foot 
up and down at the ankle in order to pump blood through the deeper veins, just in case any 
foam has entered them – movement of the calf muscles flushes away any small amounts of 
foam.   
 
Following injection, pads and bandages are applied to the leg, and then a firm stocking.  
These need to be worn for 10 days.  During that time you cannot get the bandaged part of 
the leg wet in a bath or shower.   
 
Foam sclerotherapy treatment takes about half an hour in total. Keep one hour free in case 
of delays. 
 
After treatment – leaving hospital.  You can get up and walk normally immediately after 
foam sclerotherapy.  It is a good idea to go for a walk for about five minutes after getting 
dressed, to encourage blood flow through the veins.  You can leave the hospital shortly after 
the treatment.  We will arrange a follow-up appointment at about 6 weeks after the 
procedure.      
 
 
Foam Sclerotherapy - Recovery    
 
How much does it hurt afterwards?  Other than the inconvenience of the bandages and 
stocking, foam sclerotherapy does not usually cause any immediate discomfort after 
treatment.  The varicose veins become hard, lumpy and tender: this can last for several 
days, and sometimes persists for weeks, but gradually settles.  If the veins are particularly 
uncomfortable or inflamed, you can take an anti-inflammatory painkiller like ibuprofen 
(Nurofen).  Paracetamol is an alternative, particularly if you have had any gastric acid 
problems or asthma which prevent you from taking medicines like ibuprofen. 
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What about the bandages and support stockings?  Your bandages and stocking must 
remain in place for 10 days.  After this time you can remove them.  Throw away the 
bandages and padding, but keep the stocking (do wash it) in case you need further 
treatment.   
 
Showering and bathing.  Because of the bandages and stocking, you cannot have a 
normal bath or shower for 10 days after foam sclerotherapy.  A shower may be possible by 
securing a large plastic bag over the leg or by using a special waterproof cover such as a 
Limbo waterproof protector (Thesis Technology, Chichester OP18 8AT or on prescription).  
After the bandages have been removed you can shower or bath normally.   
 
Activity.  Aim to get back to all your normal activities just as soon as you are able. The 
only special restriction is bathing and showering, which you cannot do normally for 10 days 
(see above).  The only limitation to your activity might be discomfort and tenderness (which 
can be minimised by taking painkillers) and the need to wear the bandaging and stocking.   
 
Walking.  You should start to walk about as soon after foam sclerotherapy as you are able.  
You can walk as much as you want, as soon as you want.   Your thigh may be 
uncomfortable and tender to the touch in places.  You will not cause any damage by walking.  
Take painkillers if you need them.   
 
There is no special advantage in going for a single long walk during the day, although you 
may walk as far as you wish.  Frequent walking is more important than walking a long 
distance. 
 
Standing and sitting.  During the first week after foam sclerotherapy, try to avoid prolonged 
standing, or sitting with the foot on the floor continuously for longer than about half an hour 
at a time.  Every half hour or so, go for a short walk about or do a few “tip-toe” exercises.  If 
you are sitting or resting for any length of time try to put your foot up - either on a stool or 
couch or on your bed. 
 
When can I return to work and play sports? 
 
Work.  This varies a lot between different people.  Most people are able to return to work 
within two or three days after the treatment. Some people go back to work the following day 
or even the same day. 
 
Sports.  You can return to work and sporting activity as soon after foam sclerotherapy as 
you feel sufficiently comfortable. Avoid contact sports while you are still in support stockings 
or bandages, and thereafter start with some gradual training, rather than in immediate 
competition. Do not go swimming until your bandage has been removed.   
 
Driving. You can drive as soon as you feel confident that you can make an emergency stop 
safely: practise this before you drive. We would advise you not to drive yourself home 
following foam sclerotherapy but other than that you can drive as soon as you feel able. 
 
Air travel.  The risk of deep vein thrombosis during long air flights or other long journeys in 
cramped seating is very low, but it is probably best to avoid this kind of travel for about a 
month after foam sclerotherapy.   
 
 
Foam Sclerotherapy - risks  
 
What problems can occur after foam sclerotherapy? 
 
Inflammation. The injected veins may be somewhat inflamed and hard for a few days (like 
phlebitis).   This is because the foam sclerotherapy works by causing some inflammation of 
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the vein walls, which helps them glue together.  Occasionally inflammation can be more 
severe and painful.  If this occurs then an anti-inflammatory painkiller such as ibuprofen 
(Nurofen) will help to settle the symptoms. 
 
Lumpiness and hardness.  The injected veins sometimes remain lumpy and hard for many 
weeks after treatment, but they gradually shrivel.   
 
Damage to skin.  Rarely, the skin at the injection site may break down and require 
treatment.   
 
Bruising and discolouration.  A little bruising may occur after foam sclerotherapy.  In some 
people, brownish discolouration of the skin occurs in the areas where the veins were.  
Usually this fades, but occasionally discolouration may persist: this is more noticeable in 
people with naturally pale skin. 
 
Thread veins.  Any kind of sclerotherapy can occasionally be followed by the appearance of 
tiny red or blue veins in the area which was injected.  This is uncommon.   
 
Headache/migraine-like symptoms.  Occasionally, people report headache, or migraine-
like symptoms after foam sclerotherapy.  It is thought that these are more common in people 
who have experienced frequent or severe migraines in the past.  For this reason, in this 
study, we do not treat people with foam sclerotherapy if they have had frequent or severe 
migraines in the past. 
 
Deep vein thrombosis (DVT).  Deep vein thrombosis causes swelling of the leg and can 
result in a blood clot passing to the lungs.  It is a possible complication after varicose vein 
surgery, but the risk is considerably reduced if you start moving your legs and walking 
frequently soon after the operation.  Sometimes, injections are given so that blood clots less 
than normal:  this reduces the risk of thrombosis but increases bruising.  The risk of DVT is 
about 1% (1 in 100 patients).  Rarely, a clot like this may break up and travel to the lungs.   
 
Injection into the artery.  Many thousands of patients have been treated with foam 
sclerotherapy.  Among these, there have been three reported cases of foam being injected 
into an artery rather than a varicose vein.   
 
Concern about stroke and loss of vision.  This has been a cause for concern, but there is 
no good evidence that it is a real risk when normal amounts of foam are used.  The reasons 
for the concerns have been: 
 
· There is a possibility that small amounts of foam could circulate in the blood stream, and, 
in particular, they could pass through small ‘holes in the heart’ which are present in some 
otherwise fit people.  Theoretically this could allow foam to pass to small blood vessels – 
for example those in the eye or brain.   
· Some patients have reported temporary disturbance of vision (i.e. blurred vision or loss 
of vision) after foam sclerotherapy.  The risk of this happening is about 1% (1 in 100).   
There has been concern that any disturbance of vision might be due to tiny bubbles 
entering small blood vessels in the back of the eye.  The very few patients in whom this 
has been reported have all rapidly recovered their full vision, generally within 30 minutes.  
The worry that air bubbles might cause permanent loss of vision is a theoretical one: it 
has not been reported as having happened.   
· Stroke and mini-stroke (transient ischemic attack) have been described in a very few 
patients worldwide.  One case of stroke was in a patient in whom a large volume of foam  
was used (much larger than is now recommended).  All the surgeons involved in this 
study limit the amount of foam that is used at any one time and this minimises the risk of 
stroke.  
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Temporary confusion: Among the thousands of patients that have been treated throughout 
the world with foam, a few patients have experienced some temporary confusion after the 
treatment.  Any confusion is likely to be very short-term (lasting only a few minutes).   
 
Concern about fit.  One patient has had a fit following foam, but it is unclear if this was 
related to the foam treatment.   
 
Anaphylaxis/Allergic reaction. This is rare and may cause a rash and a fall in your blood 
pressure. In extreme cases you may lose consciousness. In the unlikely event that this may 
occur, equipment and the necessary drugs will be available to enable the doctor and nurse 
to treat you immediately.  
 
Varicose veins coming back. 
Many people develop a few new varicose veins during the years after foam sclerotherapy. 
There have not been enough scientific reports on the long term results of foam sclerotherapy 
to give precise figures.  Varicose veins may simply re-grow in the areas which have been 
dealt with, or they may develop in different veins which were normal at the time of the 
original treatment.  If veins develop again they can be treated. 
 
 
Laser only or laser plus foam sclerotherapy - Procedure 
 
Laser treatment is used to seal off the main vein under the skin in the thigh or the calf.  This 
takes away the head of pressure which causes varicose veins to bulge and cause 
symptoms. Sometimes we need to use a combination of laser treatment in the thigh and 
foam sclerotherapy of the main vein at the knee or upper calf. If required, this will be done at 
the same treatment session. 
 
Laser treatment alone may cause the varicose veins to disappear or reduce in size, but if 
visible varicose veins remain after the laser treatment, you may wish to have them treated by 
foam sclerotherapy.  Foam sclerotherapy may be done at one or more later treatment 
sessions.  One hospital in the study uses phlebectomies (removal of veins through tiny 
incisions) at the same time as laser treatment. 
 
How long will I be in hospital for laser treatment?  You will have your treatment 
performed as an outpatient. The procedure itself takes about 45 minutes.  You will be in the 
hospital for about 2 hours in total, but you should keep half a day free in case of delays. 
 
What happens before the treatment?  When you arrive a nurse will meet you and will 
measure your legs for stockings and show you where to get changed.  It is best not to wear 
tight trousers as you may have difficulty putting them on over the stocking afterwards. 
 
The consultant or a member of the surgical team will talk with you about what is going to 
happen and will mark your varicose veins with a felt tip pen.  
 
What happens during laser treatment?  An injection of local anaesthetic is given to freeze 
the skin just above, or just below, the knee or in the calf.  Once the skin is numb a needle is 
inserted into a vein beside the knee. A wire is then passed up the vein to the groin and the 
laser filament is passed over the wire. You will not feel this. The position of the laser filament  
is checked using an ultrasound scanner.  The area around the vein and the skin is then 
made numb using cold local anaesthetic injections from the knee to the groin.  This usually 
requires 4 or 5 injections with a small needle.  
 
The laser is fired as it is gradually pulled back down the vein from the groin to the knee.  This 
should not be painful because of the local anaesthetic, but you may feel some pushing, 
pulling or mild discomfort during the procedure.  If you feel anything more than this you 
should say so: the procedure can then be temporarily stopped to settle this.  
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The heat from the laser closes (cauterises) the vein from the inside.  Lasers are powerful 
sources of energy and you and all the staff will wear protective goggles during the time that 
the laser is working.   
 
When the vein has been sealed up, the laser is removed from the leg and a firm stocking is 
applied. This needs to be worn for 10 days.  During that time you cannot get the stocking wet 
in a bath or shower.   
 
After treatment – leaving hospital.  Immediately following the procedure, once you have 
got dressed, you should go for a 10 minute walk.  Once you have been for a walk we will 
offer you a cup of tea and you are then free to go home. 
 
We will arrange a check up for you about 6 weeks after the procedure. By that time most of 
the varicose veins in your leg should have shrunk and many, or all of them may have 
disappeared. If there are any left they can be treated by foam sclerotherapy. 
 
 
Laser - Recovery 
 
How much does it hurt afterwards?  You may experience some discomfort or pulling on 
the inside of your thigh following the treatment.  This may be most noticeable for about one 
week after treatment, but it then settles down.   
 
People vary a lot in the amount of pain they experience after laser treatment, though most 
experience discomfort only. You will be encouraged to get up and walk immediately following 
the laser treatment. 
 
You will be given a supply of an anti-inflammatory drug, such as ibuprofen (Nurofen) or 
diclofenac (Voltarol) which are also painkillers.  We recommend that you take these regularly 
for three days.   If you have had a stomach ulcer, or asthma then you should not take anti-
inflammatory drugs of this kind: tell us and we will supply you with a painkiller which suits 
you. 
 
If any discomfort occurs after three days, take a simple painkiller such as paracetamol 
(Panadol). 
 
What about my wound?  The small cut beside your knee where the laser fibre was inserted 
is closed with an adhesive strip. It can be removed when your stocking is removed.  
 
What about the bandages and support stockings?  Your stocking must remain in place 
for 10 days after which time you can remove it.  Do not get the stocking wet during these 10 
days.  Please keep the stocking (do wash it) in case you need further treatment.  
 
Bathing and showering.  Because of the stocking, you cannot have a normal bath or 
shower until 10 days after laser treatment.  A shower may be possible by securing a large 
plastic bag over the leg or by using a special waterproof cover such as a Limbo waterproof 
protector (Thesis Technology, Chichester OP18 8AT or on prescription).  
 
What should I expect my leg to be like after laser treatment?  You may be aware of 
areas of lumpiness on the leg which may be slightly tender. This is caused by some 
inflammation in the vein that has been treated. It is not harmful and will gradually go away, 
but this may take several weeks.  The inner side of your thigh may be uncomfortable during 
the first few days. 
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Activity.  Aim to get back to all your normal activities just as soon as you are able. The 
only special restriction is bathing and showering, which you cannot do normally for 10 days 
(see above).  The only limitation to your activity might be discomfort and tenderness (which 
can be minimised by taking painkillers) and the need to wear the stocking.   
 
Walking.  You should start to walk about as soon after laser treatment as you are able.  You 
can walk as much as you want, as soon as you want.   Your thigh may be uncomfortable and 
tender to the touch in places.  You will not cause any damage by walking.  Take painkillers if 
you need them.   
 
There is no special advantage in going for a single long walk during the day, although you 
may walk as far as you wish.  Frequent walking is more important than walking a long 
distance. 
 
Standing and sitting.  During the first week after laser treatment, try to avoid prolonged 
standing, or sitting with the foot on the floor continuously for longer than about half an hour 
at a time: go for a short walk about or do a few “tip-toe” exercises.  If you are sitting or 
resting for any length of time try to put your foot up - either on a stool or couch or on your 
bed. 
 
When can I return to work and play sports? 
 
Work.  This varies a lot between different people.  Most people are able to return to work 
within two or three days after the treatment – some people go back the following day or even 
the same day. 
 
Sports.  You can return to work and sporting activity as soon after treatment as you feel 
sufficiently well and comfortable. Avoid contact sports while you are still in support stockings 
or bandages, and thereafter start with some gradual training, rather than in immediate 
competition. Do not go swimming until your bandage has been removed.  We suggest 
avoiding strenuous activity like the gym for about 2 weeks after the procedure. 
 
Driving. You can drive as soon as you feel confident that you can make an emergency stop 
safely: practise this before you drive. We would advise you not to drive yourself home 
following the laser treatment, but other than that you can drive as soon as you feel able. 
 
Air travel.  The risk of deep vein thrombosis during long air flights or other long journeys in 
cramped seating is very low, but it is probably best to avoid this kind of travel for about a 
month after your treatment.   
 
 
Laser - risks  
 
What problems can occur after the laser treatment? 
 
Bruising.  Some bruising is normal, and occasionally the leg becomes very bruised. This 
bruising appears during the first few days after laser treatment: it will all go away over a 
period of weeks. 
 
Aches, twinges, and areas of tenderness may all be felt in the legs for the first few days 
after the laser treatment. These will settle down, and should not discourage you from 
becoming fully active as soon as you are able.  
 
Tender lumps under the skin are common and are caused by blood clots that have 
collected in the places where the vein has been treated. They are not dangerous and will 
gradually disappear. It may take up to 12 weeks for all the lumps to disappear. Occasionally 
they can be quite painful during the first two weeks or so.  
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Numbness.  Areas of numbness in the skin can occasionally occur at the places where 
varicose veins were treated. This is because tiny nerves may be damaged by heat from the 
laser. This will not affect the movement of your foot or your walking. The numbness will 
usually recover over a period of several weeks. 
 
Thread veins.  Laser treatment can occasionally be followed by the appearance of tiny red 
or blue veins in the area which was injected.  This is uncommon.   
 
Deep vein thrombosis (DVT). Deep vein thrombosis causes swelling of the leg and can 
result in a blood clot passing to the lungs.  It is a possible complication after varicose vein 
surgery, but the risk is considerably reduced if you start moving your legs and walking 
frequently soon after the operation.  Sometimes, injections are given so that blood clots less 
than normal:  this reduces the risk of thrombosis but increases bruising.  The risk of DVT is 
about 1% (1 in 100 patients).  Rarely, a clot like this may break up and travel to the lungs.   
 
Damage to major vein.  Damage to the major veins in the leg is a rare complication of laser 
treatment, which we take great pains to avoid.   
 
The risks of additional foam sclerotherapy.  Remember that you may require foam 
sclerotherapy, in addition to laser treatment, to get rid of all your varicose veins. 
 
Will varicose veins come back?  Many people develop a few new varicose veins during the 
years after laser treatment. There have not been enough scientific reports on the long term 
results of laser treatment to give precise figures. Varicose veins may simply re-grow in the 
areas which have been dealt with, or they may develop in different veins which were normal 
at the time of the original treatment.  If veins develop again they can be treated. 
 
 
Surgery - procedure  
 
How long will I be in hospital for surgery?  If you are medically fit and have somebody at 
home with you then a day case operation is usual.  If you have medical conditions, if you live 
some distance away or if you are having surgery for extensive varicose veins in both legs, 
then you may have your operation as an in-patient (you may be admitted the day before your 
operation for the doctors and nurses to assess your needs; or on the morning of the 
operation, and then stay overnight).    
 
What happens before the treatment?  A member of the surgical team will check that all the 
necessary preparations have been made and will mark your varicose veins with a felt tip 
pen.  Be sure that all the veins you would like dealt with have been marked, and ask about 
any which have not. 
 
Shaving may be done before your operation or in the operating theatre.  If you are going to 
have an incision in the groin, this area will need to be shaved, but there will be no need to 
shave all the pubic hair.   The leg will need to be shaved, at least in the areas of the varicose 
veins which are going to be removed.  This makes marking of your varicose veins easier and 
means that hairs do not get into the wounds during the operation.  
 
What happens during surgery?  Surgery is usually done under a general anaesthetic.  An 
incision (2 – 4 cm long) is made over the top of the main vein in the crease of the groin or 
behind the knee.  It is tied off just where it joins the deep vein, so relieving the “head of 
pressure” on the varicose veins further down the leg.  This incision is closed with stitches, 
which are hidden under the skin. 
 
The vein is removed by passing a fine wire down it and making a small incision (less than 1 
cm long) near the knee – “stripping”. This helps to guard against varicose veins forming 
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again.  Blood flows up the many other veins in the leg after this vein has been removed and 
it is therefore safe to remove this vein. 
 
Varicose veins marked before the operation are removed through tiny cuts 
(“phlebectomies”).  These cuts can be closed with stitches or adhesive strips. 
 
After treatment – leaving hospital.  You can get up and walk about as soon as the effects 
of the anaesthetic have worn off, shortly after the operation.  If you are being treated as a 
day case, after two or three hours you should feel fit enough to go home. Before you leave 
the hospital staff will check your leg.  They will give you a note for your GP, and some 
painkillers to take with you.  They will make arrangements for you to visit a practice nurse 
the next day (or if necessary for a nurse to call) to check on you and change your bandages 
for a support stocking. 
 
If you are treated as an inpatient, the bandages on your leg/s will be changed on the 
morning after your operation for a support stocking.  You will normally be able to go home 
shortly afterwards. 
 
 
Surgery - recovery  
 
How much does it hurt afterwards?  We inject a long acting local anaesthetic into the 
groin wound at the end of the operation.  This is usually the most uncomfortable area. 
People vary a lot in the amount of pain they experience after the operation, though most 
experience mild discomfort only.  It is more uncomfortable to get up and walk after operation 
to both legs than when only one leg has been dealt with.  In either case you will be 
encouraged to get up and walk on the day of your operation when the effects of the 
anaesthetic have worn off sufficiently. 
 
Painkillers such as paracetamol or anti-inflammatory painkillers like ibuprofen (Nurofen) or 
diclofenac (Voltarol) will be prescribed for you to take after the operation.  It is important that 
you should take these if you need them to walk about and to rest with comfort.  You should 
not need them for more than a few days, but the duration of discomfort varies from person to 
person.   Occasionally tender lumps of old blood clot (haematoma) beneath the skin can 
become inflamed and very tender. This is not infection, but you may require to take anti-
inflammatory drugs for a longer period.   
 
Will I have dressings or stitches?  Stitches are placed under the skin in the groin and do 
not have to be removed.  If the surgeon has used a dressing on the groin, this can be 
removed after 48 hours.  The groin wound can be washed and gently dried from 48 hours 
after the operation, to keep the area fresh and clean. 
 
The small incisions further down the leg are closed with adhesive strips and it is best to keep 
these dry for 10 days.  10 days after the operation you can remove the strips yourself: this is 
often easiest in the bath or shower which helps to loosen them.  After that time there is no 
restriction at all in taking a shower or bath. 
 
What should I expect my leg to be like after surgery?  Bruising is common after varicose 
vein operations.  It is sometimes quite extensive and may take a month or more to settle.  In 
particular it can occur on the inner side of the thigh, where may be no incisions. This is 
caused by removing the main vein under the skin from this area.  Hard lumps are also 
common – they represent bruising in places where the varicose veins used to be.  Any 
bruising and lumpiness may be tender but you will do no harm by becoming active.  Take 
painkillers if you need them. 
 
What about bandages and support stockings?  Your bandages will be changed for 
support stocking/s the day after operation. Wear these for 10 days after the operation. There 
is no need to wear the stockings after removing the adhesive strips 10 days after the 
operation (but if you feel more comfortable with them for another few days this is quite 
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alright).  If you find the stocking/s uncomfortable or excessively hot, it is reasonable to 
remove them four or five days after the operation, provided you are easily and frequently 
active.  An alternative is to remove them at night only, and to put them on each day – but 
some people find it difficult putting them back on. They are mainly intended to support the 
leg while you are up and about during the day.   
 
Bathing and showering.   
Groin wounds:   You can wash your groin wound gently after 48 hours, as described above.  
 
Keep all the other wounds dry for 10 days so that they properly heal.  At 10 days you can 
soak the adhesive strips off in a bath or shower.   
 
You cannot have a normal bath or shower until 10 days after the operation.  Before 10 days, 
some people manage a shallow bath by putting their leg up on the side of the bath to keep it 
dry, if there are no wounds or dressings above the knee.  A shower may be possible before 
10 days by securing a large plastic bag over the leg or by using a special waterproof cover 
such as a Limbo waterproof protector (Thesis Technology, Chichester OP18 8AT or on 
prescription).   If any of the adhesive strips do come off early, the little wound beneath it is 
likely to be quite alright but you can cover it with a plaster (e.g. Bandaid) if you want. 
 
Activity.  Aim to get back to all your normal activities just as soon as you are able. The only 
special restriction is bathing and showering, which you cannot do normally for 10 days (see 
above).  
 
The only limitation to your activity should be discomfort and tenderness from bruising which 
can be minimised by taking painkillers.  If you can get back to all the things you would like to 
do within a few days of the operation, then do so. The time taken to get fully back to all 
activities varies quite a lot between different people.  If you had many large veins then you 
are more likely to be bruised and tender.  Do not let this put you off becoming active: you will 
do no harm. 
 
Walking.  You should start to walk about as soon after the operation as you are able.  You 
can walk as much as you want, as soon as you want.  Getting up from a seated position or 
bed is sometimes a little uncomfortable during the first two or three days after the operation, 
particularly where the groin or the area behind the knee has been operated on.  The whole 
leg may be stiff, and tender to the touch in places.  You will not damage any of the wounds 
by walking.  Take painkillers if you need them.   
 
There is no special advantage in going for a single long walk during the day, although you 
may walk as far as you wish.  Frequent walking is more important than walking a long 
distance. 
 
Standing and sitting.  During the first week after surgery, try to avoid prolonged standing, 
or sitting with the foot on the floor continuously for longer than about half an hour at a time: 
go for a short walk about or do a few “tip-toe” exercises.  If you are sitting or resting for any 
length of time try to put your foot up - either on a stool or couch or on your bed. 
 
 
When can I return to work and play sports? 
 
Work.  You can return to work as soon after the operation as you feel sufficiently well and 
comfortable.  After an operation on one leg there is no reason to anticipate being away from 
“office” or sedentary work for more than two or three days.  If your job involves prolonged 
standing (without the opportunity to walk about) or driving, then you should wear the support 
stocking if you return to work within two weeks of the operation.  We hope that people will be 
back at work within a week after surgery to one leg and two weeks after surgery to both legs 
– but there is no reason to remain off work that long if you can manage with reasonable 
comfort. 
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Sports.  Be guided by how your legs feel: bruising and tenderness may limit you from being 
very active or from some activities in the first few days after the operation, but you can do 
whatever is comfortable. Avoid very strenuous leg exercise (e.g. running) during the first 
week, and thereafter it is usually best to start with some gradual training, rather than in 
immediate competition.  Do not go swimming until all the wounds are healed and dry (at 
least 10 days). 
 
Driving.  You should not drive within 24 hours of a general anaesthetic.  Thereafter you can 
drive as soon as you feel confident that you can make an emergency stop without pain: 
practise this before you drive.  
 
Air travel.  The risk of deep vein thrombosis during long air flights or other long journeys in 
cramped seating is very low, but it is probably best to avoid this kind of travel for about a 
month after your operation. 
 
 
Surgery - risks  
 
What problems can occur after surgery? 
 
Discomfort.  Aches, twinges, and areas of tenderness may be felt in the legs for the first few 
weeks.  These will settle down, and should not discourage you from becoming fully active as 
soon as you are able. 
 
Lumps.  Tender lumps under the skin are common (especially in the thigh) and are caused 
by blood clots which have collected in the places where the veins were removed.  They are 
not dangerous and will gradually disappear but this can take several weeks.  Occasionally 
they can be quite painful during the first two weeks or more.  It is common for the area under 
the groin wound to feel tender for a few days and thickened for a few weeks.   
 
Infection.  Infection is an occasional problem, particularly in groin wounds.  It is more of a 
risk in people who are overweight and after operation for recurrent varicose veins. Infection 
usually settles with antibiotic treatment.  If the wound was closed by a stitch under the skin, 
this may need to be removed to allow the infection to clear up.  If an abscess forms, this may 
need to be drained at an operation under general anaesthetic and the wound will then 
require dressings – sometimes for up to a month. 
 
Scars and blemishes.  The scars on your legs are easily noticeable to start with, but will 
continue to fade for many months after the operation.  Very occasionally, some people 
develop a little brown staining where the veins were removed. Another uncommon but 
disappointing problem is the appearance of tiny thread veins or “blushes” on the skin in the 
areas where varicose veins were removed.  
 
Nerve damage.  Nerves under the skin can be damaged when removing varicose veins 
close to them and small areas of numbness are quite common. If a nerve lying alongside 
one of the main veins under the skin is damaged, then a larger area of numbness can be 
caused.  If this happens after surgery to the main vein on the inner side of the leg, then 
numbness will result over the inner part of the lower leg and foot.  If a main vein behind the 
knee needs to be dealt with, then there is a risk to the nerve which conducts feeling from the 
skin on the outer part of the lower leg and foot.   Areas of numbness often get better over 
weeks or months, but sometimes they persist in the long term. 
 
Damage to major structures.  Damage to major arteries, veins, and the main nerve which 
allows the leg to move normally have all happened during varicose vein operations, but are 
very rare complications (less than 1 in 10,000), which we take great pains to avoid. 
 
Swelling.  Damage to the tiny lymphatic vessels which drain tissue fluid from the foot and 
leg, and which run close to the veins, can occasionally cause problems. Swelling of the foot 
and ankle can occur, which usually settles over a period of several weeks, but very rarely it 
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
may persist.  Tissue fluid may rarely collect under the groin wound, forming a swelling (which 
usually goes away after a time) or very occasionally tissue fluid may leak from the groin 
wound. These problems are all more common after operations for recurrent varicose veins. 
 
Deep vein thrombosis (DVT).  Deep vein thrombosis causes swelling of the leg and can 
result in a blood clot passing to the lungs.  It is a possible complication after varicose vein 
surgery, but the risk is considerably reduced if you start moving your legs and walking 
frequently soon after the operation.  Sometimes, injections are given so that blood clots less 
than normal:  this reduces the risk of thrombosis but increases bruising.  The risk of DVT is 
about 1% (1 in 100 patients).  Rarely, a clot like this may break up and travel to the lungs.   
 
The risks of a general anaesthetic.  Varicose vein operations are almost always done 
under a general anaesthetic.  General anaesthetics have some risks, which may be 
increased if you have chronic medical conditions, but in general they are as follows: 
 
Common temporary side-effects (risk of 1 in 10 to 1 in 100) include bruising or pain in the 
area of injections, blurred vision and sickness (these can usually be treated and pass off 
quickly). 
 
Infrequent complications (risk of 1 in 100 to 1 in 10,000) include temporary breathing 
difficulties, muscle pains, headaches, damage to teeth, lip or tongue, sore throat and 
difficulty speaking. 
 
Extremely rare and serious complications (risk of less than 1 in 10,000).  These include 
severe allergic reactions and death, brain damage, kidney and liver failure, lung damage, 
permanent nerve or blood vessel damage, eye injury, and damage to the voice-box.  These 
are very rare and may depend on whether you have other serious medical conditions. 
 
Varicose veins coming back.  Many people develop a few new varicose veins during the 
years after a varicose vein operation and five years after operation about one person in eight 
has troublesome varicose veins again. Varicose veins may simply re-grow in the areas 
which have been dealt with, or they may develop in different veins which were normal at the 
time of the original operation.  If veins develop again they can be dealt with by injections or a 
further operation should they be troublesome. 
 
Section 3. Summary of the possible advantages and disadvantages for each treatment 
 
Possible advantages and disadvantages of foam sclerotherapy. 
· Foam sclerotherapy is done under local anaesthetic, but sometimes no anaesthetic is 
required at all. 
· No surgical incisions are required. 
· The veins which have been treated may remain lumpy, hard and sometimes tender for 
several weeks or even months. 
· More than one treatment session may be required, particularly for varicose veins on both 
legs and for veins which are very extensive. 
· You can become fully active as quickly as you want after foam sclerotherapy treatment. 
· Bandages and a support stocking are put on the leg after foam sclerotherapy treatment, 
and need to be worn for about 10 days.  These must be kept dry. 
· Varicose veins may gradually reappear in the years after foam sclerotherapy treatment: 
this is rather more likely than after surgery.  They can be treated with further foam 
sclerotherapy if required. 
· In summary, foam sclerotherapy is a simple treatment to have but firm compression from 
support stockings is important afterwards.  The treated veins may be hard and tender for 
some time and there may be some brown staining.  Repeat treatment sessions may be 
needed, particularly if there are varicose veins in both legs.  New veins may gradually 
appear. 
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Possible advantages and disadvantages of laser treatment.  
· Laser treatment can be done under local anaesthetic, rather than general anaesthetic. 
· No incision is needed in the groin 
· It avoids the bruising which can sometimes occur after standard surgery, but you may 
experience some lumpiness and tenderness in the thigh which can take several weeks to 
settle. 
· Foam sclerotherapy or phlebectomies may be required to get rid of all the varicose veins. 
This may mean returning for treatment on another occasion. 
· You can become fully active as quickly as you want after laser treatment. 
· Most surgeons advise wearing a support stocking for 10 days and avoiding getting the 
legs wet (in a bath or shower).  
· Laser treatment seems to give results as good as surgery up to five years but varicose 
veins may gradually reappear over the years. 
· In summary, laser treatment can be done under local anaesthetic, requiring several 
injections into the thigh.  Additional treatment may be needed to get rid of all the varicose 
veins. 
 
 
Possible advantages and disadvantages of standard surgery. 
· Standard surgery removes all the varicose veins at a single procedure.  It should not be 
necessary to have anything more done to get rid of any remaining varicose veins. 
· Varicose vein surgery is normally done under a general anaesthetic.   
· Bruising is common.  People with smaller varicose veins may get very little bruising but 
people with big varicose veins may be very bruised.  All the bruising goes away. 
· There may be some discomfort from the groin wound and occasionally the groin wound 
can become infected. 
· You can become fully active as quickly as you want after standard surgery. 
· Most surgeons advise wearing a support stocking for the first 10 days and avoiding 
getting the legs wet (in a bath or shower) during this time.    
· Standard surgery gives a good long term result to many people but varicose veins may 
gradually reappear over the years. 
· It is a tried and tested treatment which has been used for many years. 
· In summary, surgical treatment involves a general anaesthetic, an incision in the groin 
and often some bruising.  However, all the varicose veins can be dealt with thoroughly by 
a single treatment, in one or both legs. 
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Please initial 
ALL boxes 
By signing this form and initialling each box I agree that I have:  ↓ 
· read and understood the patient information leaflet (Version number ., dated 
..) for the above study and kept a copy    
     
· discussed this study with Dr/Mr/Mrs/Ms  and all my questions 
have received satisfactory answers    
     
· understood the purpose of the study and I know what my involvement will be    
I understand that: 
· my participation is voluntary  
     
· if further funding is obtained I will be followed up for five years 
     
· I am free to withdraw from the study at any time without having to give a reason 
     
· if I withdraw, this will not affect my care    
     
· my personal data will be collected and stored at the Trial office in Aberdeen    
     
· information relevant to the CLASS trial may be collected from my hospital and NHS 
records, including Office of National Statistics (ONS) and NHS central registers 
   
   
   
· relevant sections of my medical notes and data collected during the study may be looked 
at by individuals directly involved in the trial, from regulatory authorities, from the 
University of Aberdeen or from the NHS Boards or Trusts, where it is relevant to my taki ng 
part in this research.   
   
   
   
I agree that my family doctor (GP), my hospital consultant and the person I have  
nominated as my best contact may be told that I am taking part in this study 
   
   
   
I agree to take part in the study    
 
CLASS Trial Office, Health Services Research Unit, University of Aberdeen, Scotland AB25 2ZD 
  Phone 01224 XXXXXX; Fax 01224 XXXXXX; xxxxxxxxx@abdn.ac.uk 
 
Copies: 1 for patient; 1 for study notes, 1 for researcher in Aberdeen; 1 to be filed with hospital notes.
 
Comparison of LAser, Surgery  
and foam Sclerotherapy 
 
 
Study Number 
      
TRIAL CONSENT FORM 
Your signature (participant)  
Your name in block capitals  
Date   
For office use only I confirm that I have explained to the person named above, the nature and purpose of the study and the procedures involved.   
Signature  
Date  
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
CONTACT DETAILS 
Study number       
 
PATIENT DETAILS 
Title  Mr  Mrs  Miss  Ms  Other  
 
First name   
            
Surname   
            
Date of birth D D / M M / Y Y Y Y 
            
Address  
            
Home telephone  
            
Mobile telephone  
            
Work telephone  
 
GP DETAILS 
Initials   Surname  
 
Address  
 
 
 
BEST CONTACT DETAILS 
Title  Mr  Mrs  Miss  Ms  Other  
 
First name   
 
Surname   
 
Address 
 
 
 
 
Telephone number  
 
RELATIONSHIP OF BEST CONTACT TO PATIENT 
 Relative 
Please specify   Friend 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
BASELINE CLINICAL DATA 
 
Study Number       
 
 
 
AFFECTED LEG(S) 
   
Right leg only Left leg only Both legs 
   
 
 
 
 
STUDY LEG (in case of bilaterality, study leg designated as worst leg by patient) 
  
Right leg Left leg 
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LEFT LEG: CEAP CLASSIFICATION 
 
Please tick appropriate response 
 
 C0   No visible or palpable signs of venous disease. 
 C1  Telangiectasis or reticular veins. Veins less than 3 mm 
 C2  Varicose veins. Veins over 3 mm 
 C3  Edema 
 C4  Skin and subcutaneous changes 
 C4a  Pigmentation or eczema 
 C4b  Lipodermatosclerosis or atrophie blanche 
 C5  Healed venous ulcer 
 C6  Active venous ulcer 
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LEFT LEG:  Venous Clinical Severity Score (VCSS) 
Left leg affected by varicose veins Yes No  
 
  
 
If yes, complete VCSS by ticking one box in each row 
 
PAIN     
 None  Occasional, not 
restricting activity 
or requiring 
analgesics 
 Daily, moderate 
activity limitation, 
occasional 
analgesics 
 Daily, severe 
limiting activities or 
requiring regular 
use of analgesics 
 
VARICOSE VEINS i.e. >3mm 
    
 None  Few, scattered 
branch varicose 
veins 
 Multiple: LSV 
varicose veins 
confined to calf or 
thigh 
 Extensive: thigh 
and calf or LSV and 
SSV distribution 
 
VENOUS EDEMA 
    
 None  Evening ankle  
only 
 Afternoon edema, 
above ankle 
 Morning edema 
above ankle and 
requiring activity 
change, elevation 
 
SKIN PIGMENTATION 
    
 None or 
focal, low 
intensity 
(tan) 
 Diffuse, but  
limited in area  
and old (brown) 
 Diffuse over most of 
gaiter area (lower 
1/3) or recent 
pigmentation (purple) 
 Wider distribution 
(above lower 1/3), 
recent pigmentation 
 
INFLAMMATION 
    
 None  Mild cellulitis, 
limited to  
marginal area 
around ulcer 
 Moderate cellulitis, 
involves most of 
gaiter area (lower 
2/3) 
 Severe cellulitis 
(lower 1/3 and 
above) or 
significant venous 
eczema 
 
INDURATION 
    
 None  Focal, circum-
malleolar (<5 cm) 
 Medial or lateral, less 
than lower 1/3 of leg 
 Entire lower 1/3 of 
leg or more 
 
ACTIVE ULCERS, N 
    
 0  1  2  >2 
 
ACTIVE ULCERATION DURATION (longest duration; if 3 months, select >3 months 
 None  <3 months  >3 months, <1year  Not healed >1 year 
 
ACTIVE ULCER, SIZE (largest ulcer) 
    
 None  <2 cm diameter  2-6 cm diameter  >6 cm diameter 
 
COMPRESSIVE THERAPY 
    
 Not used  
or not 
compliant 
 Intermittent use  
of stockings 
 Wears elastic 
stockings most days 
 Full compliance: 
stockings + 
elevation   
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RIGHT LEG: CEAP Classification 
 
Please tick appropriate response 
 
 C0   No visible or palpable signs of venous disease. 
 C1  Telangiectasis or reticular veins. Veins less than 3 mm 
 C2  Varicose veins. Veins over 3 mm 
 C3  Edema 
 C4  Skin and subcutaneous changes 
 C4a  Pigmentation or eczema 
 C4b  Lipodermatosclerosis or atrophie blanche 
 C5  Healed venous ulcer 
 C6  Active venous ulcer 
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RIGHT LEG:  Venous Clinical Severity Score (VCSS) 
Right leg affected by varicose veins Yes No  
 
  
 
If yes, complete VCSS by ticking one box in each row 
 
PAIN     
 None  Occasional, not 
restricting activity 
or requiring 
analgesics 
 Daily, moderate 
activity limitation, 
occasional 
analgesics 
 Daily, severe 
limiting activities or 
requiring regular 
use of analgesics 
 
VARICOSE VEINS i.e. >3mm 
    
 None  Few, scattered 
branch varicose 
veins 
 Multiple: LSV 
varicose veins 
confined to calf or 
thigh 
 Extensive: thigh 
and calf or LSV and 
SSV distribution 
 
VENOUS EDEMA 
    
 None  Evening ankle  
only 
 Afternoon edema, 
above ankle 
 Morning edema 
above ankle and 
requiring activity 
change, elevation 
 
SKIN PIGMENTATION 
    
 None or 
focal, low 
intensity 
(tan) 
 Diffuse, but  
limited in area  
and old (brown) 
 Diffuse over most of 
gaiter area (lower 
1/3) or recent 
pigmentation (purple) 
 Wider distribution 
(above lower 1/3), 
recent pigmentation 
 
INFLAMMATION 
    
 None  Mild cellulitis, 
limited to  
marginal area 
around ulcer 
 Moderate cellulitis, 
involves most of 
gaiter area (lower 
2/3) 
 Severe cellulitis 
(lower 1/3 and 
above) or 
significant venous 
eczema 
 
INDURATION 
    
 None  Focal, circum-
malleolar (<5 cm) 
 Medial or lateral, less 
than lower 1/3 of leg 
 Entire lower 1/3 of 
leg or more 
 
ACTIVE ULCERS, N 
    
 0  1  2  >2 
 
ACTIVE ULCERATION DURATION (longest duration; if 3 months, select >3 months 
 None  <3 months  >3 months, <1year  Not healed >1 year 
 
ACTIVE ULCER, SIZE (largest ulcer) 
    
 None  <2 cm diameter  2-6 cm diameter  >6 cm diameter 
 
COMPRESSIVE THERAPY 
    
 Not used  
or not 
compliant 
 Intermittent use  
of stockings 
 Wears elastic 
stockings most days 
 Full compliance: 
stockings + 
elevation   
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BRIEF CLINICAL HISTORY 
 Yes  No 
Previous history of DVT    
 If yes, give details  
 
 
 
 
   
 Yes  No 
Previous treatment of varicose veins to contra-lateral leg    
 If yes,  type of treatment:   
   
  Laser treatment  
  
  Surgery  
  
  Foam sclerotherapy  
  
    
Previous foam sclerotherapy or sclerotherapy to 
tributaries of study leg 
Yes  No 
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Duplex scan of study leg 
    
Reflux >1s at the following sites Yes No Not examined 
Groin - long saphenous origin    
    
Deep vein just below SF junction  
(common femoral / superficial vein)    
    
Mid thigh - long saphenous    
    
Above knee - long saphenous     
    
Below knee - long saphenous    
    
Popliteal fossa - short saphenous origin     
    
Popliteal vein (below SP junction)    
    
Mid calf - short saphenous    
 
Diameter of trunk vein    
   Not measured 
Widest diameter below sapheno-femoral junction mm  
    
Widest diameter below sapheno-popliteal junction mm  
 
Summary of vein involvement on study leg 
 
Long saphenous  Yes   No 
      
Short saphenous  Yes   No 
 
Date of scan D D / M M / Y Y Y Y 
 
Name of person performing 
duplex scan 
 
 
 
 
Comments on scan, including 
tortuousity, depth 
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CRITERIA FOR STUDY ENTRY 
(all criteria must be fulfilled) 
Study leg:  
 Must have primary varicose veins  
  
 CEAP grade 2 or above   
  
 Size of vein: greater than 3mm and less than 15mm  
  
 1 second reflux present  
  
 Must be suitable for laser treatment - vein depth  
  
 Must be suitable for laser treatment - tortuousity  
 
 
 
 
RANDOMISATION 
Date of randomisation D D / M M / Y Y Y Y 
 
 
 
 
TREATMENT ALLOCATION 
   
Surgery Foam sclerotherapy Laser therapy 
   
 
 
Name of person undertaking 
randomisation 
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HEIGHT & WEIGHT 
Height (in cm)     Weight (in kg)    
 
EMPLOYMENT STATUS 
Self-employed An employee Other  
   Please specify below 
    
 
PHYSICAL ACTIVITY 
Type and amount of physical activity involved in your work (mark one box only) 
I am not in employment (e.g. retired, retired for health reasons, unemployed, full-time 
carer etc)  
I spend most of my time at work sitting (such as in an office)  
I spend most of my time at work standing or walking.  However, my work does not 
require much intense physical effort (e.g. shop assistant, hairdresser, security guard, 
childminder etc.) 
 
My work involves definite physical effort including handling of heavy objects and use of 
tools (e.g. plumber, electrician, carpenter, cleaner, hospital nurse, gardener, postal 
delivery workers etc) 
 
My work involves vigorous physical activity including handling of very heavy objects 
(e.g. scaffolder, construction worker, refuse collector, etc.)  
 
During the last week, how many hours did you spend on each of the following 
activities?  (mark one box on each row) 
 None 
Some but 
less than 
1 hour 
1 hour but 
less than 3 
hours 
3 hours 
or more 
Physical exercise such as swimming, jogging, 
aerobics, football, tennis, gym workout etc.     
Cycling, including cycling to work and during 
leisure time     
Walking, including walking to work, shopping, 
for pleasure etc.     
Housework/childcare     
Gardening/DIY     
 
How would you describe your usual walking pace?  (mark one box only) 
Slow pace  
(i.e. less than 3 mph) 
Steady average pace Brisk pace Fast pace  
(i.e. over 4 mph) 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
PRESENCE OF 
VARICOSE VEINS 
 
 
Study Number       
 
 
 
 
 
STUDY LEG 
Right leg Left leg 
  
 
 
 
 
We would like to know how you see the amount of varicose veins on your leg.   
On the scale below, please indicate how many varicose veins you think you have. 
 
 
            
No varicose 
veins 
        The most 
varicose veins 
I can imagine 
 
 
 
 
 
 
 
For office use only: 
       
Completed by: Participant  Research nurse    
       
Timepoint: Baseline  Six weeks  Six months  
 
NB: the participant and research nurse should complete this independently. 
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Comparison of LAser, Surgery and foam Sclerotherapy 
 
 
 
 
 
 
 
 
Confidential 
 
 
 
 
 
 
 
Thank you for helping us with our research. 
We would be very grateful if you could complete this 
questionnaire. 
 
 
 
 
 
ISRCTN51995477 
EudraCT 2008-001069-26 
Version 3 
February 2009 
Study Number 
      
R
EC
R
U
IT
M
EN
T 
Q
U
ES
TI
O
N
N
A
IR
E 
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SECTION A: DESCRIBING YOUR OWN HEALTH TODAY – (EQ-5D) 
 
By placing a cross in one box in each group below, please indicate which statements best describe 
your own health state today 
 
A1. Mobility I have no problems in walking about  
   
 I have some problems in walking about  
   
 I am confined to bed  
 
 
 
 
 
A2. Self-care I have no problems with self-care  
   
 I have some problems washing or dressing myself  
   
 I am unable to wash or dress myself  
 
 
 
 
 
A3. Usual Activities 
(e.g. work, study,  
housework, family or 
leisure activities) 
I have no problems with performing my usual 
activities  
  
I have some problems with performing my usual 
activities  
   
 I am unable to perform my usual activities  
 
 
 
 
 
A4. Pain/Discomfort I have no pain or discomfort  
   
 I have moderate pain or discomfort  
   
 I have extreme pain or discomfort  
 
 
 
 
 
A5. Anxiety/Depression I am not anxious or depressed  
   
 I am moderately anxious or depressed  
   
 I am extremely anxious or depressed  
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Your 
health 
state 
today 
A6. Please indicate on this scale how good 
or bad your own health state is today.
 
 The best health state you can imagine 
is marked 100 and the worst health 
state you can imagine is marked 0. 
 
 Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
state is today 
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SECTION B: YOUR GENERAL HEALTH (SF-36) 
 
Please fill in all the questions by crossing the relevant box of the answer that applies to you. 
 
These questions ask for your views about your health and how you feel about life in general.  Do 
not spend too much time in answering as your immediate response is likely to be the most accurate, 
but please make sure you answer every question. 
 
 
B1. In general, would you say your health is? 
 
 Excellent Very good Good Fair Poor 
 
     
 
 
B2. Compared to one year ago, how would you rate your health in general now? 
 
 Much better  
now than one  
year ago 
Somewhat better 
now than one  
year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one  
year ago 
Much worse  
now than one  
year ago 
 
     
 
 
B3. The following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much? 
 
     
  Yes, 
limited  
a lot 
Yes, 
limited  
a little 
No, not 
limited  
at all 
     
 a) Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sport    
     
 b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling or playing golf    
     
 c) Lifting or carrying groceries    
     
 d) Climbing several flights of stairs    
     
 e) Climbing one flight of stairs    
     
 f) Bending, kneeling or stooping    
     
 g) Walking more than one mile    
     
 h) Walking several hundred yards    
     
 i) Walking one hundred yards    
     
 j) Bathing and dressing yourself    
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B4. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Were limited in the kind of work or other 
activities      
       
 d) Had difficulty performing the work or other 
activities (for example it took extra effort)      
       
 
 
B5. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other daily regular activities as a result of any emotional problems (such 
as feeling depressed or anxious)? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Did work or other activities less carefully 
than usual      
       
 
 
B6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
 
     
 
 
B7. How much bodily pain have you had during the past 4 weeks? 
       
 None Very mild Mild Moderate Severe Very severe 
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B8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
outside the home and housework)? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
 
     
 
 
 
B9. These questions are about how you feel and how things have been with you during the past 
4 weeks.  For each question, please give the one answer that comes closest to the way you 
have been feeling.  How much of the time during the past 4 weeks  
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
       
 a) Did you feel full of life?      
       
 b) Have you been very nervous?      
       
 c) Have you felt so down in the dumps that 
nothing could cheer you up?      
       
 d) Have you felt calm and peaceful?      
       
 e) Did you have a lot of energy?      
       
 f) Have you felt downhearted and depressed?      
       
 g) Did you feel worn out?      
       
 h) Have you been happy?      
       
 i) Did you feel tired?      
 
 
 
B10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives etc)? 
      
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
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B11. How TRUE or FALSE is each of the following statements for you? 
       
  Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
 a) I seem to get sick a little easier than other 
people      
       
 b) I am as healthy as anyone I know      
       
 c) I expect my health to get worse      
       
 d)  My health is excellent      
 
 
 
 
SECTION C: YOUR VARICOSE VEINS 
 
C1. Please draw in your varicose veins in the diagram(s) below:- 
 
 
 
 
 
 
Legs viewed 
from the front 
Legs viewed 
from the back 
Left Right 
Right Left 
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C2. In the last two weeks, for how many days did your varicose veins cause you  pain or ache?   
(Please cross one box for each leg) 
 Right Leg Left Leg 
 None at all   
 Between 1 and 5 days   
 Between 6 and 10 days   
 For more than 10 days   
 
 
 
C3. During the last two weeks, on how many days did you take painkilling tablets for your varicose 
veins?  (Please cross one box) 
 None at all  
 Between 1 and 5 days  
 Between 6 and 10 days  
 For more than 10 days  
 
 
 
C4. In the last two weeks, how much ankle swelling have you had?  (Please cross one box) 
 None at all  
 Slight ankle swelling  
 Moderate ankle swelling (causing you to 
 sit with your feet up whenever possible)  
 Severe ankle swelling (causing you 
 difficulty putting on your shoes)  
 
 
 
C5. In the last two weeks, have you worn support stockings or tights?  (Please cross one box for 
each leg) 
 Right Leg Left Leg 
 No   
 Yes, those I bought myself without  a doctor’s prescription   
 Yes, those my doctor prescribed  for me which I wear occasionally    
 Yes, those my doctor prescribed  for me which I wear every day   
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C6. In the last two weeks, have you had any itching in association with your varicose veins?  
(Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but only above the knee   
 Yes, but only below the knee   
 Both above and below the knee   
 
 
C7. Do you have any purple discolouration caused by tiny blood vessels in the skin, in association 
with your varicose veins? (Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
 
C8. Do you have a rash or eczema in the area of your ankle?  (Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but it does not require any  treatment from a doctor or district nurse   
 Yes, and it requires treatment  from my doctor or district nurse   
 
 
C9. Do you have a skin ulcer associated with your varicose veins?  (Please cross one box for each 
leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
 
C10. Does the appearance of your varicose veins cause you concern?  (Please cross one box) 
 No  
 Yes, their appearance causes 
 me slight concern  
 Yes, their appearance causes 
 me moderate concern  
 Yes, their appearance causes 
 me a great deal of concern  
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C11. Does the appearance of your varicose veins influence your choice of clothing including 
tights?  (Please cross one box) 
 No  
 Occasionally  
 Often  
 Always  
 
 
 
C12. During the last two weeks, have your varicose veins interfered with your work/ housework or 
other daily activities? (Please cross one box) 
 No  
 I have been able to work but my work 
 has suffered to a slight extent  
 I have been able to work but my work 
 has suffered to a moderate extent  
 My veins have prevented me from 
 working one day or more  
 
 
 
C13. During the last two weeks have your varicose veins interfered with your leisure activities 
(including sport, hobbies and social life)?  (Please cross one box) 
 No  
 Yes, my enjoyment has suffered 
 to a slight extent  
 Yes, my enjoyment has suffered 
 to a moderate extent  
 Yes, my veins have prevented me 
 taking part in any leisure activities  
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SECTION D: YOUR SYMPTOMS 
 
Listed below are a number of symptoms that you may or may not have experienced since you 
developed varicose veins.   
 
Please indicate by crossing Yes or No whether you have experienced any of these symptoms since you 
developed varicose veins, and whether you believe that these symptoms are related to your varicose 
veins. 
 
  I have experienced  
this symptom  
since I developed 
varicose veins 
 This symptom is  
related to my varicose 
veins 
D1. Pain  Yes  No   Yes  No  
D2. Hardening of the skin on the 
legs  Yes  No   Yes  No  
D3. Redness of the skin on the 
legs 
 
 Yes  No   Yes  No  
D4. Sleep difficulties  Yes  No   Yes  No  
D5. Swelling of the ankle  Yes  No   Yes  No  
D6. Discolouration or brown 
staining on the leg 
 
 Yes  No   Yes  No  
D7. Stiff joints  Yes  No   Yes  No  
D8. Weight loss  Yes  No   Yes  No  
D9. Dizziness  Yes  No   Yes  No  
D10. Fatigue  Yes  No   Yes  No  
D11. Breaks in the skin or ulcers 
on the leg 
 
 Yes  No   Yes  No  
D12. Sore eyes  Yes  No   Yes  No  
D13. Breathlessness  Yes  No   Yes  No  
D14. Loss of strength  Yes  No   Yes  No  
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SECTION E: YOUR VIEWS ABOUT YOUR VARICOSE VEINS 
 
We are interested in your own personal views of how you now see your varicose veins.  Please 
indicate how much you agree or disagree with the following statements about your varicose veins 
by crossing the appropriate box. 
 
Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E1. My varicose veins will last a 
short time       
E2. My varicose veins are likely to 
be permanent rather than 
temporary 
      
E3. My varicose veins will last for a 
long time       
E4. These varicose veins will pass 
quickly       
E5. I expect to have these varicose 
veins for the rest of my life       
E6. My varicose veins are a serious 
condition       
E7. My varicose veins have major 
consequences on my life       
E8. My varicose veins do not have 
much effect on my life       
E9. My varicose veins strongly affect 
the way others see me       
E10. My varicose veins have serious 
financial consequences       
E11. My varicose veins cause 
difficulties for those who are 
close to me 
      
E12. There is a lot which I can do to 
control my symptoms       
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Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E13. What I do can determine 
whether my varicose veins get 
better or worse 
      
E14. The course of my varicose veins 
depends on me       
E15. Nothing I do will affect my 
varicose veins       
E16. I have the power to influence my 
varicose veins       
E17. My actions will have no effect on 
the outcome of my varicose 
veins 
      
E18. My varicose veins will improve 
in time       
E19. There is very little that can be 
done to improve my varicose 
veins 
      
E20. My treatment will be effective in 
curing my varicose veins       
E21. The negative effects of my 
varicose veins can be prevented 
(avoided) by my treatment 
      
E22. My treatment can control my 
varicose veins       
E23. There is nothing which can help 
my varicose veins       
E24. The symptoms of my varicose 
veins are puzzling to me       
E25. My varicose veins are a mystery 
to me       
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Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E26. I don’t understand my varicose 
veins       
E27. My varicose veins don’t make 
any sense to me       
E28. I have a clear picture or 
understanding of my varicose 
veins 
      
E29. The symptoms of my varicose 
veins change a great deal from 
day to day 
      
E30. My symptoms come and go in 
cycles       
E31. My varicose veins are very 
unpredictable       
E32. I go through cycles in which my 
varicose veins get better and 
worse 
      
E33. I get depressed when I think 
about my varicose veins       
E34. When I think about my varicose 
veins I get upset       
E35. My varicose veins make me feel 
angry       
E36. My varicose veins do not worry 
me       
E37. Having these varicose veins 
makes me feel anxious       
E38. My varicose veins make me feel 
afraid       
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SECTION F: CAUSES OF YOUR VARICOSE VEINS 
 
We are interested in what you consider may have been the cause of your varicose veins.  As people are 
very different, there is no correct answer for this question.  We are most interested in your own views 
about the factors that caused your varicose veins rather than what others including doctors or family 
may have suggested to you.  Below is a list of possible causes for your varicose veins.  Please indicate 
how much you agree or disagree that they were causes for you by crossing the appropriate box. 
 
Possible causes  Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
F1. Stress or worry       
F2. Hereditary - it runs in my family       
F3. A germ or virus       
F4. Diet or eating habits       
F5. Chance or bad luck       
F6. Poor medical care in my past       
F7. Pollution in the environment       
F8. My own behaviour       
F9. My mental attitude, e.g. thinking 
about life negatively       
F10. Family problems or worries 
caused my varicose veins       
F11. Overwork       
F12. My emotional state, e.g. feeling 
down, lonely, anxious, empty       
F13. Ageing       
F14. Alcohol       
F15. Smoking       
F16. Accident or injury       
F17. My personality       
F18. Altered immunity       
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In the table below, please list in rank-order the three most important factors that you now believe 
caused your varicose veins.  You may use any of the items from the previous page, or you may have 
additional ideas of your own. 
 
 
The most important causes for me:- 
 
 
1.
  
 
 
 
 
 
 
  
 
 
2.
  
 
 
 
 
 
 
  
 
 
3.
  
 
 
 
 
 
 
 
  
 
 
 
THANK YOU 
 
Thank you very much for your time and patience in filling in this questionnaire.  Please 
hand the questionnaire back to the research nurse or return it in the enclosed reply-paid 
envelope to the Trial Office in Aberdeen. 
 
The information you have given us will be extremely useful in helping us carry out 
research. It will be treated with the strictest confidence and kept securely. 
 
 
Thank you again for your help 
 
If you would like any further information or have any queries about the study,  
please contact: 
 
 
The CLASS Trial Office in Aberdeen (Tel: 01224 XXXXXX) 
 
 
 
This study is taking place across the UK but the questionnaires are being processed in Aberdeen at  
The Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit,  
Health Sciences Building, Foresterhill, ABERDEEN, AB25 2ZD.
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Reminder letter to participants who do not return baseline questionnaire 
 
 
Date 
 
<<Title>> <<Name>> << Surname>>   Study No.  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>>«Address3» 
<<Postcode>>«Address4» 
 
 
 
Dear <<Title>> <<Surname>> 
 
Title of Study:  
 
Thank you very much for taking part in the XXX Study.   
 
When you attended your appointment with the research nurse recently, we gave you a 
questionnaire to take home and complete.  Unfortunately we have not yet received it back from 
you (if it is in the post, sorry to bother you and please ignore this reminder).   
 
We are keen to find out how you are before your varicose veins are treated.  It is very important for 
the success of the study that we have as much information as possible about you.   
 
Some of the questions may not seem relevant but we would be very grateful if you could try to fill 
them all in.  If you have any problems in completing the questionnaires, a friend or relative may be 
able to help you.  Alternatively, please contact the CLASS Study Office; we will be happy to help in 
any way we can. 
 
Please return the questionnaire in the reply-paid envelope provided. 
 
In the meantime, if you require any further help or information about the Study, please contact the 
Study office. 
 
Yours sincerely 
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Letter to participant confirming what treatment they have been randomised to  
 
 
Date 
 
<<Title>> <<Name>> << Surname>>   Study No.  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>>«Address3» 
<<Postcode>>«Address4» 
 
 
 
Dear <<Title>> <<Surname>> 
 
Title of Study:  
 
Thank you very much for taking part in the CLASS Study.   
 
You should have received an appointment for the treatment of your varicose veins.  This will have 
been sent direct from the hospital.  If you have not received an appointment, please do get in 
touch with the CLASS study office.  The treatment you have been allocated is xxx.  You can read 
more about the treatment in the leaflet on varicose veins and treatment that you received from the 
CLASS study.  If you would like another copy of this leaflet, please get in touch with us and we can 
send one to you. 
 
We enclose a questionnaire as we are keen to find out whether your views on your varicose veins 
have changed since you agreed to take part in the study.   
 
Some of the questions may not seem relevant but we would be very grateful if you could try to fill 
them all in.  If you have any problems in completing the questionnaires, a friend or relative may be 
able to help you.  Alternatively, please contact the CLASS Study Office; we will be happy to help in 
any way we can. 
 
Please return the questionnaire in the reply-paid envelope provided. 
 
If you have any questions, or require any further information about the Study, please contact the 
Study office. 
 
Yours sincerely 
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Letter to GP informing them of their patient’s participation in CLASS 
 
 
Date 
 
Dr <<GP Name>> << GP Surname>>   
<<GP Address 1>> 
<<GP Address 2>> 
<<GP Address 3>> 
<<GP Address 4>>«Address3» 
<<GP Postcode>>«Address4» 
 
 
 
Dear Dr <<Surname>> 
 
Patient Details  <<title >> <<Name>> << Surname>> 
Date of birth: <<dob>> 
Address: <<patient address>> 
 
Title of Study: RANDOMISED CONTROLLED TRIAL COMPARING FOAM SCLEROTHERAPY, 
ALONE OR IN COMBINATION WITH ENDOVENOUS LASER THERAPY, WITH 
CONVENTIONAL SURGERY AS TREATMENT FOR VARICOSE VEINS  
 
Vascular Surgeons:  [insert names of local surgeons] 
 
Your patient has agreed to take part in this study.  This is a major research study funded by the 
Health Technology Assessment (HTA) programme of the NHS, taking place in [insert site] and in 
five other sites throughout the UK.  It is comparing three different kinds of treatments for varicose 
veins - conventional surgery, foam sclerotherapy and endovenous laser therapy in terms of their 
clinical and cost-effectiveness.   
 
Patients receive written information regarding the study and the various treatment options at their 
initial out-patient clinic visit and are then contacted to ask if they wish to take part.  If they agree 
they attend to provide consent and to have a full baseline assessment.  They are then randomised 
to one of the treatments.  Following treatment, patients will be followed up at 6 weeks and 6 
months at a clinic appointment for clinical examination, a duplex scan and completion of a 
questionnaire.  
 
I hope that you would be in accord with your patient participating in this study.  The aim is to 
provide robust data to guide the treatment of varicose veins.  Your patient will have been given 
clear written information about the potential benefits and disadvantages of the trial and we will only 
involve them after fully informed consent.  Please do not hesitate to contact me if you have any 
concerns about your patient being included in this study. 
 
With best wishes, 
 
Yours sincerely 
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Letter to GP informing them of the treatment to which the patient has been randomised 
 
 
Date 
 
Dr <<GP Name>> << GP Surname>> 
<<GP Address 1>> 
<<GP Address 2>> 
<<GP Address 3>> 
<<GP Address 4>>«Address3» 
<<GP Postcode>>«Address4» 
 
 
 
Dear Dr <<Surname>> 
 
Patient Details  <<title >> <<Name>> << Surname>> 
Date of birth: <<dob>> 
Address: <<patient address>> 
 
Title of Study: RANDOMISED CONTROLLED TRIAL COMPARING FOAM SCLEROTHERAPY, 
ALONE OR IN COMBINATION WITH ENDOVENOUS LASER THERAPY, WITH 
CONVENTIONAL SURGERY AS TREATMENT FOR VARICOSE VEINS  
 
Vascular surgeons:  [insert names of local surgeons] 
 
As you know from our previous letter, your patient has agreed to take part in this study.  This is a 
major research study funded by the Health Technology Assessment (HTA) programme of the 
NHS, taking place in six sites throughout the UK.  It is comparing three different kinds of 
treatments for varicose veins - conventional surgery, foam sclerotherapy and endovenous laser 
therapy in terms of their clinical and cost-effectiveness.   
 
Your patient has been randomised to receive <<treatment allocation>>, and, if they have not 
already received an appointment for this, they will receive one shortly. 
 
Please do not hesitate to contact me if you have any concerns about your patient being included in 
this study. 
 
With best wishes, 
 
Yours sincerely 
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Study Number 
     
 
 
 
 
 
 
 
 
Comparison of LAser, Surgery and foam Sclerotherapy 
 
 
 
 
 
 
 
 
Confidential 
 
 
 
 
 
 
 
Thank you for helping us with our research. 
We would be very grateful if you could complete this 
questionnaire. 
 
 
 
 
 
 
 
ISRCTN51995477 
EudraCT  2008-001069-26 
Version 2 
August 2008 
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 SECTION A: YOUR SYMPTOMS 
 
Listed below are a number of symptoms that you may or may not have experienced since you 
developed varicose veins.   
 
Please indicate by ticking Yes or No whether you have experienced any of these symptoms since you 
developed varicose veins, and whether you believe that these symptoms are related to your varicose 
veins. 
 
  I have experienced  
this symptom  
since I developed 
varicose veins 
 This symptom is  
related to my varicose 
veins 
A1. Pain  Yes  No   Yes  No  
A2. Hardening of the skin on the 
legs  Yes  No   Yes  No  
A3. Redness of the skin on the 
legs 
 
 Yes  No   Yes  No  
A4. Sleep difficulties  Yes  No   Yes  No  
A5. Swelling of the ankle  Yes  No   Yes  No  
A6. Discolouration or brown 
staining on the leg 
 
 Yes  No   Yes  No  
A7. Stiff joints  Yes  No   Yes  No  
A8. Weight loss  Yes  No   Yes  No  
A9. Dizziness  Yes  No   Yes  No  
A10. Fatigue  Yes  No   Yes  No  
A11. Breaks in the skin or ulcers 
on the leg 
 
 Yes  No   Yes  No  
A12. Sore eyes  Yes  No   Yes  No  
A13. Breathlessness  Yes  No   Yes  No  
A14. Loss of strength  Yes  No   Yes  No  
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 SECTION B: YOUR VIEWS ABOUT YOUR VARICOSE VEINS 
 
We are interested in your own personal views of how you now see your varicose veins.  Please 
indicate how much you agree or disagree with the following statements about your varicose veins 
by ticking the appropriate box. 
 
Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
B1. My varicose veins will last a 
short time       
B2. My varicose veins are likely to 
be permanent rather than 
temporary 
      
B3. My varicose veins will last for a 
long time       
B4. These varicose veins will pass 
quickly       
B5. I expect to have these varicose 
veins for the rest of my life       
B6. My varicose veins are a serious 
condition       
B7. My varicose veins have major 
consequences on my life       
B8. My varicose veins do not have 
much effect on my life       
B9. My varicose veins strongly affect 
the way others see me       
B10. My varicose veins have serious 
financial consequences       
B11. My varicose veins cause 
difficulties for those who are 
close to me 
      
B12. There is a lot which I can do to 
control my symptoms       
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 Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
B13. What I do can determine 
whether my varicose veins get 
better or worse 
      
B14. The course of my varicose veins 
depends on me       
B15. Nothing I do will affect my 
varicose veins       
B16. I have the power to influence my 
varicose veins       
B17. My actions will have no effect on 
the outcome of my varicose 
veins 
      
B18. My varicose veins will improve 
in time       
B19. There is very little that can be 
done to improve my varicose 
veins 
      
B20. My treatment will be effective in 
curing my varicose veins       
B21. The negative effects of my 
varicose veins can be prevented 
(avoided) by my treatment 
      
B22. My treatment can control my 
varicose veins       
B23. There is nothing which can help 
my varicose veins       
B24. The symptoms of my varicose 
veins are puzzling to me       
B25. My varicose veins are a mystery 
to me       
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 Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
B26. I don’t understand my varicose 
veins       
B27. My varicose veins don’t make 
any sense to me       
B28. I have a clear picture or 
understanding of my varicose 
veins 
      
B29. The symptoms of my varicose 
veins change a great deal from 
day to day 
      
B30. My symptoms come and go in 
cycles       
B31. My varicose veins are very 
unpredictable       
B32. I go through cycles in which my 
varicose veins get better and 
worse 
      
B33. I get depressed when I think 
about my varicose veins       
B34. When I think about my varicose 
veins I get upset       
B35. My varicose veins make me feel 
angry       
B36. My varicose veins do not worry 
me       
B37. Having these varicose veins 
makes me feel anxious       
B38. My varicose veins make me feel 
afraid       
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 SECTION C: CAUSES OF YOUR VARICOSE VEINS 
 
We are interested in what you consider may have been the cause of your varicose veins.  As people are 
very different, there is no correct answer for this question.  We are most interested in your own views 
about the factors that caused your varicose veins rather than what others including doctors or family 
may have suggested to you.  Below is a list of possible causes for your varicose veins.  Please indicate 
how much you agree or disagree that they were causes for you by ticking the appropriate box. 
 
Possible causes  Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
C1. Stress or worry       
C2. Hereditary - it runs in my family       
C3. A germ or virus       
C4. Diet or eating habits       
C5. Chance or bad luck       
C6. Poor medical care in my past       
C7. Pollution in the environment       
C8. My own behaviour       
C9. My mental attitude, e.g. thinking 
about life negatively       
C10. Family problems or worries 
caused my varicose veins       
C11. Overwork       
C12. My emotional state, e.g. feeling 
down, lonely, anxious, empty       
C13. Ageing       
C14. Alcohol       
C15. Smoking       
C16. Accident or injury       
C17. My personality       
C18. Altered immunity       
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 In the table below, please list in rank-order the three most important factors that you now believe 
caused your varicose veins.  You may use any of the items from the previous page, or you may have 
additional ideas of your own. 
 
 
The most important causes for me:- 
 
 
1.
  
 
 
 
 
 
 
  
 
 
2.
  
 
 
 
 
 
 
  
 
 
3.
  
 
 
 
 
 
 
 
  
 
 
 
THANK YOU 
 
Thank you very much for your time and patience in filling in this questionnaire.  Please 
hand the questionnaire back to the research nurse or return it in the enclosed reply-paid 
envelope to the Trial Office in Aberdeen. 
 
The information you have given us will be extremely useful in helping us carry out 
research. It will be treated with the strictest confidence and kept securely. 
 
 
Thank you again for your help 
 
If you would like any further information or have any queries about the study,  
please contact: 
 
 
The CLASS Trial Office in Aberdeen (Tel: 01224 XXXXXX) 
 
 
 
This study is taking place across the UK but the questionnaires are being processed in Aberdeen at  
The Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit,  
Health Sciences Building, Foresterhill, ABERDEEN, AB25 2ZD. 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
SURGERY 
Study Number       
 
Study leg  Right  Left  
(defined at baseline; in bilateral cases study leg designated as worst affected leg by patient) 
 
Date of surgery  D D / M M / Y Y Y Y 
 
 
Confirmation that patient is eligible for treatment: 
 
A:  Vein - exclusion criteria 
· CEAP 0/1, non-symptomatic 
· Reflux <1 second 
· Current deep vein thrombosis  
· Acute superficial vein thrombosis  
· Long or short saphenous vein less than 3mm in diameter or 
greater than 15mm 
· Tortuous veins that are considered to be unsuitable for EVLA 
due to difficulties in passing the guide wire 
 
Eligible  Not eligible  
B:  Patient co-morbidity  - exclusion criteria 
· Cardiac failure 
· Pulmonary oedema 
· Local or systemic infection 
· Pregnancy or breast feeding 
· History of hypercoagulability  
· Inability to mobilise post-procedure  
· Varicosities caused by pelvic or abdominal tumours  
· Arterial disease (ankle brachial pressure index <0.8) 
· Patients who are not fit for a general anaesthetic due to 
significant systemic disease, morbid obesity or other causes. 
Eligible  Not eligible  
 
If patient is not eligible for treatment they should not be treated in CLASS 
 
 
Was the participant randomised to receive 
SURGERY? Yes  No  
If No, please give reason why the participant is receiving SURGERY  
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 Details of treatment to study leg 
    
Long saphenous vein Yes  No  
     
If yes:     
 Stripping to  Above knee  Below knee  
     
 Phlebectomies  Yes  No  
     
 
 
    
Short saphenous vein Yes  No  
     
If yes:     
 Stripping to  Below knee    
     
 Phlebectomies  Yes  No  
     
 
 
Grade of surgeon 
Consultant        
        
Staff grade   Supervised by consultant Yes  No  
     
Trainee   Supervised by consultant Yes  No  
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 Grade of anaesthetist present  
Consultant   Associate specialist  
    
Staff grade   Registrar  
    
SHO     
 
Type of anaesthesia  
General  Epidural/spinal  
SC HEPARIN or derivative Yes  No  
HRT Yes  No  
Oral contraceptive Yes  No  
 
Timings 
Please use 24 hour clock H H  m m 
Time of entry into anaesthetic room   :   
      
Operating time  
(time between starting preparation of the patient and finishing bandaging) 
 
 H H  m m 
Time of starting preparation of patient   :   
Time of finishing bandaging   :   
Time of leaving operating room   :   
Time of leaving recovery room   :   
 
Was planned treatment completed? 
 Yes  No  
 
If No, give reason  
 
Contra-lateral leg 
Was contra-lateral leg treated  
at same time? Yes   No  
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 Stocking/bandage to study leg 
Length Full   Knee  
      
Make / grade  
      
Recommended duration according to 
protocol (10 days) 
Yes   No  
 If No: recommended duration Days  
Reason for duration of bandaging not 
10 days  
 
Procedural complications (before discharge) 
Procedural complications Yes  No    
 If yes, give details below:       
       
Wound haematoma 
If Yes: Yes  No    
 Required drainage Yes  No    
 Required overnight stay Yes  No    
       
Bleeding 
If Yes: Yes  No    
 Required overnight stay Yes  No    
       
Damage to major artery* Yes  No    
 If yes:  Common femoral  
Superficial 
femoral  Popliteal  
       
Damage to major vein* Yes  No    
 If yes:  Common femoral  Popliteal    
       
Damage to major nerve* Yes  No    
 If yes:  Femoral  Tibial  Peroneal  
       
Other Yes  No    
If yes, give details  
 
* Details of these should also be reported as a Serious Adverse Event. 
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 Anaesthetic side effects 
Anaesthetic side effects Yes  No    
 If yes, give details below:       
Blurred vision Yes  No    
       
Sickness Yes  No    
       
Muscle pains Yes  No    
       
Headache Yes  No    
       
Sore throat Yes  No    
       
Damage to teeth, lip or tongue Yes  No    
       
Allergic/anaphylactiod reactions Yes  No    
       
Other Yes  No    
       
If yes, give details 
 
 
 
 
 
Time in hospital 
Planned day-case Yes   No  
      
Planned overnight stay Yes   No  
      
Unexpected overnight stay Yes   No  
    
 
Reason for admission  
 
Date admitted to hospital D D / M M / Y Y Y Y 
 
Date discharged from hospital D D / M M / Y Y Y Y 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
FOAM SCLEROTHERAPY 
Study Number        
     
Study leg  Right  Left  
(defined at baseline; in bilateral cases study leg designated as worst affected leg by patient) 
 
Date of foam sclerotherapy D D / M M / Y Y Y Y 
 
Confirmation that patient is eligible for treatment: 
 
A:  Vein - exclusion criteria 
· CEAP 0/1, non-symptomatic 
· Reflux <1 second 
· Current deep vein thrombosis  
· Acute superficial vein thrombosis  
· Long or short saphenous vein less than 3mm in diameter or 
greater than 15mm 
· Tortuous veins that are considered to be unsuitable for EVLA 
due to difficulties in passing the guide wire 
 
Eligible  Not eligible  
B:  Patient co-morbidity  - exclusion criteria 
· Cardiac failure 
· Pulmonary oedema 
· Local or systemic infection 
· Pregnancy or breast feeding 
· History of hypercoagulability  
· Inability to mobilise post-procedure  
· Varicosities caused by pelvic or abdominal tumours  
· Arterial disease (ankle brachial pressure index <0.8) 
· Patients who are not fit for a general anaesthetic due to 
significant systemic disease, morbid obesity or other causes. 
 
Eligible  Not eligible  
C:  Other 
· Allergy to sclerosant. Eligible  Not eligible  
 
If patient is not eligible for treatment they should not be treated in CLASS 
 
Is the patient receiving foam sclerotherapy in 
accordance with their randomisation (i.e. they were 
randomised to FOAM SCLEROTHERAPY, or were 
randomised to EVLA and are receiving foam 
following EVLA)? 
Yes  No  
If No, please give reason why the participant is receiving FOAM SCLEROTHERAPY?  
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 Details of treatment to study leg 
Long saphenous vein Yes  No    
       
 If yes,  Confirm  Fibrovein  Fibrovein:air ratio 1:3  3%  
 
  Manufacturer’s lot/batch number   
 
  Expiry date D D / M M / Y Y Y Y  
 
  Total volume of foam ml  
   
 
 
Short saphenous vein Yes  No    
       
 If yes,  Confirm  Fibrovein  Fibrovein:air ratio 1:3  3%  
 
Manufacturer’s lot/batch number  As above   
 
  Expiry date D D / M M / Y Y Y Y As above   
 
  Total volume of foam ml  
   
 
 
Non-truncal varicosites Yes - calf  Yes - thigh  No  
       
 If yes,  Confirm  Fibrovein  Fibrovein:air ratio 1:3  1%  
 
Manufacturer’s lot/batch number   
 
  Expiry date D D / M M / Y Y Y Y  
 
  Total volume of foam ml  
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 Local anaesthetic 
 Yes  No  
:     
 If yes: Type of anaesthetic  
     
  Concentration  
     
  Volume  
     
SC HEPARIN or derivative Yes  No  
HRT Yes  No  
Oral contraceptive Yes  No  
 
 
Grade of surgeon performing treatment 
Consultant        
        
Staff grade   Supervised by consultant Yes  No  
        
Trainee   Supervised by consultant Yes  No  
        
Consultant nurse   Supervised by consultant Yes  No  
 
 
Duration 
Please use 24 hour clock H H  m m  
Time of entry into treatment room   :    
      
Treatment time      
 Time of start (preparation of patient)   :    
     
 Time of finish (completion of bandaging)   :    
     
 Time of leaving treatment room   :    
 
 
Was planned treatment completed? Yes  No  
 
If No, give reason 
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 Stocking/bandage to study leg 
Confirm that bandaging according to protocol - 
Velband/PehaHaft/Credelast stockings, for ten days Yes   No  
 
If not according to protocol:  
      
 Type of bandaging applied  
      
 Recommended duration Days  
Reason why bandaging not according 
to protocol  
 
Contra-lateral leg 
Was contra-lateral leg treated at same time? Yes   No  
 
Procedural complications (noted at time of treatment) 
Procedural complications Yes   No  
 If yes, give details below:      
Visual disturbance Yes   No  
 If yes, give details  
Headache Yes   No  
 If yes,  migraine with aura   headache  
Transient confusion Yes   No  
 If yes, give details/duration  
Panic attack Yes   No  
 If yes, give details/duration  
Malaise Yes   No  
 If yes, give details/duration  
Cough Yes   No  
 If yes, give details/duration  
Chest tightness/heaviness Yes   No  
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  If yes, give details/duration  
 
Vasovagal Yes   No  
 If yes, give details/duration  
 
Extravasation of foam Yes   No  
 If yes, give details  
 
Anaphylacoid reaction* Yes   No  
 If yes, give details  
 
Stroke* Yes   No  
 If yes, state hemisphere and Rankin grade  
 
Transient ischaemic attack† Yes   No  
 If yes, give details  
 
Myocardial infarction* Yes   No  
 If yes, give details  
 
Intra-arterial injection* Yes   No  
 If yes, give details  
 
Epileptic fit* Yes   No  
 If yes, give details/duration  
 
Other Yes   No  
 If yes, give details 
 
 
 
* Details of these should also be reported as a Serious Adverse Event.   
Permanent loss of vision should also be reported as a Serious Adverse Event.   
† If hospitalised after transient ischaemic attack or other complication, this should 
also be reported as a serious adverse event.   
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 Hospital admission 
Was the patient admitted to hospital immediately after the procedure? 
 Yes  No  
 
   If yes:  
Reason for admission  
Date of admission D D / M M / Y Y Y Y 
Date of discharge D D / M M / Y Y Y Y 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
LASER THERAPY 
Study Number       
 
Study leg  Right  Left  
(defined at baseline; in bilateral cases study leg designated as worst affected leg by patient) 
 
Date of laser therapy D D / M M / Y Y Y Y 
 
 
Confirmation that patient is eligible for treatment: 
 
A:  Vein - exclusion criteria 
· CEAP 0/1, non-symptomatic 
· Reflux <1 second 
· Current deep vein thrombosis  
· Acute superficial vein thrombosis  
· Long or short saphenous vein less than 3mm in diameter or 
greater than 15mm 
· Tortuous veins that are considered to be unsuitable for EVLA 
due to difficulties in passing the guide wire 
 
Eligible  Not eligible  
B:  Patient co-morbidity  - exclusion criteria 
· Cardiac failure 
· Pulmonary oedema 
· Local or systemic infection 
· Pregnancy or breast feeding 
· History of hypercoagulability  
· Inability to mobilise post-procedure  
· Varicosities caused by pelvic or abdominal tumours  
· Arterial disease (ankle brachial pressure index <0.8) 
· Patients who are not fit for a general anaesthetic due to 
significant systemic disease, morbid obesity or other causes. 
Eligible  Not eligible  
 
 
If patient is not eligible for treatment they should not be treated in CLASS 
 
 
Was the participant randomised to receive LASER 
THERAPY? Yes  No  
If No, please give reason why the participant is receiving LASER THERAPY  
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 Details of treatment to study leg 
 
Long saphenous vein Yes  No  
     
 If Yes:     
   Cannulation Above knee  Below knee  
     
Laser delivery Continuous  Interrupted  
     
Watts   Joules   
     
Length (cm)   Joules/cm   
 
Laser type/wavelength   
       
 Plebectomies Yes  No  N/A (Centres  other than Hull)  
 
 
Short saphenous vein Yes  No  
     
 If Yes:     
   Cannulation Above knee  Below knee  
     
Laser delivery Continuous  Interrupted  
     
Watts   Joules   
     
Length (cm)   Joules/cm   
 
Laser type/wavelength   
       
 Plebectomies Yes  No  N/A (Centres  other than Hull)  
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 Local anaesthetic to study leg 
Skin  Yes  No  
     
If yes: Type  
     
 Concentration  
     
Tumescent Yes  No  
     
If yes: Cooled Yes  No  
     
Volume of tumescent ml  
     
Anaesthetic added to 
Tumescent Yes  No  
     
Type of anaesthetic  
  
Concentration   
    
Sedation  Yes  No  
 
If yes: Give details 
 
 
 
 
SC HEPARIN or derivative   Yes  No  
HRT Yes  No  
Oral contraceptive Yes  No  
 
Grade of surgeon performing laser therapy 
 
Consultant    
 
Staff grade   Supervised by consultant Yes  No  
     
Trainee   Supervised by consultant Yes  No  
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Duration 
       
Please use 24 hour clock H H  m m  
Time of entry into treatment room   :    
 
Treatment time       
  Time of start (preparation of patient)   :    
 
 Time of finish (completion of bandaging)   :    
 
Time of leaving treatment room   :    
 
 
Was planned treatment completed? Yes  No  
 
If No, give reason  
 
 
 
Stocking/bandage 
Length Full   Knee  
      
Make / grade  
      
Recommended duration according to 
protocol (10 days) Yes   No  
 If No: recommended duration days  
Reason for duration of bandaging not 
10 days  
 
 
 
Contra-lateral leg 
Was contra-lateral leg treated  
at same time? Yes   No  
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Procedural complications (noted at time of treatment) 
Procedural complications Yes   No  
 If yes, give details below: 
 
     
Wound haematoma 
 If yes: Yes   No  
 Required drainage Yes   No  
 Required overnight stay Yes   No  
      
Damage to major vein*  Yes   No  
 If yes: Femoral   Popliteal  
      
Other  Yes   No  
 If yes, give details  
 
*Details of these should also be reported as a serious adverse event 
 
 
 
Hospital admission 
Was the patient admitted to hospital immediately after the procedure? 
 Yes  No  
 If yes: 
Reason for admission  
Date of admission D D / M M / Y Y Y Y 
Date of discharge D D / M M / Y Y Y Y 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
PAIN DURING TREATMENT 
 
 
Study Number       
 
 
 
 
 
 
Please rate the worst pain that you experienced while you were having your treatment.  The 
best rating is marked 0 (no pain) and the worst rating is marked 10 (worst imaginable pain). Please 
draw a cross (X) on the line that best indicates the rating of the pain you experienced while you were 
having your treatment for varicose veins. 
 
 
                          
  0 1 2 3 4 5 6 7 8 9 10   
  No 
pain 
         Worst 
imaginable 
pain 
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
6 WEEK ASSESSMENT 
Study Number       
 
STUDY LEG   Date of 6 week assessment 
 
Right   Left    D D / M M / Y Y Y Y 
 
DUPLEX SCAN Complete for study leg only 
       
 Not examined 
Complete 
occlusion 
(absent) 
Partial 
occlusion 
No 
occlusion 
(patent) 
If patent,  
is reflux 
     Present Absent 
Groin - long saphenous  
(flush with CFV - ie within 1cm)       
       
Groin - long saphenous (within 
3cm of CFV)       
       
Common femoral/superficial 
vein*       
       
Mid thigh - long saphenous       
       
Above knee - long saphenous        
       
Below knee - long saphenous       
       
Short saphenous (flush with 
popliteal - i.e. within 1cm)       
       
Short saphenous (within 3cm of 
popliteal)        
       
Popliteal vein*       
       
Mid calf - short saphenous       
* Occlusion in the common femoral vein or popliteal fossa-popliteal vein (DVT) should be reported 
as a Serious Adverse Event (if not already reported) 
 
Name of person performing duplex scan 
 
 
Date of duplex scan D D / M M / Y Y Y Y 
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CEAP CLASSIFICATION  
Complete for study leg only - Please tick appropriate response 
 C0   No visible or palpable signs of venous disease. 
 C1  Telangiectasis or reticular veins. Veins less than 3 mm 
 C2  Varicose veins. Veins over 3 mm 
 C3  Edema 
 C4  Skin and subcutaneous changes 
 C4a  Pigmentation or eczema 
 C4b  Lipodermatosclerosis or atrophie blanche 
 C5  Healed venous ulcer 
 C6  Active venous ulcer 
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 VENOUS CLINICAL SEVERITY SCORE (VCSS)  
Complete for study leg only 
PAIN     
 None  Occasional, not 
restricting activity 
or requiring 
analgesics 
 Daily, moderate 
activity limitation, 
occasional 
analgesics 
 Daily, severe 
limiting activities or 
requiring regular 
use of analgesics 
 
VARICOSE VEINS i.e. >3mm 
    
 None  Few, scattered 
branch varicose 
veins 
 Multiple: GSV 
varicose veins 
confined to calf or 
thigh 
 Extensive: thigh 
and calf or GSV 
and SSV 
distribution 
 
VENOUS EDEMA 
    
 None  Evening ankle  
only 
 Afternoon edema, 
above ankle 
 Morning edema 
above ankle and 
requiring activity 
change, elevation 
 
SKIN PIGMENTATION 
    
 None or 
focal, low 
intensity 
(tan) 
 Diffuse, but  
limited in area  
and old (brown) 
 Diffuse over most of 
gaiter area (lower 
1/3) or recent 
pigmentation (purple) 
 Wider distribution 
(above lower 1/3), 
recent pigmentation 
 
INFLAMMATION 
    
 None  Mild cellulitis, 
limited to  
marginal area 
around ulcer 
 Moderate cellulitis, 
involves most of 
gaiter area (lower 
2/3) 
 Severe cellulitis 
(lower 1/3 and 
above) or 
significant venous 
eczema 
 
INDURATION 
    
 None  Focal, circum-
malleolar (<5 cm) 
 Medial or lateral, less 
than lower 1/3 of leg 
 Entire lower 1/3 of 
leg or more 
 
ACTIVE ULCERS, N 
    
 0  1  2  >2 
 
ACTIVE ULCERATION DURATION 
    
 None  <3 months  >3 months, <1year  Not healed >1 year 
 
ACTIVE ULCER, SIZE 
    
 None  <2 cm diameter  2-6 cm diameter  >6 cm diameter 
 
COMPRESSIVE THERAPY 
    
 Not used  
or not 
compliant 
 Intermittent use  
of stockings 
 Wears elastic 
stockings most days 
 Full compliance: 
stockings + 
elevation 
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 COMPLICATIONS 
       
Numbness Yes  No    
If yes: state distribution/dimensions  
       
Persistent bruising Yes  No    
If yes: state distribution/dimensions  
       
Persistent tenderness/discomfort  Yes  No    
If yes: state distribution/dimensions   
       
Skin loss/ulceration Yes  No    
 If yes: state distribution/dimensions  
       
Lumpiness Yes  No    
 If yes: state distribution/dimensions  
       
Development of thread vein Yes  No    
 If yes: state distribution/dimensions  
       
Skin staining Yes  No    
 If yes: state distribution/dimensions  
       
Wound infection Yes  No    
 If yes:        
 Required antibiotics Yes  No    
       
 Required drainage Yes  No    
       
 Required hospital admission Yes  No    
 
       
Back-ache Yes  No    
If yes: give details  
       
Headache Yes  No    
If yes: give details  
       
Deep vein thrombosis* Yes  No    
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 If yes: state distribution/dimensions  
       
Pulmonary embolus* Yes  No    
If yes: give details of severity  
       
 
Stroke* Yes  No    
If yes: state hemisphere and 
 Rankin grade 
 
       
Myocardial infarction* Yes  No    
If yes: give details  
       
Loss of vision* Yes  No    
If yes: give details  
       
Damage to major artery* Yes  No    
 If yes: Common femoral  
Superficial 
femoral  
  
       
Damage to major vein* Yes  No    
 If yes: Common femoral  Popliteal    
       
Damage to motor nerve* Yes  No    
 If yes: Femoral  Tibial  Popliteal  
       
Other Yes  No    
 If yes: give details  
 
*If not previously reported as a Serious Adverse Event, details of these should be 
reported as a Serious Adverse Event. 
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 HOSPITAL ADMISSIONS 
  Yes  No  
Has the participant been admitted to hospital for 
any reason since the initial procedure?     
 
If yes: give reason  
Hospital admitted to  
  
   Date admitted D D / M M / Y Y Y Y 
 
   Date discharged D D / M M / Y Y Y Y 
 
TREATMENT TO STUDY LEG OUTWITH THE CLASS TRIAL PROTOCOL 
  Yes  No  
Has the participant had treatment to 
the study leg outwith the CLASS trial 
protocol since being recruited to 
CLASS? 
    
 
  
  If yes, give date of treatment  D D / M M / Y Y Y Y 
 
details of treatment 
 
 
TREATMENT TO CONTRALATERAL LEG 
  Yes  No  
Has the participant had treatment to 
the contralateral leg since being 
recruited to CLASS? 
    
 
  If yes, give date of treatment  D D / M M / Y Y Y Y 
 
details of treatment 
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Comparison of LAser, Surgery and foam Sclerotherapy 
 
 
 
 
 
 
 
 
Confidential 
 
 
 
 
 
 
 
 
Thank you for helping us with our research.
We would be very grateful if you could complete this 
questionnaire. 
 
 
 
 
 
 
  
Study Number 
      
ISRCTN51995477 
EudraCT  2008-001069-26 
Version 4 
February 2009 
SI
X 
W
EE
K
 Q
U
ES
TI
O
N
N
A
IR
E 
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 SECTION A: DESCRIBING YOUR OWN HEALTH TODAY – (EQ-5D) 
 
By placing a cross in one box in each group below, please indicate which statements best describe 
your own health state today.   
 
 
A1. Mobility I have no problems in walking about  
   
 I have some problems in walking about  
   
 I am confined to bed  
 
 
 
 
 
A2. Self-care I have no problems with self-care  
   
 I have some problems washing or dressing myself  
   
 I am unable to wash or dress myself  
 
 
 
 
 
A3. Usual Activities 
(e.g. work, study,  
housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
  
I have some problems with performing my usual activities  
   
 I am unable to perform my usual activities  
 
 
 
 
 
A4. Pain/Discomfort I have no pain or discomfort  
   
 I have moderate pain or discomfort  
   
 I have extreme pain or discomfort  
 
 
 
 
 
A5. Anxiety/Depression I am not anxious or depressed  
   
 I am moderately anxious or depressed  
   
 I am extremely anxious or depressed  
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Your 
health 
state 
today 
A6. Please indicate on this scale how good 
or bad your own health state is today.
 
 The best health state you can imagine 
is marked 100 and the worst health 
state you can imagine is marked 0. 
 
 
 Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
state is today.   
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 SECTION B: YOUR GENERAL HEALTH (SF-36) 
 
Please fill in all the questions by crossing the relevant box of the answer that applies to you. 
 
These questions ask for your views about your health and how you feel about life in general.  Do 
not spend too much time in answering as your immediate response is likely to be the most accurate, 
but please make sure you answer every question. 
 
B1. In general, would you say your health is? 
 
 Excellent Very good Good Fair Poor 
 
     
 
B2. Compared to one year ago, how would you rate your health in general now? 
 
 Much better  
now than one  
year ago 
Somewhat better 
now than one  
year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one  
year ago 
Much worse  
now than one  
year ago 
 
     
 
B3. The following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much? 
 
  Yes, 
limited  
a lot 
Yes, 
limited  
a little 
No, not 
limited  
at all 
     
 a) Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sport    
     
 b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling or playing golf    
     
 c) Lifting or carrying groceries    
     
 d) Climbing several flights of stairs    
     
 e) Climbing one flight of stairs    
     
 f) Bending, kneeling or stooping    
     
 g) Walking more than one mile    
     
 h) Walking several hundred yards    
     
 i) Walking one hundred yards    
     
 j) Bathing and dressing yourself    
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B4. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Were limited in the kind of work or other 
activities      
       
 d) Had difficulty performing the work or other 
activities (for example it took extra effort)      
       
 
 
B5. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other daily regular activities as a result of any emotional problems (such 
as feeling depressed or anxious)? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Did work or other activities less carefully 
than usual      
       
 
 
B6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
 
     
 
 
B7. How much bodily pain have you had during the past 4 weeks? 
       
 None Very mild Mild Moderate Severe Very severe 
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B8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
outside the home and housework)? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
 
     
 
 
 
B9. These questions are about how you feel and how things have been with you during the past 
4 weeks.  For each question, please give the one answer that comes closest to the way you 
have been feeling.  How much of the time during the past 4 weeks  
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
       
 a) Did you feel full of life? 
     
       
 b) Have you been very nervous? 
     
       
 c) Have you felt so down in the dumps that 
nothing could cheer you up?      
       
 d)  Have you felt calm and peaceful? 
     
       
 e) Did you have a lot of energy? 
     
       
 f) Have you felt downhearted and 
depressed?      
       
 g) Did you feel worn out? 
     
       
 h) Have you been happy? 
     
       
 i) Did you feel tired? 
     
 
 
 
B10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives etc)? 
      
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
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B11. How TRUE or FALSE is each of the following statements for you? 
       
  Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
 a) I seem to get sick a little easier than other 
people      
       
 b) I am as healthy as anyone I know 
     
       
 c) I expect my health to get worse 
     
       
 d)  My health is excellent 
     
 
 
 
SECTION C: YOUR VARICOSE VEINS 
 
C1. Please draw in your varicose veins in the diagram(s) below: 
 
 
 
 
 
 
 
Legs viewed 
from the front 
Legs viewed 
from the back 
Left Right 
Right Left 
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C2. In the last two weeks, for how many days did your varicose veins cause you pain or ache?  
(Please cross one box for each leg) 
 Right Leg Left Leg 
 None at all   
 Between 1 and 5 days   
 Between 6 and 10 days   
 For more than 10 days   
 
 
 
C3. During the last two weeks, on how many days did you take painkilling tablets for your varicose 
veins?  (Please cross one box) 
 None at all  
 Between 1 and 5 days  
 Between 6 and 10 days  
 For more than 10 days  
 
 
C4. In the last two weeks, how much ankle swelling have you had?  (Please cross one box) 
 None at all  
 Slight ankle swelling  
 Moderate ankle swelling (causing you to 
 sit with your feet up whenever possible)  
 Severe ankle swelling (causing you 
 difficulty putting on your shoes)  
 
 
 
C5. In the last two weeks, have you worn support stockings or tights?  (Please cross one box for 
each leg) 
 Right Leg Left Leg 
 No   
 Yes, those I bought myself without  a doctor’s prescription   
 Yes, those my doctor prescribed  for me which I wear occasionally    
 Yes, those my doctor prescribed  for me which I wear every day   
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C6. In the last two weeks, have you had any itching in association with your  varicose veins?  
(Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but only above the knee   
 Yes, but only below the knee   
 Both above and below the knee   
 
 
C7. Do you have any purple discolouration caused by tiny blood vessels in the skin, in association 
with your varicose veins? (Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
 
C8. Do you have a rash or eczema in the area of your ankle?  (Please cross one  box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but it does not require any  treatment from a doctor or district nurse   
 Yes, and it requires treatment  from my doctor or district nurse   
 
 
C9. Do you have a skin ulcer associated with your varicose veins?  (Please cross one box for each 
leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
 
C10. Does the appearance of your varicose veins cause you concern?  (Please cross one box) 
 No  
 Yes, their appearance causes 
 me slight concern  
 Yes, their appearance causes 
 me moderate concern  
 Yes, their appearance causes 
 me a great deal of concern  
 
C11. Does the appearance of your varicose veins influence your choice of clothing including 
tights?  (Please cross one box) 
 No  
 Occasionally  
 Often  
 Always  
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C12. During the last two weeks, have your varicose veins interfered with your work/ housework or 
other daily activities? (Please cross one box) 
 No  
 I have been able to work but my work 
 has suffered to a slight extent  
 I have been able to work but my work 
 has suffered to a moderate extent  
 My veins have prevented me from 
 working one day or more  
 
 
C13. During the last two weeks have your varicose veins interfered with your leisure activities 
(including sport, hobbies and social life)?  (Please cross one box) 
 No  
 Yes, my enjoyment has suffered 
 to a slight extent  
 Yes, my enjoyment has suffered 
 to a moderate extent  
 Yes, my veins have prevented me 
 taking part in any leisure activities  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
274
  
SECTION D: YOUR RECOVERY 
 
In this section we are interested in your activities during your recovery from your treatment for 
varicose veins.  This includes questions on:  
 
· for how long you wore your support stocking(s)  
· how soon after your treatment you were able to do certain activities without discomfort 
· whether you did anything yourself to try and help your recovery. 
 
It may be hard for you to remember the answers to some of these questions, but it would be really 
helpful if you could be as accurate as you can be from your memory.   
 
First of all, we are interested in how long you wore your support stocking(s). 
 
EXAMPLE OF HOW TO COMPLETE THIS QUESTION 
If you wore your stocking(s) all the time (day and night, i.e. 24 hours) for 5 days, then, during the day only for a 
further 3 weeks, you would complete the question as follows: 
I wore my support stocking(s): 
 
  Not at all 
   
  Day and night (i.e. 24 hours) for 5 days, then during the day only for 21 days 
   
  Other (please explain)  
   
 
PLEASE NOW COMPLETE THIS BOX TO TELL US HOW LONG YOU WORE YOUR SUPPORT STOCKING(S) 
 
PLEASE CROSS THE RELEVANT BOX AND COMPLETE THE SENTENCE 
I wore my support stocking(s): 
 
  Not at all 
   
  Day and night (i.e. 24 hours) for  days, then during the day only for  days 
   
  Other (please explain)  
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For each of the following activities we are interested in:  
· whether you do not normally do this activity; or  
· whether you normally do this activity but have not yet done so since your treatment; or 
· how soon after your treatment for varicose veins you carried out this activity.   
 
 
EXAMPLES OF HOW TO COMPLETE THESE QUESTIONS 
If you first had a bath or shower 6 days after treatment, you would answer as follows:  
Having a bath or shower:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR 6  days after my treatment OR  
weeks after my 
treatment 
  
If you never drive a car, you would cross the box as follows:  
Driving a car:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
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THE FOLLOWING QUESTIONS ARE FOR YOU TO ANSWER 
 
1. Bending the leg(s) (without discomfort):  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
2. Lifting heavy objects (without discomfort):  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
3. Moving from a standing to a sitting position (without discomfort):  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
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4. Standing still for a long time i.e. more than 15 minutes (without discomfort):  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
5. Walking short distances i.e. less than 20 minutes (without discomfort):  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
6. Walking long distances i.e. more than 20 minutes:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
278
  
7. Having a bath or shower:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
8. Driving a car:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
9. Doing housework:  
  
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
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10. Looking after children:  
 
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
11. Wearing clothes that show the legs:  
 
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
12. Partial return to normal work/employment:  
 
  I don’t normally do this 
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
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13. Full return to normal work/employment:  
 
  I don’t normally do this 
  
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
14. Going out socially (such as going to the cinema, theatre, a restaurant etc.): 
 Please describe a social activity that is important to you: 
 
  
  
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
15. Sporting activity or exercise (such as swimming, going to the gym, cycling, running, jogging, horse-riding, hill-walking, golf etc.): 
 Please describe a sporting activity that is important to you: 
 
 
 
  
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
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16. Anything else that you do that is important to you, not already mentioned: 
 Please describe the activity:  
  
  I normally do this, but haven’t done so since my treatment 
  I have done this since my treatment.  I did it for the first time:  
  
   on the day of my treatment 
 
OR  
days after my 
treatment OR  
weeks after my 
treatment 
  
 
Finally, was there anything that you did in order to help your recovery from your treatment for 
varicose veins?  For example, keeping your leg raised while sitting.   
Please complete the following sentence:   
 
To help my recovery I 
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SECTION E: PAIN 
 
E1. Please rate the worst pain that you experienced while you were having your treatment for 
varicose veins.  The best rating is marked 0 (no pain) and the worst rating is marked 10 (worst 
imaginable pain). Please draw a cross (X) on the line that best indicates the rating of the pain you 
experienced while you were having your treatment for varicose veins. 
 
                          
  0 1 2 3 4 5 6 7 8 9 10   
  No 
pain 
         Worst 
imaginable 
pain 
 
 
E2. Please rate the worst pain that you have experienced while recovering in the days and weeks 
after your treatment for varicose veins.  The best rating is marked 0 (no pain) and the worst rating 
is marked 10 (worst imaginable pain). Please draw a cross (X) on the line that best indicates the 
rating of the pain you experienced while recovering from your treatment for varicose veins. 
 
                          
  0 1 2 3 4 5 6 7 8 9 10   
  No 
pain 
         Worst 
imaginable 
pain 
 
 
 
  THANK YOU 
 
Thank you very much for your time and patience in filling in this questionnaire.  Please 
hand the questionnaire back to the research nurse or return it in the enclosed reply-paid 
envelope to the Trial Office in Aberdeen. 
 
The information you have given us will be extremely useful in helping us carry out 
research. It will be treated with the strictest confidence and kept securely. 
 
 
 
Thank you again for your help 
If you would like any further information or have any queries about the study,  
please contact: 
 
 
The CLASS Trial Office in Aberdeen (Tel: 01224 XXXXXX) 
 
 
This study is taking place across the UK but the questionnaires are being processed in Aberdeen at  
The Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit,  
Health Sciences Building, Foresterhill, ABERDEEN, AB25 2ZD. 
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Reminder letter to participants who do not return 6 week or 6 month questionnaire 
 
 
Date 
 
<<Title>> <<Name>> << Surname>>   Study No.  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>>«Address3» 
<<Postcode>>«Address4» 
 
 
 
Dear <<Title>> <<Surname>> 
 
Title of Study:  
 
Thank you very much for taking part in the CLASS Study.   
 
When you attended your follow-up appointment recently, we gave you a questionnaire to take 
home and complete.  Unfortunately we have not yet received it back from you (if it is in the post, 
sorry to bother you and please ignore this reminder).   
 
We are keen to find out how you have been getting on since your varicose veins were treated.  It is 
very important for the success of the study that we have as much information as possible about 
you.   
 
Some of the questions may not seem relevant but we would be very grateful if you could try to fill 
them all in.  If you have any problems in completing the questionnaires, a friend or relative may be 
able to help you.  Alternatively, please contact the CLASS Study Office; we will be happy to help in 
any way we can. 
 
Please return the questionnaire in the reply-paid envelope provided. 
 
In the meantime, if you require any further help or information about the Study, please contact the 
Study office. 
 
Yours sincerely 
 
 
 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
284
  
Cover letter to send with six-week questionnaire for patients who fail to attend for the six-
week follow-up appointment 
 
Date 
 
<<Title>> <<Name>> << Surname>>   Study No.  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>>«Address3» 
<<Postcode>>«Address4» 
 
 
 
Dear <<Title>> <<Surname>> 
 
Thank you very much for taking part in the CLASS Study.   
 
We are sorry that you have been unable to attend a six-week follow-up appointment.   
 
We are keen to find out how you have been getting on since your varicose veins were treated.  It is 
very important for the success of the study that we have as much information as possible about 
you.   
 
Some of the questions may not seem relevant but we would be very grateful if you could try to fill 
them all in.  If you have any problems in completing the questionnaires, a friend or relative may be 
able to help you.  Alternatively, please contact the CLASS Study Office; we will be happy to help in 
any way we can. 
 
Please return the questionnaire in the reply-paid envelope provided. 
 
In the meantime, if you require any further help or information about the Study, please contact the 
Study office.   Likewise, if you would like to re-arrange a six-week follow-up appointment with the 
research nurse, please do contact  on .. 
 
Yours sincerely 
 
 
 
 
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
285
  
 
Reminder letter for the six-week or six month questionnaire for patients who fail to attend 
for the follow-up appointment 
 
 
Date 
 
<<Title>> <<Name>> << Surname>>   Study No.  
<<Address 1>> 
<<Address 2>> 
<<Address 3>> 
<<Address 4>>«Address3» 
<<Postcode>>«Address4» 
 
 
 
Dear <<Title>> <<Surname>> 
 
Thank you very much for taking part in the CLASS Study.   
 
Recently, we sent you a questionnaire to complete.  Unfortunately we have not yet received it back 
from you (if it is in the post, sorry to bother you and please ignore this reminder).   
 
We are keen to find out how you have been getting on since your varicose veins were treated.  It is 
very important for the success of the study that we have as much information as possible about 
you.   
 
Some of the questions may not seem relevant but we would be very grateful if you could try to fill 
them all in.  If you have any problems in completing the questionnaires, a friend or relative may be 
able to help you.  Alternatively, please contact the CLASS Study Office; we will be happy to help in 
any way we can. 
 
Please return the questionnaire in the reply-paid envelope provided. 
 
In the meantime, if you require any further help or information about the Study, please contact the 
Study office. 
 
 
Yours sincerely 
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6 MONTH ASSESSMENT 
Study Number       
 
STUDY LEG   Date of 6 month assessment 
 
Right   Left    D D / M M / Y Y Y Y 
 
DUPLEX SCAN Complete for study leg only 
       
 Not examined 
Complete 
occlusion 
(absent) 
Partial 
occlusion 
No 
occlusion 
(patent) 
If patent,  
is reflux 
     Present Absent 
Groin - long saphenous  
(flush with CFV – i.e within 1cm)       
       
Groin - long saphenous (within 
3cm of CFV)       
       
Common femoral/superficial 
vein*       
       
Mid thigh - long saphenous       
       
Above knee - long saphenous        
       
Below knee - long saphenous       
       
Short saphenous (flush with 
popliteal - i.e. within 1cm)       
       
Short saphenous (within 3cm  
of popliteal)        
       
Popliteal vein*       
       
Mid calf - short saphenous       
* Occlusion in the common femoral vein or popliteal fossa-popliteal vein (DVT) should be reported 
as a Serious Adverse Event (if not already reported) 
 
Name of person performing duplex 
scan 
 
 
Date of duplex scan D D / M M / Y Y Y Y 
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CEAP CLASSIFICATION  
Complete for study leg only - Please tick appropriate response 
 C0   No visible or palpable signs of venous disease. 
 C1  Telangiectasis or reticular veins. Veins less than 3 mm 
 C2  Varicose veins. Veins over 3 mm 
 C3  Edema 
 C4  Skin and subcutaneous changes 
 C4a  Pigmentation or eczema 
 C4b  Lipodermatosclerosis or atrophie blanche 
 C5  Healed venous ulcer 
 C6  Active venous ulcer 
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VENOUS CLINICAL SEVERITY SCORE (VCSS)  
Complete for study leg only 
PAIN     
 None  Occasional, not 
restricting activity 
or requiring 
analgesics 
 Daily, moderate 
activity limitation, 
occasional 
analgesics 
 Daily, severe 
limiting activities or 
requiring regular 
use of analgesics 
 
VARICOSE VEINS i.e. >3mm 
    
 None  Few, scattered 
branch varicose 
veins 
 Multiple: GSV 
varicose veins 
confined to calf or 
thigh 
 Extensive: thigh 
and calf or GSV 
and SSV 
distribution 
 
VENOUS EDEMA 
    
 None  Evening ankle  
only 
 Afternoon edema, 
above ankle 
 Morning edema 
above ankle and 
requiring activity 
change, elevation 
 
SKIN PIGMENTATION 
    
 None or 
focal, low 
intensity 
(tan) 
 Diffuse, but  
limited in area  
and old (brown) 
 Diffuse over most of 
gaiter area (lower 
1/3) or recent 
pigmentation (purple) 
 Wider distribution 
(above lower 1/3), 
recent pigmentation 
 
INFLAMMATION 
    
 None  Mild cellulitis, 
limited to  
marginal area 
around ulcer 
 Moderate cellulitis, 
involves most of 
gaiter area (lower 
2/3) 
 Severe cellulitis 
(lower 1/3 and 
above) or 
significant venous 
eczema 
 
INDURATION 
    
 None  Focal, circum-
malleolar (<5 cm) 
 Medial or lateral, less 
than lower 1/3 of leg 
 Entire lower 1/3 of 
leg or more 
 
ACTIVE ULCERS, N 
    
 0  1  2  >2 
 
ACTIVE ULCERATION DURATION 
    
 None  <3 months  >3 months, <1year  Not healed >1 year 
 
ACTIVE ULCER, SIZE 
    
 None  <2 cm diameter  2-6 cm diameter  >6 cm diameter 
 
COMPRESSIVE THERAPY 
    
 Not used  
or not 
compliant 
 Intermittent use  
of stockings 
 Wears elastic 
stockings most days 
 Full compliance: 
stockings + 
elevation 
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COMPLICATIONS 
Numbness 
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Persistent tenderness/discomfort  
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Skin loss/ulceration 
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Lumpiness 
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Development of thread vein 
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Skin staining 
 Yes  No  
     
 If yes: state distribution/dimensions  
    
Deep vein thrombosis* 
 Yes  No  
     
 If yes: state distribution/dimensions  
      
Pulmonary embolus* 
 Yes  No  
     
 If yes: give details of severity  
    
Other 
 Yes  No  
     
If yes, give details  
 
*If not already reported as a serious adverse event, details of these should be reported 
as a serious adverse event 
HOSPITAL ADMISSIONS 
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  Yes  No  
Has the participant been admitted to hospital for 
any reason since the six week assessment?     
If yes, give reason  
 
Hospital admitted to  
  
   Date admitted D D / M M / Y Y Y Y 
 
   Date discharged D D / M M / Y Y Y Y 
 
TREATMENT TO STUDY LEG OUTWITH THE CLASS TRIAL PROTOCOL 
Has the participant had treatment to the study 
leg outwith the CLASS trial protocol since being 
recruited to CLASS? 
Yes  No  
    
  
  If yes, give date of treatment  D D / M M / Y Y Y Y 
 
details of treatment  
 
TREATMENT TO CONTRALATERAL LEG 
Has the participant had treatment to the 
contralateral leg since being recruited to 
CLASS? 
Yes  No  
    
  If yes, give date of treatment  D D / M M / Y Y Y Y 
 
details of treatment  
 
DUPLEX SCANS TO STUDY LEG 
Apart from the scans undertaken at recruitment 
and at six week and six month follow-up, has the 
participant had any additional scans to the 
study leg since being recruited to CLASS? 
Yes  No  
    
  If yes, give number of additional scans      
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Study Number 
      
 
 
 
 
 
 
 
Comparison of LAser, Surgery and foam Sclerotherapy 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
 
 
 
 
 
Thank you for helping us with our research. 
We would be very grateful if you could complete this 
questionnaire. 
 
 
 
 
 
 
 
 
 
ISRCTN51995477 
EudraCT  2008-001069-26 
Version 4 
April 2010 
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X 
M
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SECTION A: DESCRIBING YOUR OWN HEALTH TODAY  (EQ-5D) 
 
By placing a cross in one box in each group below, please indicate which statements best describe 
your own health state today 
 
A1. Mobility I have no problems in walking about  
   
 I have some problems in walking about  
   
 I am confined to bed  
 
 
  
A2. Self-care I have no problems with self-care  
   
 I have some problems washing or dressing myself  
   
 I am unable to wash or dress myself  
 
 
  
A3. Usual Activities 
 (e.g. work, study,  
 housework, family or 
 leisure activities) 
I have no problems with performing my usual 
activities  
  
I have some problems with performing my usual 
activities  
   
 I am unable to perform my usual activities  
 
 
  
A4. Pain/Discomfort I have no pain or discomfort  
   
 I have moderate pain or discomfort  
   
 I have extreme pain or discomfort  
 
 
  
A5. Anxiety/Depression I am not anxious or depressed  
   
 I am moderately anxious or depressed  
   
 I am extremely anxious or depressed  
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A6. Please indicate on this scale how good 
or bad your own health state is today. 
 
 The best health state you can imagine 
is marked 100 and the worst health 
state you can imagine is marked 0. 
 
 
 Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
state is today.   
Your 
health 
state 
today 
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SECTION B: YOUR GENERAL HEALTH (SF-36) 
 
Please fill in all the questions by crossing the relevant box of the answer that applies to you.  These 
questions ask for your views about your health and how you feel about life in general.  Do not spend 
too much time in answering as your immediate response is likely to be the most accurate, but please 
make sure you answer every question. 
 
B1. In general, would you say your health is? 
      
 Excellent Very good Good Fair Poor 
 
     
 
B2. Compared to one year ago, how would you rate your health in general now? 
     
 Much better  
now than one  
year ago 
Somewhat better 
now than one  
year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one  
year ago 
Much worse  
now than one  
year ago 
 
     
 
B3. The following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much? 
     
  Yes, 
limited  
a lot 
Yes, 
limited  
a little 
No, not 
limited  
at all 
     
 a) Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sport    
     
 b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling or playing golf    
     
 c) Lifting or carrying groceries    
     
 d) Climbing several flights of stairs    
     
 e) Climbing one flight of stairs    
     
 f) Bending, kneeling or stooping    
     
 g) Walking more than one mile    
     
 h) Walking several hundred yards    
     
 i) Walking one hundred yards    
     
 j) Bathing and dressing yourself    
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B4. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Were limited in the kind of work or other 
activities      
       
 d) Had difficulty performing the work or other 
activities (for example it took extra effort)      
       
 
 
 
B5. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other daily regular activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
       
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 a) Cut down on the amount of time  
you spent on work or other activities      
       
 b) Accomplished less than you would like 
     
       
 c) Did work or other activities less carefully 
than usual      
       
 
 
 
B6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
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B7. How much bodily pain have you had during the past 4 weeks? 
       
 None Very mild Mild Moderate Severe Very severe 
 
      
 
 
 
B8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
outside the home and housework)? 
      
 Not at all A little bit Moderately Quite a bit Extremely 
 
     
 
 
 
B9. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you 
have been feeling.  How much of the time during the past 4 weeks  
  All of  
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
       
 a) Did you feel full of life?      
       
 b) Have you been very nervous?      
       
 c) Have you felt so down in the dumps that 
nothing could cheer you up?      
       
 d) Have you felt calm and peaceful?      
       
 e) Did you have a lot of energy?      
       
 f) Have you felt downhearted and depressed?      
       
 g) Did you feel worn out?      
       
 h) Have you been happy?      
       
 i) Did you feel tired?      
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B10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives etc)? 
      
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 
     
 
B11. How TRUE or FALSE is each of the following statements for you? 
       
  Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
 a) I seem to get sick a little easier than other 
people      
       
 b) I am as healthy as anyone I know      
       
 c) I expect my health to get worse      
       
 d) My health is excellent      
 
 
SECTION C: YOUR VARICOSE VEINS 
 
C1. Please draw in your varicose veins in the diagram(s) below:- 
 
 
 
 
 
  
Legs viewed 
from the front 
Legs viewed 
from the back 
Left Right 
Right Left 
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C2. In the last two weeks, for how many days did your varicose veins cause you  pain or ache?   
(Please cross one box for each leg) 
 Right Leg Left Leg 
 None at all   
 Between 1 and 5 days   
 Between 6 and 10 days   
 For more than 10 days   
 
 
C3. During the last two weeks, on how many days did you take painkilling tablets for your varicose 
veins?  (Please cross one box) 
 None at all  
 Between 1 and 5 days  
 Between 6 and 10 days  
 For more than 10 days  
 
 
C4. In the last two weeks, how much ankle swelling have you had?  (Please cross one box) 
 None at all  
 Slight ankle swelling  
 Moderate ankle swelling (causing you to 
 sit with your feet up whenever possible)  
 Severe ankle swelling (causing you 
 difficulty putting on your shoes)  
 
 
C5. In the last two weeks, have you worn support stockings or tights?  (Please cross one box for 
each leg) 
 Right Leg Left Leg 
 No   
 Yes, those I bought myself without  a doctor’s prescription   
 Yes, those my doctor prescribed  for me which I wear occasionally    
 Yes, those my doctor prescribed  for me which I wear every day   
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C6. In the last two weeks, have you had any itching in association with your varicose veins?  
(Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but only above the knee   
 Yes, but only below the knee   
 Both above and below the knee   
 
C7. Do you have any purple discolouration caused by tiny blood vessels in the skin, in association 
with your varicose veins? (Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
C8. Do you have a rash or eczema in the area of your ankle?  (Please cross one box for each leg) 
 Right Leg Left Leg 
 No   
 Yes, but it does not require any  treatment from a doctor or district nurse   
 Yes, and it requires treatment  from my doctor or district nurse   
 
C9. Do you have a skin ulcer associated with your varicose veins?  (Please cross one box for each 
leg) 
 Right Leg Left Leg 
 No   
 Yes   
 
C10. Does the appearance of your varicose veins cause you concern?  (Please cross one box) 
 No  
 Yes, their appearance causes 
 me slight concern  
 Yes, their appearance causes 
 me moderate concern  
 Yes, their appearance causes 
 me a great deal of concern  
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C11. Does the appearance of your varicose veins influence your choice of clothing including 
tights?  (Please cross one box) 
 No  
 Occasionally  
 Often  
 Always  
 
 
 
C12. During the last two weeks, have your varicose veins interfered with your work/ housework or 
other daily activities? (Please cross one box) 
 No  
 I have been able to work but my work 
 has suffered to a slight extent  
 I have been able to work but my work 
 has suffered to a moderate extent  
 My veins have prevented me from 
 working one day or more  
 
 
 
C13. During the last two weeks have your varicose veins interfered with your leisure activities 
(including sport, hobbies and social life)?  (Please cross one box) 
 No  
 Yes, my enjoyment has suffered 
 to a slight extent  
 Yes, my enjoyment has suffered 
 to a moderate extent  
 Yes, my veins have prevented me 
 taking part in any leisure activities  
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SECTION D: YOUR SYMPTOMS 
 
Listed below are a number of symptoms that you may or may not have experienced since you 
developed varicose veins.   
 
Please indicate by crossing Yes or No whether you have experienced any of these symptoms since you 
developed varicose veins, and whether you believe that these symptoms are related to your varicose 
veins. 
 
  I have experienced  
this symptom  
since I developed 
varicose veins 
 This symptom is  
related to my varicose 
veins 
D1. Pain  Yes  No   Yes  No  
D2. Hardening of the skin on the 
legs  Yes  No   Yes  No  
D3. Redness of the skin on the 
legs 
 
 Yes  No   Yes  No  
D4. Sleep difficulties  Yes  No   Yes  No  
D5. Swelling of the ankle  Yes  No   Yes  No  
D6. Discolouration or brown 
staining on the leg 
 
 Yes  No   Yes  No  
D7. Stiff joints  Yes  No   Yes  No  
D8. Weight loss  Yes  No   Yes  No  
D9. Dizziness  Yes  No   Yes  No  
D10. Fatigue  Yes  No   Yes  No  
D11. Breaks in the skin or ulcers 
on the leg 
 
 Yes  No   Yes  No  
D12. Sore eyes  Yes  No   Yes  No  
D13. Breathlessness  Yes  No   Yes  No  
D14. Loss of strength  Yes  No   Yes  No  
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SECTION E: YOUR VIEWS ABOUT YOUR VARICOSE VEINS 
 
We are interested in your own personal views of how you now see your varicose veins.  Please 
indicate how much you agree or disagree with the following statements about your varicose veins by 
crossing the appropriate box. 
 
Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E1. My varicose veins will last a 
short time       
E2. My varicose veins are likely to 
be permanent rather than 
temporary 
      
E3. My varicose veins will last for a 
long time       
E4. These varicose veins will pass 
quickly       
E5. I expect to have these varicose 
veins for the rest of my life       
E6. My varicose veins are a serious 
condition       
E7. My varicose veins have major 
consequences on my life       
E8. My varicose veins do not have 
much effect on my life       
E9. My varicose veins strongly affect 
the way others see me       
E10. My varicose veins have serious 
financial consequences       
E11. My varicose veins cause 
difficulties for those who are 
close to me 
      
E12. There is a lot which I can do to 
control my symptoms       
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Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E13. What I do can determine 
whether my varicose veins get 
better or worse 
      
E14. The course of my varicose veins 
depends on me       
E15. Nothing I do will affect my 
varicose veins       
E16. I have the power to influence my 
varicose veins       
E17. My actions will have no effect on 
the outcome of my varicose 
veins 
      
E18. My varicose veins will improve 
in time       
E19. There is very little that can be 
done to improve my varicose 
veins 
      
E20. My treatment will be effective in 
curing my varicose veins       
E21. The negative effects of my 
varicose veins can be prevented 
(avoided) by my treatment 
      
E22. My treatment can control my 
varicose veins       
E23. There is nothing which can help 
my varicose veins       
E24. The symptoms of my varicose 
veins are puzzling to me       
E25. My varicose veins are a mystery 
to me       
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Views about your  
varicose veins 
 Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
E26. I don’t understand my varicose 
veins       
E27. My varicose veins don’t make 
any sense to me       
E28. I have a clear picture or 
understanding of my varicose 
veins 
      
E29. The symptoms of my varicose 
veins change a great deal from 
day to day 
      
E30. My symptoms come and go in 
cycles       
E31. My varicose veins are very 
unpredictable       
E32. I go through cycles in which my 
varicose veins get better and 
worse 
      
E33. I get depressed when I think 
about my varicose veins       
E34. When I think about my varicose 
veins I get upset       
E35. My varicose veins make me feel 
angry       
E36. My varicose veins do not worry 
me       
E37. Having these varicose veins 
makes me feel anxious       
E38. My varicose veins make me feel 
afraid       
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SECTION F: CAUSES OF YOUR VARICOSE VEINS 
We are interested in what you consider may have been the cause of your varicose veins.  As people are 
very different, there is no correct answer for this question.  We are most interested in your own views 
about the factors that caused your varicose veins rather than what others including doctors or family 
may have suggested to you.  Below is a list of possible causes for your varicose veins.  Please indicate 
how much you agree or disagree that they were causes for you by crossing the appropriate box. 
 
Possible causes  Strongly 
disagree 
Disagree Neither 
agree nor 
disagree 
Agree Strongly 
agree 
F1. Stress or worry       
F2. Hereditary - it runs in my family       
F3. A germ or virus       
F4. Diet or eating habits       
F5. Chance or bad luck       
F6. Poor medical care in my past       
F7. Pollution in the environment       
F8. My own behaviour       
F9. My mental attitude, e.g. thinking 
about life negatively       
F10. Family problems or worries 
caused my varicose veins       
F11. Overwork       
F12. My emotional state, e.g. feeling 
down, lonely, anxious, empty       
F13. Ageing       
F14. Alcohol       
F15. Smoking       
F16. Accident or injury       
F17. My personality       
F18. Altered immunity       
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In the table below, please list in rank-order the three most important factors that you now believe 
caused your illness.  You may use any of the items from the box above, or you may have additional 
ideas of your own. 
 
The most important causes for me:- 
 
 
1.
  
 
 
 
 
 
 
  
 
 
2.
  
 
 
 
 
 
 
  
 
 
3.
  
 
 
 
 
 
 
 
  
 
 
 
SECTION G: YOUR MOST RECENT ADMISSION TO HOSPITAL 
 
This section of the questionnaire will help us to find out how much it costs you to use health 
services. We will ask about your most recent admission to hospital, your most recent outpatient 
appointment and your most recent appointment with a GP.  We wish to know how much money and 
time were spent by you and any companion in attending these appointments and as a result of any 
hospital admission you may have had.  
 
 
If, in the last 6 months, you were not admitted to hospital please go to Section H. 
G1.  Please cross the box that best describes how you travelled.  If you used more than one form of 
transport please indicate the way you travelled for the main (longest in terms of distance) part 
of your journey. 
 
Bus   Hospital car  
Train  Ambulance  
Taxi   Other (please specify below)  
Private car     
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 G2. If you travelled by bus, train or taxi to hospital what was the total cost of the (one-way) 
journey?  Please write the cost in the box below.  Please put zero if you did not travel by bus, 
train or taxi at all or if you did not pay a fare. 
 
Cost of (one-way) fare (£) − pence 
 
G3. If you travelled by private car about how many miles did you travel one-way?  Please write the 
number of miles in the box below.  Please put zero if you did not travel by private car at all. 
 
 
 
G4. If you travelled by private car and you or your companion had to pay a parking fee how much 
did this cost?  Please write the cost in the box below.  Please put zero if you did not pay a 
parking fee. 
 
Expenditure on parking fee (£)   −   pence 
 
 
G5. When you were admitted to the hospital, how long did you spend there?  Please write the 
number of days in the box below.  
 
Number of days    
 
G6. What would you otherwise have been doing as your main activity if you had not had to be 
admitted to hospital? Please cross the box that best applies to you.  
 
Paid work  Unemployed  
Housework  Voluntary work  
Childcare  Leisure activities  
Caring for a relative or friend  Other (please specify below)  
  
  
Number of miles one-way      
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 G7. When you were admitted to hospital, did anyone come with you?   
 
Yes  Go to G8 
 
No  Go to Section H 
 
 
G8. Who accompanied you to the hospital?  Please cross the box that best describes the main 
person who accompanied you to the hospital.  
 
Partner/spouse   Paid caregiver  
Other relative   Other (please specify below)  
Friend    
 
G9. Please cross the box that best describes what your main companion would otherwise have 
been doing as their main activity if they had not gone with you to the hospital. 
 
Paid work   Unemployed  
Housework  Voluntary work  
Childcare   Leisure activities  
Caring for a relative or friend   Other (please specify below)  
    
 
 
G10. Did your main companion take time off from paid work (or business activity if self-employed)?   
 
Yes  Go to G11 
No  Go to Section H 
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 G11. Please write the number of hours your companion took off from paid work (or business activity 
if self-employed) in the box below.  Please put zero if your main companion did not take time 
off from paid work (or business activity if self-employed) to accompany you to the hospital. 
 
 
Number of hours    
 
 
G12. Whilst you were in hospital, approximately how many times did your main 
companion come to visit you? 
 
Number of times    
 
 
SECTION H: YOUR MOST RECENT OUTPATIENT VISIT 
 
If, in the last 6 months, you did not have an outpatient’s appointment, please go to Section I.   
 
H1.  Please cross the box that best describes how you travelled.  If you used more than one form of 
transport please indicate the way you travelled for the main (longest in terms of distance) part 
of your journey. 
 
Bus   Hospital car  
Train   Ambulance  
Taxi   Other (please specify below)  
Private car    
 
H2. If you travelled by bus, taxi or train to hospital what was the total cost of the (one-way) 
journey?  Please write the cost in the box below.  Please put zero if you did not travel by bus, 
train or taxi at all or if you did not pay a fare. 
 
Cost of (one-way) fare (£)   −   pence 
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 H3. If you travelled by private car about how many miles did you travel one-way?  Please write the 
number of miles in the box below.  Please put zero if you did not travel by private car at all. 
 
Number of miles one-way      
 
 
H4. If you travelled by private car and you or your companion had to pay a parking fee how much 
did this cost?  Please write the cost in the box below.  Please put zero if you did not pay a 
parking fee. 
 
Expenditure on parking fee (£)   − 
  pence 
 
 
H5. When you visited outpatients, how long did it take to travel there?  Please write the number of 
hours and minutes in the box below. 
 
Number of hours   − 
  minutes 
 
 
H6. When you visited outpatients, how long did you spend there?  Please write the number hours 
and minutes in the box below.  
 
Number of hours   − 
  minutes 
 
H7. Please cross the box that best describes what you otherwise would have been doing as your 
main activity if you had not been visiting outpatients? 
 
Paid work  Unemployed  
Housework  Voluntary work  
Childcare  Leisure activities  
Caring for a relative or friend  Other (please specify below)  
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 H8. When you visited outpatients did anyone come with you?   
 
Yes  Go to H9 
No  Go to Section I 
 
H9. Please cross the box that best describes the main person who accompanied you to 
outpatients. 
 
Partner/spouse   Paid caregiver  
Other relative  Other (please specify below)  
Friend    
 
 
H10. If your main companion travelled with you by bus or train approximately how much did they 
pay (one-way) in fares?  Please write the approximate cost in the box below.  Please put zero if 
your main companion did not travel by bus or train at all. 
 
Cost of (one-way) fare (£)   − 
  pence 
 
 
H11. Please cross the box that best describes what your main companion would otherwise have 
been doing as their main activity if they had not gone with you to outpatients. 
 
Paid work   Unemployed  
Housework  Voluntary work  
Childcare   Leisure activities  
Caring for a relative or friend   Other (please specify below)  
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 SECTION I: YOUR MOST RECENT GP APPOINTMENT 
 
I1. Please cross the box that best describes how you travelled to your most recent GP appointment.  
If you used more than one form of transport please indicate the way you travelled for the main 
(longest in terms of distance) part of your journey. 
 
Walked   Bus  
Cycled  Taxi  
Private car   Other (please specify below)  
    
 
 
I2. If you travelled by bus or taxi, what was the cost of the (one-way) fare?  Please write the cost in 
the box below.  Please put zero if you did not travel by bus or taxi or if you did not pay the fare. 
 
Cost of (one-way) fare (£)   −   pence 
 
 
I3. If you travelled by private car about how many miles did you travel one-way?  Please write the 
number of miles in the box below.  Please put zero if you did not travel by private car at all. 
 
Number of miles one-way      
 
 
I4. If you travelled by private car and you or a companion had to pay a parking fee how much did 
this cost?  Please write the cost in the box below.  Please put zero if you did not pay for parking. 
 
Expenditure on parking fee (£)   −   pence 
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 I5. When you visited the GP, how long did it take to travel there?  Please write the number of 
minutes in the box below. 
 
Number of minutes     
 
 
I6. When you visited the GP, how long did you spend there?  Please write the number minutes in the 
box below.  Please include in your answer the time spent waiting and also the time spent with 
the doctors and nurses   
 
Number of minutes     
 
 
I7. Please cross the box that best describes what you otherwise would have been doing as your 
main activity if you had not visited the GP. 
 
Paid work  Unemployed  
Housework  Voluntary work  
Childcare  Leisure activities  
Caring for a relative or friend  Other (please specify below)  
   
 
 
I8. When you visited the GP did anyone come with you?   
 
 
Yes  Go to I9 
No  Go to Section J 
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 I9. Please cross the box(es) that best describe the person(s) who accompanied you to the GP 
surgery.   
 
Partner/spouse   Paid caregiver  
Other relative   Other (please specify below)  
Friend    
 
 
I10. If your main companion travelled with you by bus how much approximately did they pay (one-
way) in fares (if anything)?  Please write the cost in the box below.  Please put zero if your 
main companion did not travel by bus at all. 
 
Cost of (one-way) fare (£)   − 
  pence 
 
 
I11. Please cross the box that best describes what your main companion would otherwise have 
been doing as their main activity if they had not gone with you to the GP's surgery. 
 
Paid work   Unemployed  
Housework  Voluntary work  
Childcare   Leisure activities  
Caring for a relative or friend   Other (please specify below)  
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SECTION J: HEALTH SERVICE UTILISATION QUESTIONNAIRE 
Please try to complete all the questions.  Most questions can be answered by putting numbers or a 
cross in the appropriate boxes.  In a few questions you are asked to write some details.  This set of 
questions is about any appointments you may have had with a general practice in the past 6 months. 
 
J1.  Have you been to see a GP because of your varicose veins during the last  6 months? 
 
 Yes No  
    
  If Yes, please give details: 
 
How many appointments did you attend with a GP because of your varicose veins?   
 
How many times did a GP visit you at home because of your varicose veins?   
 
How many times did you have a telephone conversation with a GP because of your 
varicose veins? 
  
 
 
J2.  Please make a list below of all the medication you currently take: 
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This set of questions is about any appointments you may have had with other health care workers in 
the past 6 months. 
 
 
J3.  During the last 6 months have you had an appointment with any of these  care providers 
because of your varicose veins: 
A District Nurse? Yes  No  
If Yes, how many appointments have you had?      
A Practice Nurse? Yes  No  
If Yes, how many appointments have you had?      
An NHS physiotherapist? Yes  No  
If Yes, how many appointments have you had?      
An Occupational Therapist? Yes  No  
If Yes, how many appointments have you had?      
Other? (please specify below) Yes  No  
    
  
How many appointments have you had?      
 
   
  
How many appointments have you had?     
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This set of questions is about any private health care you may have had in the past 6 months 
 
J4.  During the last 6 months have you paid for any private health care for your   varicose 
veins?   
 Yes No  
    
 
 If Yes, what sort of care did you pay for? 
  
  
 
 
If Yes, and you had appointments, how many appointments did you have?   
 
 
 
If you wish to provide further information please do so in the box below. 
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 THANK YOU 
 
 
Thank you very much for your time and patience in filling in this questionnaire.  Please 
hand the questionnaire back to the nurse or return it in the enclosed reply-paid envelope 
to the Trial Office in Aberdeen. 
  
The information you have given us will be extremely useful in helping us carry out 
research. It will be treated with the strictest confidence and kept securely. 
 
 
 
Thank you again for your help 
 
If you would like any further information or have any queries about the study,  
please contact: 
 
 
The CLASS Trial Office in Aberdeen (Tel: 01224 XXXXXX) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study is taking place across the UK but the questionnaires are being processed in Aberdeen at  
The Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit,  
Health Sciences Building, Foresterhill, ABERDEEN, AB25 2ZD.
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
CASE NOTE DATA ABSTRACTION FORM:  
USE OF SERVICES 
 
(Use of hospital services from discharge following index 
admission until the end of the last day of follow-up) 
 
 
Study Number       
 
 
Date randomised D D / M M / Y Y Y Y 
 
 
Last day of follow-up D D / M M / Y Y Y Y 
 
 
 
1. Has the patient been admitted to hospital? 
Yes  No  
If Yes, please give details below 
Specialty Date admitted Date discharged 
e.g. general surgery  2 2 / 0 7 / 2 0 0 8  0 8 / 0 8 / 2 0 0 8 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
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2. Has the patient had another operation? 
Yes  No  
If Yes, please give details below 
Specialty Date admitted Date discharged 
e.g. general surgery  2 2 / 0 7 / 2 0 0 8  0 8 / 0 8 / 2 0 0 8 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
  
  D D / M M / Y Y Y Y  D D / M M / Y Y Y Y 
 
 
 
 
3. Has the patient had any outpatient visits to the following specialties/departments?  
 
Surgical Yes  If Yes, how many visits? 
 
 No    
     
Ear, Nose & Throat Yes  If Yes, how many visits? 
 
 No    
     
Medical  Yes  If Yes, how many visits? 
 
 No    
     
Sexual Medicine/Urology Yes  If Yes, how many visits? 
 
 No   
 
     
Physiotherapy Yes  If Yes, how many visits? 
 
 No   
 
     
Occupational Therapy Yes  If Yes, how many visits?  
 No    
     
Dietician Yes  If Yes, how many visits?  
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 No    
     
Pain Team Yes  If Yes, how many visits?  
 No    
     
Other?  Yes  If yes, please specify below 
 No   
 
 How many visits?  
 
 How many visits?  
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Comparison of LAser, Surgery  
and foam Sclerotherapy 
SERIOUS ADVERSE 
EVENT REPORT 
To be completed for any serious adverse event, whether they 
are expected or unexpected, related or unrelated. 
An event is deemed “serious” if the patient died; it involved or prolonged 
inpatient hospitalization; it involved persistent or significant disability or 
incapacity; was life threatening; or resulted in congenital anomaly or birth 
defect. 
The events defined as expected are deep vein thrombosis, pulmonary 
embolism, anaphylactic shock, stroke, retinal arteriole occlusion, myocardial 
infarction, cutaneous necrosis and ulceration, epileptic fit, intra-arterial 
injection, injury to a major artery (common femoral or superficial femoral), 
injury to a major vein (common femoral or popliteal), injury to a motor nerve 
(femoral, tibial or peroneal), transient ischemic attack. 
A. Patient Details 
Hospital number  Study No.       
 
Patient’s initials   
 
Date of birth D D / M M / Y Y Y Y 
     
Age     
     
Sex  Male  Female   
 
Treating Hospital  
 
B. Adverse Event 
 
Place where adverse event took 
place / detected 
 
Date of event D D / M M / Y Y Y Y 
 
Brief details of adverse event 
 
 
 
 
 
 
Date of report D D / M M / Y Y Y Y 
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C. Cross all boxes appropriate to adverse event. 
 If any box is crossed the adverse event is serious 
 
Patient died   
Involved or prolonged inpatient hospitalisation   
Involved persistent or significant disability or incapacity   
Life threatening   
Congenital anomaly/birth defect   
An important medical event that may not be immediately life-threatening or result 
in death or hospitalisation but may jeopardise the patient or may require 
intervention to prevent one of the other outcomes listed in the definition above 
 
 
 
D. What treatment for varicose veins had the patient received? 
Laser treatment  Date(s) of procedure D D / M M / Y Y Y Y 
 
   D D / M M / Y Y Y Y 
 
Surgery  Date(s) of procedure D D / M M / Y Y Y Y 
 
   D D / M M / Y Y Y Y 
 
Foam sclerotherapy  
 
Date(s) and dose(s) of Fibrovein administered   
 
           Concentration Volume of foam 
 Batch number 
1. D D / M M / Y Y Y Y  %  ml   
                 
2. D D / M M / Y Y Y Y  %  ml   
                 
3. D D / M M / Y Y Y Y  %  ml   
                 
4. D D / M M / Y Y Y Y  %  ml   
 
Route of administration Intravenous 
   
Indication(s) for use Treatment of varicose veins (in CLASS trial) 
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E. Was the adverse event ‘expected’? 
 
Is this serious adverse event one of: 
 
· Deep vein thrombosis [following foam, laser, surgery] 
· Pulmonary embolism [following foam, laser, surgery] 
· Anaphylactic shock [following foam] 
· Stroke [following foam] 
· Retinol arterial occlusion [following foam] 
· Myocardial infarction [following foam] 
· Cutaneous necrosis and ulceration [following foam] 
· Epileptic fit [following foam] 
· Intra-arterial injection [following foam] 
· Injury to a major artery (common femoral or superficial femoral) [following 
surgery] 
· Injury to a major vein (common femoral or popliteal) [following foam, laser, 
surgery] 
· Injury to a motor nerve (femoral, tibial or peroneal) [following surgery] 
· Transient Ischemic Attack [following foam] 
 
and therefore an “expected” serious adverse event? 
 
 
Yes   
No  If NO, this could be a SUSAR 
 
F. Concomitant drug(s) and history 
Concomitant drug(s) and dates of 
administration (exclude those used to 
treat reaction) 
 
 
 
 
 
 
 
 
Other relevant history (e.g. 
diagnostics, allergies etc) 
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G. Assessment of whether event was caused by study intervention 
 
Is it reasonably likely that adverse event was caused by the study intervention? 
 Yes  No  
 
Why?  
 
 
 
 
Name and position of person 
making this judgement  
 
Date of assessment D D / M M / Y Y Y Y 
 
Any subsequent information   
 
 
 
 
 
 
H. Contact details for person initially reporting adverse event 
Name   
 
Address 
 
 
 
 
Telephone  
Email  
 
I. Manufacturing and packaging information for fibrovein 
 Complete only if patient received foam sclerotherapy 
 
Name and address  
of manufacturer 
CP Pharmaceuticals Ltd 
Wrexham Industrial Estate, Wrexham, Clwyd, LL13 
9UF 
 
Date report sent to manufacturer D D / M M / Y Y Y Y 
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Appendix 2 Additional trial results tables
TABLE 106 Pain scores during treatment and at 6 weeks following treatment: comparison of foam sclerotherapy
with surgery
Pain VAS scores
Randomised to foam
sclerotherapy
Randomised to
surgery Surgery vs. foam sclerotherapya
n Mean SD n Mean SD Effect size 95% CI p-value
Pain VAS scores completed
immediately after treatment
226 2.2 1.9 163 2.3 2.6 0.06 −0.38 to 0.50 0.796
Pain VAS scores completed
at 6 weeks
During treatment 240 3.0 2.4 227 4.0 3.0 1.04 0.57 to 1.52 < 0.001
During recovery 239 3.0 2.4 229 4.3 2.8 1.21 0.76 to 1.66 < 0.001
a Where the effect size is positive, this favours foam sclerotherapy.
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TABLE 108 Illness perception: comparison of foam sclerotherapy with surgery
Illness perception component Randomised to foam sclerotherapy Randomised to surgery
Identity score
Baseline (n, mean, SD) 265 2.6 1.5 274 2.9 1.6
Post randomisation (n, mean, SD) 137 2.7 1.5 117 3.1 1.6
6 months (n, mean, SD) 212 2.4 1.6 179 2.1 1.7
Percentage of symptoms correctly identified as being related to varicose veins
Baseline (n, mean, SD) 263 74.7% 29.8% 274 75.2% 27.4%
Post randomisation (n, mean, SD) 136 79.3% 27.1% 121 78.3% 25.8%
6 months (n, mean, SD) 205 82.1% 27.2% 154 77.1% 31.4%
Timeline acute/chronic
Baseline (n, mean, SD) 280 23.7 4.8 280 23.6 4.5
Post randomisation (n, mean, SD) 142 23.5 4.6 125 23.8 4.8
6 months (n, mean, SD) 228 21.0 5.2 196 21.2 5.1
Timeline cyclical
Baseline (n, mean, SD) 279 10.7 3.4 280 10.9 3.2
Post randomisation (n, mean, SD) 142 10.5 3.1 126 11.0 3.3
6 months (n, mean, SD) 228 9.6 3.2 199 9.9 3.2
Consequences
Baseline (n, mean, SD) 281 15.9 4.2 281 16.1 4.4
Post randomisation (n, mean, SD) 142 16.1 4.0 126 15.6 4.3
6 months (n, mean, SD) 227 13.6 4.0 196 13.9 4.1
Personal control
Baseline (n, mean, SD) 279 18.6 4.2 279 18.3 3.8
Post randomisation (n, mean, SD) 142 18.7 3.8 126 18.4 4.2
6 months (n, mean, SD) 227 19.0 4.2 197 18.9 4.1
Treatment control
Baseline (n, mean, SD) 279 19.5 2.5 278 19.3 2.3
Post randomisation (n, mean, SD) 141 19.1 2.5 126 19.0 2.3
6 months (n, mean, SD) 227 18.8 2.8 197 18.4 2.9
Illness coherence
Baseline (n, mean, SD) 276 17.7 4.1 277 17.6 3.7
Post randomisation (n, mean, SD) 142 17.9 4.1 125 18.2 4.2
6 months (n, mean, SD) 225 18.2 3.8 196 18.6 3.9
Emotional representations
Baseline (n, mean, SD) 281 15.4 4.5 280 14.9 4.7
Post randomisation (n, mean, SD) 142 15.6 4.5 126 15.1 5.0
6 months (n, mean, SD) 228 13.4 4.6 200 13.5 4.3
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TABLE 109 Illness perception: comparisons of EVLA with foam sclerotherapy, and surgery with EVLA
Illness perception Randomised to EVLA
Randomised to foam
sclerotherapy
Randomised to
surgery
Identity score
Baseline (n, mean, SD) 195 2.7 1.5 193 2.6 1.6 202 2.9 1.5
Post randomisation (n, mean, SD) 84 2.9 1.7 88 2.6 1.5 73 3.1 1.7
6 months (n, mean, SD) 141 2.2 1.7 149 2.3 1.6 125 2.1 1.7
Percentage of symptoms correctly identified as being related to varicose veins
Baseline (n, mean, SD) 200 72.4% 31.1% 193 73.8% 30.1% 201 75.1% 28.4%
Post randomisation (n, mean, SD) 83 75.8% 27.8% 87 78.7% 27.6% 77 77.1% 27.1%
6 months (n, mean, SD) 133 79.0% 32.5% 147 79.6% 29.2% 108 74.2% 33.1%
Timeline acute/chronic
Baseline (n, mean, SD) 209 23.6 4.7 206 23.4 4.8 206 23.1 4.5
Post randomisation (n, mean, SD) 90 23.1 4.7 92 23.4 4.7 80 23.4 4.5
6 months (n, mean, SD) 161 20.6 4.8 166 20.8 5.1 141 21.0 5.1
Timeline cyclical
Baseline (n, mean, SD) 208 10.5 3.3 203 11.1 3.3 209 11.0 3.3
Post randomisation (n, mean, SD) 90 10.4 3.0 92 10.7 3.1 81 11.1 3.5
6 months (n, mean, SD) 159 9.5 3.1 164 9.7 3.1 144 10.1 3.2
Consequences
Baseline (n, mean, SD) 209 16.4 4.3 206 16.2 4.3 207 16.0 4.2
Post randomisation (n, mean, SD) 90 16.0 3.6 92 16.0 3.8 81 15.7 4.7
6 months (n, mean, SD) 160 13.8 3.6 165 13.6 3.9 141 14.0 4.0
Personal control
Baseline (n, mean, SD) 209 18.5 4.1 205 18.7 4.1 206 18.6 3.7
Post randomisation (n, mean, SD) 89 18.7 4.1 92 18.6 3.9 81 18.7 4.3
6 months (n, mean, SD) 158 18.9 3.9 165 19.3 4.1 142 19.3 4.1
Treatment control
Baseline (n, mean, SD) 209 19.6 2.3 205 19.3 2.5 205 19.3 2.3
Post randomisation (n, mean, SD) 90 19.2 2.0 91 18.9 2.3 81 18.9 2.2
6 months (n, mean, SD) 157 18.8 2.5 165 18.8 2.5 142 18.3 3.0
Illness coherence
Baseline (n, mean, SD) 208 17.4 3.8 203 17.4 4.1 206 17.5 3.7
Post randomisation (n, mean, SD) 90 17.8 3.8 92 17.3 4.2 81 17.6 4.3
6 months (n, mean, SD) 156 17.9 3.3 163 17.7 3.9 141 18.4 3.8
Emotional representations
Baseline (n, mean, SD) 208 16.1 4.7 205 15.7 4.5 209 14.9 4.6
Post randomisation (n, mean, SD) 90 16.2 4.8 92 15.6 4.4 81 15.4 5.4
6 months (n, mean, SD) 159 13.6 4.2 164 13.5 4.5 145 13.5 4.6
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Appendix 3 Behavioural Recovery After treatment
for Varicose Veins study paperwork
The BRAVVO   Study  
 
 
 
 
  
 
Dear 
 
A STUDY OF PATIENTS’ VIEWS ON RECOVERY FROM TREATMENT FOR VARICOSE 
VEINS 
 
We approached you today to ask if you would be willing to take part in a discussion group.  In these 
discussion groups we are speaking to people who have recently had treatment for varicose veins to 
find out about what was important to them during in thei r recovery.  The discussion group would take 
place in a few weeks time.  For a couple of days after the discussion group we are asking participants 
to fill in a diary.  As you have recently been treated for varicose veins, we are asking you to consider 
participating and sharing your views.  
 
We enclose a leaflet giving you further information about the study.  It explains why the study is 
being done and what you would need to do if you were willing to take part in the study.  After you 
have read this letter and the information leaflet, if you would like to take part, please fill in the form at 
the bottom of this letter and return it in the envelope provided (no stamp is needed).  Travelling 
expenses to and from the discussion group will be reimbursed, together with any parking or child-care 
costs.  If you would like to participate but cannot travel to the discussion group (which would be held 
in Aberdeen) we would still like to speak with you and get your opinions by telephone or in a face-to-
face interview. 
 
Although we would be very pleased if you did join a discussion group or agree to be interviewed, we 
stress that you are under no obligation to participate in the study.   
 
If you have any questions about the study, please contact the researcher by telephone on 01224 
XXXXXX or myself on 01224 XXXXXX.   
 
Yours sincerely 
Dr Julie Brittenden 
-------------------------------------------------------------------------------------------------------------------------------------------
------ 
Name  
Address 
 
Tel no  
 
Vascular Department, Ward 36 
Aberdeen Royal Infirmary 
Aberdeen 
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Yes, I would like to take part in a discussion group or an interview.  I give permission for a 
member of the research team to contact me to arrange this. 
 
 
  
Please return this in the envelope provided.  No stamp is needed.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
332
  
University of Aberdeen 
3rd Floor 
Health Sciences Building 
Foresterhill 
Aberdeen   AB25 2ZD 
Scotland 
United Kingdom 
 
Tel:   44 (0) 1224 XXXXXX 
Fax:  44 (0) 1224 XXXXXX 
Email:   
The BRAVVO   Study 
A STUDY OF PATIENTS’ VIEWS ON RECOVERY FROM TREATMENT FOR VARICOSE 
VEINS 
 
Patient Information Leaflet 
 
 
 
 
 
 
Introduction 
You are being invited to take part in a research study.  In this study, we are interviewing 
people who have recently had treatment for varicose veins to find out about what was 
important to them during their recovery.  As you have had treatment for varicose veins, we 
are asking you to consider participating and sharing your views.  We are using the information 
from the interviews to develop a questionnaire to use in another research study of people 
having treatment for varicose veins.  Collecting information from people like yourself who 
have had treatment for varicose veins will help us make sure that this questionnaire will ask 
the appropriate questions. 
 
Information sheet for patients approached at clinic, Version 1, 21 August 2008 
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What is the purpose of this study? 
As someone who has recently had treatment for varicose veins, you might be able to help us.  
We are keen to hear from people like you about their experiences and thoughts about the 
treatment and their recovery.   
 
The information from interviews and discussion groups will tell us what is important for people 
during their recovery from treatment for varicose veins.  From this information, we will develop 
a questionnaire to use in a larger study of treatments for varicose veins. 
 
What will I have to do to take part? 
If you agree to take part in our study, we would ask you to participate in a discussion group 
with between five and seven other people who have had treatment for varicose veins.  In 
total, we hope that approximately twenty-one people will take part in this study. The 
discussion group would take place a few weeks after your treatment. 
 
A member of the study team will lead the discussion group and ask some questions.  The 
discussion will last about one hour and thirty minutes, and will include a refreshment break. 
The discussion will take place in the Health Sciences Building which is on the Foresterhill site, 
and travel, parking and child-care expenses will be reimbursed.  
 
The discussion will be tape-recorded. The tape recording will be treated confidentially. 
 
If you want to take part in the study but cannot manage to attend a discussion group, it might 
be possible to organise a one-to-one interview with you, either in person or over the 
telephone.   
 
After the discussion group or interview we will ask you to fill in a diary for a couple of days.  
We will give you a pre-paid envelope to return this to the study office. 
 
What will be done with what I say? 
We will use the transcript of the discussion to create a summary of all the opinions that were 
expressed. The tape and transcript will be stored safely and will be destroyed after the end of 
the study. 
 
The only people who will be able to hear the tape-recorded discussion will be the research 
team and a secretary at the Health Services Research Unit at the University of Aberdeen 
(who will transcribe the tape). No information will be published that could identify you. 
 
What will be done with what I write in my diary? 
We will create a summary of the information contained in all the diaries.  The diary will be 
stored safely and destroyed at the end of the study.   
 
What are the possible risks of taking part? 
We do not think that taking part in the discussion will have any risks for your health. Your 
health care will not be affected. 
 
What are the possible benefits of taking part? 
We hope that you will enjoy taking part in the discussion.  You might find it interesting to meet 
and talk with other people who have had treatment for varicose veins.  By participating in a 
discussion, you will also be helping the research team to understand issues from the 
perspectives of people who have had treatment for varicose veins.  If you enjoy taking part in 
this research, there may be an opportunity for you to continue advising the research team by 
joining our panel of service users. 
 
Will I be able to find out the results of the study? 
If you wish, the researcher will send you a written summary of the findings.  
 
Do I have to take part? 
No.  If you do not want to take part in a discussion that is fine.  You do not have to give a 
reason. If you agree to join a discussion group, but later change your mind, you can withdraw 
your consent at any time. Your care will not be affected.  
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What should I do if I do NOT want to take part? 
If you do not want to take part in a discussion, you do not need to do anything. Thank you for 
reading about the study. 
 
What should I do if I DO wish to take part? 
If you might like to take part in a discussion group, you can let us know by filling in the form at 
the bottom of your letter, and returning it to us in the envelope provided (you do not need a 
stamp).  If you do participate we will ask you to sign a consent form when you come to the 
discussion group.  You will be given a copy of this consent form to keep.   
 
Who has reviewed the study? 
This study has been reviewed by the research team and the North of Scotland Research 
Ethics Committee. 
 
Any questions? 
If you have any questions at all about the study, you can contact a member of the research 
team on the telephone numbers below.   
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 University of Aberdeen 
3rd Floor 
Health Sciences Building 
Foresterhill 
Aberdeen   AB25 2ZD 
Scotland 
United Kingdom 
 
Tel:   44 (0) 1224 XXXXXX 
Fax:  44 (0) 1224 XXXXXX 
Email:  xxxxxxx@abdn.ac.uk 
   
The BRAVVO  Study 
A study of patients’ views on recovery from treatment for varicose veins 
 
 Study No 
      
 
CONSENT FORM 
 
 
Name of Researcher:  
 
 
PLEASE INITIAL BOX 
 
1. I confirm that I have read and understand the information sheet dated May 2008 
(version 1) for the above study and have had the opportunity to ask questions. 
 
  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
  
3. I understand that the discussions I have about the study may be tape recorded but that 
these will be kept confidentially and I will not be identified individually. 
 
  
4. I agree to take part in the study on views of patients about recovery from treatment for 
varicose veins. 
 
 
 
 
     
Name of patient  Date  Signature 
 
 
 
     
Name of person taking consent  Date  Signature 
 
1 for patient; 1 for researcher 
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INTERVIEW TOPIC GUIDE, BRAVVO STUDY 
 
1. Introductions and Review 
· Introduce people in the room 
· Objective of BRAVVO study 
· What is asked of participants inc length of interview 
· Intention to audiotape 
· Confidentiality procedures 
· Participants’ rights – to withdraw, ask for tape to be switched off etc 
 
2. Check 
· Any questions 
· Procedures for reimbursement of costs 
 
3. Sound check 
· Audibility of tape 
· Sound quality of each participant’s voice (for transcriber) 
 
4. Interview 
 
Let’s begin.   First of all can you please tell us about your experience of the treatment 
itself. 
(PROMPTS - Can you remember  
· What happened? 
· Who was there? 
· How you felt? 
· How you were told to care for the leg after treatment?   
· How long after the treatment did you keep the support stockings on 
for?  
 
As I’ve said, we are interested in the milestones you have achieved throughout your 
recovery from treatment. 
A. So can you tell us some of the things that you looked forward to doing for the first 
time immediately after your treatment for varicose veins? 
(PROMPTS AS NEEDED PRESENTED AS DOT POINTS BELOW): 
· While you were still at the hospital? After you returned home? 
· After the first week? 
· Anything that you had not been able to do before your treatment? 
· When did you do these activities – how long after your treatment? 
 
B. Are there any activities that you were worried about doing for the first time after 
your treatment? 
· What activities were painful? 
· Were there any activities that you were worried might do damage? 
· When did you do these activities – how long after your treatment? 
· What happened when you did them? 
 
C.  Are there any activities that you felt particularly pleased that you had achieved 
when you did them for the first time, after your treatment?  
· When did you do these activities – how long after your treatment? 
· How did it feel? 
 
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
337
D. You all had treatment a few weeks ago – is that right? Are there any further 
milestones that you are still looking forward to doing or expecting to do that 
you’ve not been able to do yet? 
· Anything else? 
 
E. Is there anything else you remember about your recovery that you would like to 
mention? 
 
Thank you very much for your help. I will also be talking to patients who had 
different treatments and we will write to you to let you know what we find out in 
this study.  If you have got any comments about the focus group, or anything else 
about your treatment or recovery that you would like to tell us about, there are 
feedback sheets on the table.  You can fill one of these in now, or if you want to 
take a copy home we will give you a reply paid envelope to send them back 
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Appendix 4 Resource use and costing
questionnaire
Questionnaire to be completed by a member of staff familiar with the details of 
alternative procedures. 
 
Section A: Endovenous Laser Ablation (EVLA)  
1. What is the general location of this procedure e.g. clinic/theatre?    
If theatre is the usual location, please answer the following questions: 
2. On average, how long (in minutes) do patients spend on the day/short stay ward, prior to 
the procedure?     
 
3. How many patients are generally on the day/short stay ward at any one time?    
 
4. How long (in minutes) does the patient generally spend on the day/short stay ward post 
procedure?                        
If clinic is the usual location, please answer the following question: 
5. Please specify the area where the patient goes to recover post procedure (e.g. reception)? 
      
 
Please answer the following questions regarding both theatre and clinic settings: 
6. Please complete the following table relating to staff present in theatre/clinic for the 
procedure: 
Staff Band No. present Any Comments 
e.g. General Nurse Salary band Number of staff present - 
    
    
 
7. Please complete the following table which relates to major consumable items used for 
EVLA: 
Consumable Yes/No Unit Cost  Any Comments 
e.g. Laser Fibre    
    
    
 
8. Please complete the following table relating to capital equipment required for EVLA: 
Capital Equipment Make and model 
Expected 
Useful 
Lifespan 
(years) 
Unit cost  
Number of 
patients it is used 
for each year 
e.g. Laser Machine      
     
     
DOI: 10.3310/hta19270 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 27
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Brittenden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
339
Section B: Foam Sclerotherapy 
1. What is the general location of this procedure e.g. clinic/theatre?    
 
2. Please specify the area where the patient goes to recover post procedure e.g. reception? 
    
 
3. Please complete the following table relating to staff present at the procedure: 
Staff Band No. present Any Comments 
e.g. General nurse Salary band Number of staff present  
    
    
 
4. Please complete the following table relating to consumables used for foam sclerotherapy:  
Consumable  Yes/No Cost Any Comments 
e.g. Micropuncture kit    
    
    
 
5. Please complete the following table relating to capital equipment used for foam 
sclerotherapy: 
Capital Equipment Make and model 
Expected 
Useful 
Lifespan 
Unit 
cost  
Number of patients it 
is used for each year 
e.g. Ultrasound Machine 
(portable scanner) 
 
 
   
     
     
 
Section C: Surgery in a day case setting under local anaesthetic  
1. On average, how long (in minutes) do patients spend on the day/short stay ward, prior to 
the procedure?    
 
2. How many patients are generally on the day/short stay ward at any one time?    
 
3. How long does the patient generally spend on the day/short stay ward post procedure?
      
 
4. Please complete the following table relating to staff present in theatre:  
Staff Band No. present  
e.g. General nurse Salary band 
Number of staff 
present - 
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5. Please complete the following table relating to major consumable items used for surgery: 
Consumable Yes/No Unit Cost  Any Comments 
e.g. Disposable vein stripper     
    
    
 
Section D: Surgery in a day case setting under general anaesthetic   
1. On average, how long (in minutes) do patients spend on the day/short stay ward, prior to 
the procedure?    
 
2. How many patients are generally on the day/short stay ward at any one time?    
 
3. How long (in minutes) does a patient generally spend on a recovery ward post 
procedure?      
 
4. How many patients are generally on the recovery ward at any one time?    
 
5. How many nurses generally staff the recovery ward?     
 
6. How long (in minutes) does the patient spend on the day/short stay ward, after leaving 
the recovery ward, prior to discharge?     
 
7. Please complete the following table relating to staff present during surgery in theatre: 
Staff Band No. present Any Comments 
e.g. General nurse Salary band 
Number of staff 
present - 
    
    
 
8. Please complete the following table relating to major consumable items used for surgery: 
Consumable Yes/No Unit Cost  Any Comments 
e.g. Disposable vein stripper     
    
    
 
9. Please complete the following table relating to equipment required for surgery: 
Equipment item 
 Yes/No 
Make and 
model 
Lifespan in 
years Unit Cost  
No of patients 
it is used for 
each year 
e.g. Pulse oximeter      
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